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Abstract 
 
Background 
Counterfeit medicines pose a worldwide problem to governments, pharmaceutical 
companies and patients, meaning a systemic and comprehensive approach needs to be 
adopted by medicines regulatory agencies. The UK’s Medicines and Health Regulatory 
Agency (MHRA) was one of the first national agencies to develop and implement a 
strategy to combat counterfeit medicines. Exploring this experience from different 
perspectives provides an opportunity to build knowledge and inform others considering 
adopting a similar approach. 
Aims 
The aim of this research is to describe and investigate the key components in developing 
an anti-counterfeit medicines strategy in the UK; through describing and examining 
agency and stakeholder views on its development, implementation and evaluation and 
the roles of pharmacists and GPs within this. 
Methods 
A mixed method qualitative and quantitative research design was used which comprised 
four separate studies. Two semi-structured interview studies of MHRA and stakeholders 
participants were undertaken alongside two postal survey studies of community 
pharmacists and GPs. 
Findings 
The significant risk to patients resulting from counterfeit medicines underpinned the 
decision to develop and implement a national strategy. Stakeholders have an important 
role in the development of the strategy and in its implementation by securing the supply 
chain, sharing information, educating others, being vigilant and reporting suspicions.  
Pharmacists and GPs reported limited experience of counterfeit medicines. Whilst GPs 
reported receiving no related education or training, pharmacists frequently reported 
supply practices which did not align with current guidance. 
Conclusion 
There was agreement that in order to effectively combat counterfeit medicines a 
national strategy was required. Stakeholders from the pharmaceutical industry, 
regulatory bodies, medical and pharmacy professions were seen to have an important 
role in both its drafting and implementation. Pharmacists and GPs mainly believed that 
they had a role in combating counterfeit medicines however it was identified that they 
required better underpinning education and training. The research findings provide a 
framework of evidence-based guidance for developing an anti-counterfeit medicines 
strategy. 
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1.1 Introduction 
This thesis and the research reported herein concerns the phenomenon ‘counterfeit 
medicines’. More specifically, it focuses on how a national medicines regulatory agency 
drafts, implements and evaluates an anti-counterfeit medicines strategy by working with 
its stakeholders and relevant groups of health professionals. The aim of this introductory 
chapter is to identify the research topic and state the problem that has prompted the 
research, and describe the contribution to knowledge the research makes. The chapter 
finishes with an outline of the structure of the thesis.  
 
1.2 Research problem 
The counterfeiting of medicines is a worldwide problem affecting countries around the 
globe and medicines of all kinds. The World Health Organization (WHO) defines a 
counterfeit medicine as, “one which is deliberately and fraudulently mislabelled with 
respect to identity and/or source. Counterfeiting can apply to both branded and generic 
products, and counterfeit products may include products with the correct ingredients, 
wrong ingredients, without active ingredients, with insufficient quantity of active 
ingredient or with fake packaging” (1). Counterfeit medicines impose major challenges 
on national and international health and medicines regulatory agencies which need to 
adopt a systematic and harmonized approach to match and combat the global scale of 
the issue. Without decisive action counterfeit medicines would continue to pose a 
significant risk to public health including causing death. Many reports have shown an 
increase in the trading of counterfeit medicines as more criminals have been attracted to 
the activity. Counterfeit medicines have been seen in the pharmaceutical supply chain 
and are increasing being sold online which represents another challenge (2-10). 
The increasing supply of counterfeit medicines has a range of serious consequences for 
different stakeholders. For the users of counterfeit medicines, the general public, the 
most serious consequences are health and treatment related. Counterfeiters are known to 
use potentially injurious materials in their production and can be contaminated with 
toxic chemicals. These medicines can include no active ingredients, incorrect active 
ingredients or the wrong concentration of the correct active ingredient. Each of these 
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scenarios could lead to treatment failure, illness and even death. A significant amount of 
evidence is available to confirm the risk to the public of counterfeit medicines (10-17).  
Pharmaceutical companies also face a range of adverse consequences from the 
counterfeit medicines phenomenon. The pharmaceutical supply chain is both complex 
and long with medicines passing through multiple transactions meaning that there are a 
number of points at which counterfeit medicines can enter the supply chain and find 
their way to end users. The main consequences for suppliers of legitimate medicines, 
are that their profits are affected when counterfeit medicines secure market share at their 
expense, and their reputation can be damaged as ineffective or dangerous medicines are 
confused in the minds of users with medicines from legitimate suppliers, particularly 
when the counterfeiters are deliberately seeking to replicate branded medicines. The 
overall consequences in financial and reputational terms are, however, difficult to 
quantify (12, 17, 18). 
The third set of negative consequences from counterfeit medicines are those faced by 
governments, their agencies and the public health system. It is a clear duty of 
government to protect the public health and counterfeit medicines represent a clear risk 
to this health. The legitimate supply chain represents a valuable source of taxation 
revenue while the illegal trade in counterfeits does not make such a contribution. 
Another financial consequence for governments is the possibility that legitimate 
suppliers will charge public health systems more for their medicines to compensate for 
the impact of counterfeiting. For governments in developing countries there is a danger 
that legitimate pharmaceutical companies will be deterred from supplying to countries 
perceived to be high risk in terms of counterfeiting (12, 19-22).  
The implementation of effective approaches to combating counterfeit medicines is a 
matter of great importance for any country. The Medicines and Healthcare products 
Regulatory Agency (MHRA) strategy implemented in the United Kingdom (UK) is one 
of the first such approaches to combating counterfeit medicines at a national level and 
could form a template for other countries. There are, however, certain gaps in 
knowledge concerning the development, implementation and evaluation of the MHRA’s 
strategy, which this research seeks to fill.  
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1.3 The Research Context  
The research context for this study is a complex one in which multiple actors are 
engaged. Criminals are manufacturing and distributing counterfeit medical products in 
all parts of the world; pharmaceutical companies, law enforcement agencies, healthcare 
professionals and medicines regulatory agencies are engaged in combating this illicit 
trade. The key components for this research are the regulatory agency, the regulatory 
agencies stakeholders and the healthcare professionals. This is because it is these actors 
whose views can best inform an investigation into the development, implementation and 
evaluation of an anti-counterfeit medicines strategy. 
The medicine supply chain starts from the pharmaceutical companies via the 
wholesalers and distributers before the medicines are supplied to patients by their 
pharmacists. Therefore, counterfeit medicines have an impact on all the stakeholders 
involved in the medicines supply chain (1, 6, 11, 12, 20, 23). Many national and 
international medicines regulatory agencies such as the WHO and the MHRA alongside 
many non-profit organizations like the Pharmaceutical Security Institute (PSI) have 
realized the danger of counterfeit medicines (5, 13, 24). In response they have allocated 
significant resources to the prevention and combating of counterfeit medicines at both 
national and international levels, as with the MHRA’s Anti-counterfeiting Strategy 
2007-2010 (25). Responsibilities and resources for combating counterfeit medicines are 
usually given to national medicines regulatory authorities who then decide how best to 
address the problem. Within some countries this has been undertaken by the 
development of national strategies in order to ensure that the approach is holistic, 
efficient and involves all stakeholders. The UK is considered to be at the forefront of 
strategy development an implication of being one of the first countries to develop such a 
strategy. Many of the activities undertaken with the resources have shared similar 
features: communicating with the public to improve their education and awareness of 
the topic; communicating with frontline health professionals (pharmacists and general 
practitioners (GPs)); and collaborating with stakeholders and other national and 
international agencies (12, 19, 20, 24-30). Therefore, the views of those stakeholders on 
the methods needed to tackle counterfeit medicines as well as the knowledge and the 
views of pharmacists and GPs would assist the medicines regulatory agencies in 
organizing its activities for combating counterfeit medicines. 
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In order to develop such activities, it is important for the national medicines regulatory 
agency’s decision-makers to understand the drafting, implementation and evaluation 
processes involved as each of these stages are likely to strongly influence the efficacy of 
the strategy. Such decision-makers also need to understand the possible outcomes of 
these activities and methods evaluating their outcomes (vital for the development of 
future strategies) and to be clear about the role of the agency’s stakeholders, including 
frontline health professionals (pharmacists and GPs). This research therefore 
investigates current practice in the United Kingdom (UK) with respect to combating 
counterfeit medicines in order to fill gaps in knowledge of certain aspects of developing, 
implementing and evaluating a national anti-counterfeit medicines strategy in order to 
inform future practice in these processes in any country where such a strategy is being 
contemplated.   
 
1.4 Contribution of the Research 
This research aims to fill a number of gaps in the knowledge of the views and 
perceptions of key actors involved in the process of drafting, implementing and 
evaluating an anti-counterfeit medicines strategy. These gaps include how different 
stakeholders perceive their own roles and those of others in this process and in the 
overall effort to combat the counterfeit medicines problem. Furthermore, having 
enhanced our understanding of the process the research aimed to provide findings which 
could provide evidence to underpin a guidance framework which could be used by 
decision-makers at national medicines regulatory agencies to assist in their strategy 
development. The guidance framework would include recommendations based on the 
findings of this research project covering a wide range of issues related to the process 
such as identifying the various stakeholders, what their roles are, how they 
communicate and what their current perceptions, views and behaviours are in combating 
counterfeit medicines. While this research was conducted entirely within the UK 
context, its findings are expected to have some generalisability to other countries given 
the global nature of the counterfeit medicines trade. 
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1.5 Structure of the thesis   
Chapter two: Literature Review – The thesis starts with a literature review to enable 
the reader to understand the concepts relevant to understand the problem of counterfeit 
medicines by examining how counterfeit medicines are defined and what issues may 
affect the range and choice of definition, presenting statistics on counterfeit medicines 
and their different sources; and examining their effects on public health, on society and 
on the economy. The factors involved in trading in counterfeit medicines will be 
addressed to include availability of counterfeit medicines through the internet. The 
impact of counterfeit medicines on the pharmaceutical industry, on governments 
(regulatory bodies and healthcare providers), and on patients will also be considered 
together with the efforts worldwide to combat counterfeit medicines. The chapter will 
conclude by identifying the gap in knowledge about combating counterfeit medicines 
which informs the rationale for conducting this research and stating the related aims and 
objectives of this research. 
Chapter Three: Research Methodology – This chapter will detail and justify the 
research methodology that was used to conduct the current research discussing the 
underlying research approach, then justifying the choice of mixed method approach 
(qualitative and quantitative methods) for this research. 
Chapter Four: The MHRA perspective on developing an anti-counterfeit medicines 
strategy – This chapter presents the first empirical study of the research project which 
examines the views of employees of a national medicines regulatory agency about an 
anti-counterfeit medicines strategy in order to gain an understanding of the process from 
drafting to evaluating of such strategy from the position of regulators. Through using 
semi-structured interviews with MHRA participants, this study explores their views on 
developing and implementing such a strategy; the role of the agency’s stakeholders and 
frontline health professionals (pharmacists and GPs) in combating counterfeit 
medicines; and the outcomes they might be expected from such strategy and about 
methods could be used to evaluate those outcomes. 
Chapter Five: MHRA stakeholders’ perspectives on developing an anti-counterfeit 
medicines strategy – This chapter presents the second empirical study intended to widen 
the understanding of the process of developing such strategy throughout gaining the 
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views of the agency’s stakeholders in the area of anti-counterfeit medicines strategy. 
Using findings from semi-structured interviews with the participants from different 
MHRA stakeholder groups, this chapter aims to delineate agency stakeholders’ views 
on the agency stakeholders’ roles in developing and implementing such a strategy; the 
role of frontline health professionals (pharmacists and GPs) in combating counterfeit 
medicines; and the outcomes that they would be expected from such a strategy and the 
methods could be used to evaluate those outcomes. 
Chapter Six: Community pharmacists’ views of their role in combating counterfeit 
medicines – This chapter presents the third empirical study which aims to identify the 
current practice and views of community pharmacists in England in the area of 
counterfeit medicines. Using a survey study, this chapter explores findings about 
community pharmacists’ experience, knowledge and practices in relation to issues 
raised by counterfeit medicines, their views on the role of pharmacists in combating 
counterfeit medicines and their views on the communication methods used by a 
medicine regulatory agency.  
Chapter Seven: General Practitioners’ views on their role in combating counterfeit 
medicines – This chapter presents the final empirical study in this thesis to explore the 
views of general practitioners in England about counterfeit medicines. Using a survey 
study, this chapter investigates the general practitioners’ experience, knowledge and 
practices about counterfeit medicines as well as their views on the role of GPs in 
combating counterfeit medicines and their views on the methods of communication 
used by a medicine regulatory agency.  
Chapter Eight: General Discussion and Conclusion – This chapter presents a wider 
evaluative consideration of the nature and implications of how far the study findings 
have been able to address the gaps in understanding relating to the process of 
developing an anti-counterfeit medicines strategy, what these studies’ findings have told 
us about stakeholders’ views on the nature of the development process and factors 
influencing that process and its outcomes and what the implications of those findings 
may be for those people who may be involved in anti-counterfeit medicines strategy 
development in the UK and elsewhere. The research conclusions are summarised, 
evaluating the quality and appropriateness of the research design is evaluated as is the 
robustness of the research findings and their contribution to the wider field of research. 
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A set of recommendations aimed primarily at those likely to be involved in strategy 
development in the future is presented in the form of a guidance framework linked to 
specific study findings. The chapter ends by presenting the research limitations and 
recommendation for possible future research in this field. 
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2.1 Introduction 
The literature review is a pathway toward setting the objectives for the current 
exploratory research as it identifies which areas needed to be explored by revealing gaps 
in knowledge and empirical investigation and revealing what the current research could 
add to the existing knowledge corpus. The research objectives are presented at the end 
of this chapter. The literature review also evaluates the nature and scale of the 
counterfeit medicines problem to provide context for the chapters to come. In addition 
to this, the researcher anticipated limitations in the literature, in particular with regard to 
empirical and other academic studies, mainly due to the borderless and criminal nature 
of supplying counterfeit medicines. A reliance on global non-governmental 
organizations (NGOs) for prevalence statistics and the problematic nature of such data 
was also foreseen in advance. The review, which was updated continually during the 
data collection, data analysis and synthesis phases of the study, was therefore also an 
opportunity to test these assumptions. The literature review aimed to gain a better 
understanding of how and why counterfeit medicines may pose problems to 
governments, stakeholders and the public. This chapter starts by seeking to establish 
what the term “counterfeit medicines” may mean, which meaning will be useful in this 
study, and present evidence about extent, type and the seriousness of the problems they 
may pose. It will also aim to identify the sources of counterfeit medicines and describe 
how they can affect patients and consumers. Counterfeit medicines supplied via the 
internet as well as the normal supply chain will be also explored. It will then describe 
factors involved in combating counterfeit medicines, to include the technologies now 
available to support this. The consequences of counterfeit medicines for pharmaceutical 
industries, patients and consumers and governmental organizations and what efforts 
have been made to address these by different organizations will be highlighted. The 
chapter will end by identifying the aim and the objectives of this thesis. 
Counterfeiting has its origins as an ancient criminal activity which was probably first 
used when currency in the form of coins and notes was introduced. Today 
counterfeiting is pervasive throughout all areas of manufacturing, its form and focus 
depending on its potential value to the counterfeiters. In the twentieth century items 
such as handbags, watches, and perfumes where the false use of brands could return 
high profit to the counterfeiters is widespread across the globe. By the end of the 
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twentieth century, products which risked public health were identified as part of the 
counterfeiting culture. Such products have included pharmaceutical products, toys, 
cigarettes and spare parts for aircrafts and cars. However, counterfeit medicines pose a 
particularly serious danger, as they are strongly implicated in direct harms to public 
health, sometimes causing death. The counterfeiting of pharmaceuticals differs from 
other types of products because the counterfeiters attempt to imitate the physical 
packaging or appearance of the medicine being targeted, without consideration of the 
contents, which are naturally assumed to be effective by purchasers for the conditions 
they are designed to treat. Counterfeit pharmaceuticals often contain the ingredients of 
an entirely different drug, or the same drug in a different quantity or mixture. They may 
have no active ingredients at all and some may be contaminated by unidentified but 
potentially dangerous chemicals (either added in ignorance or resulting from poor 
sterilization practices) (11, 31, 32). 
In 1958, at the Conference of Experts on the Rational Use of Drugs, the World Health 
Organization (WHO) drew attention for the first time to counterfeit medicines as an 
important global issue. As apparent from counterfeit products seized, the counterfeiters 
do not differentiate between brand-innovated medicines or generic medicines. 
Counterfeiters target a wide variety of pharmaceutical products, from lifestyle to life-
saving medicines, including biological products. However, case reports have shown that 
some medicines are more often counterfeited than others, and that these are 
characterized by high prices and high levels of consumption (4, 19, 20, 33, 34). 
Counterfeit medicines do not only affect developing and also less-developed countries 
(although the incidences of counterfeit medicines in these countries are very high), they 
also affect developed countries. Many health organizations in developed nations, such 
as the US Food and Drug Administration (US-FDA), the European Medicines Agency 
(EMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA), 
have reported incidences of counterfeit medicines (8, 35). The MHRA considers 
counterfeit medicines a “major public health issue” (23). According to the WHO, in its 
report published in 2006, counterfeit medicines are becoming “a global public health 
crisis” (36). 
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2.2 Counterfeit Medicines: Understanding the Problem 
2.2.1 Counterfeit medicines: Definitions 
The words “counterfeit”, “fake” and “falsified” are all used in the pharmaceutical 
industry to refer to copies of genuine medicines. These terms are used to describe 
medicines that appear very similar to an original brand or generic medicine but are 
manufactured by an unauthorized entity. The objective of the counterfeiter is to produce 
a product that is very similar to the genuine product in its outer package, and its 
substance (colour, shape and size), and might also have a similar bar code. The 
sophistication of this procedure makes it, in some cases, very difficult to distinguish a 
real medicine from a counterfeit one. All types of pharmaceutical products can be 
counterfeited, from lifestyle medicines (which are the most common in developed 
countries), such as erectile dysfunction medication (Viagra™), anti-obesity medication 
(Alli™) and many others; to the lifesaving medicines (which are the most common in 
developing and less-developed countries), such as anti-malaria tablets, HIV/AIDS 
medicines and others. Biological medicines are also been counterfeited (2, 4, 9, 10, 12, 
33). 
Defining counterfeit medicines has been the subject of much international debate. It has 
been considered that lack of a standardized definition for such medicines has become an 
obstacle in combating the counterfeit medicines (2, 7). Mackey and Liang (2011), 
highlighted that the key challenge in standardizing a definition is possible interference 
with the definition of intellectual property with respect to copyright and trademarks (2). 
A further challenge is that not all countries have adequate legislation for dealing with 
drug counterfeiting (37). 
The WHO defines a counterfeit medicine as, “one which is deliberately and 
fraudulently mislabelled with respect to identity and/or source. Counterfeiting can 
apply to both branded and generic products, and counterfeit products may include 
products with the correct ingredients, wrong ingredients, without active ingredients, 
with insufficient quantity of active ingredient or with fake packaging” (1). This is the 
most common definition used worldwide (7). According to Attaran et al. (2011), the 
WHO definition is particularly useful because it includes the clear phrase “deliberately 
Chapter 2: Literature Review 
 
 
PhD Thesis: Developing a national strategy for combating counterfeit medicines                  14 
and fraudulently mislabelled” (27). Through this phrase, the WHO has emphasized the 
principle of intent as a key aspect of “counterfeit”; its definition also clarifies that this 
activity is “fraudulent”, and that counterfeiting can never be accidental. 
However, some countries use their own particular definition to describe counterfeit 
medicines. For instance, the US Food and Drug Administration (US FDA) defines 
counterfeit medicines as, “those sold under a product name without proper 
authorization, where the identity of the source of the drug is knowingly and 
intentionally mislabelled in a way that suggests that it is the authentic approved 
product. This definition can apply to brand name products, generic products, or the 
bulk ingredients used to make the drug product. Counterfeit drugs under this definition 
may include products without the active ingredient, with an insufficient quantity of the 
active ingredient, with the wrong active ingredient, or with packaging that falsely 
suggests the drug was manufactured by the FDA-approved manufacturer” (38). Many 
other countries are now using the US FDA definition (4).  
Likewise, the MHRA in the UK applies the definition in the EU Falsified Medicines 
Directive, which is “Any medicinal product with a false representation of: a) its identity, 
including its packaging, and labelling, its name or its composition as regards any of the 
ingredients including excipients and the strength of those ingredients; b) its source, 
including its manufacturer, its country of manufacturing, its country of origin or its 
marketing authorisation holder; or c) its history, including the records and documents 
relating to the distribution channels used” (39).  
All those definitions are trying to address similar meanings which is about purposefully 
copying a genuine medicine. For the purpose of this thesis, the definition of counterfeit 
medicines as given by the WHO will be used as it is the most common definition used 
worldwide. 
 
2.2.2 Counterfeit medicines: Statistical evidence of extent 
According to the WHO, the exact figures for the quantity and volume of counterfeit 
medicines in the supply chain, are difficult to determine. There are many reasons for 
this; the WHO receives information on counterfeit medicines from various sources 
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including medicine regulatory agencies, authorized manufacturing companies, 
independent studies and many others. Also, there is no standard methodology used in 
the studies publishing the statistics on counterfeit medicines, and many of these studies 
have been conducted only in specific periods of time and specific locations, and 
therefore only offer snapshots of the problem. Therefore, the figures that been published 
regarding the counterfeit medicines problem could be seen as the “tip of the iceberg” for 
a major worldwide problem (1, 40, 41). 
The WHO has, nonetheless, estimated that counterfeit medicines worldwide may 
constitute as much as 10% of all pharmaceutical production. However, this figure 
should be treated with caution because it can be misleading, according to the 
International Medical Products Anti-Counterfeiting Taskforce (IMPACT). The WHO 
has estimated that while less than 1% of medicines in developed countries are 
counterfeited, in some developing and less-developed countries, it may reach 60% (1, 7, 
13, 42). The European Commission estimated that counterfeit medicines represent 5-7% 
of the medicines circulated in the EU, and may be as high as 15% (23). Furthermore, the 
Centres for Disease Control and Prevention (USA) has estimated the percentage of 
counterfeit medicines in the developed world is between 1% and 10%, and could be 
30% in countries in Africa, Asia and Latin America (14). In Southeast Asia, 53% of 
anti-malarial medicines are estimated to be counterfeited. Also, 31% of TB medicines 
are estimated to be counterfeited in Botswana (3). In 2004, it was estimated that 40 to 
50% of all medicines in Nigeria were counterfeited (43). Counterfeit medicine seizures 
by custom officials within the European Union increased 384% between 2005 and 2006, 
with a further 51% increase in 2007; detentions increased by 118% in 2008 (44). 
Counterfeit cases were discovered in 89 countries in 2005, while in 2004 they had been 
found in only 67 countries (3).  
The US FDA in line with the WHO has estimated that counterfeit medicines represent 
10% of the global pharmaceutical market; but that only 1% or less are sold in the US 
market (45). In Asian countries, between 5 and 10% of all medicines are counterfeited 
according to the International Federation of Pharmaceutical Manufacturers’ 
Associations (10). In Russia, 12% of medicines are reported to be counterfeit but in the 
Ukraine it is 40% (19). The counterfeit figures in Brazil are between 5 and 7% of all 
medicines, based on data from the Brazilian Health Ministry (10). The WHO has 
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estimated that more than 20% of the pharmaceuticals in the former Soviet Republic are 
counterfeit (11). The WHO estimated in 2005 that the counterfeit medicines sold 
worldwide could be worth $35 billion (15). Also, the Centre for Medicines in the Public 
Interest (USA) expected that the value of counterfeiting  was going to reach $75 billion 
by 2010, with an annual average growth of 13% (3, 42). 
The WHO estimated that 70% of counterfeit medicines contained no active 
pharmaceutical ingredients (or incorrect ingredients). Also, between 10% and 15% of 
these counterfeit medicines contained contaminants (9). Another report published in 
2005 by the WHO covered counterfeit medicines from 20 countries, finding that an 
active ingredient was missing from the product in 60% of the 325 cases studied. This 
study found that only 4% of counterfeit medicines contained the same quantity and 
quality of medication as their genuine counterparts (46). 
The statistics on counterfeit medicines are based on estimates; an accurate estimation of 
counterfeit medicines is both problematic and complex owing to the lack of reliable 
research and standardized methodology. Some authors have asserted that the figures for 
national or international counterfeiting are little more than informed guesswork. The 
reports on counterfeit medicine figures published by the WHO (10% of world trade is 
counterfeit), or IMPACT (10–30% depending on area) are not based on any large-scale 
published scientific data (47). Most research into counterfeit medicines has employed 
the technique of “convenience sampling”, arguing that comprehensive studies are not 
feasible in practice (48), which will have biased the output results from these studies. 
Newton et al. (2009), argued that many currently published articles that have studied the 
quality of medicines have suffered from weakness on its sampling and reporting 
methods which could have affected the accuracy of the results (49). All of the above 
figures have a major limitation; counterfeit medicines are manufactured in secret and 
represent an area of criminal activity, making exact calculations of these figures largely 
impossible. The collection and collation of the data used to arrive at these figures are 
not standardized or uniform across the world because many countries do not have the 
resources needed for such an exercise (7, 50). As Outterson and Smith (2006) stated, 
“empirical, reliable and transparent statistics about drug counterfeiting are virtually 
non-existent” (51). Much of the evidence published in many reports is merely gleaned 
from citations i.e. the findings are circular and there is much duplication (51). For 
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example, the US FDA uses WHO data for worldwide counterfeit medicines, and 
European bodies use WHO data but also WHO citations from the US FDA reports (51). 
However, the US-FDA and the WHO both take the view that the published statistics 
cannot be relied upon because they might be inaccurate; the only matter on which there 
is agreement is that the penetration of this criminal activity varies considerably between 
countries (52). All these data and reports indicate that the sources of counterfeit 
medicines are widely distributed across the world, contributing to their global impact. 
 
2.2.3 Counterfeit medicines: Sources 
For various reasons identifying the sources of counterfeit medicines on a global basis is 
extremely difficult (10). The WHO states that 30% of countries have no drug regulation 
or only a limited capacity that is hardly adequate. This may be due to a lack of financial/ 
human resources or may reflect a lack of policy priority; in any case this opens the door 
to counterfeiters, allowing them to work freely, as described by Enyindaa and Tolliverb 
(43, 53). Another reason for the inability to identify the source of counterfeit medicines 
is the lack of reporting to the WHO by national governments and pharmaceuticals 
companies as those reports might affect their image. Another difficulty is that 
counterfeit medicines generally pass through many countries before reaching their 
ultimate destination; this represents a serious challenge for anti-counterfeit authorities in 
pursuit of counterfeiters. Indeed, it has been estimated that counterfeit drugs may be 
bought and sold as many as thirty times before reaching an end consumer. A final 
reason is that the ingredients for a counterfeit medication may be produced in one 
country, formulated into tablets or capsules in another country, packaged in a third 
country, and then shipped through other countries to its final destination (3, 7, 12, 42, 
54). 
Many powerful and far-reaching criminal organizations have been identified as involved 
in counterfeit medicine activities, including the Russian mafia, Mexican gangs, Chinese 
Triads and Colombian drug cartels. Those with experience in the field say that these 
organized networks are capable of producing items that are almost indistinguishable 
from the genuine product. There is also some documented evidence that terrorist 
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organizations are or have been involved in counterfeit medicines activities, such as the 
IRA (Irish Republican Army), and ETA (Euskadi Ta Askatasuna) (2, 16, 36). 
Most counterfeit medicines are produced in the Third World or developing countries. 
Many researchers and enforcement bodies consider that the largest source of counterfeit 
medicines is China (both active ingredients and finished products); in fact, in 2003 
China’s government closed down 1,300 illegal pharmaceutical factories and 
investigated cases worth $57 million. The WHO published a study which showed that in 
more than 50% of documented cases, the counterfeited medicines in question had been 
produced in China, Vietnam and the Philippines. India has also become a major source 
of counterfeit medicines; some figures estimate that 35% of the world’s counterfeit 
medicines come from India, making it the new leader in the market. Pakistan and 
Nigeria as well as Asian countries outside China are also becoming sources of 
counterfeit medicines. Latin America (especially Mexico) has become a major player, 
and now represents an important source for counterfeit medicines. Russia and the 
former Soviet Union countries are also becoming highly involved in counterfeit 
activities (3, 8, 10, 15, 16, 35, 47, 48, 55, 56). 
Although these countries are the major sources of counterfeit medicines, there is 
evidence of cases of the production of counterfeit medicines in numerous other 
countries. According to the WHO, 14% of counterfeited medicines that have been 
reported were produced in the industrialized areas of Europe. For instance, an operation 
was discovered in the UK, which produced 500,000 counterfeited tablets daily. Also, 
there have been confirmed cases of counterfeit production in Spain, the USA, France, 
Italy and Greece (2, 8-10, 15). Governments are facing a major challenge with respect 
to identifying the sources of counterfeit medicines and this requires a great deal of 
cooperation between all countries in order to tackle these sources.  
 
2.2.4 Counterfeit medicines: their effects 
The particular dangers associated with counterfeit medicines come from the 
counterfeiters’ use of whatever materials are available to copy their target medicine’s 
appearance, regardless of the potentially injurious effects of those materials. Thus, 
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counterfeit pharmaceuticals often contain the wrong or no active ingredients, or they 
may be contaminated through the addition of toxic chemicals or through poor 
sterilization practices (11). Counterfeit medicines are dangerous and can be very 
harmful to public health. The effects of counterfeit medicines can be classified in three 
groups. Firstly, when counterfeit medicines have incorrect active pharmaceutical 
ingredients, the patient will not be treated for his/her illness and this may lead to more 
complicated cases or even death. For example, in the case of anti-malaria and 
HIV/AIDS medicines, the patient might die if not treated with correct doses, and the 
fake drug might contribute to developing drug resistance to the genuine medicines (13, 
16). Secondly, serious complications can occur when a counterfeit medicine contains 
incorrect concentrations of the active pharmaceutical ingredients. For instance, when a 
cancer patient needs a precise concentration of medicine to counter the side-effects of 
chemotherapy, if that patient is not administered the correct dose, he or she could die 
(10). The third effect of counterfeit medicines is when counterfeiters add materials (that 
might be toxic) to a counterfeit medicine, merely to make it look like the genuine 
article; they may use polluted water, toxic yellow road paint, floor wax and boric acid 
(which is used to kill cockroaches) (14, 17). 
There are numerous reports from health organizations and news sources regarding 
injuries and deaths of patients that are linked to the consumption of counterfeit 
medicines. According to the WHO, counterfeits purportedly treating AIDS, bacterial 
infections, cancer, fungal infections, high cholesterol and tuberculosis have been 
documented. In 1995, for example, over 50,000 people were inoculated with fake 
meningitis vaccines in Nigeria, possibly resulting in the deaths of 2,500 children (12). 
In 2006, a US cancer patient died in Missouri after using counterfeit medicines 
(Procrit®) to reduce the symptoms of chemotherapy (15). Also in the USA, 62 people 
died in 2008 from taking a counterfeit of heparin, which had come from China (12). In 
China, the estimation for deaths due to counterfeit medicines has reached 192,000 cases 
(45). In 1998, it was reported that 400 children in Haiti, Nigeria, and Bangladesh died 
after ingesting counterfeit paracetamol (acetaminophen) syrup that was made using 
diethylene glycol (7). In addition, the estimate for death worldwide caused by 
counterfeit anti-malarial and anti-TB medicines is 700,000 (12). In 2005, more than 
1,000 were hospitalized in Russia due to counterfeit medicines (23). There are also 
many reports of patient deaths from medicines bought online in the USA, New Zealand 
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and Canada (2). In 1998, there were 200 cases of unwanted pregnancies for women who 
used counterfeit contraceptive pills in Brazil (15). 
The effects of counterfeit medicines can be generally summed up as increasing 
morbidity and mortality, adverse effects, therapeutic failure, inaccurate reports of drug 
resistance due to substandard medicines and a rise in drug-resistant pathogens. These 
cases indicate that a key difference between most other counterfeit goods and 
counterfeit medicines is that the use of the latter leads to especially serious public health 
dangers. A further deleterious health effect arises when consumers find that the drugs 
they are taking or have been prescribed are less than effective; then they can 
understandably lose confidence even in the genuine product which might lead to 
consumers to seek treatment from traditional medicines (23, 31). The dangers associated 
with counterfeit medicines place a great responsibility on governments to protect the 
public, something which requires a systemic approach. 
 
2.2.5 Counterfeit medicines and the Internet 
One type of service which has recently greatly increased is online pharmacy and this is 
due to their convenience and the offer of a wide range of products as well as anonymity 
to the purchaser. Consumers can now buy their medication at any time of the day and 
from anywhere in the world. For disabled patients and those living in rural areas, online 
pharmacies provide direct-to-door delivery. Online medicines are frequently more 
affordable than those purchased from retail pharmacies which incur greater overheads. 
Finally, online pharmacies can provide consumers with a great deal of information 
about the drugs and their actions, which can enable them to make an informed decision 
(57-62). 
However, online pharmacies also have some significant drawbacks for consumers. In 
most cases, the consumer cannot be sure whether or not the online pharmacy is 
legitimate. The quality of online products is also a cause for concern; it is difficult to 
determine whether drugs purchased online are counterfeit, unapproved or illegal. Most 
of the time, online pharmacies sell their medicines without a valid prescription, and they 
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may ask for and hold a great deal of personal information. In many cases, online 
pharmacies market products with false or misleading health claims (58-60, 63). 
Internet pharmacies afford an excellent opportunity for counterfeiters to distribute their 
counterfeit medicines in the global market. It is very difficult for government agencies 
to correctly identify online pharmacy websites and then to find counterfeit products 
(64). Gallagher and Chapman (2010), classified online pharmacies into three groups 
which are the legitimate sites within its country, sites registered in other countries, and 
illegitimate sites (57). Legitimate sites are authorized and regulated by the local 
government. For example, in the UK, online pharmacies must register with the General 
Pharmaceutical Council (GPhC) (65). The second group of sites are online pharmacies 
that are not registered in the local jurisdiction but might be registered in other country 
and may sell medicines following consultation (questionnaire or telephone interview) 
(57). The final group of websites are online pharmacies that are not regulated in any 
country and sell medicines without prescription or consultation; these are the most 
unsafe websites, and their location cannot usually be identified. These sites are 
generally designed in an attractive manner and many of them try to appear to represent 
well-known pharmacies, perhaps in Canada or the UK, However, the study conducted 
by Gallagher and Chapman (2010) and its three-fold classification was reliant on the 
location information published by the websites themselves which we know may not be 
reliable.  According to the US FDA, online pharmacies are often comprised of multiple 
related sites and links. The WHO reported that many internet pharmacies do not reveal 
their real-world address (60, 66, 67).  
The WHO estimated that almost 50% of medicines purchased over the Internet are 
counterfeit (1). A report published by the US FDA and the US Customs claimed that 
88% of online medicine shipments to US patients are counterfeit. In addition, the US 
FDA has estimated that medicines purchased from online pharmacies are worth $1 
billion a year, and this figure is expected to rise (42). A report for the US FDA claimed 
that of the 11,000 internet pharmacy sites that claimed to be Canadian, only 1,009 
(1.95%) actually sold prescription drug products, and that of those 1,009 websites, only 
214 were registered to a Canadian entity (11). A study conducted by the US FDA in 
2005 found that 85% of online pharmacies claiming to be Canadian in origin actually 
were from other countries (14). 
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Both the US FDA and the MHRA have published warnings about the dangers of 
unwittingly purchasing counterfeit medicines from online pharmacies (62). A survey 
conducted by the UK MHRA that covered 2,076 UK adults found that over 14% of 
consumers had been able to purchase prescription-only medicines (i.e. without a valid 
prescription) (44). Another study showed that 78% of UK GPs believed that patients put 
themselves in harm’s way by buying from online pharmacies (44). In Europe, 20% of 
consumers of medicines declared that they bought from the Internet (2). 
The dangers of online pharmacies were dramatically revealed in an operation organized 
and coordinated by INTERPOL, called Operation Pangea which occurred every year. 
The main objective of those operations is to tackle illegal online trading in counterfeit 
medicines. In those operations, INTERPOL worked with the World Customs 
Organization (WCO), the Permanent Forum of International Pharmaceutical Crime 
(PFIPC), the Heads of Medicines Agencies Working Group of Enforcement Officers 
(HMA WGEO), the Pharmaceutical Security Industry (PSI) and the electronic payments 
industry. In the last of these operations (Pangea VII) 113 countries and 198 agencies 
participated in the operation. The results were that more than 11,800 illegal websites 
were identified, 9.6 million fake and illicit medicines seized (such as slimming pills, 
cancer medication, erectile dysfunction pills, cough and cold medication), which were 
worth $32 million; also,  1,249 investigations were launched, and 434 arrests were made 
(68). 
In conclusion, it is not easy to investigate the legitimacy of online pharmacies as the 
task is very complex and resource intensive. Until now, there is no international 
legislation dedicated to regulating online pharmacies. Therefore, governments will need 
to educate their consumers of the safe method for buying medicines from online sources 
(14, 59, 60, 63). Also, governments need to work together to stop the sale of counterfeit 
medicines online and need to put in place effective education activities informing both 
public and healthcare professionals about the danger of counterfeit medicines. 
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2.2.6 Counterfeit medicines and the supply chain 
To understand how counterfeit medicines reach patients and consumers, it is important 
to highlight the various processes through which the medicines are transported from the 
pharmaceutical manufacturing companies to the destination market. In the ideal 
scenario of medicines supply chains, the pharmaceutical manufacturing companies ship 
their medicines directly to their main wholesalers. These wholesalers then distribute the 
medicines directly to hospitals or retail pharmacies, which then dispense these 
medicines to patients or sell them to consumers. However, in the real world, the 
pharmaceutical supply chain is both complex and long. Medicines pass through multiple 
transactions, going back and forth, before reaching the supply point. The risk of 
counterfeit medicines reaching patients and consumers increases with the increasing 
complexity of the supply chain (27, 43, 69). 
To counteract the risk of the counterfeit medicines penetrating the supply chain, many 
major pharmaceutical manufacturing companies have started to distribute their products 
through a “closed” pharmaceutical distribution system, in which both manufacture and 
wholesale are conducted in a wholly transparent and highly-scrutinized supply chain. 
This process is designed to track the transit of medicines all the way to the destination. 
The objective of this is to reduce the risk of counterfeit medicines reaching patients and 
consumers. This closed pharmaceutical supply chain is monitored by regulatory 
agencies such as the MHRA. These agencies seek to secure the supply chain in order to 
prevent counterfeit medicines from entering. Therefore, this makes it more difficult to 
obtain medicines that have not passed through the approved framework; by increasing 
these types and levels of control, incidences of counterfeiting should be reduced. 
However, not infrequently, medicines can travel a much more circuitous route before 
reaching the pharmacies or hospitals. For example, wholesalers may sell their medicines 
to other wholesalers to cover temporary shortages or to reduce overstocked items, or 
they may send them to other smaller companies for repackaging (to change the 
medicines from bulk to unit-of-use containers). Thus, it is common in the 
pharmaceutical supply chain for medicines to pass through several transactions before 
reaching their destination. This variety of transaction activities affords an opportunity 
for counterfeiters to introduce their fake products into the supply chain. Another key 
threat in terms of counterfeits entering the medicine supply chain is related to parallel 
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imports and to the risk of confusion that arises from this kind of trade. This practice is 
legal in many countries, for example, a European wholesaler may buy and then import 
medicines from another European country at a low price, and then resell them back to 
that country at a higher price in order to profit from fluctuations in market demand. 
However, the speculator is allowed, within certain limits, to redesign the packaging in 
order to make the medicines more attractive to the target market, and this may result in 
confusion on the part of the purchasing entity; it is here that counterfeit medicines may 
be introduced into the destination market. (8, 26, 32, 34, 43, 69). Therefore, all parties 
involved in the medicines supply chain would have duties to combat counterfeit 
medicines and government needs to work closely with these parties. 
 
2.2.7 Motivations for trading in counterfeit medicines 
The increasing trade in counterfeit medicines all over the world is driven by a number 
of key motivations, which reflect the reasons for counterfeiters starting in the first place. 
However, it is an uncommon motive for the counterfeiter to intentionally harm people 
which is very rare. An example of an exception was in the USA in 1982, when 
Tylenol™ was contaminated with poison by an unknown person, which resulted in 
seven deaths (8). 
The most important motivations underpinning trading in counterfeit medicines is that 
huge economic benefits are to be gained (2, 11, 12, 14). The production of counterfeit 
medicines requires little capital and simple equipment; therefore, counterfeiters can 
generate considerable profits by producing at a low cost and then selling at a price 
commensurate with genuine medicines. Some authors have estimated that the profit 
margin can reach 2,000% of production cost, which goes some way to explaining the 
estimated value of worldwide counterfeit medicines as being $75 billion (in 2010). For 
criminal organizations, trading in counterfeit medicines has become an alternative to 
trafficking in narcotics due to their high profitability (9, 14). 
An additional motivation that accelerates the trade in counterfeit medicines is the very 
low risk of getting caught. This could be due to the nature of the product; the medicine 
is ingested and the packaging is discarded. Thus, the active (or otherwise) ingredients 
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are metabolized in the body, and are consequently difficult to identify at a later date, 
especially if the patient has ingested numerous other substances as part of normal 
treatment. This means that any evidence of counterfeiting is, on the one hand, destroyed 
as refuse, and on the other, converted into other chemical compounds and dispersed (10, 
11, 20). Some healthcare professionals (physicians and nurses) as well as some patients 
have little doubt that a significant amount of therapeutic failure might be because of 
counterfeit medicines, although this is very difficult to substantiate. Therefore, it is 
important that healthcare professionals generally, in assessing treatment failure or 
iatrogenic illness, consider the possibility of the presence of counterfeit medicines. 
Also, it is important to educate healthcare providers (physicians, nurses and 
pharmacists) and patients more widely about the existence, effects and means to avoid 
counterfeit medicines (3, 12). 
Another motivating factor is in the low penalties for trading in counterfeit medicines 
which permit counterfeiters to go about their trade with little fear. For example, in the 
USA, selling counterfeit trademark goods such as handbags may result in the dealer 
being sentenced to up to 10 years in prison, yet trading in counterfeit medicines has 
only been subject to up to 3 years in prison. However, this has begun to change: for 
instance, in November 2007, the Chinese State Food and Drug Administration 
introduced severe penalties for trading in counterfeit medicines, which could mean life 
imprisonment or even the death penalty. Also, the Council of Europe recently adopted 
the MEDICRIME convention, which increases the penalty for trading in counterfeit 
medicines. Nevertheless, there is still no international legal framework for tracking, 
apprehending and sentencing counterfeiters (10, 12, 27, 44, 70). 
Finally, the availability of modern digital printing technologies for packaging and 
labelling, poverty, inadequate health facilities, corruption and the high cost of drugs 
(from taxes and tariffs) all increase motivations for trading in counterfeit medicines 
(12). All these motivating factors have contributed to increasing the supply of 
counterfeit medicines worldwide, which in turn has increased the risk imposed on 
public health. This has put the medicines regulatory agencies in a position of great 
responsibility for the protection of consumers. 
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2.2.8 Technologies available to help combat counterfeit 
medicines 
Modern technology is seen to play a crucial role in combating the actions of 
counterfeiters. In general, the technologies that can be used in combating counterfeit 
medicines can be classified into three categories: packaging or labelling; technological 
authentication; and data carrier identification through the supply chain. The first relates 
to the integrity of the outer packaging and the inner labelling or leaflets; these can carry 
tamper-evident features, for example, security seals, glue on perforated cartons and 
cartons fitted with breakage evidence devices. The second category relates to 
pharmaceutical products being authenticated by covert and overt technologies, such as 
immunoassay (biochemical markers), reactive inks, holograms, watermarks, colour-
shifting inks, guilloches, fibres or threads. The third category relates to the medicine 
being identified at each stage of the supply chain through a data carrier (micro-chip 
tags). The strategy in this category of technological weapons is to serialize all medicines 
with unique codes to facilitate their identification (and authentication) at each stage of 
the supply chain (Radio-frequency Identification (RFID) is an example of this category) 
(10, 43, 71). All the above technologies vary in terms of cost and efficacy. However, it 
is essential to select the tool that is best suited to each country’s level of development 
and it is unrealistic to expect the least developed countries to have access to the most 
costly technology. For example, the biggest problem is in the developing world, where 
resources are limited, poor control mechanisms exist, and many medicines are supplied 
outside conventional means. The current technologies used in combating counterfeit 
medicines often have fundamental defects, which affect their intended performance. 
This was exemplified in 2005, when a study conducted in the USA by a large US 
pharmaceutical wholesaler found that more than 25% of the RFID tags were unreadable 
(4, 11, 20). 
National health and medicines regulatory agencies are facing many challenges with 
respect to counterfeit medicines which flags up the need for a systemic approach that 
could be adapted by an agency in order to combat counterfeit medicines. Also, 
cooperation between parties in the medicines supply chain as well as the other national 
health and medicines regulatory agencies are essential to combat counterfeit medicines. 
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2.3 Consequences of Counterfeit Medicines 
Many parties (stakeholders) deal with medicines along the medicines supply chain in 
one way or another. From a business perspective this would be the pharmaceuticals 
manufacturing companies (branded and generic), wholesalers and distributers. From a 
regulating and providing treatment perspective this would be the government 
(departments of health, medicines regulatory agencies and health professionals). Finally, 
comes the patient as end user. Counterfeit medicines would have an impact on all those 
stakeholders and they could cause many problems on different levels. Counterfeit 
medicines can inflict a great deal of harm to the pharmaceutical industry, as well as 
posing a significant risk to public health. In addition, counterfeit medicines can have an 
impact on various government bodies.  
 
2.3.1 The impact of counterfeit medicines on the 
pharmaceutical industry 
The process of inventing, developing, testing and licensing a new medicine needs much 
investment on the part of pioneer pharmaceutical companies, in terms of time, 
manpower and money. The estimated cost to put a new product on the market in 2004 
was between $800 and $900 million. This estimation was based on the generalization 
that only one product will successfully reach the market after the company has 
examined and tested 5,000 molecules. In addition, the process of launching an 
innovative product on the market is a very lengthy one and can be up to 15 years. Not 
all innovative products that have been released onto the market will generate profits for 
the pharmaceutical company as only 30% result in profits which are sufficient to cover 
the costs of research and development. The pharmaceutical industry is considered a very 
costly and high-risk business (10, 17, 21). 
Counterfeit medicines have damaging effects on pharmaceutical companies. Trading in 
counterfeit medicines takes profits from innovative manufacturers, who must then 
recoup their considerable research and development costs from elsewhere. As a result of 
the reduced profits, innovative pharmaceutical companies may be forced to reduce 
investment in new medicines. Counterfeiters target generic as well as branded 
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medicines, and the profits of generic pharmaceutical companies will also be reduced; 
this will have consequences on the availability of low cost, high quality generics (12, 
17, 20).  
Counterfeit medicines damage the brand image and brand value of genuine medicines, 
and diminish their reputation in the eyes of patients. Pharmaceutical companies can 
have their reputation for quality compromised and they can be exposed to litigation 
should consumers be harmed by counterfeit versions of their medicines as the 
consumers do not know they used counterfeit medicines (29, 35, 55). Damage to 
reputation does not only affect branded medicines; the medicines of good quality 
generic companies also suffer from reputational damage from counterfeit medicines (8, 
26). The negative impact on pharmaceutical companies caused by counterfeit medicines 
has led some pharmaceutical companies to cease cooperating and sharing the 
information they have with other stakeholders. Because accurate figures on the extent of 
counterfeit medicines are not available, assessing the damage to the product’s brand is 
complex and difficult to define (12, 17, 18).  
Counterfeit medicines seize market share from the genuine ones. Thus, the genuine 
pharmaceutical companies have to adjust their production and this can have 
ramifications on the supply chain. Also, genuine pharmaceutical companies have to 
spend a great deal of money in tracing the counterfeiters and in taking them to court (26, 
72). Recently, many genuine pharmaceutical companies have begun to be more 
proactive and now hire investigators to trace the source of counterfeit medicines and to 
work with national authorities. They also now publicize their anti-counterfeiting 
strategies and technologies (3, 55). Sources citing the threats to pharmaceutical 
companies’ financial strength need, however, to be balanced against the proven 
profitability and high profit margins of the major companies. Reports have shown that 
despite the rise of global counterfeiting, leading companies have been able to maintain 
higher average profit margins than any other sector (73). While still remaining highly 
profitable despite the costs of counterfeiting, the potential consequences of 
counterfeiting for the industry raises the need for the industry to be part of the efforts to 
combat counterfeit medicines and have a role in the national strategy. 
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2.3.2 The impact of counterfeit medicines on governments, 
regulatory bodies and healthcare providers 
The effects of counterfeit medicines are evident beyond the pharmaceutical companies 
and patients; they also have a significant impact on the reputation of government 
agencies. Patients who have had an experience with counterfeit medicines may think 
that the relevant regulatory authority was unable to protect them and that it is not fit for 
purpose and that may lead patients to seek treatment from other recourses like 
traditional medicines. For this reason, some governments do not publish figures on 
counterfeit medicines that could affect its image (12, 28). 
Governments of many countries exact taxation from companies (including 
pharmaceutical manufacturers) in terms of percentage of profits. This also applies to 
wholesalers, distributors and retailers, which will be used to improve their public health 
systems. Counterfeit medicines bypass the regular distribution chain, and therefore a 
large amount of revenue that should have gone to the government and to their health 
systems is lost. Also, counterfeit medicines increase the costs of medicines paid for by 
the government (as well as by patients) because the pharmaceutical companies have to 
increase their prices to recoup their losses from counterfeit medicines (12, 19, 20). 
Another impact of counterfeit medicines on governments would be through increasing 
the country’s unemployment level. This could happen in two ways: pharmaceutical 
companies lower their number of employees due to the losses incurred from counterfeit 
medicines, and potential international investors tend not to invest in a country that has a 
counterfeit medicines problem (21, 22). Therefore, governments need to coordinate with 
other interested organizations including the pharmaceuticals companies in its efforts to 
combat counterfeit medicines.  
 
2.3.3 The impact of counterfeit medicines on patients 
There are different types of impact on patients which have a more or lesser direct 
relation to their health and treatment. In most cases, patients take a medicine assuming 
that it will be genuine; therefore, patients are unlikely to suspect that any harm that may 
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have occurred would be caused by a counterfeit medicine. It is in this hidden way that 
counterfeit medicines threaten public health (26, 72). Counterfeiters are producing 
medicines which could cause therapeutic failure in patients. Also, in cases of infectious 
disease, inaccurate active ingredients can increase resistance to medicine on the part of 
pathogens. In these ways, counterfeit medicines contribute to the public health risk by 
aiding the spread of infectious diseases, and compromising the fight against them (2, 12, 
28, 55). 
Counterfeiters minimize the costs of production by using cheap impure ingredients, 
using unhygienic manufacturing processes and not following the good manufacturing 
practise of cleaning the machines between different production batches. The 
consequences of these are that counterfeit medicines cause harm to patients, increasing 
morbidity and mortality, and exposing patients to the risk of experiencing adverse 
events (or not achieving their treatment goals) (2, 20, 55). 
Patients who take counterfeit medicines and then do not improve as they expected from 
taking an apparently reputable medicine can lose confidence in conventional allopathic 
drugs and even in the health system. Especially in developing countries, the widespread 
distribution of counterfeit medicines can lead to people seeking out alternative 
medicines such as traditional remedies and unlicensed healers as being more 
trustworthy  (12, 27). 
Additionally, because of counterfeiting leading to reduced revenue flows to the 
pharmaceutical industry, increased litigation costs, as patients anticipated that the 
medicine is genuine, and ever-rising insurance rates, consumers will be asked to pay 
more for their medicines. Counterfeiting also has consequences for developing 
countries; their markets can become less profitable, meaning that pharmaceutical 
companies are less likely to invest in research and development to combat diseases that 
are endemic, which in turn makes these poorer countries less attractive to foreign 
investors (19, 35, 55). 
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2.4 Efforts to combat counterfeit medicines 
Since the early modern appearance of counterfeit medicines, the WHO, as well as some 
national medicines regulatory agencies, have been making efforts to combat counterfeit 
medicines through different approaches and different levels of engagement.  
 
2.4.1 International and national agencies 
The task of tackling counterfeit medicines has been taken on by many international and 
national health and medicines agencies. At the international level, the WHO recognized 
the importance of tackling counterfeit medicines in a systematic way; therefore, in 1999, 
the WHO published guideline entitled “Guidelines for the Development of Measures to 
Combat Counterfeit Medicines”, where the WHO tried to provide comprehensive 
guidance (30). Rather than having a strategy specifically designed to combat 
counterfeiting, it has developed an approach aimed at aiding the strategies of other 
countries. The WHO therefore became involved in training law enforcement officers 
and laboratory technicians, in helping to advance technology, and in supporting and 
developing the regulations of the countries.  
The guidelines published by the WHO propose particular courses of action to be 
followed by countries to remedy their counterfeit medicines problem. These include 
raising the political priority of combating counterfeit medicines; alerting countries to the 
dangers of counterfeit medicines; developing a suitable legislative framework to protect 
the medicines supply chain and improving the screening of medicines at ports of entry; 
establishing medicine regulatory authorities, with  effective enforcement powers; 
increasing the enforcement of the existing medicine control laws; developing 
partnerships between governmental agencies and pharmaceutical companies  to foster 
communication and cooperation; and increasing patient education and awareness 
concerning counterfeit medicines. In 2005, the WHO developed a system (“Rapid Alert 
System” (RAS)) to help countries and the partner organizations in the Western Pacific 
Region to be notified of any counterfeit medicine case. This system would immediately 
alert those using it about any such incident and the action that should be taken. 
Moreover, as part of the efforts in the fight against counterfeit medicines, the WHO 
Chapter 2: Literature Review 
 
 
PhD Thesis: Developing a national strategy for combating counterfeit medicines                  32 
formed and launched the International Medical Products Anti-counterfeiting Taskforce 
(IMPACT) in 2006. IMPACT is a partnership of international organizations, non-
governmental organizations, enforcement agencies, pharmaceutical manufacturing 
associations and drug and regulatory authorities. The objective of IMPACT was to stop 
the production and trade in counterfeit medicines, but it also focused on improving 
coordination and harmonization between its members. However, the drawback for 
IMPACT was that it did not have legislative authority nor the financial resources to help 
its members (3, 5, 7, 8, 20, 74). 
Also at an international level, in European countries, the MEDICRIME convention has 
been adopted by the Council of Europe as the first international agreement to 
criminalize the trading in counterfeit medicines. The Council of the European Union 
and the European Parliament adopted the Falsified Medicine Directive in 2011 which is 
scheduled to be implemented fully by 2018. This directive requires all medicines to 
have a unique serial number applied during their manufacture and that this should be 
displayed on the medicine packaging in the form of a 2D barcode. Every prescription 
only medicine (POM), except those exempt resulting from their risk assessment, will be 
covered while all over the counter medicines (OTCs) will be exempted unless identified 
as being at high risk of counterfeiting. Prior to supplying the medicine to the patient 
they will be scanned and the unique number checked against a database (20, 44, 75, 76). 
National health and medicine regulatory agencies add to international efforts to combat 
counterfeit medicines. For example in the USA, the FDA has developed its own stance 
on combating counterfeit medicines, which shares some of the same points as the WHO 
method and has six main objectives: to secure both the medicine and its packaging, to 
secure the passage of medicines throughout the distribution chain, to enhance regulation 
and enforcement, to increase penalties for the counterfeiting of medicines, increasing 
vigilance and awareness of such counterfeiting, and developing international 
collaboration (3, 4, 34, 38, 77, 78).  
In Nigeria, the National Agency for Food and Drug Administration and Control 
(NAFDAC) as one of Africa’s leading agencies in combating counterfeit medicines, has 
conducted several activities to combat counterfeit medicines. As part of its efforts 
NAFDAC adopted a Mobile Authentication Service (MAS) which helps patients make 
sure that their medicines are not counterfeit by using their mobile phones, as well as 
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collaboration with pharmaceutical companies and other national medicine regulatory 
agencies. In 2010, Health Canada published a policy on Counterfeit Health Products as 
part of the effort to combat counterfeit medicines in the country. This policy was 
focussed on educational activities and advice to the public, health professionals and 
members of the supply chain about counterfeit issues; developing a vigilance system; 
working with its stakeholders; conducting marketing lab tests; and working with other 
international regulators (4, 34, 38, 43, 77-81). 
In the United Kingdom, the MHRA which is responsible for regulating medicines and 
medical devices to protect public safety, launched its “Anti-counterfeiting strategy 
2007-2010”. The strategy was the first document published by a national medicines 
regulatory agency that aimed to tackle counterfeit medicines in the country across three 
key areas, communication (with the public and health professionals), collaboration 
(with stakeholders and agencies at a national and international level) and regulation (by 
gathering intelligence, investigation and risk assessment of the threat of counterfeit 
medicines in the supply chain). In 2012, the MHRA published its second strategy which 
was called “Falsified Medical Products Strategy 2012-2015”. The second strategy was 
a natural successor to the first strategy; and it was also based on three main key points 
(prevention, incident management and investigation). For the prevention area, the 
MHRA aimed to prevent counterfeit medicines reaching the public through a series of 
activities: communication (with public and health professionals), collaboration (with its 
stakeholders) and participate in the international activity to combat counterfeit 
medicines. For incident management, the MHRA aimed to be more efficient in handling 
any incidence of counterfeit medicines and improve the medicines recall process when 
needed. Regarding the investigation part, the MHRA aimed to be pro-active in 
investigation through its enforcement group within the agency to detect counterfeits and 
evaluate and monitor medicines supplied online and work with other law enforcement 
counterparts at an international level. In addition to these strategies the MHRA 
published, in collaboration with the Dispensing Doctors Association (DDA) and the 
Royal Pharmaceutical Society of Great Britain (RPSGB), guidance for pharmacists and 
dispensing doctors which contained information and advice on counterfeit medicines 
(23, 25, 39, 44, 82-85). 
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The common features seen in the published international and national activities to 
combat counterfeit medicines are in highlighting educative communication with the 
public, raising public awareness about counterfeit medicines and improving 
collaboration with counterpart agencies and stakeholders. However, the method used to 
develop and implement such activities and to evaluate their impact is not reported in the 
literature. Also, the literature did not report any cooperation between different 
organizations in the development of those activities which suggests that each 
organization develops its own activities in isolation from other organizations.  
 
2.4.2 Non-profit organizations 
Many non-profit organizations, from national professional bodies, to global alliances 
and manufacturer representatives, have also played a part in the worldwide efforts to 
combat counterfeit medicines and many such organizations deal with such issues as all 
or part of their activities. For instance, in 2002, some of the pharmaceutical companies 
formulated the Pharmaceutical Security Institute (PSI) which is now has twenty-eight 
pharmaceutical manufacturers members. PSI activities would help in tackling 
counterfeit medicines by sharing information and working with the national medicines 
regulatory agencies. Also, in 1999 health professionals worldwide (pharmacists, GPs, 
dentists, nurses, and physical therapists) formed a non-profit organization called the 
World Health Professions Alliance (WHPA). The WHPA has been part of the efforts of 
combating counterfeit medicines through educating its members. Another non-profit 
organization, is the Alliance for Safe Online Pharmacies (ASOP), which focuses mainly 
on counterfeit medicines via online sources, The ASOP is playing a role in combating 
counterfeit medicines through increasing the awareness of the danger of buying 
medicines via online websites through education activities for patients and health 
professionals; raising awareness of the danger of such websites to the policymakers and 
other internet stakeholders and working in collaboration with medicines regulatory 
agencies to improve the safety of online pharmacies (24, 86-88). 
In the UK, the General Pharmaceutical Council (GPhC), which is responsible for 
regulating pharmacists, pharmacy technicians and pharmacy premises in Great Britain, 
as well as the Royal Pharmaceutical Society (RPS), which is the professional 
Chapter 2: Literature Review 
 
 
PhD Thesis: Developing a national strategy for combating counterfeit medicines                  35 
membership body for pharmacists seeking to continue improving pharmacy services in 
UK are both working with MHRA on the issue of counterfeit medicines through 
educating their members, including, for example, publishing the guidance for 
pharmacists and dispensing doctors on counterfeit medicines (65, 84, 89). 
All these efforts and activities on the part of many organizations and agencies combine 
to highlight the seriousness of the danger of counterfeit medicines to the public health, 
and to demonstrate that they are working individually and in some cases cooperatively 
to combat counterfeit medicines. 
 
2.4.3 Health professionals 
Many medicines regulatory agencies’ efforts to combat counterfeit medicines, like the 
MHRA’s strategies as well as the WHO’s guideline, flag up the importance of working 
with healthcare professionals in order to raise their awareness of counterfeit medicines 
which will help in combat counterfeit medicines (25, 39, 90). However, the methods 
used for raising such awareness in healthcare professionals have not been described. 
The role of health professionals (pharmacists and GPs) is reported in some literature as 
to be vigilant for any counterfeit medicines, as well as to educate and raise awareness 
among their patients of the danger of counterfeit medicines. Also, for pharmacists there 
is mention of the need to secure the supply chain from any penetration by counterfeit 
medicines and to report any suspicions of this to their national medicines regulatory 
agency (3, 12, 91, 92). However, in this literature these roles are reported as derived 
from authors’ opinions rather than from empirical research directly involving those 
health professionals (pharmacists and GPs). Neither has health professionals’ awareness 
of counterfeit medicines been determined within this literature. Therefore, the views of 
pharmacists and GPs on the issue of counterfeit medicines and their role in combating 
counterfeit medicines need to be understood by the national health and medicines 
regulatory agencies. 
In summary, even with no unified definition of counterfeit medicines, all definitions 
commonly used share the same conceptual meaning of purposefully-produced 
unregulated copies of genuine medicines that are physically very similar to the genuine 
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medicines and which may or may not have pharmaceutically active ingredients. In 
addition, figures that try to estimate the scale of counterfeit medicines in the worldwide 
legitimate pharmaceutical supply chain raise concern as the accuracy of those figures 
may be limited by, for instance, a lack of formal reporting mechanisms and different 
methodologies have been used to identify them. However, these figures could serve to 
flag up to the national medicines regulatory agencies the seriousness of the counterfeit 
medicines problem.  
Identifying the source of counterfeit medicines is no easy task although the literature 
has indicated that counterfeit medicines may mainly come from countries such as India 
or China. Counterfeit medicines can, nonetheless, also be produced in any country 
including those with a highly regulated pharmaceutical market such as the UK or the 
USA. Many published reports show how counterfeit medicines impose a danger to 
consumers as they might cause death or at least lead to treatment failure. Also, the 
danger associated from buying medicines from online sources is very high as it been 
estimated that at least 50% of medicines bought online would be counterfeit and that is 
because online sites are an effective method for counterfeiters to distribute their 
products. The literature also shows that weak pharmaceutical regulatory systems, weak 
penalties, low risk of being caught, and high economic profits all provide reasons for 
the increasing trade in counterfeit medicines. 
The legitimate pharmaceutical industry is also affected by counterfeit medicines which 
could be seen in reducing profits, increasing the industry costs, and damage to the 
reputation of genuine medicines. The impact of counterfeit medicines extends to 
governments through undermining government agencies’ reputations, as they would 
been seen as not protecting the public from counterfeit medicines and reducing tax 
income. Patients are also affected by counterfeit medicines through therapeutic failure, 
increased resistance to some medicines and increasing morbidity and mortality. 
Correspondingly, some hope can also be seen for addressing the counterfeit medicines 
problem worldwide as exemplified by the efforts of international and national health 
and medicines agencies as well as of other non-profit organizations. At international and 
national levels, the WHO and many national medicines regulatory agencies like the 
MHRA began to combat counterfeit medicines with the cooperation of non-profit 
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organizations through publishing guidelines or strategies aiming to organize activities 
on tackling counterfeit medicines.  
The process of designing, developing and implementing such strategies could not be 
identified within these publications. This knowledge would be important for other 
countries trying to introduce their own strategies. Neither did such publications include 
the expected outcomes from such activities nor methods which could be used to 
measure these outcomes was not found in the publications.  
Whilst the role of health professionals (pharmacists and GPs) in combating counterfeit 
medicines is frequently included in such strategies, healthcare professional views on 
their training needs, potential contribution and preferred communication methods are 
unknown. 
 
2.5 Research aim and objectives 
2.5.1 Rationale 
While the incomplete and problematic nature of counterfeit medicines statistics has 
been correctly identified; it is clear that they are a significant danger to public health 
and the legitimate supply chain and that there is a strong reason to believe that this 
threat will grow in the future as more supply goes through the online route. Therefore, 
on a general level an anti-counterfeit medicines strategy represents a valid and 
important field of study. Furthermore, many of the activities to combat counterfeit 
medicines have been shown to involve different approaches and different levels of 
engagement revealing a lack of consistency of approach among jurisdictions as well as a 
lack of published evidence of some of these methodologies. The WHO evidence clearly 
demonstrated that counterfeit medicines are a greater danger in countries where the 
medicines regulatory system is weak; cooperation between the national medicines 
regulatory agencies would make them more efficient and address any weakness might 
they have (93).  
While there is also evidence of co-operation this can be ad hoc and periodic. A more 
comprehensive and systematic approach is needed which could be used by any national 
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medicines regulatory agency to strengthen its efforts in combating counterfeit medicines 
by putting in place a strategy which appropriately apportions responsibilities and 
describes roles and practices for its successful implementation and evaluation. The more 
countries which broadly align themselves in strategic terms the more international co-
operation there is likely to be and the more likely these activities are to be effective (5, 
93). Moreover, the absence of either empirical study of the experiences and perceptions 
of health professionals (pharmacists and GPs) in respect to counterfeit medicines, 
revealed in the process of conducting this review confirms that there is a need for 
exploratory inquiry in this area to identify these experiences and views including those 
on their own roles in combating counterfeit medicines and their communication with the 
national medicines regulatory agency. Finally, the researcher has a personal motive as 
part of his work duties is to run activities to combat counterfeit medicines at a national 
level for the Saudi Food and Drug Authority (Saudi-FDA).  
These reasons together offer a rationale for conducting a research study as potentially 
useful for evidencing and informing understanding of what might be key components of 
approaches to combating counterfeit medicines. These in turn could provide principles 
for informing the processes for developing a national strategy for combating counterfeit 
medicines including by any national medicines regulatory agency. 
 
2.5.2 Aim and objectives 
This research therefore aims to investigate current practice with respect to combating 
counterfeit medicines in UK in order to understand key components in developing anti-
counterfeit medicines strategies 
Therefore, the objectives of this research are: 
- To describe and understand the process involved in the development, 
implementation and evaluation of a national anti-counterfeit medicines strategy. 
- To describe and understand the views and roles of pharmacists and GPs in 
combating counterfeit medicines. 
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2.6 Conclusion 
Counterfeit medicines have been shown here to be a threat to public health all over the 
world. However, such medicines also can be seen to have consequences for 
pharmaceutical companies as well as governments. The literature review presented in 
this chapter shows that some activities have been undertaken to combat counterfeit 
medicines at an international and national level alongside efforts by non-profit 
organizations. However, the method of developing, implementing and evaluating those 
activities as well as the degree of cooperation among different partners involved in 
medicines supply chain is unknown. Also, the views and the roles of pharmacists and 
GPs in combating counterfeit medicines have not been identified in the literature. 
Therefore, research that addresses those issues is needed in order to help any national 
agency to develop its own strategy to combat counterfeit medicines. 
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3.1 Introduction 
This research aims to investigate current practice in the UK with respect to combating 
counterfeit medicines in order to inform future practice in these processes in any 
country where such a strategy is being contemplated. The key components for this 
research are the regulatory agency, the regulatory agencies stakeholders and the 
healthcare professionals. This is because it is these actors whose views can best inform 
an investigation into the development, implementation and evaluation of an anti-
counterfeit medicines strategy. Therefore methods need to be used which are considered 
appropriate for meeting the data needs of the research. 
When working in a complex multidisciplinary field, a researcher can adopt specifically 
selected approaches and use various research methods, involving “plans and the 
procedures for research that span the steps from broad assumptions to detailed methods 
of data collection, analysis, and interpretation” (94). Therefore, in order to select the 
research approach that fulfils the research question, researchers should understand the 
available research approaches, their strategies, methods and techniques. In light of that, 
researchers would be able to identify the research methodology that would suit the 
research objectives.  
This chapter will highlight the research methodology applied in this research; first by 
identifying the underlying research approach and then the related research strategy, after 
this is will explain the rationale behind the choice of the mixed-methods approach and 
the chosen methods of data collection and analysis. 
 
3.2 Research Approach and Design 
The research approach is derived from the researcher's beliefs, preferences, and past 
experiences each of which can influence how the researcher may conduct their research 
and the rationale behind their choices for their research strategy (95). These may be 
informed by one or more paradigms in use within contemporary relevant research 
communities. According to Bryman, a paradigm is “a term deriving from the history of 
science, where it was used to describe a cluster of beliefs and dictates that for scientists 
in a particular discipline influence what should be studied, how research should be 
done, and how results should be interpreted” (96). The research paradigm will therefore 
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frame the nature of reality (ontology); the relationship between this reality and the 
researcher (epistemology); and the various techniques applied when examining this 
reality (methodology) (97-99). A research paradigm is a set of basic tenets framing the 
ideas of the researcher about “What is the nature of reality?”, “What is the relationship 
between the inquirer and the known?”, and “How do we know the world, or gain 
knowledge of it?” (100).  
The research problem requires that data on the views, perceptions and practices of the 
key actors in the development, implementation and evaluation are collected and 
analysed. Different methodological approaches have been identified as guiding 
researchers in different research fields; these include: positivism, constructivism and 
post-positivism. Positivism based on the assumption that social phenomena are 
objectively measurable and can be analysed using scientific methods via generation and 
testing of a hypothesis, mirroring the natural sciences. Whereas, constructivism, which 
suggests that “truth is a particular belief system held in a particular context, and it is 
interested in the values which underpin the findings”, meaning that phenomena can be 
analysed and understood by experiencing things and reflecting on those experiences (96, 
101, 102). Therefore, constructivism claims that individuals (including researchers) 
construct (or interpret) reality based on their own subjective perceptions of the social 
world and that, in contrast to positivism, there is no one single objective reality. Post-
positivism is a paradigm that shares features from both constructivism and positivism. 
Post-positivism assumes that reality exists imperfectly and is open to different 
perceptions upholding the assumption that the researcher’s background, knowledge, and 
values combined with the theories they subscribe to can influence both what is observed 
and how they observe it. Post-positivism emphasises the importance of multiple 
research methods to gain a better picture of what is happening in reality (96, 97, 101, 
103, 104).  
The research in this thesis requires the post-positivist approach based as it is on data 
collected and analysed using both qualitative and quantitative research methods that 
have been selected in order to gain an understanding of the issues associated with 
developing, implementing and evaluating an anti-counterfeit medicines strategy. In 
determining the research strategy there are two approaches, quantitative and qualitative. 
Qualitative research methods “usually emphasize words rather than quantification in 
the collection and analysis of data” (96). On the other hand, according to Creswell, 
quantitative research approach is defined as “an inquiry into social or human problems, 
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based on testing a theory composed of variables, measured with numbers and analyzed 
with statistical procedures in order to determine whether the predictive generalizations 
of the theory hold true” (94).  
Qualitative research aims to study the phenomena in-depth using data gathering 
methods including among others: interviews, documents and participant observations, to 
gain understanding and explain a particular social phenomenon. Researchers conduct 
qualitative studies when they need to distinguish people from their environments and to 
understand their individual actions in these environments, something which is made 
possible through a process of communication. Qualitative research assists researchers to 
understand people, societies and cultural issues for which quantification is problematic 
and subjective data need to be collected and examined (96, 105, 106). 
From the perspective of analysis, quantitative research is associated with deductive 
reasoning, which progresses from the general to the specific and is referred to as a top-
down approach; whereas qualitative research approach tends to be associated with 
inductive reasoning, which goes from the specific to the general and is known as a 
bottom-up approach. A quantitative research approach is most effective where pre-
existing knowledge must be considered in order to be able to generalize the study’s 
findings; this allows the researcher to employ standardised data collection methods to 
document any prevalence. A quantitative study emphasises metrics as a basis for the 
collection of data and its analysis and usually derives and tests a model based on 
measurement to derive objective knowledge. In contrast, qualitative studies examine 
meanings in place of numbers during data collection and analysis and is concerned with 
questions of interpretation not numerical measures (102, 107, 108). 
 
3.2.1 Researcher bias 
All researchers have their own set of values and personal beliefs and these need to be 
recognised as it would not be feasible to entirely set these values and beliefs aside 
during the research process (96). As part of the post-positivist approach underlying this 
research it is important for the researcher to clearly state how researcher subjectivity 
and bias is inevitably present in this research and to understand its consequences. The 
researcher works as a pharmacist within another country’s medicines regulatory agency 
(Saudi Food and Drug Authority) with past working experience of the issue of 
Chapter 3: Research methodology 
 
PhD Thesis: Developing a national strategy for combating counterfeit medicines                  45 
counterfeit medicines. Therefore, it would not be possible to carry out this work without 
developing a personal perspective and set of assumptions regarding counterfeit 
medicines and how to combat them. When considering this data it is therefore important 
to recognise that the data collection and interpretation processes may have been affected 
by this perspective and personal assumptions. 
 
3.3 Research Strategy 
A research strategy is essentially a plan of action and is key to ensuring that the research 
questions are addressed in an appropriate manner consistent with all of the topics, 
questions and objectives of the research. The selection of a research strategy will be 
influenced by the research paradigm drawn on, the research approach adopted, the 
specific research aims and questions, the time and resources available, and the existing 
knowledge available to the researcher on the research problem being investigated (109).  
 
3.3.1 Mixed Methods Research  
Although normally associated with opposing epistemological beliefs and contrasting 
research strategies, qualitative and quantitative research approaches are not simply 
contradictory in terms of a researcher seeking to understand his/her field of study. In 
fact, it is increasingly recognised that each method presents different opportunities to 
access different kinds of knowledge which when combined offer a deeper understanding 
and richer interpretation (110). The nature of the research problem being investigated 
determines the choice of study approach as the researcher aims to build a wider picture 
of the phenomenon being studied. The selected approach should also enable the 
researcher to validate the research findings. For this research, it was concluded that a 
mixed methods approach offered the best opportunity to achieve the aims. A mixed-
method study is described as “research in which the investigator collects and analyses 
data, integrates the findings, and draws inferences using both qualitative and 
quantitative approaches or methods in a single study or program of inquiry” (111). By 
using mixed methods, a researcher is better able to build a wider picture of the 
phenomenon at hand and validate the research findings, while working within the 
inherent method limitations (96, 112). In light of that, to fulfil the research objectives, 
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both the qualitative and quantitative approaches have been used which defines this 
study as mixed-method research. 
In order to achieve the research objectives, in-depth study was needed to gain better 
understanding of the current practice with regard to development, implementing and 
evaluating anti-counterfeit medicines strategy, which required qualitative studies. Also, 
to gain the pharmacists and GPs views with respect to their roles in combating 
counterfeit medicines which required quantitative studies. According to Bryman, mixed 
method research is “a term that increasingly employed to describe research that 
combines the use of both quantitative research and qualitative research” (96). In using 
a mixed method approach, the researcher can discover more about the phenomenon 
being studied by combining the strong points of qualitative and quantitative research 
while at the same time compensating for the weaknesses in each method. The use of a 
variety of data collection methods applied to different sources can enhance the validity 
of the findings and reduce the inherent weaknesses of a one method approach.  
 
3.4 Research Design 
This research, therefore, combines qualitative and quantitative strategies in its research 
design. A research design is effectively a framework for the collection and analysis of 
data (96). Four main mixed-method research designs have been identified: triangulation 
design, embedded design, explanatory design, and exploratory design (94, 96, 106, 111-
113).  
Triangulation design refers to combining quantitative and qualitative methods to 
explore the same data set in order that the results can be mutually corroborated or at 
least compared.  
Embedded design has one data set playing a supportive secondary role in a study based 
primarily on the other data type. An embedded design is based on the premise that a 
single data set is insufficient, that a number of questions need answering, and that each 
type of question requires a different type of data to answer it.  
Explanatory design refers to using one set of data to explain the results from the other 
set of data. It is two stage date collection process, the first stage is quantitative data 
collection then the second qualitative data collection. This design is used to explain 
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significant (or non-significant) results from the quantitative data by using qualitative 
data.  
Exploratory design is similar to the explanatory design through using quantitative and 
qualitative methods in two stages; however, in the exploratory design qualitative data 
are collected firstly then quantitative data. The assumption here is that quantitative 
investigation is not appropriate until exploratory qualitative methods have put in place a 
foundation of understanding.  
This research shares characteristics with three of the above-described mixed-method 
research designs. Firstly, in conducting four separate studies, two qualitative and two 
quantitative, the research is aiming to bring the benefits associated with triangulation to 
this research. Secondly, in order to gain support for the findings from qualitative studies 
from quantitative investigations, this research also adopted an embedded mixed-method 
approach. A qualitative method was used in the first two studies (chapter 4 and chapter 
5) to gain better understanding of the phenomena being examined. Then, quantitative 
methods were used in chapter 6 and chapter 7 to support the understanding of the 
phenomena. Thirdly, this research is exploratory because significant aspects of the 
research problem concerning the development, implementation and evaluation of an 
anti-counterfeit medicines strategy have yet to be defined and this is understood to be 
the initial research into these aspects of the problem. This research design is also 
associated with post-positivism because the researcher’s motivations for and 
commitment to research are recognised as central and important to the research. Having 
said this the researcher avoids allowing prior knowledge and assumptions to lead to a 
dogmatic attitude to the research problem. Additionally, this research reflects the feature 
of post-positivism which recognises the value of both qualitative and quantitative 
methods either separately or combined together in mixed methods approaches. 
 
3.5 Research Methods 
In conducting research, researchers may select from a variety of methods available for 
data collection, such as observations, interviews, documents, field surveys and 
experimental surveys, which need to be appropriate to their research design. 
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3.5.1 Data collection  
Data collection is the basic process in any research project and is dependent on the 
study’s aim and objectives and is further influenced by the researcher’s environment. 
For a coherent study, the choice of data collection methods is based on its research 
objectives and underlying approach (96, 97, 102). As this research needed to acquire a 
deep understanding of the views of the participants regarding the counterfeit medicine 
issue, semi-structured interviews were appropriate for collecting data on the participant 
views as these would provide data in which participants could provide their own 
qualitative insights on their own experience facilitated by a conversation with the 
researcher. In addition, to provide measurable and descriptive data on the knowledge, 
understanding and experiences of a sample of both pharmacists and GPs working in 
England, i.e. quantitative data suggested that a questionnaire survey would be suitable 
to collect these data. The participant recruitment procedures for the interview-based 
qualitative studies involving MHRA participants and MHRA stakeholders are explained 
in chapters 4 and 5 respectively. The sampling methods used, and the implementation 
and administration of the questionnaires for the quantitative studies of pharmacists and 
GPs are explained in chapters 6 and 7 respectively. 
 
3.5.1.1 Qualitative data collection methods 
In qualitative research, personal semi-structured interviews are commonly used to 
collect meaningful and relevant information, enabling the researcher to gather large 
amounts of rich data relevant to the phenomenon under study. The qualitative data 
collected from MHRA representatives and MHRA stakeholders would be relevant to 
addressing the research problem because the participants can be viewed as experts 
capable of offering important insights into the processes of developing, implementing 
and evaluating an anti-counterfeit medicines strategy. Mason (2002) explains that the 
qualitative interview technique is usually recognised as a means providing meaningful 
and relevant information that would achieve research’s objectives (96, 102, 106, 114). 
Therefore, the personal interview method was adopted as a data collection technique as 
it met the requirements of the two exploratory studies involving MHRA participants and 
MHRA stakeholders respectively.  
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Having decided on face-to-face interviews the researcher must then select the 
appropriate format and technique for the interviews. This choice essentially involves 
identifying the most effective degree of structure along a continuum from structured at 
one end (suited to a research area where much of the information is known) to 
unstructured at the other (suited to a largely unknown research area) or somewhere 
between the two (semi-structured). Semi-structured interviews are well suited to this 
context as the researcher is cognisant of most of the issues in the field but would like to 
learn more from highly experienced practitioners and gather more in-depth data and a 
richer interpretation, as well as to learn of issues that he has not hitherto encountered. 
Face-to-face semi-structured interviews afford the opportunity for the researcher and 
interviewees to probe complex issues in depth and to clarify answers; developing a 
rapport will be necessary as some of the issues may be security-sensitive (96, 102, 106). 
Therefore, the data collection starts with two sets of semi structured personal interviews 
with participants from MHRA and participants from MHRA stakeholders (see chapter 4 
and chapter 5) that help in identifying issues associated with developing a counterfeit 
medicines strategy to be explored further and supported by the subsequent studies with 
pharmacists and GPs (chapter 6 and 7). In conducting the interviews and subsequently 
analysing the data the researcher was mindful that the counterfeit medicines issue might 
be considered as a sensitive issue for the country, and that the researcher might be seen 
by participants as an outsider (or an international audience) which may affect the data 
they communicate with the researcher, in that the participants (particularly those from 
the MHRA) may be more guarded in their responses than they would be in another 
environment.  
 
3.5.1.2 Quantitative data collection methods 
A survey method is a research strategy in which is used “at a single point in time in 
order to collect a body of quantitative or quantifiable data in connection with two or 
more variables” (96). The studies involving GPs and pharmacists needed to yield data 
on a range of issues concerning their practices and preferences apropos of counterfeit 
medicines and their possible roles in combating them. Such data need to have a 
reasonable degree of generalisability. The survey method is one of the commonest 
designs in social research. The survey is generally associated with a quantitative 
approach and allows gathering of a specific and limited range of quantitative data that 
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can be representative of the whole population at a low cost (98, 115-117). For 
quantitative data, a questionnaire survey tends to be a common strategy with which 
researchers can gain more control over the research process and can obtain 
representative findings that can be generalised to the whole population at a low cost. 
Therefore, a questionnaire survey was used in this thesis to support and elaborate upon 
some of the findings from the qualitative research such as confirming or not whether 
these health professionals agreed with MHRA representatives and MHRA stakeholders 
on matters such as the roles health professionals could play in combating counterfeit 
medicines. A questionnaire survey enables a lot of data to be collected from a relatively 
large sample of people in a short period of time and so is a highly practical research 
method. A self-completion questionnaire is convenient for the respondent and does not 
have the potential for interviewer variability which in this instance is beneficial (94, 96, 
102, 106, 118, 119). Hence, the qualitative study was followed by two quantitative 
studies using a questionnaire survey (chapter 6 and chapter 7) to help understand the 
roles of health professionals in combating counterfeit medicines.   
 
3.5.2 Data Analysis 
Having two methods of data collection and collecting both quantitative and qualitative 
data meant that two distinct methods of data analysis were also required. Together, the 
analysis of these data helped to build understanding of the current practice concerning 
counterfeit medicines in the UK with a view to generating findings and 
recommendations which may assist a medicine regulatory agency in the future 
development of anti-counterfeit medicines strategy. 
3.5.2.1 Qualitative data analysis methods 
The qualitative data analysis needed to produce findings on the views and perceptions 
of MHRA representatives and MHRA stakeholder participants on a range of issues 
related to the development, implementation and evaluation of an anti-counterfeit 
medicines strategy. Four main criteria were set for the selection of data analysis method. 
Firstly, it had to be a tested analytical technique for data collected using semi-structured 
interviews. Secondly, it needed to be highly systematic and provide an auditable 
process. Thirdly, it needed to be flexible enough to work with either an inductive or 
Chapter 3: Research methodology 
 
PhD Thesis: Developing a national strategy for combating counterfeit medicines                  51 
deductive approach. Fourthly, it needed to be within the capabilities of the researcher 
(98, 116, 120, 121).    
For the qualitative data collected using face-to-face interviews the framework analysis 
approach was used. This analytical technique falls into the broader category of 
qualitative content analysis or thematic analysis.  Framework analysis approach, has 
become widely used as a means of analysing primary qualitative data, particularly in 
fields of healthcare research and policy making research. The framework analysis 
approach has been highlighted as being a reliable and appropriate tool for research 
which has already been defined as highly focused, specific questions, a defined and 
limited timeframe, a sample which is pre-designed (e.g. professional participants) and a 
priori issues that require addressing. The framework analysis approach sees the 
researcher apply an analytical framework comprising codes and categories (also referred 
to as indexing) which are used to manage and organise the data. A thematic framework 
is derived from this into which the data are placed according to a process of charting, 
mapping and interpretation.  
 
3.5.2.2 Quantitative data analysis methods 
Quantitative data analysis is required to generate findings on the practices and 
preferences of healthcare professionals (pharmacists and GPs) on a range of issues 
related to counterfeit medicines. Quantitative data analysis is more standardised than the 
qualitative equivalent and as such involves less choice for the researcher with respect to 
which analytical tests should be applied to the data. Once the completed postal 
questionnaires were received back from respondents, the responses were entered into 
two software application for analysis: Microsoft Excel and the Statistical Package for 
the Social Sciences (SPSS) software. The data were summarised using descriptive 
statistics, a process which enabled the demographic characteristics of each group of 
respondents to be summarised and also helped detect outliers and entry errors (102, 
122). Following the descriptive statistics further analysis of the data was undertaken, 
mainly bivariate analysis to establish empirical relationships between two variables, 
mainly a particular characteristic with a behaviour or view. Fisher's exact test, chi-
squared analysis, the Mann-Whitney U test and Kruskal-Wallis test were each used.  
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3.6 Ethical Considerations  
The researcher should consider the ethical implications of their work to insure that their 
work does not harm participants or the public or infringe their rights. According to 
Diener and Crandall, researchers should divide their considerations of ethical issues into 
four areas: harm to participants, informed consent, invasion of privacy and deception 
(96, 123). In this study the researcher considered the implications of the research for the 
qualitative and quantitative study separately as in each case the implications were 
different. The risk of harm through participation in the interview studies was considered 
to be negligible but not zero. As either the MHRA participates or stakeholders 
participates in the research may have been perceived as having potential conflicts of 
interest or consequences which may have been negatively perceived by the participants. 
This risk was greatly reduced by both clarifying that the performance of the MHRA was 
not a line of inquiry for the study and by ensuring that the research was undertaken on 
an anonymous and confidential basis. Furthermore, the researcher anonymised any 
personally-identifying information, and where necessary to use direct quotations in the 
reports or publications, they were edited in such a way as to protect the identity of the 
speaker. 
The principle of informed consent was strictly applied in this research. For the interview 
study a signed informed consent form was obtained before each interview. For the 
survey questionnaire, completion of the questionnaire which was accompanied by an 
explanation of the nature and purposes of the study was considered informed consent. 
Giving informed consent does not mean giving up the right to privacy. Anonymity and 
confidentiality were the two main ways privacy was maintained (96). Also, all studies in 
this research were approved by University of East Anglia Faculty of Medicine and 
Health Ethics Committee (Appendices 1.1, 2.1, 3.1 and 4.1), no NHS ethical approval 
was required in this research. 
 
3.7 Conclusion  
The current study needed to describe and understand the process of the developing, 
implementing and evaluating an anti-counterfeit medicines strategy as well as describe 
Chapter 3: Research methodology 
 
PhD Thesis: Developing a national strategy for combating counterfeit medicines                  53 
and understand the views of pharmacists and GPs on their roles in combating 
counterfeit medicines. This chapter presented a detailed description of the research 
methodology used in this research and set out the key methodological choices made in 
order to arrive at a research design which matched the objectives of the research. After 
discussing the researcher’s epistemological standpoint and the choice of a post-
positivist approach, this chapter justified the choice of a mixed qualitative and 
quantitative design for this research based on the need to collect and combine findings 
from data from different samples in order to present a complete picture of the processes 
involved in developing, implementing and evaluating a national anti-counterfeiting 
medicines strategy and also to understand the views and describe the roles of 
pharmacists and GPs in combating counterfeit medicines. The main determining factors 
in the research design were the nature of the findings which needed to be generated. 
While the data from the MHRA representatives and the MHRA stakeholder participants 
needed to be rich and more nuanced and did not require generalisability, the data from 
the health professionals needed to cover a wide range of issues uniformly and with a 
reasonable degree of generalisability. This study was therefore designed to employ both 
qualitative and quantitative data collection techniques, specifically face-to-face 
interviews and a questionnaire survey. 
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4.1 Introduction 
In this study, the qualitative data collected from MHRA representatives is highly 
relevant to addressing the research problem because the participants can be viewed as 
experts capable of offering important insights into the processes of developing, 
implementing and evaluating an anti-counterfeit medicines strategy. Furthermore, their 
organisation has already developed two such strategies and could form a template for 
other countries. There are, however, certain gaps in knowledge concerning the 
development, implementation and evaluation of the MHRA’s strategy, and the study 
described in this chapter is intended to go some way to filling these gaps.  
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) is a 
government agency that is responsible for regulating all pharmaceutical products, 
medical devices and blood components for transfusion in the UK to ensure these 
products are safe and effective for consumers. The participants for this study were 
therefore staff and managers working at the MHRA whose place in the divisional 
structure of this organisation will now be described to provide context for the study. The 
MHRA also protects the public from the risks that are associated with medicines; 
including illegal and counterfeit medicines. The MHRA evaluate the risk-benefit ratio 
of products to ensure the benefits of the pharmaceutical products and medical devices 
justify any risks. To fulfil its responsibilities, the MHRA is divided into nine divisions: 
inspection, enforcement and standards (IE&S) division; licensing division; policy 
division; vigilance and risk management of medicines (VRMM) division; 
communications division; devices division; operations and finance division; human 
resources division; and information management division. 
1. Inspection, Enforcement and Standards Division 
This division is responsible for ensuring that the manufacture and distribution of 
medicines in the UK complies with the required standards. To ensure compliance, it 
subjects all UK manufacturers, wholesalers and medicine importers to licensing and 
inspection. The process involves examining clinical trials and toxicology laboratories. 
The Inspection, Enforcement and Standards (IE&S) division collects information about 
and examines potentially illegal advertising, manufacture, importation and sale or 
supply of human medicines. This can also lead to related activities, which sometimes 
extends to taking legal action. The IE&S division is also responsible for providing 
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services to the agency for laboratory testing, for distinguishing between medicines and 
products, assessing the import of unlicensed medicines, and ensuring that suitable 
actions are taken after any reports.  
2. Licensing Division 
Many responsibilities fall under the scope of the licensing division which focuses on 
examining and accepting or declining applications for marketing authorization for 
medical products, new methods of administration or new formulations for current drugs, 
generic drugs, parallel import applications, and non-safety variations to active licenses 
for medicinal products. It also has the responsibility to examine various medicinal 
products, which include high tech biotechnology product applications, chemical 
medicinal products, homeopathic and herbals. Its licensing responsibilities include those 
for examining and authorising clinical trials.  
3. Policy Division 
The policy division works with the other divisions to ensure the agency’s regulatory and 
public health mandate aligns with the external environment in which the agency works. 
The division works across the agency co-ordinating its regulatory approach and 
responding to developments. It also coordinates the agency’s EU and international 
business and its corporate strategy. 
4. Vigilance and Risk Management of Medicines Division 
The objective of the Vigilance and Risk Management of Medicines (VRMM) division is 
to protect public health by ensuring the safety, quality and efficacy of marketed 
medicines. The work of the division involves several inter-related functions including 
pharmacovigilance and pharmacoepidemiology, research and intelligence, benefit-risk 
review, access to medicines. This division’s responsibilities include ongoing vigilance 
in monitoring any health risks presented by marketed medicines.  
5. Communications Division 
The communications division helps towards the agency’s mission to safeguard public 
health, by ensuring that the agency communicates in a clear, accurate and timely way 
with all its stakeholders. The division has an enquiry line to provide information to the 
patients, public and others who have an interest in the MHRA’s work. It also maintains 
a publicly available internet website including detailed information on medicines and 
medical devices and operates a 24-hour press office. This division runs conferences and 
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events to explain MHRA work with its stakeholders. It also carries out market research 
to assess the needs of the agency’s stakeholders, and recommends actions to address 
those needs.  
6. Devices Division 
This division is responsible for all medical devices manufactured or marketed in the 
UK. All reports of illegal incidents involving such devices are made to the devices 
division. These reports are received from different parties including the UK National 
Health Service (NHS), private hospitals, care homes, manufacturers and from the 
public. The division gives healthcare practitioners adequate advice to make better use of 
devices and ensure safety.  
7. Operations and Finance Division 
All of the agency’s financial activities are controlled by this division. It assists the 
agency by ensuring customers are having value for money, distributing information, 
advice and assistance on financial issues. This division cooperates with other divisions 
of the agency to develop its own budgets. It will also assess and report on monthly 
budgetary performance and publishes accounts. 
8. Human Resources Division 
In cooperation with MHRA managers and staff, this division provides professional 
human resources services such as continuous learning and development culture. 
9. Information Management Division 
The responsibility for information management lies with this division. It entails the 
development and conducting of all aspects of the agency’s information management 
strategy, like e-Business and the General Practice Research Database.  
Some of these divisions might therefore have more or less direct involvement in the 
activities conducted by the MHRA to combat counterfeit medicines such as the IE&S 
division; whereas, some divisions might have a lesser degree of involvement in these 
activities, for example the policy division. Therefore, the view of participants from such 
divisions could be very helpful in developing a ‘big picture’ understanding of the 
process from the strategy development to the evaluation of an anti-counterfeit medicines 
strategy. Also, gaining their definitions of the function and duties of the MHRA’s 
divisions could help build a more precise understanding of their view on how such a 
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strategy would be implemented. It is from the above described organisational structure 
that two anti-counterfeit medicines strategies have emerged in the manner now 
described. 
In 2007, the MHRA published its first strategy to combat counterfeit medicines in the 
UK that covered the period 2007-2010. The MHRA titled it “Anti-Counterfeiting 
Strategy 2007-2010”, and it aimed to reduce the risks to patients and consumers in the 
UK from the threats posed by counterfeit medicines while increasing the risk to those 
behind this illegal activity. This strategy was based on three main streams of activity: 
communication, collaboration and regulation. Under this strategy the communication 
component was designed to reassure the public by providing it with timely, accurate 
information, as well as publicising contact numbers to report suspected incidents of 
counterfeiting. Collaboration was aimed at identifying products at most risk of being 
counterfeited, enabling resources to be targeted appropriately, ensuring timeliness of 
countermeasures by facilitating reporting and follow-up, and taking part in international 
initiatives aimed at combating counterfeit medicines. With the regulation element the 
MHRA aimed to disrupt the counterfeit medicines market and increase both the risk of 
prosecution and the severity of penalties for counterfeiting. Following its first anti-
counterfeiting strategy, the MHRA published its second strategy called the “Falsified 
Medical Products Strategy 2012-2015”, which was also aimed at protecting the public 
in the UK from the threat of counterfeit medicines. Like the first strategy, this one 
comprised three main components: prevention, incident management and investigation. 
Through prevention activities, the MHRA’s objective was to reduce how many 
counterfeit medicines entered the regulated supply chain in the UK. The purpose of 
incident management activities was to make sure that reported incidents of fake or 
counterfeit medical products were investigated quickly and efficiently, with the main 
focus on reducing the risks to public health. Finally, the investigation component aimed 
to implement the investigation and when necessary deploy all available legislative 
powers to bring prosecutions against those responsible for the manufacture, distribution 
and supply of counterfeit medicines and other medical products (25, 39, 44, 82).  
The literature review for this study found the UK’s MHRA to be the only national 
medicines regulatory agency that published an anti-counterfeit medicines strategy aimed 
at combating counterfeit medicines in a systemic manner. However, the process 
involved in the design, development and implementation of the strategy could not be 
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found within these publications. Such knowledge would be very useful for researchers 
into counterfeit medicines and policymakers in government or government agencies in 
other national agencies trying to introduce their own national strategy in this area. 
Furthermore, the reviewed publications omitted describing the desired outcomes from 
implementing the strategy something which would have been useful in devising suitable 
evaluation criteria. The setting of outcomes and their evaluation would enable the 
government, the agency, its stakeholder and the wider public form an opinion as to the 
effectiveness of the strategy. By clearly describing and explaining reasons for and 
experiences of the MHRA’s process of developing, implementing and evaluating its 
strategies from an insider viewpoint, one of the objectives of this study, an important 
research need would be satisfied.  
 
4.2 Aims and Objectives 
The aim of this study is to gain a better understanding of the views of MHRA managers 
and staff on the anti-counterfeiting strategies of the MHRA successively published in 
2007 and 2012, by exploring their views on its processes from development to 
evaluation.  
Therefore, the objectives of this study in relation to an anti-counterfeit medicines 
strategy are: 
- to explore the drivers for the development and implementation of an anti-
counterfeit medicines strategy. 
- to describe an agency’s process for development of its strategy. 
- to describe the processes through which a medicines regulatory agency 
implements its strategy. 
- to explore the likely form of the engagement with and involvement of 
stakeholders in the process. 
- to describe the strategy outcomes and how these should be evaluated. 
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4.3 Methods 
Face-to-face interviews were conducted with key persons from the MHRA to 
understand the perspectives from inside this organisation. This study focuses on gaining 
a more complete and complex understanding of the counterfeit medicines issues by 
drawing on the experiences of key participants at the MHRA through exploring their 
views on the issues associated with the anti-counterfeiting strategies of the MHRA and 
particularly on how such a strategy should be developed, implemented and evaluated 
including the participant perceptions of the roles of pharmacists and general 
practitioners (GPs) and other stakeholders. In this study a qualitative approach was 
selected to facilitate the collection and analysis of rich data, comprising their views and 
experiences which facilitates the highlighting of key values, and relevant language used, 
which in turn enables the generation of conclusions and recommendations (96).  
A semi-structured interview format was adopted as it offered participants the flexibility 
to pursue their own threads of thought, something important because of the exploratory 
nature of the study. The interview questions combined main questions asked of all 
interviewees with a set of sub-questions pertinent to each interviewee; using a question 
topic guide (Appendix 1.2). This approach gave the researcher more flexibility over the 
order for asking the questions and for pursuing topics of importance to each 
interviewee. The research question guide included the research questions designed to 
explore the knowledge, experiences and opinions of the participants relating to their 
strategy for combating counterfeit medicines. The researcher also referred to a set of 
optional sub-questions that could be used flexibly during the interview to clarify or 
gather more details on a certain point where the researcher saw the need to gain a deeper 
or more contextual understanding of that issue. 
 
4.3.1 Participant recruitment 
The main aim of this research was to explore the knowledge, experiences and opinions 
of key personnel from the medicines regulatory agency with respect to a strategy to 
combat counterfeit medicines. Starks and Trinidad (2007) argue that a purposive 
sampling method is suitable for recruiting participants who have experienced the 
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phenomenon under study (124). This research therefore recruited key personnel from 
the MHRA, who were organisation members in a position to have an overview of the 
work conducted by their agency, which could address the first objective of this thesis 
which was to describe and understand the process involved in the development, 
implementation and evaluation of a national anti-counterfeit medicines strategy. The 
purposive sampling approach here therefore aimed to recruit participants from the 
senior echelons and non-senior of staff within the agency, who should then have been 
well-placed to assist in identifying all the factors and characteristics seen as important 
for the agency in developing and implementing their anti-counterfeiting strategy. 
Mason (2002) states that sampling, data generation and data analysis are processes that 
should be conducted dynamically and interactively in order to develop a set of 
dimensions that focus on exploiting the participants’ experience (in this context, 
experience of anti-counterfeiting) (106). The participants were key personnel within the 
agency who were linked to activities that have been, are being or are planned to be 
undertaken in combating counterfeit medicines in the UK. The participants were 
identified by the researcher from the MHRA’s organizational structure and selection 
was based on their job description. However, some names on the proposed participant 
list were changed by decision-makers from the MHRA at the point   of seeking approval 
of this study. The participants received and signed a consent form. A preliminary 
questionnaire was used to gather demographic data (qualification, age group, work 
experience, etc.) in order to ensure that the sample was as diverse as possible. The 
sample comprised both males and females, having various work experiences. 
Eleven key personnel from the MHRA were successfully recruited for the interviews. 
All participants received the following: 
- An invitation letter explaining the nature, aims and implications of the study 
(Appendix 1.3). 
- An information sheet explaining the topic and organisation of the study, and its 
aims and intended outcomes, as well the implications of the study for the 
participants who wished to take part (Appendix 1.4). 
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- An Interview Consent Form to be addressed to the researcher, signed by the 
participant as confirmation that he/she has agreed to be part of the research 
(Appendix 1.5). 
After a positive response from a potential participant, the researcher arranged the date 
and time for the interview with him/her in the agency’s building.  
 
4.2.2 Ethical approval 
This study was approved by University of East Anglia Faculty of Medicine and Health 
Ethics Committee (Appendix 1.1) 
 
4.2.3 Research Questions Topic Guide 
The interviews with the MHRA personnel covered eight broad questions (Appendix 
1.2); six of these (Questions 2 to 7) focused on the core topic of the interview, and were 
designed to reflect the aim of the study. However, the researcher had other sub-
questions to be asked during the interview depending on the flow of the interview. 
These questions and sub-questions were developed by the researcher to 
comprehensively cover factors relating to the MHRA’s strategy to combat counterfeit 
medicines. However, the research team recognised that new factors might be added to 
this research following the interviews, depending on what the researcher learned.  
The first question in the interview “Can you please tell me about your role” was the 
opening question for the interview. The objective of this question was to give the 
participant the opportunity to talk about his/her responsibilities and experiences in the 
agency. Also, it informed the researcher of how long he/she had been in their current 
position to assist the researcher in identifying how the participant is linked to the 
various counterfeit medicine issues. Also, a personal opinion of the participants 
regarding the counterfeit medicines issues was asked as a warm-up for the main 
interview questions. 
Chapter 4: The MHRA perspective on developing an anti-counterfeit medicines strategy 
 
PhD Thesis: Developing a national strategy for combating counterfeit medicines                63 
The second question in the interview was the first question directly addressing the main 
research topic, aiming to elicit the participant’s understanding of how the agency views 
the counterfeit medicines issue. These MHRA participants were employed at about the 
time when the first strategy was developed. The researcher attempted, through the sub-
questions, to explore any relevant areas not spontaneously offered by the participants 
and to cover the factors that assisted in developing the views that had evolved inside the 
agency and assisted in identifying the precise factors that motivated such an agency into 
combating counterfeit medicines. This also pursued whether there were any changes in 
these motivation factors between the first and the second anti-counterfeiting strategies. 
The third question was aimed at gaining an overview of how the first MHRA anti-
counterfeiting strategy was formulated. The sub-questions highlighted the departments 
that were involved in the formulation process and why these departments were chosen. 
Moreover, as the MHRA’s Anti-Counterfeiting Strategy 2007-2010 was divided into 
three branches (Collaboration, Regulation and Communication) while the MHRA’s 
Anti-Counterfeiting Strategy 2012-2015 was divided into three different branches 
(Prevention, Incident management, and Investigation), the sub-questions attempted to 
clarify why these branches were chosen. Also, the sub-questions allowed the 
participants to talk more widely about the process of formulating the strategy. 
The fourth question focused on the implementation process of the counterfeit medicines 
strategy. The sub-questions sought to identify the departments that were involved in the 
implementation process; as well as, it identified what the participant thinks about the 
involvement of these departments and allowed him/her to talk about the factors that led 
to this selection. The sub-questions addressed the department managers’ general 
responsibilities in the implementation process.  
One branch of the MHRA’s Anti-Counterfeiting Strategy 2007-2010 was related to 
communicating with health professionals. Question 5 focused on the roles designed for 
pharmacists and GPs in the strategy to combat counterfeit medicines. The sub-question 
aimed to illuminate the way in which the MHRA communicated this role to them and 
what the participants thought of this communication. Besides these issues, the roles of 
other stakeholders were addressed in this part of the interview, including the manner in 
which those roles were communicated to them. 
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The sixth question related to the outcomes of the anti-counterfeiting strategy. In this, the 
researcher wished to identify the expectations of the MHRA toward the strategy. In the 
sub-question, the researcher emphasised the types of outcome that were expected and 
described by the participants. 
The seventh question was the last question pertaining to the core topic of the interview 
and explored the evaluation process relating to the outcomes of the strategy. The sub-
questions led the participants to comment on the criteria that will be used to evaluate the 
outcomes and the selection methods for these criteria. Moreover, the sub-questions 
allowed the participants to talk about the department responsible for the evaluation of 
and the justification for its selection. A sub-question was asked about the evaluation 
results of the MHRA’s Anti-Counterfeiting Strategy 2007-2010. 
Question 8 was the final question and was designed to give the researcher the 
opportunity to thank the participant for his/her time and to give the participant the 
opportunity to add more information or comments. Also, if the participant had any 
questions relating to the interview or the research, he/she was given an opportunity to 
put them to the researcher. Then, the researcher ended the encounter. 
 
4.3.4 Data analysis 
The data collected in this study were the spoken words of participants from the MHRA. 
Semi-structured, face-to-face interviews, with their use of open-ended questions, 
typically generate high volumes of data and as the participants can be considered 
experts in the field being studied the data collected could be expected to be highly 
relevant. With this in mind, a data analysis method was required which would enable 
the researcher to manage the data and also summarise and synthesise it, but do so in a 
transparent and systematic way. Resources on qualitative data analysis were consulted 
before the framework analysis approach was chosen (94, 96, 119). The framework 
analysis approach is now widely used as a means of analysing primary qualitative data, 
particularly when relevant to policy making (116). The  approach has been highlighted 
as appropriate for research which has specific questions, a defined and limited 
timeframe, a sample which is pre-designed (e.g. “professional participants”) and a 
priori issues identified from the outset as requiring to be addressed (115). However, the 
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researcher, as in most qualitative approaches to analysis, analysed the data by 
identifying the themes that emerged from the interviews. The further developed 
analysis, relating to the range of themes, was used to generate a theory relating to the 
anti-counterfeiting medicines strategy from the perspective of key personnel from the 
MHRA. The researcher anonymised any personally-identifying information, and where 
it was necessary to use direct quotations in the reports or publications, they were edited 
in such a way as to protect the identity of the speaker. 
Nvivo software was used for data analysis; the data transcripts were entered and then 
the software was used to generate codes from the data transcripts, which were 
subsequently grouped those codes. Then the researcher generated the themes emerged 
from the data manually. The researcher developed the themes from the codes that 
emerged from the software, thereby becoming more engaged with data, which greatly 
assisted the researcher in the data analysis phase. The codes generated and the themes 
emerged from that data were reviewed and supported by the supervisory team. 
 
4.3.5 Researcher training for interviews and on-going support 
To enable this research, the researcher was enrolled on the research methods courses 
that provided by Faculty of Medicine and Health Sciences, University of East Anglia. In 
addition, the researcher attended skills-specific qualitative research methods short 
courses, organized by NatCen Social Research Centre, focusing on interviewing 
methods. The researcher was actively supported by the supervisory team to ensure 
appropriate and accurate interview management and transcription from the outset. 
 
4.3.6 Structure of interviews 
It is important to ensure that the interview organisation can encourage an in-depth, 
freely-expressed discussion of sensitive issues. The researcher therefore conducted the 
interviews in a private room in the MHRA building at a time when the interview was 
unlikely to be interrupted. The interviewers had been ask for permission to audio-record 
the interview (an interview consent form have been signed by all participants). 
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4.4 Results 
This study included eleven key personnel from the MHRA, at different employment 
levels. A data saturation was reached from the semi-structured interviews lasting for up 
to 90 minutes were conducted with them by the researcher at the participants’ 
workplace building in London, UK. The study results started by exploring the 
participants’ views about the counterfeit medicines circumstances in the UK before the 
anti-counterfeit medicines strategy. Then, the drafting and implementing of an anti-
counterfeit medicines strategy were highlighted by the participants. Also, the study 
addressed the role of pharmacists and general practitioners (GPs) as well as other 
stakeholders in combating counterfeit medicines. Finally, the views of participants on 
the outcomes from an anti-counterfeit medicines policy and the methods used to 
evaluate those outcomes were discussed. 
 
4.4.1 Understanding the MHRA position before the anti-
counterfeit medicines strategy 
To understand the context in which an anti-counterfeit medicine strategy could be 
developed, the overall environment surrounding the decision-makers at the MHRA 
needed to be understood. The study therefore started by exploring the participants’ 
views regarding the counterfeit medicines issue, and then moved to find out how the 
problem of counterfeit medicine in the UK was perceived before the strategy was 
introduced. The participants then described the factors that they thought had motivated 
the decision-makers at the MHRA to develop an anti-counterfeit medicines strategy. 
They highlighted the factors that they perceived as key to the published strategy and 
discussed whether, in their view, there had been any changes to those factors between 
the first and the second of MHRA anti-counterfeit medicine strategies. The participants 
also described the limitations that they thought the agency encountered at the time the 
anti-counterfeit medicine strategies were being developed. 
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4.4.1.1 Individuals’ views on counterfeit medicines issue 
The participants explained their perceptions of the effects of counterfeit medicines on 
the public and on the health system drawing on their views regarding both its relevance 
and its prevalence in the UK pharmaceuticals market. They were able to express their 
views on the responsibility and reaction of the MHRA regarding this problem.  
The participants who voiced their perceptions of the effects of counterfeit medicines 
expressed strong feelings on the issue, all arguing that it represented a risk to public 
health and that it was innocent consumers who suffered the most from counterfeit 
medicines, and could potentially die as a result of consuming them. This feeling was 
consistently expressed at all levels of professional positions at the MHRA. The risk to 
the public from counterfeit medicines was seen by many participants as arising because 
such medicines were manufactured and distributed in conditions unregulated by the 
regulatory agency; also, these products may have contained ingredients that had not 
been approved by the agency. The perceived risk arising from such lack of control was 
clearly stated by one of the senior managers within the MHRA: 
“Counterfeit medicines are by definition a risk to public health. They’ve 
been made in conditions that are uncontrolled, so they can contain 
impurities. They can be defective because of the uncontrolled conditions of 
the manufacture, but they will also on occasions contain the wrong active or 
no active or the wrong amount of active substance.……… They’ll have been 
distributed under uncontrolled conditions” [MM09] 
Also, some participants considered that counterfeit medicines would affect the trust of 
the public in the health system. 
“It undermines the trust in the system, it undermines trust in pharmacists 
and doctors; it undermines trust in medicine.” [MD11] 
One participant qualified this by suggesting that the seriousness of the potential problem 
depended on the type of medicine, and whether or not it was categorized as being for a 
life-limiting condition or for a non-life limiting condition. 
“It depends on the medicine. I think if the counterfeit medicine is for a life-
limiting condition then I think that’s pretty unforgiveable to manufacture 
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and sell that type of medicine. I think if it’s for a non-life limiting condition 
then I would consider it to be similar to a counterfeit DVD or watch or 
something similar or counterfeit Coca-Cola or something else.” [MC04] 
The appearance of counterfeit medicines in the UK in the past was understood by most 
of the participants as starting with rare cases in the legitimate supply chain and then 
growing into a significant issue. It was seen as increasingly serious because now 
counterfeiting occurs with all kind of medicines. 
“They tended to be lifestyle drugs but we’ve seen over that time a move into 
mainstream drugs, including things like anti-schizophrenics and cancer 
agents.” [MP09] 
All the participants felt that combating counterfeit medicines was a central aspect of 
their work within the MHRA and took their responsibilities in doing so very seriously. 
They emphasised the need to work in a well-structured manner and to work together to 
safeguard the public from counterfeit medicines and prevent their spread as much as 
they could. 
“It’s probably the most important aspect of it we deal with at the MHRA 
because our objectives are to safeguard public health and I would imagine 
that’s the worst possible scenario where people are trying to counterfeit 
legitimate medicines.” [EP15] 
Participants emphasised their common belief in the dangers of counterfeit medicines to 
consumers and since it become a major issue they felt it had become an important task 
for the MHRA to tackle. 
 
4.4.1.2 MHRA views on the problem of counterfeit medicines in UK 
before the strategy 
The participants tried to explain how the counterfeiting problem was perceived as 
increasingly recognised by characterising a previous general attitude denial and a 
widely-shared feeling that everyone could have confidence in the supply chain because 
it was adequately overseen by the regulators. The participants described a change for the 
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worse of the appearance of counterfeit medicines in the UK market and the reaction of 
the MHRA to that change. 
This earlier attitude of denial was shared by the regulators and many within the 
industry, according to the participants’ interpretation of the situation. Most participants 
commented that no one spoke of the issue of counterfeit medicines in the UK or indeed 
in the Western world, believing that such harmful practices only happened in Africa and 
Asia. 
“In the past there was a perception that counterfeit medicines did not exist 
in the UK or European marketplace. So, within the MHRA, there was 
denial about counterfeit products.” [SM04] 
A few participants believed that the main focus of the MHRA at that time was on 
testing the quality of generic drugs against a brand leader, but there was no testing for 
illegal/counterfeit products. They also identified reluctance among regulators to 
recognise counterfeit medicines as a problem because they felt that they had a very well 
regulated system in the UK and that many within the MHRA lacked adequate 
knowledge of counterfeiting practices.  
“Also, because there was a lack of knowledge and also there was perhaps a 
feeling of if we ask too many questions we might get answers that we don’t 
want to hear.” [MI09] 
Denial was not only prevalent for regulators; it was also widespread within the 
pharmaceutical industry. The participants commented that the branded pharmaceutical 
companies appeared to them as being in fear of their products’ reputation from the bad 
reputation that might affect their brand from the counterfeiting. Therefore, those 
companies were dealing with any case of counterfeiting in a secretive way and not 
sharing information about this with the regulatory agency.  
“The industry was in denial as well because they didn’t want adverse 
publicity; they didn’t want to risk their reputation. If they did find 
counterfeits they’d keep it quiet, keep it to themselves, they didn’t want 
anybody to know” [SM04] 
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The regulator participants highlighted the feeling of confidence in the UK supply chain 
they perceived at the agency, saying that this was because of the regulatory system that 
was then in place; that the supply chain was secure, that MRHA conducted inspections 
regularly, and that therefore counterfeit medicines would not be found in pharmacies. 
Also, some participants recalled that in the past the regulatory agency believed if there 
had been any cases, it would have been reported by companies or through the patient or 
health professionals directly to the MHRA, so the agency will know about it. 
“If there were wide-scale counterfeits, we would know about it because 
MHRA have a very well developed adverse drug reporting system (called 
the Yellow Card System, which has been operating for 45 years), which is 
an adverse reporting system not just from healthcare professionals but also 
from the public; they can report directly into it.” [MM09] 
All participants stated that they believed that the MHRA decision-makers thought 
counterfeit medicines cases were limited to the internet market and possibly to non-
licensed markets such as pubs and nightclubs. Therefore the decision-makers had a 
feeling that such medicines would not be seen in regulated supply chain.  
“MHRA were aware that that the online market existed but we didn’t 
necessarily perceive it to be a huge problem in getting into genuine 
wholesalers and genuine pharmacies.” [MC09] 
According to the all participants, a wake-up call for the MHRA came when a number of 
counterfeit products suddenly appeared in high street pharmacies. In 2005, the MHRA 
decision-makers realized that the UK pharmaceutical market had changed and they 
began finding cases of counterfeit medicines in the regulated supply chain; also, these 
cases were on the increase. 
“Prior to 2005 there was almost nothing ever detected of counterfeit 
medicines, then, between 2002 and 2007, we had a succession of cases of 
identified counterfeits in the UK supply chain. So almost nothing and then 
14 cases (in the legitimate supply chain) in 4 or 5 years and we could see 
that this was a new position in the UK.” [MM09] 
The participants said they felt that the MHRA decision-makers then assumed that the 
problem of counterfeit medicines in the UK market would only grow, so that the 
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MHRA had to take the issue much more seriously. All participants thought that the 
MHRA had sufficient resources and an effective team that could start combating the 
problem before any other country. 
“MHRA have a very well-developed fraud team here and enforcement team 
and a big inspectorate. And because of that, MHRA became aware in the 
UK of the possibility that there were counterfeit medicines out there before 
a lot of other member states did.” [SC15] 
Participants perceived the MHRA as proactive and started to combat counterfeit 
medicines in the UK even before a strategy had been developed. Participants across all 
employee levels specifically stated that some initiatives were undertaken by the MHRA 
to tackle the issue even though they were not structured into a cohesive strategy. 
“Between 2004 and 2007, MHRA had, like, an informal in-house anti-
counterfeit strategy, if you like, so we had various areas of work which we 
were doing as a result of counterfeited cases.” [MI09] 
Overall, from the viewpoints of the participants, in the past there appeared to have been 
common denial across the regulatory agencies and pharmaceutical industries in western 
countries. This was explained by the perception of having a good supply system and 
effective reporting system in these countries; and furthermore for protecting the product 
image by pharmaceutical companies. Also, there was a belief among the decision-
makers within the regulatory agencies that the counterfeit medicines cases were limited 
to the internet and non-licensed channels. Once the MHRA found counterfeit medicines 
in the regulated supply chain in the UK, the MHRA started to take this seriously as a 
threat to public health and then launched activities to combat counterfeiting which 
began a few years before the strategy had been devised. 
4.4.1.3 Motivating factors in creating an anti-counterfeit medicines 
strategy 
To help consider what motivated decision-makers at the MHRA to develop a strategy to 
combat counterfeit medicines, the participants were asked to identify reasons for their 
decisions. Participants considered some of these motivating factors as external ones, 
whereas other factors were driven from within the MHRA as internal factors. Also, the 
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participants expressed how they thought these motivating factors affected the strategies 
developed. Finally, the participants described how they thought such motivating factors 
may have changed between the first and the second MRHA anti-counterfeit medicines 
strategies. 
The external motivating factors described by the participants as informing decisions to 
develop the strategy, were the appearance of the counterfeit medicines cases, the agency 
duty to protection of the public, securing the supply chain, and pressure from 
stakeholders. Most participants considered the increase in the number of counterfeit 
cases found by the MHRA (or reported to them) in the UK’s legitimate supply chain as 
the most important motivating factor.  
“Quite a lot of cases in the UK where they have actually reached the 
legitimate supply chain. So that was a driver really, to look at the resources 
and see if any more needed to be put into it, as a result of that, the strategies 
were developed.” [MP09] 
Other external motivating factors mentioned were the responsibility of the MHRA to 
protect public health and to secure the pharmaceutical supply chain in the UK. 
Moreover, some participants argued that some pressure from stakeholders on the 
MHRA in the form of inquiries as to how those stakeholders could protect themselves 
from counterfeit medicines had required the MHRA to do more to fight counterfeit 
medicines in the UK, something eventually leading to the production of the first 
strategy.  
“We faced questions from our Minister; parliamentary questions were being 
asked as well; and quite rightly, the members of the public, and the press. 
Also other stakeholders were then asking us the same questions. 
Wholesalers were also starting to ask, probably more from a point of view 
of 'how do we protect ourselves'.” [MI09] 
On the other hand, another group of participants thought that the MHRA’s decision-
makers did not develop an anti-counterfeiting strategy because of being exposed to 
pressure from the stakeholders but rather that this was driven by internal factors. 
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“No, I wouldn’t say there was any pressure from stakeholders – media, 
industry, wholesalers, the Government – on MHRA to fight counterfeit 
medicines.” [EP15] 
The internal motivating factors participants mentioned included the personality of the 
MHRA’s staff at that time and the support they had from senior management and 
persistent key individuals; they also thought the decision-makers saw the MHRA as 
holding a leading position worldwide.   
“The personalities of the people who drove the anti-counterfeiting strategy; 
we had some very good people and they saw what was going on, they saw 
the risk to public health, not only in the UK but worldwide, and they drove it 
through. So it was the persistence and the professionalism of a few key 
people within MHRA that drove it through, plus the backing of the board of 
directors, the executive directors.” [SM04] 
However, participants did not widely agree that the leading position of the organisation 
was a key motivating factor. Some participants thought that it was a factor in 
developing the strategy. 
“There’s certainly a pressure on the UK agency, as well on the US FDA, to 
try and drive the change forward because of the size of the agency and the 
respect we have within the regulatory authorities.” [MC04] 
Other participants did not think the leading position of MHRA had been a motivating 
factor for the decision-makers to develop such strategy. 
“There was no pressure on MHRA as one of the leading regulatory 
authorities worldwide to start developing a strategy. So, no any sort of 
signal coming down that 'we’re the MHRA, we’re the leader, we need to 
deal with this'.” [MI09] 
All the participants felt that the motivating factors mentioned here were reflected in the 
strategy, and tried to highlight this by giving examples (as stated by some of the 
participants) from the strategy that supported their view. 
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“It also talks about more international rules and actions that are supposed 
to strengthen the supply chain and as goods moving around from country to 
the end user. Then making it more difficult to get illegal medicines into the 
supply chain is a key thing, which is what ourselves and lots of the other 
agencies involved are thinking about.” [MC04] 
Some participants thought that there had been no changes in the motivating factors 
underlying the decision to develop the second strategy since the first strategy.  
“I don’t think there were any changes from that really. As I said, the second 
strategy document was just really an evolution of the first one.” [MP09] 
Participants perceived that counterfeit medicine cases in the UK supply chain, 
protection of the public health, securing the supply chain, and some pressure from 
stakeholders were the external motivating factors for MHRA decision-makers to 
develop an anti-counterfeit medicines strategy. The possible internal motivating factors 
mentioned were the personality of the MHRA’s staff, the management support and its 
world leading position. All participants felt that these motivating factors were reflected 
in the strategy while some saw no change in those factors between the two strategies.  
 
4.4.1.4 Limitations and boundaries on developing an anti-counterfeit 
medicines strategy 
To characterise what was said about the context for developing an anti-counterfeiting 
strategy, participants were seen to distinguish between the internal and the external 
limitations that decision-makers at the MHRA had to face when planning to develop the 
strategy. Most participants stated that the decision-makers had to deal with staff and 
resource limitations, a lack of communication and some resistance within the MHRA.  
“I mean obviously resources are limited and if you’ve identified a particular 
problem and you need resources to address it” [SC15] 
In terms of external limitations and boundaries, some participants stated that any 
regulatory agency should consider regional and international legislation and boundaries 
when developing an anti-counterfeiting strategy. Also, most participants thought a 
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regulatory agency needed support from other government agencies who may create 
barriers to effective actions and cooperation from the relevant industry.  
“There are certain areas where we might have wanted to do more but the 
legislation as it was then drafted from Europe wouldn’t permit us to do.” 
[SC15] 
Some internal and external limitations and boundaries were seen to challenge the 
decision-makers in any regulatory agency when developing an anti-counterfeit 
medicines strategy. Participants considered such internal limitations were staff and 
resources, the lack of internal communication and resistance within the agency. They 
stated the external limitations were about dealing with regional and international 
legislation and boundaries, having support from other government agencies and from 
industry. 
To summarize, participants described their perceptions of the context that the agency 
faced in deciding to develop an anti-counterfeit medicines strategy as a sense within the 
agency of the dangers of counterfeit medicines (to the public and to the health system) 
and its responsibility to tackle the problem. Also, participants said the denial attitude 
among the regulatory agency and pharmaceuticals industries and the believing in secure 
supply chain had been changed once counterfeit medicines had been found in the 
regulated supply chain. The MHRA started its activities to combat it even before the 
MHRA’s strategy developed. Thus, the agency started to combat counterfeit medicines 
activities by defining specific motivating factors (internally and externally) which led 
the agency to seek to develop an anti-counterfeit medicines strategy. Participants 
believed that decision-makers within an agency should understand its limitations when 
developing such a strategy. 
 
4.4.2 Drafting an anti-counterfeit medicines strategy 
The preceding sections have built some understanding of the overall environment 
surrounding the decision-makers at the MHRA for devising an anti-counterfeit 
medicines strategy, as interpreted by the participants. This section covers the process of 
drafting an anti-counterfeit medicines strategy, using the MHRA’s strategy as an 
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example. These participants described the process of drafting the MHRA’s anti-
counterfeit medicines strategy offering their thoughts for what they believed could be 
done to improve the strategy drafting process. Participants also highlighted the role of 
the MHRA anti-counterfeiting stakeholder groups. Finally, participants illustrated their 
views on any differences between the content of the first and second MHRA anti-
counterfeit medicines strategy. 
 
4.4.2.1 The process of drafting an anti-counterfeit medicines strategy 
The actual process of drafting the first and second MHRA anti-counterfeit medicines 
strategy was described by only a few participants; however, the remaining participants 
did indirectly express some ideas about the drafting of these strategies. The department 
that led in drafting the strategy and the departments involved in the drafting process 
were illustrated by the participants. Also, participants identified the stakeholders who 
had a role in the drafting process and highlighted various aspects of the process.  
A few of the participants who were not directly involved in the drafting process were 
able to articulate what they thought took place. All of these agreed that the 
responsibility of leading and drafting an anti-counterfeit medicines strategy should lie 
with the enforcement department within Inspection, Enforcement and Standards (IE&S) 
Division. 
“I think it was written mainly by the enforcement group” [MC09] 
Those participants nonetheless had varying views regarding the departments that were 
involved in drafting the strategy. Participants identified certain other departments within 
the IE&S division which were involved, specifically the Inspections Department as they 
were practitioners and they can reflect the situation in the field and secondly the 
Defective Medicines Report Centre as it received the reports for defective products. 
Also, other divisions within the MHRA were included; participants stated the Vigilance 
Risk Management of Medicines (VRMM) Division as it deals with reports received 
from the public and health professionals and can help in detecting the signals of any 
counterfeit medicine in the supply chain. The communication division was also 
mentioned as being part of the drafting in so far as they were responsible for the 
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communications delivered from the MHRA to its stakeholders. There was a mixture of 
opinions among the participants about what part was played by the policy division; 
some of the participants thought the policy division was part of the drafting process as 
they were perceived as playing an important role in it. 
“I’m just saying that drafting those sorts of documents is where the policy 
function skills should be brought to” [SC15] 
Other participants did not see the policy division as playing a part in drafting. However, 
on their view, the policy division had only viewed the first draft of the strategy and 
checked whether there were any legal conflicts in it. A final group of the participants 
did not see the policy division as having any role in the drafting the strategy. 
“Personally can’t see a reason why policy should be involved” [EP15] 
Some participants described stakeholders involved in the strategy drafting process as 
including representatives of the police, customs and pharmaceuticals industry. Others 
suggested that there were some other kinds of input as a consultation from similar 
national regulatory agencies and international pharmaceutical organizations.  
“I’m not quite sure and I would imagine they would have representation on 
our policy, you know, somewhere or another, I don’t know whether they 
come here or not but we will certainly seek their advice I would imagine” 
[MC04] 
The participants not directly involved in the drafting the MHRA’s anti-counterfeit 
medicines strategy appeared to assume that the drafting process was conducted by an 
internal committee within the MHRA. This committee was led by the enforcement 
department and included the departments that they mentioned before as having had a 
role in the drafting process. As described by the participants, this committee held initial 
consultations with industry and other stakeholders and asked for their input. This 
committee also conducted consultations between themselves and other divisions, then 
compiled the first draft and held the second round of consultations with industry and 
other stakeholders and took their feedback. Finally, the committee would complete the 
strategy and sent it to MHRA’s top management for approval. 
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“I imagine we would have consulted with industry and the security people 
within pharma companies” [MC04] 
The actual drafting was described by only few participants, their account sharing some 
features described by those not directly involved in the drafting process. In drafting the 
MHRA’s strategies, there was no drafting committee organized by MHRA decision-
makers for this task. Instead it was led and carried out mainly by a few people from the 
enforcement department within the division of Inspection, Enforcement and Standards 
(IE&S) as mentioned by participants describing the actual process of the drafting. 
Participants gave reasons for this as being that the anti-counterfeiting strategy deals 
with a very specific crime and the enforcement team has the ability to deal with it. 
“The drafting was by this Division [IE&S] because of the specialist nature 
of the content” [MM09] 
“People in the enforcement group are from a law enforcement background 
……. and we know what to look for to spot the indications of people that 
are counterfeiting” [EP15] 
Participants stated their understanding that the enforcement team had some input in 
terms of comments from other MHRA’s division and departments (the communication 
division, the inspectorate, the Defective Medicines Reporting Centre). The MHRA’s 
legal advisors also provided some legal consultation on the strategies. While the policy 
division within MHRA did not play a role in the drafting stage as mentioned by a 
participant; however, this participant believed that MHRA’s strategy was not therefore 
seen as suffering from this. 
“You might have expected that the drafting of a strategy like that would be 
done at least in close collaboration with the policy division. On this 
occasion it wasn't. ………. However, this did not affect the document.” 
[SC15] 
The people who were drafting the strategy within the enforcement team were not seen as 
having consulted any stakeholders. Instead, the drafters identified the MRHA 
stakeholders in relation to counterfeit medicines during the drafting process. Those 
stakeholders were identified as the key pharmaceutical companies, the pharmaceutical 
organisations, and other UK law enforcement departments. Then, it was reported that 
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this drafting team tried to understand from their experiences the stakeholders’ 
expectations of the MHRA in combating the counterfeit medicines issue in the UK and 
the elements in an anti-counterfeit medicine strategy those stakeholders expected to find 
in the strategy. The drafters also drew on the previous experiences of the enforcement 
department in drafting the strategy as highlighted by a senior manager. 
“What do they expect from us, what would they look for in a strategy, what 
do we need to communicate then, but it was very much ourselves drafting 
that” [MI09] 
Before the drafting process, the enforcement group were seen as already realizing that 
counterfeit medicines had become an issue in the UK which needed to be addressed. 
Participants mentioned most activities as included in the strategies had actually been put 
in place and begun to be used to tackle counterfeiting before the strategy had been 
developed. The people who were drafting the strategy reviewed and grouped those 
activities; organizing them in a structured way to build a strategy. 
 “a lot of the processes we had already started, we just hadn't formalised 
them. So it was really a case of us looking at it, right what are we doing, 
why are we doing it, what is it achieving and let’s draw those things into 
the strategy” [MI09] 
The first draft, as described by the participants, was then shared within the IE&S 
division, in particular the Inspectorate department and Defective Medicines Reporting 
Centre, for comments on the first draft. The drafters then sought evaluation feedback on 
the first draft and any amendments seen as necessary were implemented. 
“After the draft has gone out, ‘this is the approach we’re taking to this’, 
you know. And their comments would come back, we’d make amendments” 
[MD09] 
The next step was for the drafting team to send out the strategy to the MHRA’s senior 
executive team and non-executive board for approval and signing off and then to 
publish it. This process of the drafting the anti-counterfeiting strategy was seen to be 
repeated by the drafting team to the MHRA’s first and second strategies. 
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“The drafting of the first and the second strategies were following the 
same procedure” [MD09] 
Nonetheless, those participants who explained the actual drafting of the strategies also 
recommended potential improvements for developing an anti-counterfeiting strategy, in 
what they referred to as an ideal world. One idea was to set up a drafting committee 
which involved various key players within the regulatory agency. 
“It would be healthier if you had a small committee that sat from various 
parts of the agency to develop the drafting of the strategy” [MD09] 
Participants suggested that the members of this committee could be from various 
departments within the division of Inspection, Enforcement and Standards (IE&S) 
Division like the enforcement department, the inspection department, the laboratory 
department and, the Defective Medicines Report Centre. The committee could be joined 
by other divisions like pharmacovigilance division, policy division, and the 
communications division. They saw inspectors' input as needed because inspectors were 
the practitioners in the field and could help in many ways like collecting information 
and samples. The role of the laboratory would be to help to plan for the testing 
capabilities which would create an understanding of the best and quickest way of doing 
the analysis and sharing the results with other members. They saw policy involvement 
as needed to ensure the strategy was well written and raised no legal conflicts. However, 
this view of the role of the policy division in the drafting committee was not shared by 
all participants. Pharmacovigilance division input in the drafting was seen as valuable as 
reports of drug side effects come to them, and they could detect any signal suspicious 
counterfeit cases in the supply chain from these reports. Most participants recognised 
that help from the communications division in wording and writing the strategy could 
make it easy reading for the public and other stakeholders and in developing a 
simplified way to communicate it. In contrast, the communications division was seen as 
not having any role in the drafting stage particularly as the committee could involve 
lawyers to help at the drafting stage for the legal advices. The licensing division was 
also seen as helpful at the drafting stage to identify products which might be at high risk 
of counterfeited as seen by one participant. Participants believed the involvement of 
those departments and divisions in the drafting activities would increase the sense of 
ownership of the strategy. 
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“I think it would engage multiple disciplines across the agency, because 
everyone has I suppose one part or several parts that they can bring 
together to help culminate and drive a strategy or produce a strategy” 
[MC04] 
Most of the participants said the chairing of the committee should be left to the 
enforcement department. One participant highlighted another view that the drafting 
committee could be led by the policy division. According to him this gives the 
enforcement department a more objective view as they are the most significant 
contributor and would be challenged internally about their thinking and their processes. 
Participants identified stakeholders able to play an important role in drafting an ideal 
anti-counterfeiting strategy as pharmaceuticals manufacturers, wholesalers, distributors, 
brokers, and the pharmaceuticals importers, police and customs. Patient groups were 
also seen as having a role in the stakeholder group, as able to assist the committee in 
understanding the motive factors that encourage people to obtain medicines from 
outside the regulated supply chain and put themselves at risk in so doing, and if best 
methods of overcoming this behaviour could be included in the strategy. Participants 
stressed the drafting committee should have some degree of engagement with 
stakeholders. They suggested this would necessitate trust, sharing of information, 
working together, and understanding each other’s agenda and priorities. The drafting 
committee was seen as needing to undertake consultation and ask for input from 
stakeholders at the outset of the drafting stage. This initial consultation could be 
conducted by the chair of the drafting committee through meeting with each stakeholder 
group and asking them for their ideas. Participants also warned that open forum 
consultations involving all stakeholders could be risky because of conflicting interests 
among the stakeholders. After the initial consultation, the drafting committee would 
formulate the strategy and then request another round of consultation. Participants 
highlighted that the decision-makers should consider timing, resources, energy and 
effort needed when conducting a consultation in drafting anti-counterfeiting strategy. 
These recommendations from those participants who played a direct part in the drafting 
of the MHRA’s anti-counterfeiting strategies echoed the views of other participants 
regarding the development of the MHRA’s first and second strategies. They underlined 
that the agency should having a committee to draft such a strategy within the agency 
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and of interacting with the stakeholders to understand their expectations and to learn 
from their experiences. 
 
4.4.2.2 MHRA's Anti-counterfeiting stakeholders group 
Some participants drew attention to the role of the MHRA's anti-counterfeiting 
stakeholder groups, which they thought could usefully play a part in the developing an 
anti-counterfeit medicine strategy. This was a group formulated and chaired by the 
Inspection, Enforcement and Standards (IE&S) Division; having started its work in 
2006 before the first MHRA anti-counterfeit medicines strategy had been published. Its 
members were drawn from MHRA’s stakeholders (branded pharmaceutical 
manufacturers, generic pharmaceutical manufacturers, wholesalers, importers and 
parallel traders) and representatives from MHRA (from enforcement, inspection, and 
laboratory departments); and representatives from UK’s law enforcement agencies 
(from police and from customs). Pharmaceutical organizations were also represented in 
the group by the Pharmaceutical Security Institute (PSI) and the General Pharmaceutical 
Council (GPhC). The group was meeting twice a year, chaired by the enforcement 
department within IE&S Division. 
“an anti-counterfeiting stakeholders group had been formulated by MHRA. 
….by 2005 (sic) the first meeting that was chaired by MHRA was started. 
The stakeholders involve in this group are UK-police, UK-customs, 
pharmaceutical manufacturers (branded and generic), wholesalers, 
importers” [MI09] 
According to the participants, the MHRA set up this group in order to build trust 
between the stakeholders and to exchange information and intelligence regarding the 
counterfeit issue in the UK and the wider world and furthermore, to target resources 
where the risk of counterfeit medicine was greatest. One participant saw an essential 
output from the anti-counterfeiting stakeholders group, as “a watch list of medicines”; a 
term used in the MHRA’s strategy documents, as a key element for combating 
counterfeit medicines in the UK. The “watch list of medicines” usually comprised 
twelve or fourteen medicines at high risk of being counterfeited based on the most 
recent intelligence from the anti-counterfeiting stakeholders’ group members. However, 
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one participant believed that the watch list was not as helpful as expected. He thought 
that the counterfeiters would shift their activities from the medicines on the list to other 
medicines.  
“if there’s a watch list of products I think the counterfeiters will turn to the 
other products not on the list” [MP09] 
Some participants saw the anti-counterfeiting stakeholders group formulated by MHRA 
can be helpful in the drafting stage of an anti-counterfeit medicines strategy. So during 
the initial phase of the drafting stage the drafting committee could request suggestions 
and input from that group. These suggestions can be used for drafting the strategy and 
then drafting committee could begin a wider consultation phase. 
Some participants mentioned the MHRA's anti-counterfeiting stakeholders. This group 
was set up by the MHRA before its strategy was published with the objective to build 
trust and share information among stakeholders. Participants said an outcome from this 
group was used by MHRA in its strategy; and that this group could be more helpful in 
the drafting committee for an anti-counterfeit medicines strategy. 
 
4.4.2.3 The difference between the first and the second strategies 
Participants seemed to make very similar observations about what differences they 
recognized between the first and the second of the MHRA’s anti-counterfeit medicines 
strategies. Participants had described the first strategy as the foundation that steered the 
direction of the agency whereas the second strategy was the development of the first one 
which was building on the resultant experience. 
“From my perspective it was always the first one that really steers the 
direction of the agency. The second one is just adding a bit of details” 
[MD09] 
All participants saw the key components of the two strategies as similar. However, 
participants considered the difference between the first and the second strategies were 
only in grouping and presenting of those activities within the strategy.  
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“So I think it's, the activities are probably pretty similar, I think it’s just the 
way of grouping them slightly differently” [MC04] 
In the first strategy, the three main elements were strands around communication, 
collaboration and regulation. At that time of drafting the first strategy, the MHRA was 
tackling counterfeit medicines which were something new in the UK. The MHRA’s aim 
in terms of communication was to ensure stakeholders including both the public and 
healthcare professionals have sufficient information about counterfeit medicines, how to 
avoid them, and how to report any related suspicions to the MHRA. For the 
collaboration part MHRA focused on close working relationships with its stakeholders 
and other regulatory bodies to ensure an awareness and recognition of the threat from 
counterfeit medicines, and encourage collaborative working where appropriate. In the 
regulation part, the MHRA planned to conduct a threat assessment of the risk from 
counterfeit medicines and to prepare market surveillance projects. Therefore, it seemed 
sensible to participants that the strategy should be built around these three elements 
which would help the decision-makers to build more knowledge on respect of the 
counterfeiting in UK market.  
“In the first one we didn’t know the extent of the problem. We needed to 
have a much better understanding of the counterfeiting business” [SM04] 
Some participants agreed that the first strategy provided more description of what the 
MHRA was doing to address the counterfeiting problem, some saw the second strategy 
as explaining more about why the MHRA was undertaking these activities.  
“the first strategy is more about actually the what we were doing – 
communicating, collaborating or regulating – whereas the second one is 
probably more to do with why we’re doing it” [MI09] 
Some participants also highlighted some enhancements had been made in the second 
strategy in respect to the activities of the changes relating to the supply chain and more 
details had been added to the incident handling, and financial investigation activities 
due to the international nature and the international implications of the counterfeiting 
medicines crime which had developed from the experience of the MHRA in applying 
the first strategy. 
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 “So a lot of the strategy is similar, we've just fine-tuned it, but incident 
handling was the big thing we wanted to point out, and also we wanted to 
point out the financial investigation and we increased our capacity to do 
financial investigations.” [MI09] 
Participants believed the first anti-counterfeit medicines strategy was a milestone for the 
MHRA which directed the activities of the agency. The main activities within the first 
and the second MHRA’s strategies were viewed as the same, however, participants 
stated the grouping of those activities was different.  
Summarizing participants’ views on drafting an anti-counterfeit medicines strategy, 
only a few were directly involved in actually drafting the strategies, but the others had 
some indirect ideas about drafting these strategies. Participants involved in the drafting 
process offered some recommendations to improve the drafting of an anti-counterfeit 
medicines strategy which were reflected in ideas offered by the other participants. These 
suggested that the drafting process should be led by the enforcement department within 
the agency, and a drafting committee should be composed of members from diverse 
departments and divisions within the agency. They also thought the agency’s 
stakeholders should play a consultancy role during the drafting of an anti-counterfeit 
medicines strategy. Participants stated that MHRA stakeholders, representatives from 
the MHRA, representatives from UK law enforcement agencies and representatives of 
pharmaceutical organizations were brought together to compose an MHRA anti-
counterfeiting stakeholders group. An outcome from this group (“a watch list of 
medicines”) had been used in the anti-counterfeit medicines strategy; in addition, 
participants believed this group could play more roles in drafting the strategy. 
Participants believed the main activities to combat counterfeit medicine within 
MHRA’s first and second strategy were the same, but that there were differences 
between both strategies in how those activities were grouped. 
 
4.4.3 Implementing an anti-counterfeit medicines strategy 
By 2007, the MHRA had approved, published and was implementing its first anti-
counterfeit medicines strategy. This section examines participants’ comments on the 
implementation of the first MHRA’s strategy. They specifically identified the 
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departments responsible for directly managing and implementing it, those playing some 
role in implementing it, and the implementation process and their opinions on it. 
 
4.4.3.1 The departments leading the implementation 
A few participants said the overall ownership of the anti-counterfeit medicines strategy 
should lie with the top management of the agency as it is the agency’s strategy and their 
success as an agency for combating the counterfeit medicines in the UK is bound 
closely to the success of the strategy. In relation to running and implementing the 
strategy, all participants stressed that the IE&S division particularly its enforcement 
department, should lead here with its head being mainly responsible for running it.  
“The implementation – the primary responsibility still stays within this 
Division [IE&S] and with the Enforcement group within this Division 
[IE&S]” [MM09] 
Participants explained their reasons for seeing it as essential for one person to be 
responsible for the implementation of the strategy because implementing this kind of 
strategy involved multiple departments could fail without communication between 
departments or the overall process could break down. This did not mean that the 
responsible person would do all the work, but would ensure that the strategy runs 
smoothly and there are good communications between the departments involved in the 
implementation.  
“this person is responsible’ and then they don’t necessarily do the work for 
the implementation but they liaise with the departments and make sure that 
they're doing the appropriate work and communicating appropriately with 
one another” [MC04] 
Also, they saw implementing this strategy as requiring a person who fully understands 
the counterfeit medicines issue and understands what the agency is trying to achieve. 
Participants also selected the enforcement department to implement the strategy because 
many activates within the strategy seen by them are part of the enforcement 
department’s duties and in general part of IE&S div
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“the implementation I think would always come down to our IE&S division 
because we've got the biggest stake in it” [MI09] 
Furthermore, participants saw the IE&S division as having the biggest role in the 
strategy because this is the only division within the MHRA actually dealing with the 
medicines in practice, with the enforcement department which dealt most with incidents 
of counterfeiting that are reported to the MHRA, supporting participants' view of the 
enforcement department as the right department to implement this strategy. 
 
4.3.3.2 Departmental roles in implementation 
The anti-counterfeit medicines strategy was seen by participants as cutting across 
several departments within the agency, therefore besides the enforcement departments 
responsible for the implementation they thought other departments should have a role. 
“So within the agency I’d say most divisions have a role in making sure that 
the strategy is implemented” [SM04] 
They saw three other divisions as having relevant roles: the policy division, the 
communication division and pharmacovigilance division. In addition to those divisions, 
some other departments would have a more indirect role in the implementation as 
highlighted by the participants.  
The policy division within the agency was seen as linking the MHRA with other 
government ministries, therefore their main task would be informing other government 
departments about the new regulations which would be applied by the MHRA to reflect 
the strategy.  
“the implementation of the strategy required changes to our guidance and to 
our legal position, then policy would be a key interface for doing that” 
[MM09] 
Also, participants believed if the anti-counterfeit medicines strategy needed any change 
in current legislation, the policy division would negotiate on behalf of the MHRA with 
other government agencies, so the change would support the implementation of the 
strategy.  
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“Interviewer: you mentioned the Policy Division – is the Policy Division a 
part of the implementation? 
Respondent: Yes they are because where the implementation of the strategy 
required changes to our guidance and to our legal position, then policy 
would be a key interface for doing that” [MM09] 
Moreover, as the UK is a member of the European Union, changes to medicine 
regulations in UK must also be consistent with overall European legislation. Therefore, 
the policy division was seen as playing a significant role to make sure that any change 
to the MHRA’s medicine regulations as a result of the implementation were not in 
conflict with the European arena. 
“The other thing is that a number of these medicines have been European 
authorisations, not strictly UK so of course then that brings in the European 
element, the European Medicines Agency and those issues as well” [MP09] 
Participants saw the role of the Communication Division as being to support the 
enforcement department in implementing the strategy by communicating with the 
MHRAs’ stakeholders, raising public awareness and dealing with media in general.  
“the Communication Division has worked closely with us you know both in 
terms of for instance the public awareness but also Enforcement activity 
generates a lot more press interest and media interest than most other 
areas. So the Communications Division have supported Enforcement in its 
responding to television and radio and the press and so on” [MM09] 
However, they thought this role ought to be carried out in close contact with the 
enforcement department as the message may contain some words that are not suitable to 
the audience as participants highlighted. That is because the communication division 
does not have technical knowledge about the problem and therapeutic knowledge about 
potential impacts on the public. Therefore, within MHRA, the enforcement department 
was working very close with the communication division in the implementation of its 
role.  
“I mean I have seen cases where communications have been drafted initially 
by the press office but sometimes they contain content which is unsuitable, 
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you know, they might talk about tablets as being pills or they might 
dramatize the potential risks. The issue is probably that no-one in the press 
office is a pharmacist or a law enforcement person, they’re communication 
people” [MP09] 
Participants described how the pharmacovigilance division (VRMM) dealt with reports 
via a system of ‘yellow card’ warnings sent from health professionals and the public to 
the MHRA. They can detect any flags or signals of any suspicion of counterfeit 
medicines from those defect reports or lack of efficacy reports which they receive and 
then report these cases to the enforcement department when they consider something 
unusual. Therefore, the pharmacovigilance division played an important role in the 
implementation of the strategy as described by the participants. 
“VRMM, they're the ones that may detect the signal of hang on a second 
we've got a batch that we’re getting a lot of reports for lack of efficacy we 
need to make sure that that’s flagged as a defective medicine, not 
necessarily a counterfeit, and then we would investigate or we would 
basically refer on to case referrals to look into further” [MC09] 
Participants also mentioned other departments could taking specific roles in the 
implementation of the strategy: the laboratory department helping through analysing the 
samples of suspicious items and by developing quicker and efficient techniques for 
analysis; the inspection department especially Good Distribution Practice (GDP) 
inspectors would be part of the hands on implementation as members of the MHRA 
working in the field and visiting pharmaceuticals warehouses view pharmaceutical 
shipments at first hand to see what is actually being traded, stored and distributed. 
Participants recognised that because of resource limitations, the inspectors only 
managed to obtain a snapshot of what was happening but they still felt this was valuable 
in monitoring counterfeit medicine cases, as those inspectors can evaluate how the 
warehouses following the MHRA’s regulations and also can judge some of those 
warehouses need more monitoring. 
“It’s only a very small snapshot because there’s a limited number of them – 
but you know we can see and they can go and they can see maybe which 
wholesalers are less willing to follow the rules perfectly well and more 
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willing to bend them and then maybe we could be more suspicious about 
how those wholesalers may act” [MC04] 
Dealing with counterfeit medicine cases required the MHRA to undertake prosecutions 
as part of implementation, therefore, the finance department and government lawyers 
were also seen to play a role in the implementation as seen by participants. 
“Finance obviously have a role because we’re a very expensive division. 
When we’re doing a prosecution, a big prosecution, then we will have 
Queen’s counsel which is very very expensive, you know, it’s thousands and 
thousands of pounds” [SM04] 
Therefore, to sum up, the participants underlined their views about who could play a 
role in the implementation of an anti-counterfeit medicines strategy, namely the policy 
division, the communication division, pharmacovigilance division and the inspection 
and finance department as all important for implementation an anti-counterfeit 
medicines strategy. 
 
4.4.3.3 Implementation process of an anti-counterfeit medicines 
strategy 
Participants reviewed their perceptions of the managers' performance in the 
implementation process of the MHRA’s anti-counterfeit medicines strategy. Generally, 
all divisions and departments within the MHRA were reported as having to work 
through an annually-published business plan. That for the IE&S division had objectives 
fed through from the various departments within the division. The enforcement 
department's plan set out their intended objectives, some of which would relate to the 
implementation of the anti-counterfeit medicines strategy which would then cascade 
into the objectives of individual people within that department whose annual appraisal 
would review these objectives against their performance measured on meeting the 
objectives. Ultimately, the working out of the strategy was broken down into and 
dependent on specific tasks that individuals undertook. 
“Enforcement is a group within the Inspection, Enforcements and Standards 
Division – and Enforcement would publish a business plan each year which 
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indicates the actual objectives that they intend to complete within that year 
and a number of those objectives would relate to the implementation of that 
strategy and then that would cascade down to the objectives of individual 
people within that group and they would be subject to an annual review of 
their objectives and their own performance would be measured on the basis 
of those objectives and so on. So ultimately the outworking of the strategy 
ends up with jobs that individuals have to undertake” [MM09] 
However, for the implementation of the strategy to be agency-wide it was recognised by 
some participants that the implementation needed to be ‘joined up’ and communication 
between the departments with a role in the strategy was seen to be crucial; therefore, the 
whole agency would need to work together to combat counterfeit medicines; 
participants stressed failure to do so would mean that things can get lost and forgotten. 
As the enforcement department is responsible for implementation, the head of 
department’s success or failure depends not just on his or her own department but on 
other departments as well. 
“you need to make sure that, as a whole, you're all joined up so that you 
know the communication is there from the start is to, yes we’re going to run 
this strategy so we want to implement it so therefore you need to have that 
communication between each department, rather than ‘OK you work in a 
silo, you work in a silo, you work in a silo’, you're having that 
communication across the board” [MC09] 
To make sure the strategy was well implemented participants thought each department 
with a role in the strategy should have a contact person or project leader for the anti-
counterfeit medicines strategy. Those persons should have regular meetings or even 
email communication for regular feedback and updates on the implementation to ensure 
continuous communication. 
Participants who commented on the strategy implementation judged that the managers 
involved in the implementation of the first MHRA’s anti-counteracting strategy were 
working well. They justified this opinion by pointing out that members of the 
enforcement department had been asked to participate in conferences, workshops and 
symposiums to reflect the experience of the MHRA in combating counterfeit medicines; 
also that their European counterparts felt the need to adopt a similar approach to the 
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MHRA regarding combating counterfeit medicines. They saw also the decrease in the 
number of counterfeit medicines as an appropriate measure of the good implementation 
by managers. 
“I think we did well to implement the strategy” [MI09] 
“I would kind of reference the activities at European level, the very strong 
belief that we had a very effective anti-counterfeiting approach” [SC15] 
To sum up, participants agreed that the implementation of an anti-counterfeit medicines 
strategy would be the responsibility of the enforcement department within the 
Inspection, Enforcement and Standards (IE&S) Division as having the main role and 
interest in the strategy with the policy, communication and pharmacovigilance 
divisions. In addition, laboratory department, inspection department and finance 
department could play a specific role in the implementation of the strategy. Participants 
highlighted the importance of communication between those divisions and departments 
to ensure effective implementing of an anti-counterfeit medicines strategy. 
 
4.4.4 Roles of pharmacists and general practitioners (GPs) 
and other stakeholders in an anti-counterfeit medicines 
strategy 
This section of the research findings will cover the contribution of the pharmacists and 
general practitioners (GPs) in combating counterfeit medicines as those who deal 
directly with patients. Participants described the role of pharmacists and GPs in an anti-
counterfeit medicines strategy and roles which might have been played in the strategy 
by other MHRA stakeholders. 
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4.4.4.1 Pharmacists and General Practitioners (GPs) and the anti-
counterfeit medicines strategy 
Participants’ views on the pharmacists and the GPs roles in the strategy against 
counterfeit medicines have been addressed along with what decision-makers within an 
agency should consider when defining those roles and how those roles should be 
communicated to the pharmacists and GPs. 
Some participants saw the role of the pharmacists and GPs in the strategy as rather 
limited, especially for the GPs because of their lack of physical contact with medicines. 
They also saw pharmacists and GPs as not having enough knowledge about the 
counterfeiting issue. 
“there is a lack of knowledge and understanding because most doctors don’t 
handle the medicines themselves, they just write a prescription, they never 
see the medicines” [SM04] 
However, other participants said the pharmacists and GPs acted as gatekeepers to 
patients, so that their roles would in fact be very important in the strategy. 
“They have clearly a duty of care towards their patients or their customers . 
. . . So I think they’ve got a very fundamental role in the whole work” 
[MC15] 
As a role pharmacists could play to protect patients from the counterfeit medicines, 
participants thought pharmacists should be vigilant about medicines’ packaging and 
printing and to actively consider that those medicines about which they receive a 
complaint from patients might be counterfeited, after discounting other reasons.  
“we want them to think is I've looked at all possible other solutions, really 
can’t work this out, maybe we should just consider if it’s a counterfeit” 
[MI09] 
Another important role for the pharmacists mentioned by all participants was to be a 
source of reporting of any incident to the MHRA either as a lack of efficacy as a 
medicine or as a counterfeit case. The pharmacists could report to the MHRA through 
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the tools promoted by the MHRA which are the Yellow Card scheme, the MHRA’s 
Counterfeit Hotline and the Defective Medicines Report Centre. 
“Pharmacists are involved in the sense that they are the final point often 
between the supply chain and the patient and Pharmacists need to be aware 
– to report any suspicions that they have” [SC15] 
They also thought it important for pharmacists to ensure that they sourced their 
medicines from a secured supply chain. 
“It’s about ensuring that where they’re sourcing their medicines from is 
reliable and trusted and probably authorised and a licensed source” 
[MD09] 
A final role identified for the pharmacists was to perform an awareness and advisory 
function for their patients, about buying from online sources or advising and reassuring 
the patient in the case of a particular medicine being recalled.  
“So I think they’ve got a very fundamental role in the whole work about you 
know buying medicines on-line and the dangers associated with counterfeit 
medicines” [MC15] 
Participants identified GPs as having a similar role to pharmacists again in terms of 
being vigilant for any suspicion of counterfeit cases reported to them by patients, also as 
a good source of reporting to the MHRA through the Yellow Card scheme, the 
MHRA’s Counterfeit Hotline and the Defective Medicines Report Centre. GPs had a 
role as an awareness and advisory source for patients.  
“Doctors - we would see them as well as a potential reporting source” 
[MD09] 
Participants also raised points to be considered by decision-makers when defining the 
roles of pharmacists and GPs in combating counterfeit medicines. As participants 
generally saw the pharmacists and GPs as largely unaware and they needed better 
communication from the MHRA. 
“they’ve got to tell them more than once because those people I saw had 
never heard anything, they didn’t have a clue what was going on” [EP15] 
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Also, as pharmacists and GPs were considered by participants as very busy people they 
needed quick access to the information and more engagement from the MHRA. 
“For me it’s about quick access to the information that they need and in a 
format that they are most receptive to” [MC15] 
The requirement for patient-pharmacist and patient-GP confidentiality needed to be 
appreciated by the MHRA decision-makers including when pharmacists and GPs 
reported a case to the MHRA.  
“But if they were to give information regarding counterfeiting or any 
suspicions of counterfeiting, they need to be assured that it’s completely 
confidential. So they have to be given that sterile corridor to be able to talk 
to someone without any comeback on them at all” [EP15] 
Also, they believed that pharmacists and GPs needed to be confident that any case 
reported to the MHRA will be treated very seriously. 
“we have I think developed a more 24-hour approach to reporting incidents 
or sort of mechanisms that actually encourage people to report and 
encourage them to believe that we will take seriously what they have 
reported” [SC15] 
Finally, participants drew attention to the small but possible incidence of corruption 
among these two groups which they thought the MHRA needed to consider when 
deciding what information to share.  
“I’ve dealt with corrupt pharmacists- not many, obviously-, you know, who 
have dealt with counterfeit so you’ve got to be very careful what 
information you share” [EP15] 
Participants recommended a few methods of communicating their roles in the strategy 
to pharmacists and GPs. Participants said the media tools can and have already been 
utilised for this.  
“we use a number of what we call media tools to get information out to 
Healthcare Publications – so for example we might put out what we call it a 
press release to the Media to highlight to them a particular issue and we 
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send that from our own office via e-mail and that goes directly to the e-mail 
address of the journalist so that they get the information through that route” 
[MC15] 
Participants identified those media tools which could be used to communicate the roles 
of pharmacists and GPs to them as press releases to the general media or, being 
selective, to each professional publication like pharmaceutical journals.  
“we can be quite selective and say ‘right, there’s a real issue here for GPs 
to do x, y and z and therefore we may just contact the Trade Publications 
for the GP Media and get them in for a briefing or we may send information 
out to directly to them on e-mail” [MC15] 
They also thought MHRA’s website could be used by sending emails to the subscribers 
for MHRA news updates and using the local radio and newspapers, particularly those 
published in other languages. 
“I think local radio, local newspapers and because now of course you’ve got 
Polish newspapers, Spanish newspapers, all kinds of things” [EP15] 
However, the level of resource available to the agency was an important factor in using 
the media tools. Participants stressed that media tools were not guaranteed to provide 
the pharmacists and GPs with the messages that the MHRA would like to send to them 
as this was highly dependent on them reading these emails and also depended on the 
media to deliver the messages.  
“there’s no guarantee that they’ll cover the story or write a story about it or 
broadcast a story about it. So because clearly it depends on the news 
agenda of the day, it depends whether their editor likes it or not” [MC15] 
An additional potential method, participants suggested to be used to communicate with 
the pharmacists and GPs was working with their professional bodies (like the Royal 
Pharmaceutical Society) as they were responsible for regulating them and could be more 
efficient in delivering the messages. Participants saw working with the professional and 
regulatory pharmaceutical body as more effective than working with the equivalent GP 
body. 
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“we don’t have responsibility for regulating either of those groups of people 
so we would work through the bodies that do regulate and to try get the 
message out, you know, that’s been more effective with the Royal 
Pharmaceutical Society than it has with GPs” [MD09] 
The final method mentioned by participants to engage with pharmacists and GPs was 
through the training tools as the issue of counterfeit medicines could be brought to 
pharmacists’ and GPs’ attention in e.g. undergraduate courses. 
“I mean I think as an undergraduate so you’re putting it on the radar of 
pharmacists at an early stage” [MD09] 
Participants thought the MHRA could contribute in delivering the message about the 
counterfeit medicines issue to pharmacists and GPs through other kind of training tools 
like workshops, conferences, seminars and forums organized by their professional 
bodies. They also saw the MHRA as able to work with professional bodies to make the 
counterfeit medicines issue part of their Continuous Professional Development (CPD) 
Programmes; as they have to participate in continuing professional development and 
they have to undergo an assessment by their professional body. 
“We could maybe do some kind of continuing professional development 
module for Pharmacists or Doctors because they all have to do CPD – some 
kind of regular development on the latest ways and key messages in anti-
counterfeiting or something like that” [MC04] 
Participants had some concerns about the efforts being made by the MHRA to deliver 
the message on the roles of the pharmacists and GPs. They believed the pharmacists and 
GPs were not getting sufficient information from the MHRA and thought more effort 
can be made in this area. 
“they didn’t seem to get a lot of information really and I’m not quite sure 
how much information we give them. Which I don’t think is good enough 
really” [EP15] 
Up to this point participants were seen to describe the roles of the pharmacists and GPs 
in combating counterfeit medicines as about being vigilant for any suspicion of 
counterfeit cases, being a good source of reporting to the medicines regulatory agency 
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and having an awareness and advisory function to the patients as well as needing to 
source their medicines from the secured supply chain. Also, elements seen as needing to 
be considered for their roles were needing to counter their general unawareness of the 
counterfeit medicines issue by better communication from the medicines regulatory 
agency and quick access to the information, given their very busy routines. However, 
the medicines regulatory agency needs to show that it respects the confidentiality of the 
reporter, show the seriousness in dealing with this issue and the amount of information 
shared with the pharmacists and GPs regarding counterfeit medicines issue were also 
among those elements. To communicate their roles in the strategy to pharmacists and 
GPs, participants recommended using media tools, working with their professional 
bodies and training like undergraduate courses and CPD. 
 
4.4.4.2 MHRA’s stakeholders and the anti-counterfeit medicines 
strategy 
Participants gave illustrations of their views regarding MHRA stakeholders in respect to 
the anti-counterfeit medicines strategy and their roles in combating counterfeit 
medicines in general and methods they thought could be used to communicate these 
roles to them. 
Participants defined the MHRA stakeholders within the pharmaceuticals industry as 
manufacturers, wholesalers, distributors, brokers, parallel importers, importers and 
exporters together with the law enforcement agencies like police, customs and border 
agencies. Other organizations like the Pharmaceutical Security Institute, Interpol, the 
World Health Organisation, and the General Pharmaceutical Council were also 
identified as stakeholders. Furthermore, the broader UK government, MHRA’s 
international counterparts, patient groups and transportation companies were added to 
the list of MHRA stakeholders. All these stakeholders were seen as being able to play 
various roles in the anti-counterfeit medicines strategy. 
The roles that could be played by the stakeholders were highlighted by the participants 
as securing the supply chain, protecting public health, sharing information, reporting to 
the MHRA, being vigilant and working in collaboration with the MHRA. Participants 
thought manufacturers and traders working in the pharmaceuticals industries should 
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work together and with the MHRA to secure the medicines supply chain from the 
manufacturers to the patients.  
“our view is that all the stakeholders should do their bits to secure the 
supply chain … everyone has to do their little bit to secure their part of the 
supply chain” [MI09] 
Participants also identified the MHRA as working with industry, police, customs, 
border agencies, and broader government in general in protecting public health. 
“The Police and clearly you know they have a role in protecting Public 
Health as well and we would work closely with them” [MC15] 
Sharing information between stakeholders was stressed by participants as being 
important. Some participants saw that MHRA as having a good record of cooperation 
and sharing information with industry, wholesalers, police, and custom, also 
organizations like the Pharmaceutical Security Institute, Interpol, the World Health 
Organisation, and the General Pharmaceutical Council.  
“the information you get and the more stakeholders and relevant 
stakeholders that you’re engaged with, the more little pieces of information 
you pick up that help you adjust to the way that these guys are operating” 
[MD09] 
Stakeholders were also seen as having a role to be vigilant for any suspicion of 
counterfeit cases so as to help secure the supply chain and protect public health. They 
saw all stakeholders with a role in the supply chain of the medicines, such as 
wholesalers or distributors, as needing to be mindful of the vigilance aspect of their 
work and to have training programmes for their workers on that aspect. 
“I suppose that the stakeholder side of things is more, kind of, the vigilance 
aspect of we know it. so I suppose it’s really around the vigilance side of 
things of, you know, wholesalers being vigilant of who they're receiving 
product from” [MC09] 
Participants also identified reporting any suspicions or cases of counterfeiting to the 
MHRA as one of the stakeholders’ key roles. Stakeholders in the pharmaceuticals 
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industry like wholesalers and parallel importers might come across a case of suspicion 
of counterfeit medicines which they should report to the MHRA. They also believed 
that police and customs should report any case of counterfeit medicines beside the other 
medicine related crimes, to the MHRA. Also, as the medicines are transported through 
private companies, these companies would have a duty to report any suspicions to the 
MHRA. 
“there’s Transport Agency and stuff like that because, obviously, these 
products have to be couriered and transported around, so if there’s 
concerns with a transportation company, that they're doing something that 
they shouldn't be doing, then again they may be able to give us information” 
[MC09] 
A final role shared among all MHRA stakeholders, according to the participants, was to 
work collaboratively to help the MHRA to combat counterfeit medicines. 
“We work with other regulators because we don’t have jurisdiction in 
countries outside the UK but they do, so we’ll work closely with other 
regulators and we’ll work with groups like Interpol – which are 
international Police activities and we’ll work with people like the World 
Health Organisation who also has an international role. So dealing with 
pharmaceutical crime has to be an international, cross agency activity” 
[MM09] 
Participants thought that the MHRA could make use of the media to communicate 
the stakeholders’ roles and also that a  manager from the MHRA could participate 
in stakeholder gatherings such as forums, or MRHA team members could make 
presentations to the stakeholders; so the message can reach to those stakeholders. 
“at an international level there would be the permanent forum on 
international pharmaceutical crime. We’d send a manager there to do that” 
[MD09] 
Participants defined stakeholders for the MHRA’s anti counterfeit medicines strategy as 
including the pharmaceuticals industry to other enforcement agencies and at the 
international level. They saw stakeholders’ roles as being to secure the supply chain, 
protect public health, sharing information, to be vigilant, reporting to the MHRA any 
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suspicions and working in a collaborative manner. Also, by using the media and 
engaging with the stakeholders, the MHRA could effectively communicate those roles 
to the stakeholders. 
 
4.4.5 Outcomes of an anti-counterfeit medicines strategy 
The MHRA had published its first anti-counterfeit medicines strategy in 2007 and the 
second strategy was published in 2012. These participants highlighted the outcomes that 
decision-makers in the medicines regulatory agency had or should have expected from 
an anti-counterfeit medicines strategy and how outcomes should be formulated in the 
strategy. 
 
4.4.5.1 Outcomes to be expected from an anti-counterfeit medicines 
strategy 
The participants described the outcomes that the decision-makers within an agency 
should be seeking from an anti-counterfeit medicines strategy. They stressed the 
importance of setting the objectives from the outset, as this would direct the efforts and 
resources to the said objectives and also publicly indicate that the agency is working 
hard to tackle the counterfeit issue. 
“it gives you, you know, you’ve then thought about in advance what you're 
going to measure against and then it gives you something to focus your 
measurement against at the end” [MI09] 
The first outcome from the strategy highlighted by some participants was changing 
people’s behaviour and perceptions as an outcome from an anti-counterfeit medicines 
strategy.  
“….. to really try and help influence behaviour and you know change 
people’s perceptions if that's what we want to do” [MC15] 
Participants appeared to understand that an agency needs to undertake many activities 
within the strategy to raise public awareness of the dangers of counterfeit medicines on 
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the consumer’s health, including buying from un-regulated online sources. These kinds 
of awareness-raising activities should also be targeted at the agency’s stakeholders and 
could be extended to an international level. The activities have the dual purpose of 
changing people’s behaviour and perceptions and gaining more visibility in the eyes of 
the public and industry showing that the medicines regulatory agency is combating 
counterfeit medicines. 
“We want to see evidence of a growing awareness in the public of the risk of 
Internet purchases of product” [MM09] 
Another strategy outcome wanted from the strategy which was shared by all the 
participants was to make the pharmaceuticals supply chain more secure. They perceived 
the agency as trying to strengthen the supply chain and make it very hard for 
counterfeiters to put their counterfeit products into the supply chain. 
“…strengthening the supply chain or making the supply chain secure is a 
key” [MC15] 
Also, they saw the agency as looking to their anti-counterfeit medicines strategy to 
improve collaboration and information sharing among all those stakeholders involved 
with the medicines business. All participants saw working together nationally and 
internationally as important for helping in the fight against the counterfeiting of 
medicines.  
“I think that’s really what we’re trying to achieve is that we need to work 
together with industry, with the public to identify any falsification but also 
prevent the falsification in the first place” [MC09] 
All participants reported that protecting public health through decreasing the risk of 
counterfeit medicines to the patients would be another desirable outcome from the 
strategy. 
“if we don’t safeguard public health then any strategy you put up is out of 
the window” [EP15] 
Another outcome from the strategy seen as important was reducing the number of 
counterfeit medicine cases in the supply chain 
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“I think the outcome would be that we minimise the number of counterfeit 
medicines that get in the legal supply chain” [MC04] 
However, the reduction in the number of counterfeited products in the supply chain 
should, according to the participants, be treated with caution as it might not be seen by 
itself as an indication of the success of the strategy. Therefore, the declining incidence 
of counterfeits should be taken as a percentage of the overall number of cases the 
agency look at. A few participants even disagreed with the idea that the number of 
counterfeit cases could be seen straightforwardly as an outcome of the strategy, since 
many other factors could be involved; for example, the criminals have not targeted the 
country or the agency could not see the counterfeit products in its supply chain.  
“the number of cases you get are dependent upon the intelligence you 
receive, whether your country is being targeted or not by the counterfeiters 
and there are many other factors. So you can’t say we will decrease the 
number of counterfeit medicines in the UK by X per cent” [SM04] 
Participants said the agency has been unable to devise suitable key performance 
indicators for the number of counterfeiting cases in the supply chain. 
“All we know of the ones that we’ve found are not the total that are out 
there” [SM04] 
Participants also saw as a good outcome the agency seeking to changing the legislation 
and the regulations by the government to make them stronger in relation to counterfeit 
medicine crime, not only at the national level but also internationally through the 
government (in this case within the European Union). 
“The fact that we’ve got a European directive that now actually expands 
European legislation, or extends it, means – and that we have played a 
leading role in making sure that that legislation is as we wanted it to be” 
[SC15] 
Convicting people for counterfeit medicine crimes and sending them to prison with 
strong sentences was another hoped-for outcome from an anti-counterfeit medicines 
strategy. 
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“some outcome measures and we looked at the number of convictions we’d 
had during the time of that strategy, so the people we’d prosecuted for 
counterfeit medicines cases” [MI09] 
Some participants’ final desired outcome was an increase in the number of the incidents 
freely and openly reported to the agency by its stakeholders. 
“if they report it to us freely and openly then that would be an outcome” 
[SM04] 
In response to the possibility that the decreasing number of counterfeit medicines cases 
reported in the supply chain (as an outcome from the strategy) could be seen by 
outsiders as the agency not working hard enough to combat the counterfeit medicines, 
all participants believed that this claim could not be accepted as the strategy has helped 
the agency more to actually make people think twice about putting counterfeiting 
medicines in the supply chain. This assumption was justified by participants because 
they saw the strategy increase the activities of market surveillance through more testing 
medicines, increasing risk for counterfeiters through more stakeholders’ engagement, 
increasing awareness throughout the supply chain players and the public. Also, it is 
because more people within the agency are become dedicated to this issue. 
“you’ve got not only us, not only the public, not only Healthcare 
professionals you’ve also got industry who are looking very carefully . . . . . 
So it’s not true that in any way we’re less vigilant” [MM09] 
However, a view was mentioned by some participants that an agency might face a 
decrease in the number of cases reported. They said this could be a result from the 
efforts made by the agency causing the counterfeiters to become more careful in their 
activities and hence being detected less often.  
“I think that’s one of the key things to evaluate is to say ‘well are we getting 
as much falsification’, not necessarily, I suppose, it’s a double-edged sword 
with that, because have we driven it more underground so we’re not getting 
reports and we’re not seeing it, or is it that we've actually reduced it” 
[MC09] 
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Participants posited what types of outcomes the agency’s decision-makers should expect 
from an anti-counterfeit medicines strategy, namely: changing people’s behaviour and 
perceptions to counterfeit medicines; more securing of the supply chain; increased 
collaboration and sharing of information among stakeholders; increased public health 
protection from counterfeit medicines; decreasing the number of counterfeit medicines 
cases that reach the supply chain; more tightening of the legislation and regulations; 
more convictions of people involved in this crime; and growth in the incidences 
reported to the agency. 
 
4.4.5.2 Formulating the outcomes expected from an anti-counterfeit 
medicines strategy 
Participants appeared to implicitly query the means of formulating outcomes during the 
drafting stage of the MHRA’s anti-counterfeit medicines strategies in expressing their 
view of outcomes to be expected from an anti-counterfeit medicines strategy. 
Participants stated that the outcomes from the MHRA’s anti-counterfeit medicines 
strategies were not included within the strategy. The MHRA’s hoped-for outcomes were 
written in a general way within the strategy as being to increase the risk to those 
involved in counterfeiting and protecting the public by decreasing the incidence of 
counterfeit medicines.  
“all we’d said was that the success of the strategy is a reduction in the risk 
to the patients of suffering adverse reactions to the counterfeit medicine and 
medical devices; and an increase in the risk to those engaged in 
manufacturing, distributing and supplying. So, you know, that was kept 
fairly open” [MD09] 
This generalised approach to the setting of outcomes from MHRA’s strategy was 
justified by participants because the overall picture of the counterfeiting issue in the UK 
was not clear for the drafting team during the drafting of the first strategy. Having said 
this, participants believed this has not changed in the second strategy.  
“we didn’t write in any target for that because we had no way of knowing – 
what you don’t know is whether the environment actually is getting worse as 
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you are seeking to correct the situation. So in fact the job gets harder rather 
than easier. These sorts of things we didn’t know at the time we wrote the 
strategy so the outcomes that are reflected from the strategy are not 
quantitative, they’re not specified exactly” [MM09] 
Some participants suggested the specific outcomes from the strategy had been left by 
the drafting team for each department to set its own outcomes based on the strategy’s 
overall objectives. Other participants said that at the end of the implementation of the 
first MHRA strategy, the department that led the implementation would had evaluated 
outcomes that were observed and achieved from the strategy. 
“we didn’t really sort of think what the expected outcomes might be, but at 
the end of it when we said ‘right let’s have a look at the outcomes, let’s have 
a look at how many people were convicted, how many cases we've had 
where we've had to recall or counterfeit medicines in a legitimate supply 
chain and how much money we've seized from criminals’, the key one really 
was number of incidences on the legitimate supply chain” [MI09] 
Other participants particularly wanted the outcomes to be written clearly during the 
drafting stage and that these outcomes should be measurable.  
“I would hope that they would be – when writing the strategy they are clear 
about what it is they’re trying to achieve and how they’re going to achieve it 
and how they will know whether they’re successful or not” [MC15] 
Participants stressed that outcomes expected from the strategy should be formulated 
during the drafting stage, which was not the case with either of the MHRA’s anti-
counterfeit medicines strategies. 
 
4.4.5.3 Operation Pangaea 
Many participants made mention of Operation Pangaea during the study in relation to 
success out come from the MHRA’s anti-counterfeit medicines strategy. According to 
them, Operation Pangaea was first carried out in London in 2009 when the MHRA 
seized illegal medicines and shut down websites illegally trading in counterfeits. Over 
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the years Operation Pangaea attracted more countries to participate in it; subsequently, 
Operation Pangaea ballooned into a vast international cooperative activity with 
coordination passing from the MHRA to Interpol. The Interpol since then took the 
responsibility of these operations which became an annual event. Participants said that 
the MHRA continues to play an active part in the activity as secretary. They also 
believed that Operation Pangaea was an excellent example of how national initiatives 
can become international ones 
Operation Pangaea was seen by some of those participants as a great success for the 
MHRA’s anti-counterfeit medicines strategy not just in enforcement terms but also as 
part of the communication activities, especially in terms of raising public awareness 
about the danger of websites that were selling medicines.  
“again was part of the implementation about communication strategy, 
getting the message out, and that Pangaea proved to be a real winner as far 
as that’s concerned” [MD09] 
Other participants mentioned Operation Pangaea it was seen as a success in terms of co-
operation activates within the strategy.  
“now have this Operation Pangaea which, you know, hundreds of agencies 
are involved in which is an international action” [MC04] 
Participants identified Operation Pangaea as an example of success in the MHRA’s anti-
counterfeit medicines strategies though with different opinions as to which type of 
outcome it represented.  
Participants thus, focussed on the outcomes that the decision-makers within the agency 
should expect from their anti-counterfeit medicines strategy such as changing people’s 
behaviour, securing the supply chain, decreasing the number of counterfeiting cases, 
changing legislation and regulations among others. Also, participants emphasised that 
these outcomes should be clearly written during the drafting stage of the strategy. 
Operation Pangaea was mentioned by the participants as an example of the success of 
MHRA’s anti-counterfeit medicines strategy from communication activities and co-
operation activates within the strategy. 
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4.4.6 Evaluating the outcomes of an anti-counterfeit medicines 
strategy 
This study also obtained the views of the participants on how the decision-makers 
within the medicines regulatory agency should evaluate the strategy’s outcomes, the 
criteria and methods that should be used, who would be responsible for evaluation and 
what they thought of the evaluation of the MHRA’s anti-counterfeit medicines strategy.  
 
4.4.6.1 Criteria and methods for evaluating the outcomes 
Participants saw conducting such an evaluation as very important for the decision-
makers within a regulatory agency. However, they recognised the difficulty of 
conducting an overall evaluation for such a strategy. Participants highlighted their idea 
of appropriate criteria for evaluating the strategy; furthermore, they mentioned the 
methods for evaluating the outcomes from the strategy which can be used by the 
agency. 
“I want to be able to identify from the strategy what the objectives of the 
strategy were and then have the elements that they were putting in place to 
achieve those objectives and then you would clearly be able to take a 
judgement based on some research as to whether or not those have been 
satisfied” [SC15] 
However, participants also identified difficulties that face a regulatory agency in 
conducting such an evaluation and described them from different angles. One difficulty 
that could face the agency is the lack of sufficient data for the counterfeiting cases being 
recorded at national level. To overcome this, participants suggested that the decision-
makers within the agency could carry out an evaluation on the basis of either regional or 
even international level data.  
“you have to come up with innovative ways of doing it and sometimes a 
country on its own doesn’t have sufficient statistics to create any meaningful 
conclusions from that. That’s why you have to do it on either a regional or a 
global level to get a better picture” [MD09] 
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Participants also said most regulatory agencies had extensive workloads and limited 
resources; this makes it difficult to conduct a thorough evaluation. However, 
participants said when the strategy had clear objectives that will make the evaluation 
easier for the agency. 
“That’s all resource intensive and having worked at a busy agency that is 
full on, it’s hard to devote time to that discipline. But if you were starting 
with a clean slate I think that would be the way to go” [MD09] 
They also saw some kinds of outcomes from the strategy as difficult to evaluate due to 
their nature, and they gave some example of those outcomes including measuring public 
perception and public awareness. Also, as one participant observed, measuring 
communication effectiveness with stakeholders could be highly problematic as it is not 
easy to measure the efficacy of communication. 
“We want to see evidence of a growing awareness in the public of the risk of 
Internet purchases of product.  That's more difficult to measure” [MM09] 
Given the perceived difficulties mentioned by participants, only some participants felt 
able to identify criteria that they felt could be used to evaluate the strategy. These 
included the number of counterfeit medicine incidences that reach the supply chain, the 
number of inspections carried out by agency inspectors, the number of reports to the 
agency regarding suspicion of counterfeit medicines, the number of media articles and 
interviews regarding the counterfeiting issue, the number of recall of medicines because 
of counterfeiting and the number of successful prosecutions. Such criteria could be 
readily quantified for use in the evaluation. Also, participants observed that any change 
in the law as a result of the strategy could be used as measurement criteria and that the 
agency should try to evaluate its public and stakeholder awareness activities. 
“We want to see evidence of a growing awareness in the public of the risk of 
Internet purchases of product” [MM09] 
A few participants had ideas for the methods they thought should be used by the agency 
to measure the criteria that could be used to evaluate the strategy; most frequently they 
referred to statistical analysis.  
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“Yeah, that would be just purely looking at the statistics, you know, it would 
be looking at the – we’d look at the statistics” [MD09] 
Another method identified by those few participants was a survey of the agency’s 
stakeholders asking for their feedback on the strategy or of the public or health 
professionals asking them for feedback, or a survey study of the public to measure the 
success of its awareness activities.  
“Respondent: some sort of probably stakeholder survey.          
Interviewer: In what sense? 
Respondent: As to whether they consider that the strategy is working well or 
that there are other areas that could be, you know, all of that I think would 
be useful” [MD09] 
They also suggested the agency could ask other national agencies for feedback on its 
strategy or could apply a benchmarking exercise with them. 
“we could ask for feedback from again other agencies and other countries 
and other agencies like ourselves to ask about what do we do, how do we do 
it, is it helpful the things” [MC04] 
To summarise, some participants provided ideas concerning how decision-makers 
should evaluate an anti-counterfeiting strategy at the MHRA. They highlighted some of 
the difficulties in achieving evaluation such as the paucity of nationally recorded data 
on counterfeiting cases and resource limitations. For the evaluation, quantified criteria 
could be applied including the number of counterfeit medicine incidents that reached the 
supply chain, the number of inspections carried out by agency inspectors and the 
number of reports to the agency regarding suspicion of counterfeit medicines. Only few 
participants thought the evaluation could be mainly achieved by using statistical data 
and by conducting surveys of the public and stakeholders. 
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4.4.6.2 Responsibility for evaluating the strategy outcomes 
Participants gave diverse views about who should be responsible for conducting an 
evaluation of the outcomes from an anti-counterfeiting strategy. Some participants 
suggested this task should be carried out by the department that led the strategy 
implementation, as this department has a very close relationship with the strategy. 
“whoever is responsible for that strategy is responsible for evaluating it and 
how it is evaluated or ensuring that if other” [MC15] 
Another view held by participants was that each department should evaluate itself, and 
then all departments would send its evaluation to a committee or a specific department 
that gathers all the evaluations together. They did not appear to think there would be 
any sort of bias if the department evaluated itself. However, they thought the risk 
associated with this suggestion is that the departments could be become more subjective 
which could indeed be a source of bias. 
“I think the departments themselves should evaluate the, I suppose their own 
metrics” [MC09] 
Also, participants said the evaluation could be completed by those responsible for 
drafting the strategy. 
“I would imagine that those how have drafted the counterfeiting strategy 
then they will be responsible for then pulling together the evaluation for it, 
yeah” [MC15] 
Participants suggested giving the responsibility of the evaluation to an internal auditor 
or a different department within the agency that does not have any link with the strategy 
because an internal evaluator would know the structure of the agency and how things 
interconnect within the agency. 
“In terms of effectiveness inside, you’d need a separate, you’d need 
somebody separate to those that have either developed the strategy or are 
running it on a daily basis to look at it with a fresh pair of eyes to determine 
whether there is anything else that could be done or could be done better” 
[MD09] 
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However, participants saw disadvantages with all these ideas, as that any evaluation 
process conducted entirely internally would be open to suggestions of bias and an 
incentive to produce a positive result.  
“there is a risk that somebody will say ‘well they’re only reviewing their 
own strategy, of course it’s come out well” [SC15] 
Participants’ final suggestion for evaluation was that it could be completed by an 
external evaluator such as an external auditor or another government agency. 
Participants therefore stressed that the strategy should be properly drafted with clear 
objectives to enable any such external evaluator to analyse whether or not the agency 
achieved them. 
“I think it's reasonably healthy to have an external auditor come in to audit 
your effectiveness in this area. I think that would give the director general 
or whoever, the chief executive, some level of confidence that there’d been 
that external review and it’s a fairly healthy” [MD09] 
In summary, participants’ views on evaluation of the outcomes from the anti-
counterfeiting strategy suggested a number of options: it could be carried out by the 
department that led the strategy, each department could do it for itself, or it could be 
done by those who drafted the strategy, or it could be conducted by an individual or 
department with no link with the strategy, or, finally, an external evaluator. 
 
4.4.6.3 The evaluation of the MHRA’s anti-counterfeit medicines 
strategy 
Participants reviewed their knowledge of the evaluation result from the MHRA’s anti-
counterfeit medicines strategy and their feelings regarding the outcomes of this strategy. 
They also discussed what type of evaluation had been conducted.  
Most participants had no information as to whether any evaluation had been conducted 
for the first MHRA anti-counterfeit medicines strategy, pointing out that they had not 
taken part in any kind of evaluation or simply lacked knowledge in that area.  
“Interviewer: And are you aware of any results for the first evaluation? 
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Respondent: No. I really wasn’t involved” [MP09] 
Nevertheless, participants shared the view that the MHRA was successful in its anti-
counterfeit medicines strategy, based on their knowledge of successful investigations 
that had been carried out into cases of counterfeiting and the sentences given to 
perpetrators, they also referred to the drop in the number of counterfeit medicine cases 
since the strategy was launched.  
“I don’t think we have slackened off in our efforts so you could say the 
strategy was successful” [SC15] 
Only a few participants had ideas about the kind of evaluation that had been carried out 
for the first MHRA anti-counterfeit medicines strategy. According to those who 
commented on that evaluation, there was no overall evaluation conducted for MHRA’s 
anti-counterfeit medicines strategy. Participants stressed, the evaluation was restricted 
to specific aspects of the outcomes, like the number of counterfeiting cases, the number 
of prosecutions and the sentences resulting from those prosecutions. This kind of 
evaluation did not cover other, possibly relevant, aspects of the outcomes such as public 
awareness. 
“there’s some evaluation, but it’s not covering every aspect I don’t think” 
[MM09] 
Most participants did not have any direct information about the evaluation of the 
first MHRA anti-counterfeit medicines strategy, although there was a widely-
shared perception that it had been successful. Others did suggest an evaluation had 
taken place but that this had not been comprehensive.  
 
4.5 Discussion 
The use of semi-structured interviews for data collection purposes was satisfactory in 
enabling the views from MHRA participants. The participants were able to pursue their 
own threads of thought without being restricted by the interviewer meaning a good 
degree of richness of depth was achieved as exemplified in the extracts reproduced 
above. There may have been an element of presenting the organisational line in some 
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responses from some participants, but on the whole it is considered that the data and 
findings are reflective of the views of the participants. This study aimed to capture the 
views and perceptions of MHRA participants on the anti-counterfeiting strategies 
published by the MHRA in 2007 and 2012 which would help in understanding its 
process from development to post hoc evaluation. This required participants to reflect 
back, particularly in the case of the now completed first strategy. This is more 
problematic than asking for views on current matters probably at the front of their 
minds, but nevertheless the data gained are considered useful. The framework approach 
to data analysis was also appropriate in identifying the main themes emerging from the 
data. 
Findings showed participants sharing the view that the agency recognised the dangerous 
consequences arising from counterfeit medicines, which contrasted with an attitude of 
denial that was shared among the regulatory agency and pharmaceuticals industries 
about counterfeit medicines in the UK. Furthermore, appearance of counterfeit medicine 
cases in the supply chain, protection of public health, securing supply chain, and 
pressure from stakeholders were believed by the participants to be motivating factors for 
the agency to develop an anti-counterfeit medicines strategy. Participants highlighted 
that the agency’s limited staff and resources, the lack of internal communication and 
resistance within the agency were internal limitations; whereas, regional and 
international legislation, having support from other government agencies and from 
industry were seen as external limitations that the agency should consider when 
planning to develop its anti-counterfeit medicines strategies in the future.  
In relation to the process of designing an anti-counterfeit medicines strategy, findings 
showed that participants believed this would be best done by a drafting committee 
across several agency’s departments/divisions probably led by the enforcement 
department and enriched by the agency stakeholder’s consultation role. Findings also 
showed the steps during the drafting stage that could be applied in order to develop such 
strategy. The drafting committee would start with initial thoughts for a strategy which 
was then shared with stakeholders to obtain their input. Then, the drafting committee 
will use the input from the stakeholders to write the first draft for the strategy which 
then would also be shared with the stakeholders. Finally, the committee would complete 
the strategy and send it to senior managers for approval before publishing it.  
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Findings also showed participants thought that such a strategy would be more effective 
if the implementation process become a responsibility of the enforcement department in 
cooperation with other departments/divisions. Participants particularly emphasised the 
importance of communication between the agency’s divisions and departments to 
ensure effective implementation of an anti-counterfeit medicines strategy. 
Participants’ were found to identify pharmacists’ and GPs’ potential roles in supporting 
an agency in combating counterfeit medicines as being vigilant, reporting any suspicion 
to the agency, maintaining awareness, advising patients about the issues and buying 
medicines from secure suppliers. Participants were found to suggest that stakeholders 
could support the strategy by securing the supply chain, protecting public health, 
sharing information, being vigilant, reporting to the MHRA any suspicions and working 
collaboratively with the agency. 
The study found that the outcomes of such a strategy were likely to change people’s 
behaviour, secure the supply chain, decrease the number of counterfeiting cases, change 
legislation and regulations. Participants also identified a lack of nationally recorded data 
on counterfeiting cases which, combined with resource limitations, might make it 
difficult for the agency to evaluate the strategy. They also suggested that to overcome 
these difficulties in evaluation, the agency might use quantitative measures for the 
evaluation process such as the number of counterfeit medicine incidents that reached the 
supply chain and the number of reports to the agency regarding suspicion of counterfeit 
medicines. 
A limitation of this study is that it was developed in the context of a very limited range 
of published literature, specifically making reference to anti-counterfeit medicines 
strategies. In fact only two articles were found that commented specifically on the 
MHRA’s anti-counterfeiting strategy, and both were written by the same author, 
Chaplin (52, 82). Another limitation related to recruiting participants, who were 
selected with some influence exerted by decision-makers at the MHRA. The initial 
participant list was developed by the researcher, based on the departments and divisions 
within the MHRA, which indicated their roles within the published MHRA strategies. 
During the stage of seeking approval to conduct this study from the MHRA decision-
makers, some names on the proposed participant list were changed by those decision-
makers; this was justified by them as they argued that the new names would be more 
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suitable for this study. This may have led to some bias in the study, as those new 
participants might have been included to affect the image of the MHRA presented 
during the interviews. To minimize the possibility of this bias, the researcher tried to 
explain to the participants at the beginning of each interview that the study was not 
aimed at evaluating the MHRA’s work; also, the researcher tried not to ask questions 
that could be directly linked to the MHRA’s performance. A further limitation to this 
study is related to the researcher, as he is from other country (Saudi Arabia) and works 
as a pharmacist with that country’s national medicines regulatory agency (Saudi Food 
and Drug Authority). Participants might perceived this as a form of international audit 
and may have felt defensive toward the MHRA as a response to the research situation 
and may not have given as full a picture of their views about the strategy as they could 
have given. Also, the background knowledge and experience of the researcher may have 
introduced some level of bias to the data analysis undertaken by the researcher because 
as a pharmacist working within a national regulatory agency in another country the 
researcher cannot have worked without developing a personal perspective and set of 
assumptions regarding counterfeit medicines and how to combat them. 
While it could be seen as one type of limitation that not all participants were wholly 
engaged with all the processes of the MHRA’s anti-counterfeiting strategies covered in 
this study, because one focus of this study was to detail and distinguish the different 
roles that people played in developing and advancing the strategy and because all study 
participants did some work in the area of combating counterfeit medicines as a part of 
their duties within the MHRA, it can be argued that such variation actually represents a 
study strength. Also, another strength of this study is that it is the first study that has 
addressed the views of participants from a medicines regulatory agency on issues 
associated with an anti-counterfeit medicines strategy. 
This study generated several findings which were grouped to six main themes that 
accomplished the following study objectives: i) understanding the medicines regulatory 
agency position before the anti-counterfeit medicines strategy; ii) highlighting the 
process of drafting an anti-counterfeit medicines strategy, taking MHRA’s anti-
counterfeit medicines strategy as a model; iii) the participants’ comments on the 
implementation of the anti-counterfeit medicines strategy; iv) identifying the potential 
role of GPs, pharmacists and other stakeholders in combating counterfeit medicines; v) 
outcomes that could be derived from an anti-counterfeit medicines strategy; and vi) 
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identifying potential evaluation criteria and methods for an anti-counterfeit medicines 
strategy. 
i) Understanding the medicines regulatory agency position before an anti-
counterfeit medicines strategy 
The study participants were in agreement that counterfeit medicines are very risky to 
public health and may even cause death, as Chika et al. (12) have reported (e.g. 62 
deaths in the USA due to a counterfeited Heparin). They also agreed and were most 
greatly concerned because little was known about the extent of the manufacturing and 
distribution of counterfeited medicines. It would be worth to consider expressions of 
agreement here may have been influenced by the participant’s knowledge that the 
interviewer (researcher) had background experience of the counterfeit medicines issue. 
Participants agreed that  the counterfeit medicines could have a significant impact on 
the reputation of government agencies, as argued by Nsimba SED (28), and it could 
affect the public’s trust in the health system. Therefore, this study showed that agency 
participants saw it as a vital duty for their agency to effectively combat counterfeit 
medicines. Those elements were considered by the agency participants as the driving 
factors for a medicines regulatory agency to develop an anti-counterfeit medicines 
strategy. 
Findings show that MHRA’s percipients believed the pharmaceutical companies were 
in denial about counterfeit medicines, a possibility also highlighted by Bate et al. in 
2011 (18), and other medicines regulatory agency staff. This suggests that decision-
makers should understand that the counterfeiting of medicines may not be restricted to 
developing countries but can happen anywhere. Furthermore, holding the view that 
there are well-regulated systems in place could lead to over-confidence in the medicines 
supply chain and a complacency which would make the supply chain vulnerable. Also, 
participants  notified that the agency should understand that the pharmaceutical industry 
might not share information that they hold on counterfeit medicines fearing their 
products may gain a bad reputation (12, 18). Also, it should be noted that expert study 
participants emphasised the need for a medicines regulatory agency to be proactive in 
combating counterfeit medicines even before any strategy was put in place.   
The most important consideration identified in this study was the discovery of 
counterfeit medicine cases in the legitimate supply chain. In terms of motivating factors, 
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this suggests that a medicines regulatory agency might consider the need to decrease the 
number of counterfeit cases, the need to protect the public health, and the need to secure 
the supply chain as external motivating factors to develop such a strategy. These 
motivating factors are all evident in the stated aims and objectives of the MHRA’s anti-
counterfeiting strategies (25). Also, another external motivating factor study participants 
identified was stakeholder pressure on an agency to develop such a strategy. However, 
it was considered in this study as the least important motivating factor and was not 
accorded the same weight as the other external factors; also there appeared to be no link 
between the seniority of the MHRA participant and their perceptions of this factor. In 
examining internal motivating factors for developing an anti-counterfeit medicines 
strategy, participants suggested that the personality and attitude of the agency’s staff, 
along with the availability of management support, would be relevant here. Also, 
another less emphasised internal factor might be the worldwide leadership position of 
the agency as seen in this study. It appears from this study that whilst the reputation of 
the agency as a worldwide leader in medicines regulation and external pressure to create 
a strategy were recognised as drivers their importance was perceived as less than the 
desire to protect public health, secure the supply chain and reduce the number of 
counterfeit cases.  
Participants perceived the need for the agency to identify its external and internal 
motivating factors alongside the external and internal limitations experienced by the 
MHRA; so the final findings in this theme concerned the limitations and boundaries of 
the medicines regulatory agency in developing its anti-counterfeit medicines strategy. 
Bryson (125) argues that a public organization seeking to develop an effective strategy 
should analyse both its external and internal environments. A medicines regulatory 
agency cannot work in isolation from its operating environment, and therefore regional 
and international legislation were considered as external limitations for the agency when 
planning to develop an anti-counterfeit medicines strategy as such legislation also 
shapes this environment. The implication of this was interpreted in this study as 
participants believing that the agency was being held back from certain areas of anti-
counterfeiting activity by limitations beyond their control such as those arising from 
legislation drafted to cover the European Union. Participants also identified a lack of 
support from other government agencies and relevant companies as a further external 
limitation. Not only external limitations were considered in this study, limitations within 
the agency itself, which may be staff and resource limitations, lack of internal 
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communication, and resistance to change within the agency. Understanding and 
evaluating those external and internal limitations is part of the process of identifying the 
agencies strengths, weakness, opportunities and threats (referred to as a SWOT 
analysis) which is a valuable tool in the development of any strategy (125). This 
assumption was supported by the study findings which showed that the participants 
perceived the need for the agency to identify its external and internal motivating factors 
alongside the limitations, which might be consider as delimitations for an agency in 
order to develop such a strategy. 
ii) How an agency could draft an anti-counterfeit medicines strategy 
This study highlighted features of the drafting process seen as relevant for 
understanding the process of developing an anti-counterfeiting strategy. Whilst only 
some of the participants in this study were directly involved in drafting the MHRA’s 
anti-counterfeiting strategies, all contributed to MHRA efforts to combat counterfeiting. 
This gave the researcher the opportunity to elicit a broader and potentially more 
objective set of views about drafting than if the study had recruited only those directly 
involved in strategy development. Findings showed that the views of those who were 
directly involved in the development process were closely aligned with those of the 
participants who were not directly involved in the strategy development. 
The findings also suggested that an internal drafting committee perhaps called “the 
strategic management team” should be responsible for drafting an anti-counterfeiting 
strategy (126). Participants saw the responsibility of leading this internal drafting 
committee could be given to the enforcement department. This opinion would carry 
logical weight as producing and distributing counterfeit medicines is a criminal activity 
and the enforcement department may have greater motivation and experience for 
dealing with such activities. Participants may have held this view because they were 
influenced by the two already-published MHRA anti-counterfeiting strategies that had 
been drafted by the enforcement department. However, few participants offered the 
alternative opinion that the policy division/department could lead here. Some 
participants argued that the policy department may be more appropriate as they may 
have a better understanding of external stakeholder perspectives and could offer a more 
holistic approach; also, if the policy division took on this role might give more freedom 
to the enforcement department to contribute more objectively. A third option which was 
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not raised by the participants in this study but may, on reflection be worth considering is 
that a senior manager from the agency rather than a department might take the lead here 
as this may encourage more even participation with all departments/divisions involved 
in this committee feeling they have the same weight and are not dominated by a single 
department/division.   
The participants also proposed departments and divisions that might be represented on 
the internal drafting committee for an anti-counterfeiting strategy. These included the 
departments dealing with inspections, defective medicines reports, the laboratory, 
pharmacovigilance, communications, policy, government lawyers and licensing. 
Participants gave reasons for involving these departments which included: the 
inspections department as reflecting the situation in the medicines supply chain field; 
the laboratory department as being responsible for product testing; the department 
responsible for dealing with defective product reports (in case of the MHRA, the 
Defective Medicines Report Centre); and the department/division that deals with 
pharmacovigilance duties within the agency as being likely to play an important part in 
detecting the signals of any counterfeits in the supply chain. The strategy would need to 
be communicated to the agency’s stakeholders, and therefore the division/department of 
communications would also be part of the drafting process. The policy 
division/department was seen as helping ensure that any strategy would align with other 
government policies; government lawyers providing legal advice ; licensing as helping 
identify the products at likely high risk of being counterfeited. Involving this range of 
departments/divisions could also enhance the agency’s feeling of ownership over the 
strategy within the agency, which participants expressed as important. This finding 
raises a question for those medicine regulatory agencies in other countries who may not 
have so many departments/divisions and who would need to evaluate their own 
structure and then create its internal drafting committee.  
Involving agency stakeholders in the drafting process was also seen as valuable by 
study participants. Those stakeholders would be pharmaceutical manufacturers (branded 
and generic), wholesalers, distributors and brokers. Also, police, customs and patient 
groups (if existing). The involvement of these stakeholders was seen in this study to 
increase the level of trust as well as the sharing of information between the agency and 
those other stakeholders; also, it would help build understanding of each other’s agenda 
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and priorities, meaning they are likely to then work together more fruitfully to tackle 
any counterfeiting issues. 
Participants expressed a view that once an internal drafting committee had been 
established and its membership identified, the committee should start with a 
consultation phase with the agency’s stakeholders, to identify the needs and 
expectations of these stakeholders. The participants proposed the chair of the committee 
should lead consultations; while recognising the timing, resources, energy and effort 
required for those consultations. The internal committee should prepare a first draft 
having also considered stakeholders’ input, with a second consultation round with 
stakeholders as essential; to seek comments and feedback on the first draft. The drafting 
committee would need to finalize the strategy, having made any amendments as 
necessary to accommodate stakeholders’ comments. After finalizing the strategy, the 
internal drafting committee would send it to the agency’s higher management for 
approval, before the agency finally published its strategy. Participants saw these steps as 
constituting a systematic organized method for drafting an anti-counterfeiting strategy. 
Study participants underlined the importance of formulating an anti-counterfeiting 
stakeholder group; as seen with the MHRA. This group was seen as having an input into 
developing anti-counterfeiting strategy and that involving them would continue to help 
to build trust between the agency and its stakeholders, which could encourage more 
information-sharing over a range of counterfeiting issues. Participants were found to 
support the proposal for the agency to set up such a group to be set to include agency 
members alongside stakeholders with a role in combating counterfeit medicines. Such 
stakeholder members would continue to be drawn from the pharmaceutical industry 
(branded and generic manufacturers, wholesalers, importers and parallel traders), 
representatives from government law enforcement bodies (police and customs), and 
representatives from pharmaceutical organizations such as the Royal Pharmaceutical 
Society. The study findings showed that an agency was seen as being able to use this 
group’s outputs in drafting its anti-counterfeiting strategy, as seen when the MHRA was 
reported as including in its strategies “a watch list of medicines” drawn from the anti-
counterfeiting stakeholder group.   
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iii) How an agency could implement an anti-counterfeit medicines strategy 
The study found that study participants’ findings saw leading and running an anti-
counterfeit medicines strategy as a task for one person from the enforcement 
department/division within the agency. They saw this as ensuring the smooth running of 
the strategy throughout the whole agency, as such a strategy would involve multiple 
departments/divisions within the agency. This is supported by the assertion of Theodore 
et al. that “If plans are not implemented in a very purposeful way, then the strategies 
will not take hold, no matter how compelling or inspiring the planning process” (126). 
Participants supported allocating this task to the enforcement department/division as it 
had more duties to perform in relation to the strategy than any other 
department/division, so that the strategy would be incorporated into its duties in the 
natural course of events and also would not be forgotten. It should be recognized that 
the implementation of the MHRA’s anti-counterfeiting strategy had previously and 
currently been allocated to the enforcement department which may have therefore 
encouraged the participants to see it as the ‘natural order of things’.  
The researcher raised some potential limitations with the participants which they did not 
feel had materialised. Participants did not recognise any lack of cooperation from other 
department/division managers (with the leading enforcement department) arising 
because they may perceive matters related to the strategy as the duty of the enforcement 
department/division manager. Also, they did not perceive a potential issue with 
department/division managers not accepting tasks that come from a person at a similar 
management level which would affect the implementation of the strategy. It may be that 
the participants were comfortable with having the enforcement division take the lead as 
this was the course taken for the first two strategies adopted by the MHRA. One 
alternative would be to have one of the senior managers of the agency assigned as the 
leader to give added weight to the importance of successful implementation and solve 
any inter-departmental issues.  
The study’s findings identified the departments/divisions that would have a role to play 
in the implementation an anti-counterfeiting strategy alongside the enforcement 
department/division. These are: the policy, communications, pharmacovigilance, 
laboratory, Good Distribution Practice (GDP), inspection and finance 
departments/divisions and possibly government solicitors. The implementation of such 
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a strategy may need to change in line with government legislation and regulations, and 
the policy department/division would have a role in this part of the implementation. In 
addition, the policy department/division would be the link between the agency and other 
government agencies, and it would ensure that the implementation of the strategy 
remains consistent with regional and international legislation. The communication 
department/division would assist in the implementation by raising awareness in both the 
public and the agency’s stakeholders; it would also deal with the media in general. The 
participants emphasized that this role should be done in coordination with the 
enforcement department/division. As the pharmacovigilance department/division deals 
with defect reports or lack of efficacy reports from health professionals and the public, 
it could play a role in the implementation by detecting flags or signals relating to any 
suspicion of counterfeit medicines, and then reporting these cases to the enforcement 
department; the laboratory department/division would then be able to move more 
quickly and efficiently in testing and analysing suspicious items. The GDP inspectors 
would also assist in the implementation as they are working in the field, and would be in 
a position to report the real-world circumstances to the agency. The finance department 
and government solicitors would help in the implementation through dealing with any 
prosecutions of counterfeiters. 
It was also found that the expert participants from the MHRA perceived the need for the 
best possible communication and cooperation between those departments/divisions 
involved in the implementation of the strategy and was vital for the strategy’s ultimate 
success. In addition, the allocation of tasks in the implementation should be part of the 
annually revised business plan for each department/division. One means of promoting 
good communication and cooperation highlighted by the participants was the 
identification of a contact person or project leader. 
iv) Identifying the potential role of GPs, pharmacists and other stakeholders in 
combating counterfeit medicines 
Participants were found to identify four roles that pharmacists and GPs could play in 
combating counterfeit medicines and which were also be identified in some of the 
literature (3, 12, 91, 92, 127). First, was for pharmacists and GPs to be vigilant for any 
suspicion of counterfeit cases, particularly relating to packaging and printing. Second, 
was that these two groups would be a good source of reports to the medicine regulatory 
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agency for any suspicions, which Besançon called reactive risk communication (128). 
Third, was because pharmacists and GPs are in contact with patients, they were seen as 
having a role of raising awareness and giving them advice on the danger of counterfeit 
medicines, in particular on buying from online sources. The final role that pharmacists 
and GPs (mainly dispensing doctors) could play was seen as being to source their 
medicines from a secured supply chain. It should be noted that the roles identified by 
participants in this study were not set out in the MHRA anti-counterfeit medicines 
strategies but were likely to have related to participants’ personal experiences. Having 
said this, the work  done by the MHRA in association with the Royal Pharmaceutical 
Society (RPS) and the Dispensing Doctors Association who cooperated to publish 
“Counterfeit Medicines Advice for Healthcare Professionals: Guidance for Pharmacists 
and Dispensing Doctors” is an example of the agency working together with health 
professionals (84). This guidance aimed to educate pharmacists and dispensing doctors 
to be vigilant, to report to the agency and to source their medicines from a secured 
supply chain. However, it cannot be evidenced from the literature whether pharmacists 
or dispensing doctors had received or were aware of this guidance, whether they 
accepted these roles or whether they were applying guidance recommendations to their 
practice. Neither were the roles of general practitioners (GPs) reported as being 
addressed by any of the MHRA activities; or whether GPs were aware of or accepted 
the guidance.    
Another study finding highlighted three methods of communication between the 
medicines regulatory agency and pharmacists and GPs about counterfeit medicines. 
First was using media tools, such as press releases or websites, or more specific targeted 
media tools, such as bulletins in professional publications (e.g. pharmaceutical 
journals). However, this study did not clarify the criteria for choosing between these 
different media tools nor anything about pharmacists and GPs use of these media tools 
nor did existing literature. A second route of communication raised was via the 
professional organizations of pharmacists and GPs, as they are responsible for 
regulating their members’ practice which could represent a more efficient and targeted 
means for delivering messages to these healthcare professionals. This study neither 
identified how the agency could work with the professional organizations; nor the 
degree of such cooperation. However, the guidance jointly published by the MHRA and 
the RPS could be an example of such cooperation; but, the success of this method of 
communication has not been evaluated by the MHRA or the RPS. The third method 
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highlighted in this study was the suggestion of using training tools in communicating 
roles to pharmacists and GPs; these tools could be post-qualification workshops, 
conferences and seminars, as part of their continuous development programme (CDP) 
or introduced into undergraduate courses. However, this study did not evaluate these 
methods or which of the tools would be more welcomed by pharmacists and GPs. 
Study participants did identify agency stakeholders who might play a role in combating 
counterfeit medicines as being from the pharmaceuticals industry (importer, wholesaler, 
generic and branded manufacturers), those from the government’s law enforcement 
agencies (customs and police), and other organizations like the Royal Pharmaceutical 
Society. They were identified as having roles in working with the agency to secure the 
supply chain; information-sharing and collaboration. Also, they thought stakeholders 
should be vigilant for any suspicious cases and should report them immediately to the 
agency. Participants highlighted that the MHRA engaged with its stakeholders via the 
MHRA's anti-counterfeiting stakeholder groups. However, the success of this 
engagement was not evaluated, and neither has any literature evaluated the views of the 
stakeholders on the value of the likelihood that they might take on these roles. 
v) Outcomes that could be derived from an anti-counterfeit medicines strategy 
Study participants foresaw several outcomes from an anti-counterfeiting strategy 
However, participants stressed that setting strategy outcomes was not an easy task and 
that a regulatory agency should attempt to establish them from the outset, during the 
drafting stage. Setting measurable targets was described as very difficult making it 
unsurprising that these were not included in the strategy. While participants did not 
identify any specific outcomes as being stated within the MHRA’s published strategies, 
they were able to identify these outcomes from their own personal experiences.  
The outcomes that have emerged from study participants’ experiences were : changing 
people’s behaviour and perceptions relating to counterfeit medicines through raising 
public and stakeholder awareness; making the pharmaceutical supply chain more secure 
to protect it from penetration by criminals; and improving collaboration and 
information-sharing among stakeholders (nationally and internationally) considered 
essential in these days (129). However, these outcomes were identified in a general way 
without participants specifying how the strategy could incorporate them within the 
strategy or fulfil them. 
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However, a potentially problematic outcome reported by the participants would be if the 
number of counterfeit medicine cases in the supply chain reduced; some saw this as a 
positive outcome, whereas others saw such a reduction as misleading because 
confounding factors could have been at play, such as counterfeiters not targeting the 
country or the agency failing to identify cases in the supply chain. Therefore, 
demonstrably decreasing the number of counterfeit medicine cases could be a good 
outcome but one that should be treated cautiously.  
Two more outcomes highlighted by study participants were to strengthen legislation and 
regulations in relation to counterfeit-medicine crimes and punishing counterfeiters with 
stiffer sentences. But, this study did not identify how the strategy might achieve these 
outcomes as amending legislation and sentencing policy is not within the remit of a 
medicines regulatory agency. 
vi) Identifying potential evaluation criteria and methods for an anti-counterfeit 
medicines strategy 
The previous theme concerned what outcomes could be expected from an anti-
counterfeit medicines strategy. The final theme addresses the methods of evaluation of 
these outcomes. In line with Chaplin (2008), study findings suggested that evaluating 
such a strategy might not be easy as seen from participants view, but that the evaluation 
would nevertheless be an important task (82). This difficulty was seen to arise from the 
lack of data on counterfeiting; however, to minimise this difficulty the agency could 
conduct their evaluation based on either regional or even international data. Another 
difficulty seen for executing an effective evaluation is that a medicines regulatory 
agency usually have both extensive workloads and limited resources; nevertheless, 
study participants highlighted the need for the strategy to set clear objectives from the 
outset which would simplify the evaluation process meaning less resources may be 
required. Another difficulty might be that some expected outcomes of the strategy (such 
as public awareness) would be difficult to measure. Therefore, the agency should 
identify and anticipate any such difficulties and put in place measures to overcome 
them. 
The study findings have helped indicate potential criteria that could be used to evaluate 
such a strategy. According to these findings, the agency could use the quantified 
outcomes included in the strategy, to conduct such evaluation; which might be 
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incidences of counterfeit medicines reaching the supply chain, the number of reports of 
suspected counterfeiting cases, the number of recalls due to counterfeiting cases, the 
amount of communication activities (such as media articles and interviews), the number 
of inspections, and the number of successful prosecutions. However, it is important to 
note that participants were not aware of any evaluation conducted on MHRA’s anti-
counterfeit medicines strategy and those criteria suggested by them were based on their 
personal views and had not been tested before. 
A further two potential evaluation criteria emerged from this study. These were changes 
in legislation or regulations resulting from the strategy and benchmarking exercises 
undertaken by the agency with other national agencies. However, the effect of any 
legislative changes would be unknown until sometime after they have been introduced. 
The benchmarking criteria might also be misleading as the topic of counterfeit 
medicines could be considered sensitive and other agencies might give out false results.  
This study does not offer a clear single answer about who should be responsible for 
carrying out the evaluation, as participants did not agree on this issue, perhaps because 
the participants were not part of any evaluation process. However, their responses 
suggested a few options which could be used in assigning responsibility for conducting 
an evaluation of its anti-counterfeiting strategy. In total, five options emerged from the 
study findings with potential to help the agency with this task.  First was for the 
department that led the implementation to also do the evaluation, as this department 
would have a close relationship with the strategy. A second option would be for each 
department to evaluate itself, and then for all the evaluations would be gathered together 
by a certain committee. The third option was for the drafting committee to carry out the 
evaluation of the strategy they authored. These options might have advantages as the 
evaluation would be conducted by someone who was familiar with the strategy which 
could make it easier and quicker to complete. However, self-evaluation which this 
effectively would be, is always going to be open to accusations of bias, something 
which should be considered. The fourth was for an internal auditor or a different 
department (with no link with the strategy) could do the evaluation. This option might 
impose less bias as an internal auditor does not have any link to the strategy, but still 
coming from within the agency means that some residual concern over bias will still be 
there. The final option was for decision-makers to hire an external evaluator (such as an 
auditor) or another government agency carry out the evaluation. This option would 
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eliminate any bias in the evaluation as the external auditor would not have any conflict 
of interest and would increase the evaluation’s validity; but would require cooperation 
from the different agency’s departments/divisions. However, as none of these options 
have been tested or evaluated before so their relative merits remain unknown.  
 
4.6 Conclusion 
The findings from this empirical chapter provide an insight into the process of 
developing, implementing and evaluating an anti-counterfeit medicines strategy from a 
medicine regulatory agency perspective. This study identified as useful or potentially-
useful, elements that help improve wider understanding of the issues associated with an 
anti-counterfeit medicines strategy from design to implementation and evaluation. 
These might also be informative for decision-makers within other medicine regulatory 
agencies to consider in developing counterfeit medicines strategy. Study findings have 
emphasised the need for decision-makers to recognise that counterfeit medicines 
represent a threat to public health, and reasons why their proliferation could have a 
significant impact on the agency’s reputation, in turn potentially affecting the public’s 
trust in their health system. Therefore, combating counterfeit medicines is increasingly 
likely to be a central aspect of any agency’s duties. This suggests that decision-makers 
may need to guard against denying the presence of counterfeit medicines, or in having 
over-confidence in the supply chain. Findings also indicated that decision-makers 
should understand that sometimes the pharmaceutical industry may not share 
information they may have about such problems, as they may fear for the reputation of 
their products.  
Thus, the decision-makers were seen as needing to be proactive in combating 
counterfeit medicines; to analyse the external and internal environments of the agency 
when planning to develop a strategy so as to identify and assess the relevant external 
and internal motivating factors for developing such a strategy as well as any potential 
limitations. The motivating factors to develop such a strategy were seen in the study as 
the occurrence of counterfeit medicine cases in the supply chain, protection of public 
health and securing the supply chain as well as the personality and attitudes of the 
agency’s staff, along with the availability of management support. Likewise, any 
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potential limitations such as the quality and availability of agency staff and resources, 
quality of internal communication, resistance within the agency, barriers provided by 
regional and international legislation, lack of support from other government agencies 
and from industry should be identified and assessed in seeking to develop an anti-
counterfeiting strategy.  
Decision-makers might refer to this study when planning and drafting such a strategy to 
identify key components of the process. These were: establishing an internal drafting 
committee from the agency’s departments/divisions with an existing role in combating 
counterfeiting activities; identifying the agency’s stakeholders for all counterfeiting 
issues. During the first stage, the drafting committee could conduct a consultation 
process with those stakeholders; then, the committee would draw up a first draft, which 
would be reviewed by the stakeholders for any comments or feedback. Following this, 
the committee would finalize the strategy and would ask for management approval 
before publishing it. 
In the implementation phase, many departments/divisions were seen as needed to 
implement such a strategy; but, the assigning of one department to a leading role in 
implementation was viewed by the participants as highly requisite. For both the drafting 
and implementation of the strategy, the importance of locating the centre of 
responsibility appropriately is clear and careful consideration should be given to 
whether it is placed in one department/division or centralised to ensure equal 
partnership and ownership. Furthermore, the importance of communication between 
those divisions and departments to ensure effective implementation was also 
recognised.  
The roles of agency’s stakeholders could assume to support the strategy implementation 
were seen as securing the supply chain, protecting public health, sharing information, 
being vigilant, reporting to the agency any suspicions and working in a collaborative 
manner with the agency. Moreover, this study identified the roles that participants felt 
should be assigned to pharmacists and GPs to support an agency in combating 
counterfeit medicines. These were to be vigilant, to report any suspicion to the agency, 
to have an awareness raising and advisory function to the patients and to buy medicines 
from secure suppliers. Recognising the roles of agency’s stakeholders as well as 
pharmacists and GPs could assist the decision-makers in incorporation within an anti-
counterfeit medicines strategy during the developing and implementing stages, through 
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understanding the roles that can reasonably be expected from each group and how the 
agency should communicate these roles to them. Whilst this study reported the views 
held by representatives from the MHRA the views of agency stakeholders, including 
GPs and pharmacists, on their roles and these suggestions are, up to this point, 
unknown. There is a strong indication in the data that stakeholder engagement was 
restricted at the early stages, during the development of the strategy, and there could be 
a case for engagement of stakeholders earlier and more extensively, something which is 
considered in the next chapter. 
Finally, the study recognized the need to set the desired strategy outcomes from the 
outset. Changing people’s behaviour, securing the supply chain, decreasing the number 
of counterfeiting cases, and changing legislation and regulations were each identified as 
outcomes that would be expected from an anti-counterfeit medicines strategy. In order 
to evaluate those outcomes the agency might use quantitative criteria for the evaluation 
process like the number of counterfeit medicine incidents that reached the supply chain 
and the number of reports to the agency regarding suspicion of counterfeit medicines. 
However, the lack of nationally recorded data on counterfeiting cases and resource 
limitations might be inhibiting factors for the successful conduct of strategy evaluation. 
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5.1 Introduction 
A medicines regulatory agency does not operate in isolation from its environment. Any 
anti-counterfeit medicines strategy developed by a medicines regulatory agency will 
impact on stakeholders. This study elicits the views of representatives of MHRA 
stakeholder groups on a counterfeit medicines strategy. The qualitative data collected 
from MHRA stakeholder participants is relevant to addressing the research problem as 
the participants can be viewed as experts capable of offering important insights into the 
threats from counterfeit medicines to both patients and to the medicines supply chain. 
There are certain gaps in knowledge concerning the development, implementation and 
evaluation of anti-counterfeit medicine strategies, and as in the study reported in chapter 
4, the study described in this chapter is also intended to go some way to filling these 
gaps.   
A medicines regulatory agency will deal with many stakeholders who have an interest 
in its work in one way or another. Those stakeholders relevant to counterfeit medicines 
issues were identified by participants in the agency study (see Chapter 4). These 
stakeholders include the pharmaceuticals manufacturing companies (branded and 
generic) with strong interests in protecting their products reputation and its economic 
revenue, and which may be represented by a trade association in some countries as seen 
in the UK. Also, medicines wholesalers, distributers, and parallel traders who deal with 
medicines on a daily basis and which might also be represented by a trade association in 
some countries as seen in the UK. Additionally, government law enforcement agencies 
(including police and customs) which have the authority to apprehend the counterfeiters 
and non-profit organisations (NGOs) which deal with health professionals, for example 
the General Pharmaceutical Council (GPhC) and the Royal Pharmaceutical Society 
(RPS). 
Some stakeholder groups have initiated their own activities to combat counterfeit 
medicines. For example, pharmaceutical companies formed the Pharmaceutical Security 
Institute (PSI) with the aim of tackling counterfeit medicines by sharing information 
and cooperating with the national medicines regulatory agencies. There are also 
examples of close cooperation between the MHRA and major pharmaceutical 
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corporations such as the work carried out by Pfizer and the MHRA to educate the public 
of the danger of counterfeit medicines (24, 130). 
Findings from the previous study (Chapter 4) highlighted a number of activities that 
stakeholders might undertake in developing an anti-counterfeiting medicines strategy. 
Also, the MHRA participants identified specific roles that agency stakeholders might 
play in combating counterfeit medicines which would help in implementing such a 
strategy.  The views of the MHRA stakeholders on their role in the strategy were not 
indicated in previous studies and therefore needed to be examined, not simply because 
they have yet to be evidenced in this context but more importantly any complete 
conceptualisation of the process of developing, implementing and evaluating the 
strategy needs to include the stakeholders dimension and it is this dimension which the 
current study aims to add. 
As agency stakeholders usually work more closely with pharmacists and GPs, this gives 
value here to stakeholders’ perspectives on the roles of these healthcare professionals in 
combating counterfeit medicines. As MHRA participants had views expressed only 
limited views on setting outcomes for an anti-counterfeiting medicines strategy and how 
to evaluate such a strategy, eliciting the views of stakeholders on these two issues could 
also be useful in having outsider views which might assist in gaining more 
understanding. Therefore, eliciting the views of the stakeholders on the processes of 
developing, implementing and evaluating an anti-counterfeiting medicines strategy and 
the view of the stakeholders on the degree of stakeholders’ involvement in such strategy 
would improve overall understanding of the issues associated with the development of 
an anti-counterfeit medicines strategy and would help in supporting and enriching the 
findings of the study involving MHRA participants. 
 
5.2 Aims and Objectives 
The aim of this study is to gain an understanding of the views of the stakeholders of the 
MHRA in relation to an anti-counterfeiting strategy, by exploring their views on its 
processes from development to evaluation.  
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Therefore, the objectives of this study in relation to an anti-counterfeit medicines 
strategy are: 
- to identify stakeholders’ perceived reasons for a medicines regulatory agency to 
develop such a strategy; 
- to identify how stakeholders see their role in its development and implementation; 
- to identify stakeholders’ perceptions of the potential roles of pharmacists and GPs in 
supporting the strategy; 
- to describe the stakeholders views on the strategy’s outcomes and how these should 
be evaluated. 
 
5.3 Methods 
This study aimed to gain a more complete and complex understanding of the counterfeit 
medicines issues by exploring from MHRA stakeholder participants’ views on an anti-
counterfeiting strategy. In this study qualitative methods were selected to facilitate the 
collection and analysis of rich data, comprising their appropriately-informed views and 
experiences, which facilitates the highlighting of key values and relevant language,  
which in turn enables the generation of conclusions and recommendations (96). 
Furthermore, these views should represent individual participant’s opinions though it is 
understood that may be formed in the context of the particular stakeholder groups they 
are from. 
Semi-structured interviews offered the flexibility to participants to pursue their own 
threads of thought, something required to achieve the aims of the study and something 
important because of the exploratory nature of the research. The interview questions 
combined the main questions to be covered in all interviews and a subset of questions 
pertinent to each interviewee and were included in an interview guide. This approach 
gave the researcher more flexibility, both over the order in which the questions were 
asked and to pursue topics of importance to each interviewee. The interview guide 
therefore included questions aimed at exploring the knowledge, experiences and 
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opinions of the participants related to a strategy for combating counterfeit medicines. 
The researcher also held an optional set of prompt questions to clarify or gather more 
details on a certain point as situation-appropriate to gain a deeper or more contextual 
understanding of that issue. 
 
5.3.1 Participant recruitment 
The main aim of this research was to explore the knowledge, experiences and opinions 
of key participants from different MHRA stakeholder groups, who were familiar with 
the workings of the MHRA in respect of the counterfeit medicines issue, regarding a 
strategy to combat these counterfeit medicines. Starks and Trinidad (2007) argue that 
the purposive sampling method is appropriate for recruiting participants who have 
experienced the phenomenon under study (124). Therefore, this research applied  a 
purposive sampling approach in recruiting participants from key MHRA stakeholder 
groups from within the pharmaceuticals industry, who were anticipated to be able to 
assist in identifying all the factors and characteristics seen as important for developing 
and implementing an anti-counterfeiting strategy. 
Mason (2002) states that sampling, data generation and data analysis are processes that 
should be conducted dynamically and interactively in order to develop a set of 
dimensions that focus on exploiting the participants’ experience (in this context, 
experience of anti-counterfeiting activity) (106). The participants were key members of 
MHRA stakeholder groups from within the pharmaceuticals industry who were linked 
in different ways to activities that have been, or are planned to be undertaken in 
combating counterfeit medicines in the UK. The participants were identified by the 
researcher with some assistance from a gatekeeper through identifying names and their 
working position of some participants and based on their participation in the MHRA's 
anti-counterfeiting stakeholder groups. The participants received and voluntarily signed 
an informed consent form. A preliminary questionnaire was used to gather demographic 
data (qualification, age group, work experience, etc.) in order to ensure that the sample 
was as diverse as possible. The sample was planned to comprise both male and female 
participants, with diverse work experiences; however, only male participants could been 
recruited. 
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A limit of 12 participants was set as a maximum for this study who have been selected 
to represent different stakeholders groups. To recruit the participants, the researcher 
requested the assistance of a ‘research access gatekeeper’, who was a member of the 
wider project supervisory team and had actively supported the project from its 
inception. All participants received the following: 
- An invitation letter explaining the nature, aims and implications of the study 
(Appendix 2.2).  
- An information sheet explaining the topic and organisation of the study, and its 
aims and intended outcomes, as well the implications of the study for the 
participants who wished to take part (Appendix 2.4). 
- An Interview Consent Form to be addressed to the researcher, signed by the 
participant as confirmation that he/she has agreed to be part of the research 
(Appendix 2.5). 
The researcher provided participants with further information on the study (where 
needed) and arranged the date and time for the interview in a suitable room at their 
place of work. A pre-paid envelope was provided to help maximise the response rate. If 
no response was received, no further letters were sent to that prospective participant. 
The outcomes from the previous study (Chapter 4), enabled the researcher to identify 
potential participants. In addition, two MHRA participants suggested some individuals 
from the stakeholder groups who could, in their opinion based on their participation in 
the MHRA’s anti-counterfeiting group, make a relevant contribution to the study as they 
would have good experience of the MHRA’s strategies. The researcher then finalized a 
list of 12 potential participants who were represented from different stakeholder groups. 
Those candidates were contacted through email by a gatekeeper to introduce the 
researcher and the study to them; then the researcher followed up and contacted them by 
email. Only two of those 12 potential participants replied to the email; one of them 
agreeing and the other declining to take part in the study. The remaining 10 potential 
participants neither replied to the emails sent by the gatekeeper nor to those sent by the 
researcher. At that point, the researcher sought support for the recruitment from the 
MHRA’s senior manager, who agreed to send emails to those 10 potential participants 
and explained to them that the MHRA had taken part in this research and encouraged 
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them to do likewise. However, even with the assistance of the MHRA’s senior manager, 
none of these10 potential participants responded to the emails.  
To overcome this obstacle, the researcher had to compromise and tried to identify 
participants who could still be considered as able to represent MHRA stakeholders 
regarding the counterfeiting medicines issue, even if they had not had direct links with 
the MHRA’s anti-counterfeiting medicines strategies. However, one criterion for 
selecting these new potential participants in that they must have some knowledge and 
hold some role within their organizations which related to counterfeiting medicines. The 
research team assisted the researcher by using their connections to find new potential 
participants from MHRA stakeholder groups. Finally, the researcher managed to recruit 
five more participants bringing the total to six. Those participants are representatives 
from the UK pharmaceuticals manufacturing industry, the UK pharmaceuticals 
wholesalers/distributors group and other pharmaceuticals organizations in the UK. 
 
5.3.2 Ethical approval 
This study was approved by University of East Anglia Faculty of Medicine and Health 
Ethics Committee (Appendix 2.1). 
 
5.3.3 Research Questions Topic Guide 
The interviews with MHRA stakeholders comprised nine questions, eight of which 
focussed on the core topic of the interview (Questions 2 – 8), and were designed to 
collect data which could reflect the aim of the study. The researcher also had other sub-
questions prepared that might be asked during the interview depending on the flow of 
the interview. 
The research team developed these questions and sub-questions (Appendix 2.2) to cover 
all the factors relating to a regulatory agency’s strategy to combat counterfeit medicines.  
The question “Can you please tell me about yourself?” was the opening item for the 
interview. The objective of this question was to gi
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talk about his/her background and work experience. Also, it informed the researcher of 
how long he/she had been in their current position; this was to assist in identifying how 
the participant was linked to the various counterfeit medicine issues. 
The second question in the interview was the first one pertaining to the main research 
topic; it acted as a warm up question. The researcher’s aim from this question was to 
define how stakeholders can work with a medicines regulatory agency in preventing the 
counterfeiting of medicines from the participant’s perspective and also to gain a better 
understanding of whether the participants think an anti-counterfeiting strategy is 
needed. 
The third question focussed on the participant’s views regarding the role of the 
stakeholders in developing an anti-counterfeiting strategy. The sub-questions were to 
highlight what they believe is needed to improve this role; also, participants could give 
their opinion regarding the development process of such a strategy. 
The fourth question focussed on the roles of the stakeholder in an anti-counterfeiting 
strategy from the participant’s viewpoint. The sub-questions covered the methods used 
to communicate those roles and what could be done to improve these methods. 
Additionally, barriers preventing stakeholders fulfilling these roles were highlighted. 
The fifth question addressed the roles of pharmacists and GPs in an anti-counterfeiting 
strategy from the participant’s perspective. The sub-questions covered the methods used 
to communicate those roles and the participants’ view of those roles in MHRA 
strategies. 
The sixth question emphasised the implementation process of the counterfeit medicines 
strategy. The sub-questions attempted to identify what the participant thought the role of 
stakeholders should be in the implementation. The sub-questions addressed views on 
the implementation of the MHRA’s strategy. 
The seventh question related to the outcomes of the anti-counterfeiting strategy. It 
sought to identify the expectations of the strategy from the participants’ perspective. In 
the sub-questions, the researcher emphasised the formulation of the outcomes that were 
expected and described by the participants and additionally what the participants 
believed the MHRA expected from its strategy. 
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The eighth question was the last question of the main research topic and explored the 
evaluation process of the outcomes of the strategy. The sub-questions led the 
participants to comment on the criteria that would be used to evaluate the outcomes and 
the selection methods for these criteria and what stakeholders can do to help in the 
evaluation process. In addition, the participants gave their opinion regarding the 
MHRA’s evaluation of its own strategy. 
Question nine was the last question of the interview and gave the researcher the 
opportunity to thank the participant for his/her time as well as to give the participant the 
opportunity to add more information or comments. Also, if the participant had any 
questions related to the interview or the research, he/she was free to put them to the 
researcher at this point. Then, the researcher ended the meeting. 
 
5.3.4 Data analysis 
The data collected in this study were the spoken words of participants from MHRA 
stakeholders, specifically pharmaceutical companies. As with the previous study 
(chapter 4), semi-structured, face-to-face interviews, with their use of open-ended 
questions, typically generate high volumes of these data and as the participants can be 
considered experts in the field being studied the data collected could be expected to be 
highly relevant. With this in mind, a data analysis method was required which would 
enable the researcher to manage the data and also summarise and synthesise it, but do so 
in a transparent and systematic way. Resources on qualitative data analysis were 
consulted before the framework analysis approach was chosen (94, 96, 119).    
The framework analysis approach is now widely used as a means of analysing primary 
qualitative data, particularly when relevant to policy making (116). The approach has 
been highlighted as appropriate for research which has specific questions, a defined and 
limited timeframe, a sample which is pre-designed (e.g. “professional participants”) and 
a priori issues identified from the outset as requiring to be addressed (115). However, 
the researcher, as in most qualitative approaches to analysis, analysed the data by 
identifying the themes that emerged from the interviews. The further developed 
analysis, relating to the range of themes, was used to generate a theory relating to the 
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anti-counterfeiting medicines strategy from the perspective of MHRA stakeholders. The 
researcher anonymised any personally-identifying information, and where it was 
necessary to use direct quotations in the reports or publications, they were edited in such 
a way as to protect the identity of the speaker. 
Nvivo software was used for data analysis; the data transcripts were entered and then 
the software was used to generate codes from the data transcripts, which were 
subsequently grouped those codes. Then the researcher generated the themes emerged 
from the data manually. The researcher developed the themes from the codes that 
emerged from the software, thereby becoming more engaged with data, which greatly 
assisted the researcher in the data analysis phase. The codes generated and the themes 
emerged from that data were reviewed and supported by the supervisory team. 
 
5.3.5 Structure of interviews 
It is important to ensure that the interview organisation can encourage an in-depth, 
freely-expressed discussion of sensitive issues. The researcher therefore conducted the 
interviews in a private room in the participants’ work place building at a time when the 
interview was unlikely to be interrupted. The interviewers had been ask for permission 
to audio-record the interview (an interview consent form have been signed by all 
participants). 
 
5.4 Results 
Overall, the researcher approached sixteen potential participants who covered the 
different MHRA stakeholder groups and included members from the UK 
pharmaceuticals manufacturers (branded and generic), UK pharmaceutical traders 
(wholesalers, distributors and parallel traders), UK law enforcement agencies (police, 
border agency and UK customs) and other pharmaceuticals bodies (Royal 
Pharmaceutical Society, General Pharmaceutical Council and Pharmaceutical Security 
Institute). However, only six participants replied and agreed to take part in the study 
(table 5.1). A data saturation was reached from the semi-structured interviews lasting 
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for up to 90 minutes were conducted at the participants’ workplace in different UK 
cities.  
Table 5. 1 Role of participants within stakeholder groups 
Participant’s code Role within the stakeholder groups 
SK01 Pharmaceutical Regulatory Organization  
SK02 Wholesaler 
SK03 Wholesaler 
SK04 Manufacturers Association 
SK05 Manufacturers Association 
SK06 Wholesaler 
 
The presentation of the findings starts by exploring the participants’ views about 
counterfeit medicines in the UK and the need for an anti-counterfeit medicines strategy. 
Then, the need for involving stakeholders in the development of an anti-counterfeit 
medicines strategy and their roles in the drafting and implementation of such a strategy 
are addressed. Also, the study highlights the role of pharmacists and GPs in combating 
counterfeit medicines and the way those roles can be communicated. Lastly, the views 
of participants on the expected outcomes from an anti-counterfeit medicines strategy 
and the methods used to evaluate those outcomes are discussed. 
 
5.4.1 Personal opinions about combating counterfeit 
medicines 
To understand the MHRA stakeholders’ perceptions and interpretations in respect of 
counterfeit medicines, the study started by seeking their views about counterfeit 
medicines in the UK and more specifically the issue of the online sale of such 
medicines. Here, the participants highlighted their assessment of the need for an anti-
counterfeit medicines strategy for any regulatory medicines agency in their fight against 
counterfeit medicines. The participants also revealed their judgment regarding the 
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MHRA’s anti-counterfeit medicines strategy as an example of the effort to combat the 
issue in the UK. 
 
5.4.1.1 Participants’ views in respect to counterfeit medicines 
When expressing their views on the danger of counterfeit medicines, participants 
differentiated between those obtained through a legitimate supply chain and those 
purchased through online websites. The participants explained the changes in the 
legitimate supply chain in recent years and referred to the dangers associated with 
generic medicines. Regarding the online websites, they described some of the 
challenges that would face governments with those sites. 
All participants believed that counterfeit medicines are imposing a high risk on 
consumers in the UK as well as globally. Their view was formed from the number of 
cases that had been found in the UK’s legitimate supply chain. Some participants 
perceived the issue of counterfeit medicines in the UK as being more serious than the 
government realises as it is not that easy to identify the scale of it in the legitimate 
supply chain. 
“In the legitimate supply chain coming through community pharmacy, you 
know, spot checks wouldn’t necessarily pick up on what the problem is. So I 
think on the one side it’s an underestimated problem” [SK03] 
However, those participants still view the danger of counterfeit medicines in the UK as 
being less than in some other countries. 
“It’s obviously a bigger threat in places like Africa and Asia where there 
are a lot more cases” [SK05] 
Furthermore, most participants argued that the incidence of counterfeit medicines in the 
UK in recent years was less than it was 5 years ago. This was concluded because no 
cases have been found in the UK legitimate supply chain in the last 5 years. But, this 
does not mean that the effort to combat the issue of counterfeit medicines in the UK has 
decreased. 
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“The evidence has been that there haven’t been any substantial recent cases 
of genuine or legitimate counterfeits” [SK01]   
In respect of the danger from counterfeit medicines for generic medicines, the views of 
the participants were diverse. Some participants did not differentiate between the 
counterfeiting risks associated with generic medicines and branded medicines even 
though the price of generic medicines is relatively low in the UK.  
“I’ve never, ever accepted the argument that for example that generics are 
not a risk because they're too low in price” [SK03] 
Those participants said that even if the price was low for generic medicines the 
counterfeiters can still make money from them because sales volumes are high. So, the 
profit margin for generic medicines was slim but with high volumes sold it is still 
attractive for the counterfeiters. Another reason for the participants interpretation is the 
degree of the awareness linked to generic medicines is low compared to branded 
medicines.  
“I think you know people are less, there’s less awareness about the potential 
of counterfeiting generics, than there is of, you know, the lifestyle drugs” 
[SK01] 
Some participants do not disregard the risk of counterfeiting of generic medicines but 
said the counterfeiting of generic medicines is very rare. Their interpretation was based 
on the fact that the price of generic medicines in the UK is very affordable and may in 
fact be one of the lowest priced countries in the world. In addition, the UK market is a 
freer market so generic medicines are priced freely by drug companies. Another reason 
mentioned by participants is that generic medicines in the UK are supplied by many 
different companies and usually the consumers do not recognize the generic names, 
therefore it is less attractive to counterfeit this kind of medicine. Hence overall the risk 
from counterfeiting for generic medicines was perceived as low but was not excluded 
altogether.  
“In this country [counterfeited generic medicines] hasn’t really been a 
threat and isn’t really on our radar” [SK04] 
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Some participants have offered explanations for the threat of counterfeit medicines 
being high within the legitimate supply chain in the UK. The first one addressed was 
that the lack of supply of some medicines in the UK attracted the counterfeiter to fill the 
gap.  
“I think you know, you're probably aware about short supply issues. That 
can sometimes I think lead to counterfeiting issues in its own right, because 
of the demand” [SK01] 
The other reason offered was the high price for some branded medicines in the UK 
which make it attractive for counterfeiters. The final reason mentioned was the 
relatively light penalties provided for in the relevant legislation for trading in counterfeit 
medicines compared to trade involving illicit drugs, something which also makes it 
attractive for counterfeiters.  
“penalties for counterfeiting medicines are far, far less than penalties for 
selling, you know, illicit drugs, you know, selling cocaine or heroin” [SK03] 
All participants mentioned the threat of counterfeit medicines linked with supply 
through online websites. They perceived that the major threat for consumers comes 
from online websites rather than the legitimate supply chain. 
“I think for me the real, the real challenge from counterfeit medicines is one 
that is largely a problem of the growth of the internet and online provision” 
[SK03] 
Participants justified their views by stating that it is very difficult for governments to 
control what was being sold through the internet. The counterfeiters can actually 
distribute their product very easily via the internet and can do so while running low 
risks of being caught.  
“The risks of having a whole batch seized and tracking people and using 
individuals basically in that country, the risks are lower if you use the 
internet” [SK01] 
Also, the participants believed the number of consumers using online websites is 
increasing which increases the threat. The final justification for concern offered by the 
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participants was the lack of data revealing the number of websites that sold counterfeit 
medicines. 
Participants mentioned a few challenges that the government faced in relation to the sale 
of counterfeit medicines through online websites. One challenge would be the difficulty 
for any government that wishes to regulate online sales of medicines as the location of 
these websites is either unknown or is in another jurisdiction. This leads to another 
challenge which is the need for cooperation and communication between countries to 
overcome this threat.  
“But that demands a lot of international cooperation to do that. So I think 
that for me, that’s where the biggest problem lies, but that’s also the biggest 
challenge” [SK03] 
Furthermore, according to the participants, a challenge facing the government is 
understanding the motivation for consumers to use the internet to buy their medicines 
which may go beyond mere cost and this understanding could help the government 
according to some participants. 
“So understanding the motivation hopefully will help inform how you need 
to tackle the problem” [SK04] 
To recap, participants described their views in respect to the counterfeit medicines as 
being a threat to consumers in the UK through the legitimate supply chain but argued 
that the risk is much greater from medicines via the online websites. They addressed the 
risk of generic medicines being counterfeited in the UK. Finally, participants 
highlighted the challenges for government that were associated with the threat of 
counterfeit medicines via online sellers.  
 
5.4.1.2 Participants’ views in respect of an anti-counterfeit medicines 
strategy  
Having illustrated their views with reference to the counterfeit medicines issue, 
participants emphasized the need for an anti-counterfeit medicines strategy and the 
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reasons for their viewpoints. Also, they described their views regarding the MHRA’s 
anti-counterfeit medicines strategy. 
All participants agreed on the need for an anti-counterfeit medicines strategy for any 
medicine regulatory agency combating the threat. Some of the participants saw it as a 
must for the agency to have such strategy.   
“I think it should, I think every country should take it seriously. I think it 
would be very unwise not to take it seriously, because it is a real threat I 
think” [SK05] 
Participants gave a number of reasons for their views on the need for a strategy.  Such a 
strategy would help the government to protect public health from the threat arising from 
counterfeit medicines. Also, without such a strategy a country’s legitimate supply chain 
would be targeted by counterfeiters. Some participants believed that by having a 
strategy, awareness of the issue of counterfeit medicines will be higher among the 
regulatory agency and its stakeholders. This will help the agency to be ready should any 
case appear in the supply chain and to deal with it in an effective way. Furthermore, 
participants said the issue of counterfeit medicines is a complicated one, and without 
such a strategy the supply chain would be at risk and the counterfeiters would find a 
weak point to put their product into the market. 
“It’s got to be done right, because if you have a small chink in the system, 
without a strategy then the problem is the counterfeiters will find a 
loophole. If you, if you fail to plan, then you plan to fail. That’s why they 
should have a strategy” [SK02] 
One participant highlighted their belief that when a medicines regulatory agency does 
not have an anti-counterfeit medicines strategy to match other countries they put 
themselves at risk as their system will be seen as vulnerable and will be targeted by the 
counterfeiters. This view applied even if the agency did not believe they had a 
counterfeiting issue in its system as it would stop the counterfeiters from considering 
targeting the country’s market. The last reason mentioned concerned the reputation of 
the agency in the public mind, as without such a strategy the agency would be seen as 
not doing enough to protect public safety. 
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“you’ve got to do everything you can to protect them. And therefore if a 
regulator which is actually in the public interest is not acting to save 
patient’s lives, then they are not doing their jobs. So I think every regulator 
must, not should, have a strategy” [SK02] 
Two points were highlighted by a few participants regarding the importance of an anti-
counterfeit medicines strategy. Firstly, the agency should understand the actual size of 
the pharmaceuticals market that it regulates and the effect counterfeiting has on this 
market.  
“It is a tricky balance. And quite often and this again is a challenge for 
regulators” [SK03] 
Also, the agency should be careful to be balanced in the strategy so they can address the 
potential problem but not to the degree where it might have a negative impact on the 
continuous supply of medicines to patients. 
Considering the effort made by the MHRA on the issue of counterfeit medicines in the 
UK and the outcomes seen from its anti-counterfeit medicines strategy, all participants 
thought that the MHRA had performed well on the issue and pointed to how the strategy 
helped the MHRA to pursue its aims. To support their view, participants highlighted the 
successes that had come out of the MHRA strategy. They said that the agency had been 
successful in removing the threat from the UK supply chain. 
“The actual strategy that MHRA have used has actually been successful in 
perhaps removing the threat from the UK supply chain” [SK01] 
Also, highlighted was the fact that the MHRA had put a lot of their resources into 
defeating counterfeiting and had worked very closely with the other enforcement 
agencies. Besides this, the MHRA understood the dynamics of the market and therefore 
listened to people more and had become more attentive to what its stakeholders say. 
This, according to participants, made the MHRA the leader in the effort to combat 
counterfeit medicines. 
“MHRA have obviously done a great job in the UK and we are probably at 
the forefront of this kind of activity through them” [SK05] 
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One participant stated that even with the success of the MHRA’s anti-counterfeit 
medicines activities, it should re-evaluate its strategy as traditionally the strategy was 
more about the legitimate supply chain, whereas the danger from online websites is 
increasing. 
To sum up the participants’ beliefs regarding the counterfeit medicines issue, they saw 
it as threat to public health, however, they believed the risk from online websites was 
greater than the legitimate supply chain for many reasons including the difficulty in 
controlling the internet and the low penalties associated with counterfeit medicines 
compared with trading in illicit drugs. The perceptions of the counterfeiting danger 
associated with generic medicines in the UK were split between those participants who 
felt the risk was no less  than for branded medicines while others felt the risks of 
generics being counterfeited in the UK was very low. Perceived risk may be linked to 
the precise role of the individual and the organisations for which they worked. For 
example, a participant only involved with a supplier of branded medicines may be more 
likely to see their own medicine category as being at high risk from counterfeiting. 
Also, all participants highlighted the need for an anti-counterfeit medicines strategy for 
any regulatory agency. Furthermore, they believed that the MHRA’s anti-counterfeit 
medicine strategy was successful and a demonstration of the importance of having such 
a strategy. 
 
5.4.2 The views of the participants on developing and 
implementing an anti-counterfeit medicines strategy 
This part will focus on the views of the participants on how the agency’s stakeholders 
were involved in developing an anti-counterfeit medicines strategy and which 
stakeholders they thought should be part of this process. They described what the 
stakeholders could do at the drafting stage to help the agency. Finally, it considers how 
participants described the roles stakeholders could play in the implementation of an 
anti-counterfeit medicines strategy. 
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5.4.2.1 Should the stakeholders be involved in the development of an 
anti-counterfeit medicines strategy? 
All the participants who could comment on the involvement of stakeholders in the 
development of strategy agreed that these stakeholders should have a role from the 
beginning of the drafting of the agency’s strategy.  
“So it’s important to have stakeholders involved very early on so they can   
support it, and to spot any weaknesses in it, from very early on before it’s 
moved too far down the line” [SK02] 
A few of them also added that the leading role in the drafting must be played by the 
agency as it is the agency’s strategy. The degree of stakeholder involvement in the 
developing of such a strategy was not entirely clear for these participants as a medicines 
regulatory agency has a diversity of stakeholders. 
“In an ideal world yes; I don’t know how much they would input in to that 
because I think they’re background will be different” [SK01] 
Whereas, other participants believed the substance of stakeholders’ involvement would 
be in providing information to the agency during the drafting stage as these stakeholders 
are at the ground level and they see more things first hand than the agency and this 
would help the agency to become better informed. 
“So actually providing all that information so the MHRA can take a better, 
well informed opinion and can focus it” [SK04] 
Participants illustrated many reasons for their belief in the importance of stakeholders’ 
involvement. Most of them stated that such a strategy would not be successful in any 
country without the involvement of its stakeholders.   
“If you don’t then it’s not going to be successful; simple as that” [SK01] 
Also, participants thought the agency and its stakeholders were equally interested in 
making the anti-counterfeit medicines strategy work; therefore, the stakeholders should 
be involved at the drafting stage.  
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“It probably wouldn’t be the best way to go forward yeah to go ahead and 
try and draft a strategy without some kind of involvement of stakeholders, 
because at the end of the day everyone’s got to make it work” [SK05] 
Another reason given, to involve stakeholders was to get them to ‘buy in’ to it and this 
will encourage them to support its implementation.  
“It’s essential that you get some buy in and some involvement from them in 
drafting up, because if it’s not workable, it’s not practical, it becomes too 
much of a burden. It’s going to fail” [SK03] 
Participants argued that the strategy cannot be drafted or the issue of counterfeit 
medicines successfully combated without the involvement of the full range of 
stakeholders as no single one holds the complete picture of the problem on their own.  
“So yeah without the industry, don’t think the MHRA can make that kind of 
announcement on their strategy, without forming dialogue with everybody 
else” [SK06] 
Finally, participants commented that the stakeholders deal with medicines in their daily 
work, and part of their effort is to try to prevent penetration of the legitimate market by 
counterfeiters and being alert to what is going on out in the real world. They are ideally 
placed to spot any weaknesses. As a result, engaging with the stakeholders’ experiences 
will be very helpful in drafting the strategy.  
“I think they need to involve the stakeholders who are on the ground 
actually dealing with these things and the sorts of issues on a day to day 
basis” [SK01] 
All the reasons emphasised by the participants lead them to believe in the importance of 
involving stakeholders in the drafting stage of an anti-counterfeit medicines strategy by 
the agency.  
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5.4.2.2 The stakeholder groups who should be involved in the drafting 
stage of an anti-counterfeit medicines strategy 
Participants tried to identify those stakeholders who should help the agency in 
developing its anti-counterfeit medicines strategy. They said the pharmaceutical 
industry was one of them, which included generic manufacturing and research-based 
manufacturing as they have a responsibility for their products and brands. This can be 
achieved through trade associations such as the British Generics Association. Also, the 
wholesalers were considered key players as they have responsibility to monitor where 
they are buying products from. Participants said wholesalers can be represented either 
through its trade association or individually. The distributors and parallel importers and 
exporters should also be among those stakeholders helping the agency. 
“I think there may be merit in looking to involve people that are actively 
involved in the parallel trade of medicines to Europe” [SK01] 
Furthermore, the law enforcement agencies need to be included which would mean the 
regulator of pharmacies, the police, border control and customs. In addition a few 
participants mentioned that pharmacists within hospitals and the community should be 
represented as stakeholders.  
“You’ve got the hospital pharmacists. Community pharmacists. Got the 
industry, pharmaceutical industry” [SK02] 
Finally, one participant said it would be helpful for the agency to listen to patient groups 
in the drafting stage to capture their perspective. 
“I think there is obviously a need for I think broader communication to 
patients” [SK03] 
Participants pinpointed the agency’s stakeholders that could be part of the drafting stage 
of an anti-counterfeit medicines strategy from the pharmaceutical industry and law 
enforcement. 
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5.4.2.3 The role of stakeholders during the drafting stage of an anti-
counterfeit medicines strategy 
Participants stated that the actual drafting of an anti-counterfeit medicines strategy 
should be initiated by the medicines regulatory agency as it is ultimately responsible for 
it. Assertion of the need for a drafting committee comprising the agency and its 
stakeholders to draft such a strategy was, however, not a constant among the 
participants. Some participants did not see that the strategy could be drafted through 
such drafting committee as the agency owned the strategy. On the other hand, other 
participants insisted that this kind of strategy needed a committee to develop it as the 
stakeholders play an important part of the development. A third group of participants 
could not come out with any view on this matter. 
“Whether they should be actively sitting around as a committee, drafting the 
actual policy or not I’m not always sure” [SK01] 
The process of drafting the strategy with a contribution from the agency’s stakeholders 
was described by the participants. They believed the agency should start the drafting by 
conducting an internal analysis to evaluate the problem and to identify the strengths and 
weaknesses. This would be a start point and not necessarily that detailed. The next stage 
would be consultation with stakeholders and an open discussion about improving the 
strategy. 
“We’re developing our own opinions, but this is very much a template to get 
your views and then call them in to that meeting and that’s then your first 
stage” [SK04] 
Then the agency would go back with all the feedback and comments from the 
stakeholders and develop a second draft of the strategy. However, the agency would not 
be bound by the feedback. 
“So yes I mean we have consulted, but you know, but as part of the 
consultation process, you know, they are free to believe what they want to 
believe” [SK03] 
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When the second draft is ready, the agency would conduct a second round of 
consultations and would also open the process for public comment to allow those 
interested to further widen its relevance. 
“I would then open it up to probably to public consultation. Because there 
may be people beyond the people that you’ve initially thought of that would 
be helpful” [SK04] 
Lastly, the agency would finalize its anti-counterfeit medicines strategy based on the 
public comments and the second round of stakeholders’ consultation and publish the 
strategy. Participants stressed that without consultation and feedback the strategy cannot 
move forward. 
 
5.4.2.4 The roles of stakeholders in implementing an anti-counterfeit 
medicines strategy 
In respect to the roles that a medicines regulatory agency’s stakeholders could play in 
the implementation of an anti-counterfeit medicines strategy, all participants assumed 
the agency cannot apply the strategy on its own and that it could not be implemented 
without the involvement of stakeholders. 
 “I think you can’t really impose a strategy without the involvement and 
willing and active involvement of stakeholders” [SK05] 
To support their assumption, they said that anything the agency said or did because of 
the strategy was going to affect stakeholders. Also, the agency would be policing the 
strategy but the stakeholders would operate most of it and would ultimately dictate its 
success or failure. Another reason is that the involvement of the stakeholders would add 
more power to the strategy as a number of agencies or associations would be working 
behind it. 
“But if they're all behind one particular target, then you’ve got the power of 
3 or 4 agencies all looking at one particular aspect” [SK01] 
Chapter 5: MHRA stakeholders’ perspectives on developing an anti-counterfeit medicines 
strategy 
 
PhD Thesis: Developing a national strategy for combating counterfeit medicines                  155 
The availability of the resources to implement such a strategy is an issue as no agency 
would have enough resources to complete the work in isolation. One participant 
commented that any anti-counterfeit medicines strategy simply would not work 
properly if the stakeholders cannot make it work, so their involvement is essential.  
In relation to what stakeholders can do for the implementation of an anti-counterfeit 
medicines strategy the participants defined some roles that stakeholders could play. 
Stakeholders would be involved through collaboration and cooperation with the 
medicines regulatory agency and with each other for combating counterfeit medicines. 
“I think there is that responsibility to help educate regulators on the market 
dynamics, because you know, the markets in buying and selling of medicines 
which is legitimate, you know, can be quite complex and complicated” 
[SK03] 
Another role identified by participants involves the stakeholders having open 
communication with the agency and exchanging information with it. The stakeholders 
would also gather their own intelligence in respect to counterfeit medicines issues and 
help the agency in its investigation. 
“Providing intelligence to the regulators when in your everyday business 
you may pick up on, you know, cases where someone is trying to sell you 
something” [SK03] 
The stakeholders were perceived as needing to support the agency by providing the 
technical expertise that they have. An additional role for stakeholders was to work hard 
to secure the supply chain by checking the credentials of the people they bought from. 
“secure the supply chain and to get stakeholders to be, act responsibly 
within that supply chain and to try and secure their routes of supply, their 
supply chain, upstream supply chain to make sure that that’s secure, that 
you’re only buying from accredited secures” [SK05] 
Furthermore, according to the participants, the stakeholders would be vigilant for any 
suspicion in the supply chain that might sound the alert for counterfeiting. The 
stakeholders would have a role in reporting any of the suspicions or actual cases of 
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counterfeiting to the agency. Finally, the stakeholders would play a role in education 
and awareness for their own members and the general public about the counterfeiting of 
medicines. 
To summarise, participants said the medicines regulatory agency’s stakeholders have a 
role in the development of an anti-counterfeiting strategy and should be involved in the 
drafting from the beginning because this will not only improve the quality of the 
strategy but also its ultimate implementation. Also, the stakeholders who should play a 
part in the drafting stage were defined by the participants as members of the 
pharmaceuticals trades (manufacturers, wholesalers, distributors and parallel traders), 
the law enforcement agencies and maybe patient groups. Stakeholders would help the 
agency in drafting such a strategy through consultations and feedback. For the 
implementation of the anti-counterfeiting strategy, the stakeholders would have an 
essential role in collaboration and cooperation with the agency, securing the supply 
chain and educating and raising awareness among their own members and the general 
public. 
 
5.4.3 Role of Pharmacists and General Practitioners (GPs) in 
combating counterfeiting medicines 
Participants highlighted their views in regard to the roles that pharmacists and GPs 
could have in combating counterfeit medicines. Also, they commented on ways of 
communicating those roles to pharmacists and GPs. 
 
5.4.3.1 Stakeholders’ views on the role of the pharmacists 
Participants believed that pharmacists have a major role to play in the effort to combat 
counterfeit medicines as they are the last link between the supply chain and the patients. 
Those pharmacists are considered to be on the frontline as they see and handle the 
medicines on a daily basis.  
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“They are the last stop gap between the patients getting the right medicine 
and the patient getting the wrong medicine” [SK02] 
The participants distinguished some roles that pharmacists could play to combat 
counterfeit medicines. The main and most important role pharmacists can play as 
identified by all participants is to work hard to secure their supply chain by purchasing 
their products only from reliable and licensed sources. 
“Pharmacists need to be sure that they’re purchasing medicines from 
companies that are licensed to do so. So that is the most important thing 
that they can do” [SK04] 
In addition, the participants perceived the need for pharmacists to be vigilant about any 
alteration to the medicines’ packaging even if they have received it from trusted 
suppliers. Also, pharmacists should identify comments and feedback from patients 
which might indicate counterfeiting.  
“You know the minute a security seal has been tampered with or the pack 
looks damaged, or it doesn’t look, or it looks out of the ordinary, yeah they 
can question it, yeah just to be vigilant” [SK06] 
Another role that pharmacists can play to help in the combating of counterfeiting 
medicines as described by the participants would be exercising their duty to report any 
suspicious cases to the medicines regulatory agency. Besides this they should report the 
feedback from patients too. 
“it very clear to people that if you have concerns about the quality of 
medicines they have to be reported, it’s a professional obligation that you 
report them on to the marketing organisation or the licensing authority 
organisation which is MHRA” [SK01] 
Also, participants said the pharmacists would have a role in raising awareness among 
and educating patients on the danger of counterfeit medicines as they deal with patients 
on a day-to-day basis and they are trusted by the patients. 
“They need to make the patient aware, if they’re not aware, because not a 
lot is actually reported in the media from time to time, but you know 
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because the pharmacist is face fronted, you know, the patient coming in 
trusts what the pharmacist tells them” [SK06] 
The final role, pharmacists can educate the patients on the best method that patients can 
use if they would like to buy medicines from online sources such as, for example, only 
using websites that are accredited by the GPhC. 
 
5.4.3.2 Stakeholders’ views on the role of General Practitioners (GPs) 
Considering the roles that GPs play in combating counterfeit medicines, some 
participants thought there would be no role that GPs can play as the GPs do not 
physically deal with medicines. However, they considered the dispensing doctors’ role 
would be the same as the pharmacists’. Whereas, other participants said GPs would 
have some role but it would be less important than the pharmacists’ role. A few roles 
were defined by the participants for GPs. Participants said GPs could be a source of 
education and awareness for the patients on the danger of the counterfeiting medicines 
and how the patients could protect themselves.   
“I suppose using the reputation of GPs with the public in those areas where 
you can educate the public is probably a good thing” [SK04] 
Additionally, the GPs should be vigilant to the feedback and complaints from patients 
concerning their medicines. Finally, GPs should report any suspicion they may have in 
respect to the counterfeiting issue to the medicines regulatory agency.   
“The professional duties are in GPs, but certainly if they become aware that 
there’s a counterfeit I would suspect that they have an obligation to report 
that” [SK01] 
For the dispensing doctors, the participants added one more role they can play which is 
to secure their supply chain in the same way as the pharmacists.  
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5.4.3.3 Communicating the roles of pharmacists and GPs 
With the respect to the roles that have been identified for the pharmacists and GPs in 
combating counterfeit medicines, participants also mentioned the methods that could be 
used to communicate those roles. Some participants believed that pharmacists and GPs 
need more information and support from the medicines regulatory agency and their 
professional bodies in regard to counterfeit medicine issues. A few participants also 
highlighted the need for training the pharmacists and GPs and educating them when at 
university level. 
“I think it’s a variety of sources to educating pharmacists at university” 
[SK01] 
In addition, participants claimed the best source of communication for the pharmacists 
and GPs would be their professional bodies because the messages that come from those 
bodies would be more tailored and specific to either the pharmacists or GPs and not as 
general as if the information came from the medicines regulatory agency. 
“I think the information has to come from the, either the professional body. 
So the General Pharmaceutical Council or you know or the General 
Medical Council or from the Royal College of General Practice for example 
or from, you know, the associations representing pharmacy” [SK03] 
Finally, the communication tools that might be used with the pharmacists and GPs as 
seen by the participants would be professional journals and articles and also the internet, 
emails and social media. These communication tools should be used on a regular basis 
so the pharmacists and GPs were reminded of the topic of counterfeit medicines. 
In summary, participants believed that pharmacists could play five important roles in 
combating counterfeiting medicines. Pharmacists should secure their supply chain, be 
vigilant to packaging, attentive to the feedback from patients, report any suspicions and 
be a source of awareness and education for the patients. GPs have less important roles 
than pharmacists: GPs could be a source of education and awareness for the patients, be 
vigilant and report any suspicion to the medicines regulatory agency. Also, participants 
believe the best communication to pharmacists and GPs in respect to counterfeiting 
would come from their professional bodies. 
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5.4.4 The expectations from the anti-counterfeit medicines 
strategy 
This section highlights the participants’ views on the outcomes that a medicines 
regulatory agency might expect from an anti-counterfeit medicines strategy. Also, the 
participants discuss their opinions on the evaluation concept for the outcomes from such 
strategy. 
 
5.4.4.1 Stakeholders view on the outcomes from an anti-counterfeit 
medicines strategy 
As a general statement, participants believed that medicines regulatory agencies should 
be realistic in their expectations from its anti-counterfeit medicines strategy. Also, from 
the beginning the regulatory agency needs to be quite clear about what it is trying to 
achieve from the strategy. However, all participants agreed that defining exact outcomes 
would be difficult as, at the outset, the agency does not have the full picture of the 
problem of the counterfeiting of medicines in the country when they are drafting the 
strategy.  
“that can be quite difficult when you’re not exactly sure what the scope of 
what you’re trying to, well the scope of the problem, what it is at the 
beginning” [SK01] 
Participants tried to identify what the results could be from a successful anti-
counterfeiting strategy. The most important outcome would be protecting the public as 
this is the duty of any government. Another possible outcome seen by participants is 
securing the supply chain, so that counterfeit medicines would not reach the patients. 
“The second good strategy is that you’re closing the loopholes where they 
can introduce counterfeit medicines in to the system” [SK02] 
One outcome would be a reduction in the number of counterfeit medicine cases in the 
supply chain. Participants believed that if counterfeit medicines continue to reach the 
patients then public confidence in the supply chain will be lost.  
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“Patients get what it says on the box, you know, and they can take it with 
confidence that what they’re getting is what it says on the box, you know, so 
the bottom line is to make sure that it’s, that patients are safe” [SK05] 
Another outcome would be changing people’s behaviour in respect to counterfeit 
medicines and that could be achieved through better education and raising awareness.  
“I think there is a bit that says better education, better awareness, hopefully 
- To the patient, to the consumer, to the patient, would certainly make them 
think, you know, even though I want to, the risk is too high and therefore I 
won’t buy it” [SK03] 
Also, changing behaviour would lead to another outcome which is an increase in the 
number of reports to the medicines regulatory agency from the public as well as from 
pharmacists. Besides this, an increase in the number of product seizures and the number 
of prosecutions and tighter penalties would also be an expected outcome from the 
strategy as seen by the participants.  
“I think objectives really should be about, you know, tighter penalties for 
those that you can identify and deal with” [SK03] 
Likewise, an increase in the number of unregulated websites, which could be sources of 
counterfeit medicines, closed by the agency would be a positive outcome. The final 
outcome would be an improvement in international cooperation in combating 
counterfeit medicines because the problem of counterfeiting is worldwide and a single 
country cannot deal with it by itself.  
 
5.4.4.2 Stakeholders’ views on the methods could be used to evaluate 
the strategy’s outcomes 
All participants agreed that any kind of evaluation for an anti-counterfeiting strategy 
would the responsibility of the agency as it is the owner of this strategy. However, there 
was doubt among some participants as to whether the medicines regulatory agency 
could effectively conduct this kind of evaluation. 
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“When you try to stop something happening, it’s very difficult to prove that 
you’ve stopped it happening, that it hasn’t happened” [SK05] 
Other participants’ opinions were also that to evaluate such a strategy would be very 
difficult for the agency. They believed the agency might only be able to partly evaluate 
the strategy, specifically for those parts over which it had direct control (manufacture 
and wholesale) and even here the evaluation would only be basic.   
The tools that could be used to conduct an evaluation for such a strategy would be the 
kind of metrics that the agency designs for that purpose. 
“I think you need to be sensible in the way that you will design the kind of 
metrics. The kind of measurements that will inform the evaluation” [SK03] 
Participants suggested the agency use the number of counterfeit medicine cases that 
have been reported or detected. The economic value of counterfeit medicines seized and 
the cost of patients’ hospitalisation due to counterfeit medicines. 
“I mean hospitalisations I suppose I don’t know how many, I don’t think 
MHRA have really done much research in to how much money or what the 
costs are of, on patient health and caring for people that have taken 
counterfeit medicines” [SK01] 
In addition, the number of reports by patients, pharmacists and GPs that relate to 
counterfeit medicines can be measured. The agency can also use the number of 
prosecutions and sentences for people trading in counterfeit medicines. Finally, to 
measure the change in public behaviour as a result of the strategy, the agency could 
conduct a public survey regarding their views on the counterfeiting of medicines.   
“I think doing polling of the public after maybe 3 years or 5 years, you know 
what is your attitude towards purchasing medicines” [SK04] 
In respect of the role of stakeholders in the evaluation of the strategy, participants 
thought stakeholders would have a limited role. They said the stakeholders could help 
the agency by providing it with the data they have regarding the counterfeit medicines 
issue. Also, the stakeholders can feedback to the agency on what they have seen on the 
ground. Finally, the stakeholders help the agency by providing expertise when needed. 
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One participant suggested that evaluation could be carried out by an independent body, 
the reason being to avoid possible bias that could arise should the agency evaluate its 
own work. 
“Because then you’re not biased, you’re not skewed in your results and 
therefore there’s more authenticity, more recognition, more integrity if it’s 
an outside group like an academic institution or university or something” 
[SK02] 
This section presented the views of the participants on the potential outcomes from an 
anti-counterfeit medicines strategy. They believed that it would not be an easy task for a 
medicines regulatory agency to define specific outcomes from such a strategy. 
However, they managed to mention some outcomes that could be expected from the 
strategy such as protecting the public, securing the supply chain and changing people’s 
behaviour in respect to the counterfeiting medicines issue. The evaluation of those 
outcomes would be a difficult task for the agency as seen by the participants. They said 
the agency could use metrics including the number of counterfeit medicine cases and 
the number of reports by patients, pharmacists and GPs to conduct the evaluation. 
 
5.5 Discussion 
The aim of this study was to gain further understanding of the issues associated with 
developing an anti-counterfeit medicines strategy through eliciting the stakeholders’ 
views about the process from development to evaluation. Having a multi-dimensional or 
triangulated understanding is important if a complete conceptualisation of how to 
develop an effective anti-counterfeit medicines strategy is to be reached. This study 
therefore first elicited the views of the participants on the need for an anti-counterfeit 
medicines strategy. The study found that stakeholder participants clearly perceived 
counterfeit medicines as a significant risk to public health and that the main source of 
this risk was online supply. They also identified the difficulty of controlling the internet 
and the low penalties associated with counterfeit medicines compared with trading in 
illicit drugs which they saw as being associated with online websites. In other words, 
they saw the ease of reaching the market and low risk for counterfeiters in terms of 
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chance of detection and penalties as particularly attractive to criminals and drawing 
them to online routes. The threat to generic medicines from counterfeiting was found to 
be perceived by some but not all participants as less acute than the threat to branded 
medicines. Stakeholders were also found to believe that an anti-counterfeit medicines 
strategy is a requirement for any national medicines regulatory agency to successfully 
combat counterfeit medicines.  
This study also highlighted how the stakeholders view their own role in the process of 
developing and implementing an anti-counterfeit medicines strategy, stressing that they 
should be involved in the drafting of such a strategy from the beginning as this would 
improve the quality of the strategy and facilitate the implementation process. They saw 
their roles during strategy development as being consultative and providing feedback. 
Participants believed the stakeholders’ roles in implementing the strategy would be 
essential and which would be able to draw on their collaboration and cooperation with 
the agency, securing the supply chain and educating and raising awareness among their 
own members and the general public. 
Stakeholders also expressed views on the roles of pharmacists and GPs in supporting 
the strategy, identifying five roles for pharmacists. These roles were: securing their 
supply chain, being vigilant to packaging, being attentive to the feedback from patients, 
reporting any suspicions to the medicines regulatory agency and being a source of 
awareness and education for the patients. They saw roles of GPs as less important than 
those of pharmacists in relation to this issue. Nevertheless, they suggested that GPs 
could be a source of education and awareness for the patients, be vigilant and report any 
suspicion to the agency. Participants also believed that communicating those roles to 
pharmacists and GPs would be better achieved via their professional bodies. 
Finally this study elicited the views of the stakeholders on the anticipated outcomes of 
an anti-counterfeit medicines strategy and how these desired outcomes could be 
evaluated. The study found that participants perceived that both identifying the 
outcomes and evaluating them post hoc would be a problematic task. Nevertheless, 
protecting the public, securing the supply chain and changing people’s behaviour in 
respect to counterfeit medicines could be set as desired outcomes of the strategy. While 
seen as problematic participants observed that quantitative metrics such as the number 
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of counterfeit medicine cases and the number of reports by patients, pharmacists and 
GPs may form part of the evaluation.  
A major limitation of this study occurred during the recruitment stage. The aim of this 
study was to get the views of main MHRA stakeholders, who had direct involvement 
with the MHRA’s activities in combating counterfeit medicines in the UK. However, 
only one participant was recruited who was fully involved with these MHRA activities. 
The rest of participants were not directly involved with the MHRA’s activities; 
however, their work tasks were related to counterfeit medicines. However, this study 
was designed to gain a better picture on the issue associated with an anti-counterfeit 
medicines strategy from development to evaluation rather than an examination of the 
MHRA’s activities under the two already published strategies; therefore this minimises 
the effect of this limitation on the overall study’s findings. Another limitation is related 
to the number of participants involved on this study. Only six people agreed to take part 
in this study which might give weakness to the study as those participants did not 
represent all stakeholder groups. A further limitation may be the background knowledge 
and experience of the researcher which may have introduced some level of bias to the 
data analysis undertaken by the researcher because as a pharmacist working within a 
national regulatory agency in another country the researcher cannot have worked 
without developing a personal perspective and set of assumptions regarding counterfeit 
medicines and how to combat them. Another limitation of this study is that it was 
developed in the context of a very limited range of published literature specifically 
making reference to anti-counterfeiting medicines strategies; which could be used to 
assist the researcher in identifying appropriate methodologies and in providing some 
context in which to discuss the findings.   
While not all participants were wholly engaged with the MHRA’s anti-counterfeiting 
medicines activities, which could be seen as a limitation to this study, this could also be 
considered as a strength as the participants will not have been influenced by or biased 
toward those activities. Overall, the stakeholder participants demonstrated in their 
responses that they held appropriately-informed views with respect to the counterfeit 
medicines strategy which met the criteria set out in the methods section. Also, another 
strength for this study is it would be the first study that addressed the view of the 
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stakeholders on the issues associated with developing an anti-counterfeit medicines 
strategy. 
This study generated findings which could be conceptually grouped into four main 
themes relevant to the study objectives as follows: i) understanding the medicines 
regulatory agency’s stakeholders’ opinion about combating counterfeiting medicines; ii) 
understanding stakeholder perceptions of the roles of the medicines regulatory agency’s 
stakeholders in the strategy’s development and implementation processes; iii) 
understanding stakeholder perceptions of the roles of pharmacists and GPs in combating 
counterfeiting medicines; and iv) the outcomes expected from an anti-counterfeiting 
medicines strategy and its evaluation methods. The discussion of the findings which 
follows is organised into these four themes.  
i) Understanding the medicines regulatory agency’s stakeholders’ opinions about 
combating counterfeiting medicines: 
It was found that stakeholder participants shared a common perception of the risks for 
consumers from counterfeit medicines which participants viewed as not being restricted 
to the UK but as a global risk; this view is supported by published reports (2, 12, 28, 
55). Furthermore, the risks associated with counterfeit medicines were perceived by the 
participants to be lower in the UK than other countries, which could be justified from 
participants’ belief in the effective efforts conducted by the MHRA in combating 
counterfeit medicines in the UK. It is worth considering that there may have been a 
reluctance among participants to make observations which could be interpreted as 
critical of the MHRA, especially to a researcher from another country. Participants also 
recognized that the efforts in combating counterfeit medicines in the UK had not 
subsided as a result of the MHRA’s data which showed that the number of cases found 
in the legitimate supply chain has been reducing. Participants identified three driving 
factors behind the emergence of counterfeit medicines in the country: lack of 
availability of some legitimate medicines which encourages patients to look for those 
medicines online; secondly, the light penalties for engaging in the supply of counterfeit 
medicines that makes it attractive for criminals; and thirdly, the high price of some 
branded medicines in the country. 
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The study found that some participants perceived the risk from counterfeiting of generic 
medicines to be lower in the UK than the risk to branded medicines, while others saw 
no difference. The logic of the former was, that with generic medicines sold more 
cheaply and at lower margins than their branded equivalents, counterfeiting them was 
less lucrative for the counterfeiters who would be more attracted to the profits to be 
made by supplying counterfeit branded drugs. In addition, the names of generic 
medicines are not recognized by patients. In contrast, other participants perceived the 
threat of counterfeiting as being the same for generic and branded medicines as the 
counterfeiters might gain profit from selling higher volumes of generics than branded 
medicines thus making up for the thinner margins. This difference in participants’ views 
might result from the specific backgrounds of the participants and the interests of their 
respective organisations. Having said this, the evidence from MHRA recall data, which 
shows that all recalls made were for branded medicines, indicates support for views of 
participants who rated the risk to generics as lower; also, it might reflect the focus of the 
vigilance activities i.e. more time was spent on branded products than on generics (131).  
It was also found that participants were more concerned with the threat of counterfeit 
medicines purchased online rather than through the legitimate supply chain. The reasons 
for the higher threat, according to participants, were the fact that: counterfeiters found it 
lot easier to distribute counterfeit medicines via the internet; regulatory control and 
interceding in the supply of counterfeit medicines is much more problematic when they 
come through the online channel as the location of the websites that sell counterfeit 
medicines is either unknown or in another country; the number of consumers using 
websites to buy medicines is increasing; and there are no data available revealing the 
number of websites that sold counterfeit medicines. In support of this view, it has been 
reported that 10% of men obtain medicines without prescription via the internet (132). 
According to the current study, when tackling counterfeit medicines being supplied 
online a regulatory agency would face a number of challenges. These include the need 
for cooperation and communication between countries to overcome this threat from 
online sources as the location of these websites is either unknown or is in another 
jurisdiction and building an understanding of the motivations behind consumers’ 
decisions to use the internet to buy their medicines.  
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The study found that the stakeholder participants were unanimous in recognising the 
need for any medicines regulatory agency to have a strategy in place. The strategy 
would help the agency to organise and prioritise its activities, to protect public health 
and the pharmaceutical products supply chain; and would increase awareness of the 
issues and what was being done to address them among all stakeholders. A more 
nuanced concern from the participants was that the MHRA should calibrate its 
responses to the counterfeit medicines problem in such a way which does not run the 
risk of having a negative impact on the supply chain of pharmaceutical products. The 
participants, representing the interests of their respective organisations, appeared to 
have a concern that should the MHRA be too vigorous in its attempts to raise awareness 
of the counterfeiting issue the public may lose confidence in the supply chain in the UK 
and ultimately buy less medicines from the pharmaceutical companies. It was also 
found that the stakeholders valued the efforts made by the MHRA in combating the 
counterfeit medicines in the UK. Participants acknowledged that the MHRA’s strategies 
had made the supply chain safer for patients, and that had been achieved by working 
closely with other enforcement agencies in the UK and that the agency had been making 
a valuable contribution to the stakeholders of the pharmaceuticals market. The 
statements by participants expressing support for the efforts already made by the 
MHRA were positive but highly general in nature. Again, the researcher considered the 
possibility that these stakeholders were reluctant to comment on specific issues which 
may appear to qualify their support for the agency. One possible exception was the 
emphasis placed on paying greater attention to the threat posed by the online supply 
channel with its inference that this may have not been given sufficient priority in the 
past.    
ii) Understanding stakeholder perceptions of the roles of the medicines regulatory 
agency’s stakeholders in the strategy’s development and implementation processes 
It was found that participants saw the involvement of an agency’s stakeholders in the 
process of drafting an anti-counterfeit medicines as important. Justification for this 
comes from the belief that stakeholders are more directly linked to the field activities 
and could potentially provide more valuable information than the agency might obtain 
through its own endeavours. Also, it was argued by the participants that the involvement 
of stakeholders would increase the sense of ownership and would provide a more 
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complete picture of the counterfeiting issue within the country through the sharing of 
stakeholder experiences. Therefore, the earlier engagement of stakeholders in the 
process was believed by participants to increase the likelihood of success for the 
strategy. 
Moreover, the study identified different stakeholder groups which may become part of 
the strategy’s drafting process which are representatives of pharmaceuticals industries 
(branded and generic) which may be their respective trade associations; wholesalers, 
distributors and parallel traders who could also be represented by their trade 
associations or individually; the country’s law enforcement agencies (police, customs 
and regulators of the pharmacies); and finally the pharmacists (community and hospital) 
as well as patients. However, the degree of the involvement each group might have in 
the drafting process was not addressed by the participants. This might be because 
participants did not have direct involvement or past experience with drafting an anti-
counterfeit medicines strategy.   
In terms of the specifics of responsibility for and input into the drafting process the 
participants were clear that the responsibility lay with the medicines regulatory agency. 
The role of stakeholders in the drafting process as interpreted by participants would 
commence with a consultation on an initial concise document that had been written by 
the agency. The advantage of this, as seen by participants, would be that it would help 
the agency in identifying its own strengths and weaknesses effectively conducting a 
SWOT analysis for the agency (125). This role could be performed through a committee 
involving both the agency and its stakeholders which will allow the stakeholders to 
share their feedback and advice to improve the document. The next role that 
stakeholders could perform in the drafting process as suggested by participants, would 
be following completion of the first draft of the strategy. Participants interpreted this as 
a second round of consultation for further improvements between the agency and its 
stakeholders. The possibility of also involving the general public at this stage was also 
raised by participants. Ultimately, however, it was recognised that the agency would 
finalise the document itself as those primarily responsible for it.  
The theme of stakeholder roles also covered the implementation process of an anti-
counterfeit medicines strategy and it was found that participants viewed the 
involvement of stakeholders in this process as a prerequisite. In all, seven specific roles 
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were identified: communication and sharing of information between the stakeholders 
and the agency regarding counterfeiting medicine matters; securing the pharmaceuticals 
supply chain; staying vigilant and alert to any suspicious actions regarding medicine 
counterfeiting; reporting any suspicious activities to the agency; conducting their own 
intelligence activities; supporting the agency with skills and expertise; and finally 
assisting the agency in educating and growing awareness among the members of the 
various stakeholder groups and also among the general public. 
There is a clear recognition among the participants in this study that the medicines 
regulatory agency has limitations on its resources and abilities and cannot carry out all 
aspects of the implementation by itself. Furthermore, even if it could go it alone, this 
would be neither desirable nor fully effective. Combined with this there is an 
understanding that major pharmaceutical companies are highly resourced in both 
financial and knowledge/expertise terms. They also have substantial commercial 
interests, including reputational interests, to protect, giving them substantial motivation 
to participate in the implementation of the strategy and contribute to its success. On a 
cautionary note a medicines regulatory agency would need to recognise that private 
sector pharmaceutical companies also have responsibilities to shareholders whose 
interests may not always align with the agency’s or indeed the general public’s interests.  
iii) Understanding stakeholder perceptions of the roles of pharmacists and GPs in 
combating counterfeiting medicines 
Findings showed that the role of pharmacists arise from their patient-facing position in 
the supply chain being the last link before the medicine reaches the patients and the fact 
that they deal physically with medicines every day as highlighted be participants. On 
the other hand, the GPs’ roles differently because they do not physically deal with the 
medicines. Stakeholders recognised that both pharmacists and GPs are the people most 
likely to identify problems which have affected patients and need to be aware of the 
possibility of counterfeit medicines being a cause of a patient’s problem. 
Findings identified five roles that pharmacists might do to help in the fight against 
counterfeit medicines; which are: securing their supply chain by only purchasing from 
reliable sources, remaining vigilant to any sign of counterfeiting medicines in their 
stock, receiving feedback from patients, reporting any suspicious cases to the medicine 
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regulatory agency and educating and raising awareness among the patients regarding 
counterfeit medicines especially those which are sold online. Moreover, three roles that 
GPs might play in combating counterfeit medicines have been revealed in this study 
Those roles are GPs being a channel through which to educate the patients and to raise 
awareness regarding the dangers of the counterfeit medicines, staying vigilant to the 
comments and feedback from patients that might indicate a possible counterfeit 
medicine case, and reporting to the medicine regulatory agency any suspicions that they 
might have. The proposed roles for pharmacists and GPs have also been discussed in 
some publications and, as with those publications, this study could not address the 
perceptions of pharmacists and GPs in these roles (3, 12, 91, 92, 127, 128). 
Furthermore, findings showed that stakeholder participants believed that pharmacists 
and GPs might need more information and support from the medicines regulatory 
agency in respect to counterfeit medicines as well as from their professional bodies. 
Professional journals, email and social media were seen as appropriate communication 
tools for pharmacists and GPs. The participants highlighted the need for more training 
for pharmacists and GPs in regards to the counterfeit medicines issue which could be 
fulfilled at the pre-registration or post-registration level. This study did not explore how 
pharmacists and GPs perceive these stakeholder observations.  
iv) The outcomes expected from an anti-counterfeiting medicines strategy and 
evaluation methods 
Stakeholders stressed that the agency should be realistic and have a clear vision from 
the beginning about the objectives that could be achieved from an anti-counterfeiting 
medicines strategy, as participants considered the setting and evaluation of outcomes 
would be problematic. The stakeholders believed the ultimate objective from such 
strategy is to protect the public from the risks associated with counterfeit medicines. In 
light of this, the findings identified six outcomes that could be expected from the 
strategy as seen by stakeholders. Those outcomes are: securing the pharmaceuticals 
supply chain; reduce the number of counterfeit medicines penetrating the legitimate 
supply chain; educating and raising awareness to change people’s behaviour regarding 
pharmaceutical counterfeiting issues; improve cooperation in combating counterfeiting 
medicines. Additionally, increasing the number of reports from public and health 
professionals of any suspicion of counterfeiting. Finally, increasing the number of 
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actions taken by the agency against, and closures of, unregulated websites which may 
be involved in the supply of counterfeit medicines 
This study also addressed the question of the view of stakeholder participants’ on how 
the outcomes of an anti-counterfeit medicines strategy should be evaluated. Participants 
did not see such an evaluation as an easy task for a medicines regulatory agency as the 
agency might not know the full picture the counterfeit of medicines in the country 
during the drafting stage. They thought that the agency could opt to develop certain 
metrics to help in the evaluation process to include: the number of counterfeiting cases 
recorded, the number of the reports from the public and health professionals, and the 
number of prosecutions and sentences handed down in counterfeiting cases. Participants 
also identified some novel approaches as measuring the effectiveness of a counterfeit 
medicines strategy. These included measuring the economic value of the counterfeit 
medicines seized, the hospitalization costs of patients suffering due to counterfeit 
medicines and the degree of change in public behaviour as a result of an anti-
counterfeiting medicines strategy. On the other hand, the participants did not address 
the viability of using such criteria to conduct a strategy evaluation, which would require 
the agency’s time and resources. Clearly, any benefits derived from setting up and 
conducting an evaluation process need to be weighed against resources required to so 
do, as these resources may be diverted away from the ‘front-line’. There also may be a 
tendency at an agency in a country which is believed to have a secure supply chain that 
such evaluation was unnecessary. A third possibility is the general organisational trait of 
reluctance or resistance to new methods of performance measurement, although in the 
UK such measurement of public agencies is now almost universal.  
Participants saw the role of a medicines regulatory agency stakeholders in the 
evaluation process was limited. This perception may have arisen because they were not 
part or aware of any evaluation conducted by the MHRA on its strategies, which might 
have limited their comments on the evaluation process as a whole. However, these 
participants did recognise that stakeholders could help in providing the agency with the 
data and expertise that it might need to conduct the evaluation. Finally, the participants 
made a suggestion regarding the use of an independent body to conduct this monitoring 
and evaluation as this would counteract any potential bias arising from the agency 
essentially writing its own report card. This external and independent monitoring and 
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evaluation option may be a viable alternative provided it did not involve additional costs 
or perceptions of extra bureaucracy as this may not be supported by the government. 
 
5.7 Conclusion 
This study aimed to explore stakeholders’ views on an anti-counterfeiting strategy 
which would widen understanding of the issues associated with the processes from 
development to evaluation of such a strategy by adding an additional dimension to the 
previous study with MHRA representatives. Stakeholders held the view that counterfeit 
medicines posed a risk to consumers in all countries. Also, the perceptions of 
stakeholders associated with the counterfeiting of branded and generic medicines was 
found to vary among the participants and are likely to vary in the wider stakeholder 
population which is something that the agency should take into account. The study 
showed an anti-counterfeiting strategy was considered necessary for a medicines 
regulatory agency to effectively combat counterfeit medicines. However, there was a 
note of caution from the stakeholder participants that the agency should proceed with its 
strategy in a measured way so that it did not produce undesirable consequences for the 
supply chain, such as lowering consumer confidence. The study revealed that 
participants perceived the role of stakeholders at the drafting stage to be one of 
consultation and giving feedback. Stakeholders were seen as essential to the 
implementation which would not be effective without such input. This participation in 
the implementation would be in the form of collaboration and cooperation with the 
agency, securing the supply chain and educating and raising awareness. Regarding the 
roles of pharmacists and GPs, the stakeholder participants suggested certain roles 
which, from their standpoint, may be suitable for these healthcare professionals. The 
study also explored the issues surrounding anticipated outcomes and evaluation of these 
outcomes. The anticipated outcomes included securing the pharmaceuticals supply 
chain; reducing the number of counterfeit medicines penetrating the legitimate supply 
chain; educating and raising awareness; and improved cooperation. However, this study 
reported that the role stakeholders could play in the evaluation process would be limited 
and stakeholders could only help the agency in providing the data and expertise. Also, 
this study revealed that in the opinion of agency stakeholders the agency might need to 
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develop a range of performance metrics to evaluate the progress of the strategy. Also, a 
recommendation was made by participants aimed at eliminating any bias in the 
evaluation of the strategy by appointing an independent body to conduct the evaluation 
process. To continue building a multi-dimensional conceptualisation of the processes of 
developing, implementing and evaluating an anti-counterfeit medicines strategy, the 
views and practices of pharmacists and GPs regarding counterfeit medicines and their 
perceptions of their roles in combating them will be explored in the next two chapters.   
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6.1 Introduction 
The MHRA plays the leading role in developing and implementing an anti-counterfeit 
medicines strategy as do its stakeholders; however, their contact with the end users of 
such medicines, the general public, is limited. It is health professionals such as 
pharmacists and GPs who have most of this direct contact. Pharmacists are responsible 
for dispensing medicines to patients in the UK and so form part of the supply chain, 
physically handling the medicines and directly communicating with the end user. 
Therefore, in order to build a multi-dimensional, triangulated conceptualisation of the 
processes of developing, implementing and evaluating an anti-counterfeit medicines 
strategy and so address the research problem, then views, perceptions and practices of 
pharmacists need to be understood.   The quantitative data collected from pharmacists is 
intended to provide a broadly representative picture of the views preferences and 
practices of the pharmacist population concerning a range of counterfeit medicines 
issues.  
Pharmacists are frequently the final link in the medicines supply chain before medicines 
reach the patients and therefore are the last barrier protecting patients from counterfeit 
medicines. The roles that pharmacists can play in combating counterfeit medicines have 
been identified in the literature as sourcing their medicines from secure supply chains, 
being vigilant for any suspicion of counterfeited medicines, reporting any of those 
suspicions to the national medicines regulatory agency and raising patients’ awareness 
regarding counterfeit medicines (3, 12, 91, 92). These roles were also identified by the 
participants from both the MHRA study (chapter 4) and the stakeholders study (chapter 
5). However, the views of pharmacists themselves on their roles to combat counterfeit 
medicines have not been examined in the literature, nor by the MHRA.  
In addition, the MHRA, the WHO and many other national and international medicines 
agencies highlighted the need for the agencies to have dialogue with pharmacists (as 
one of the health professionals groups) to improve their awareness and educate them on 
counterfeit medicines. Also, findings from participants in the MHRA study (chapter 4) 
and the stakeholder study (chapter 5) addressed how the respective participants viewed 
the communication methods with pharmacists. But, neither the literature nor the two 
earlier studies (chapters 4 and 5) examined the awareness of pharmacists about 
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counterfeit medicines nor the views of pharmacists about the communication methods 
that could be used by the agencies. However, the MHRA with cooperation with the RPS 
and DDA had tried to have communication about counterfeit medicines with 
pharmacists by publishing a guidance leaflet “Counterfeit Medicines Advice for 
Healthcare Professionals” (appendix 5). This guidance was aimed to improve 
pharmacists’ awareness of counterfeit medicines by educating them about the definition 
of counterfeit medicines and highlighting the counterfeit medicines situation in the UK. 
Also, the guidance identified the actions to be taken should a suspected case of 
counterfeiting arise; and it offered a few suggestions for pharmacists which would help 
them in sourcing their medicines from a secure supply chain (10, 25, 39, 90). Then 
again, the awareness of pharmacists about this guidance, whether or not they adopted 
the recommendations, and whether this guidance has influenced the pharmacists 
practice to a secure supply chain remained unknown. Therefore, this highlighted a need 
to identify the pharmacists’ awareness and experience of counterfeit medicines as well 
as examining their views of their roles in combating them. Addressing the research 
problem requires constructing a complete conceptualisation of the process of 
developing, implementing and evaluating the strategy which requires the data collected 
in this study to add the pharmacist dimension.   
 
6.2 Aims and Objectives 
This study aimed to understand the views and describe the roles of community 
pharmacists in combating counterfeit medicines.   
Therefore, the objectives of the study were: 
- to describe the knowledge and experience of pharmacists working in England 
about counterfeit medicines and what they saw as educational opportunities 
available to them to enhance this.  
- to identify the current practices of England’s community pharmacists in securing 
the medicine supply chain. 
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- to describe how England’s community pharmacists view their roles in 
combating the counterfeiting of medicines. 
- to identify what methods community pharmacists working in England preferred 
for a medicines regulatory agency to communicate with them. 
- to examine how educational opportunities and past experience of England’s 
community pharmacists affected their views and practice relating to counterfeit 
medicines. 
 
6.3 Methods 
In this study the aim was to gain an understanding of pharmacists’ views on a range of 
issues related to counterfeit medicines. As this constituted a large and geographically 
spread population, and as the sample needed to offer a reasonable degree of 
generalizability for the results, certain research methods were ruled out, including the 
face-to-face interviews used in the previous two studies (chapters 4 and 5).  It was 
decided that a survey questionnaire would be a more appropriate method of data 
collection and as the full addresses of the workplaces of pharmacists were readily 
identifiable it was further decided to administer this by post. 
This study is one of two aimed at providing support to the findings of the previous two 
studies involving MHRA participants and MHRA stakeholder participants. Including a 
quantitative research design offered the means of triangulating within this group of 
studies by addressing its objective of describing the knowledge and experience of 
England’s community pharmacists on the counterfeit medicines issue. The quantitative 
research method is most appropriate where pre-existing knowledge must be taken into 
consideration; this allows the researcher to employ standardised data collection methods 
to document any prevalence of knowledge being examined. In this study the researcher 
needed quantifiable answers to questions aimed at establishing the distribution of types 
of views and practices across members of a group, the extent to which these views and 
practices were shared and what variables may influence the holding of a particular view 
or the adoption of a particular practice. All these requirements indicate that a 
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quantitative study was appropriate. Hence, a retrospective descriptive survey was used 
to describe the sample and to examine any associations between variables (102). 
The quantitative methods used in this study were selected because they were most 
appropriate for the second objective of the study which was to describe and understand 
the views and roles of pharmacists and GPs in combating counterfeit medicines. These 
methods were also appropriate for accessing the population and were consistent with the 
desire for generalisability. The benefits of triangulation as “an opportunity to enrich 
research findings and deepen insight” were a consequence of the choices as the 
qualitative approach of the first two studies could now be complemented and 
strengthened with quantitative input (133).   
 
6.3.1 Ethical approval 
This study has been approved by University of East Anglia Faculty of Medicine and 
Health Ethics Committee (Appendix 3.1), no NHS ethical approval required as this 
study only included community pharmacists. 
 
6.3.2 Questionnaire Development 
6.3.2.1 Questionnaire design 
This study is designed based on the findings from two qualitative studies carried out by 
the researcher in respect of developing a national strategy for a medicines regulatory 
agency to combat counterfeit medicines (chapter 4 and chapter 5). Those studies 
captured the views of members of the MHRA (Chapter 4) and of key stakeholders 
(Chapter 5). The participants from those studies defined some of the roles that could be 
carried out by pharmacists to assist in combating counterfeit medicines. Also, those 
participants described the methods that could be used by the MHRA to communicate 
with pharmacists. As well as using the outcomes from those previous studies, this study 
is also based on the guidance leaflet for pharmacists and dispensing doctors titled 
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“Counterfeit Medicines Advice for Healthcare Professionals”, which was published by 
the MHRA, the RPS and the DDA (10). 
Accordingly, the researcher designed a questionnaire to be sent to community 
pharmacists working in England (Appendix 3.2). The questionnaire aimed to cover the 
aims and objectives of this study. Section 1 of the questionnaire covered any past 
experiences community pharmacists might have had of counterfeit medicines. Section 2 
aimed to cover any education or training opportunities experiences of counterfeit 
medicines that community pharmacists might have had, and any recommendations they 
may have for such education or training opportunities in the future. Section 3 of the 
questionnaire covered the dispensing and purchasing practices of the community 
pharmacists. Section 4 sought community pharmacists’ views on their role in combating 
counterfeit medicines, and what would be the best method to communicate information 
on counterfeit medicines to them. Section 5 of the community pharmacists’ 
questionnaire covered personal information of the participants which would help the 
researcher to show that the study participants were representative of the general 
community pharmacist population. 
 
6.3.2.2 Questionnaire validity 
Validity in a survey study can be measured through assessing how far the questions 
collect accurate data and whether or not they are relevant to the study objective (117). 
To achieve face validity, the questionnaire was evaluated and answered by academics 
and practice pharmacists working at the UEA’s Pharmacy School prior to launching the 
survey. Moreover, the face validity has been further examined during the piloting stage. 
Content validity was established in this research through the careful selection and 
refinement of items during questionnaire development, based on the qualitative data 
derived from the previous studies as well as on the evaluation and judgement of peers at 
the UEA’s Pharmacy School. 
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6.3.2.3 Improving the response rate 
To increase the response rate for these questionnaires, the researcher applied the 
findings of the review study conducted by Edwards et al. (2009) (134). The 
questionnaire was designed to be short and should not take more than 10 minutes to 
complete. The UEA logo was added to the front page to indicate that these 
questionnaires are sponsored by the university. The researcher reassured recipients in 
the invitation letter and on the first page of the questionnaires that confidentiality would 
be maintained and that questionnaires were anonymous. All pharmacies premises 
included in the study were contacted by phone to obtain the name of potential 
participants and thereby enable the invitation letter to be personalised. All invitation 
letters were personalized and all the potential participants received a pen with the UEA 
logo as an unconditional incentive. A postcard has been included with the questionnaire 
which completed and sent back by participants. The postcard allowed the researcher to 
identify the participants who required follow-up. A stamped addressed return envelope 
was provided with each questionnaire to increase the response rate. A follow-up letter, 
which contained a second copy of the questionnaire, was sent to potential participants 
who had yet to return the postcard.  
 
6.3.3 Participants and sample size calculation 
6.3.3.1 Sampling unit 
The target population for this study was England’s community pharmacists; it has been 
reported that the number of community pharmacists working in England is 11,495 
(135). The researcher used English pharmacy premises as the sampling unit which were 
randomly selected. A database was provided to the researcher by the General 
Pharmaceutical Council (GPhC). Using the pharmacy premises as a unit of sampling is 
believed to be an acceptable methodology for sampling pharmacists (117). 
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6.3.3.2 Sample size estimation 
A final sample size of 400 respondents provides 95% CI of + or – 3% around a response 
to question of 10%; and + or – 5% around a response to question of 50%. Assuming that 
60% the sample return the questionnaire the researcher needed to post the questionnaire 
to approximately 650 pharmacists (136). 
 
6.3.3.3 Method of sampling 
The random sampling method is desirable as it allows the application of probability 
statistics and generalisation to the population from which the sample is drawn (96). 
Moreover, the random sampling method is fundamental to achieving external validity 
for the study (102). The researcher used the random sampling (using a random number 
generator provided within Excel) to identify 1 in 20 pharmacy premises which were 
included in this study. These pharmacy premises were contacted by phone and the 
community pharmacists who were working at the time of calling were asked to 
participate in this research. The total number of community pharmacists included in this 
study was 660. 
 
6.3.4 Implementation and follow-up 
6.3.4.1 Questionnaire implementation 
For the pharmacists’ survey, once the pharmacy premises had been selected, the names 
of the pharmacists who agreed to participate were identified. This assisted the 
researcher to personalise the invitation letter and the envelope sent to each pharmacist. 
Each envelope sent to a pharmacist included a personalised invitation letter (Appendix 
3.3), a questionnaire (Appendix 3.2), a prepaid envelope to return the questionnaire, a 
pharmacist’s postcard (Appendix 3.4), a prepaid envelope to return the postcard and an 
incentive pen. 
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6.3.4.2 Follow-up process 
Those pharmacists in the sample who had not completed and returned a postcard 
received a follow-up reminder letter (Appendix 3.5) three weeks after the first letter. A 
copy of the questionnaire was included with the reminder letter. No more action was 
taken after this point. 
 
6.3.5 Data analysis 
All data were analysed using Microsoft Excel and the Statistical Package for the Social 
Sciences (SPSS) software. The data were summarised using descriptive statistics; also, 
Fisher's exact test, chi-squared analysis, the Mann-Whitney U test and Kruskal-Wallis 
test were used to compare pharmacist groups based on their responses on the 
questionnaires. The chi-squared test is considered invalid if 20% or more of the cells 
have an expected count of less than 5. 
 
6.4 Results 
6.4.1 Response rates 
The initial response rate for the pilot stage (65 questionnaires) after one follow up was 
64.6% (42 out of 65 questionnaires). No modification was applied to the invitation letter 
or the questionnaires as the pilot stage showed a good response rate. The response rate 
after the pilot stage reduced to 33.2% (194 out of 585 questionnaires); 490 pharmacists 
(83.8%) received a follow-up reminder letter. 
The overall response rate to the pharmacists’ questionnaire was 36.3% (236 out of 650 
questionnaires). In addition, the overall missing data from the pharmacists’ answers to 
the questionnaire was 0.87%. 
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6.4.2 Demographic data 
Table 6.1 summarises the demographics of respondents and provides a comparison 
between independent and multiple pharmacies. It can be seen that a greater proportion 
of respondents from independent pharmacies were male.  
Table 6.1 Pharmacists’ gender and working place 
 
No. (%) 
Working at 
Independent community 
pharmacy 
Multi-chain community 
pharmacy 
Gender 
Male 138 (58.5%) 63 (68.5%) 74 (51.4%) 
Female 97 (41.1%) 28 (30.4%) 69 (47.9%) 
Missing 1 (0.4%) 1 (1.1%) 1 (0.7%) 
 Total 236 92 144 
 
In relation to the pharmacists’ length of service; 22.9% (54 pharmacists) of the study 
sample had a length of service of 5 years or less, 9.7% (23 pharmacists) of the 
pharmacists 6 to 10 years, 7.2% (17 pharmacists) 11 to 15 years, 5.5% (13 pharmacists) 
16 to 20 years and 11% (26 pharmacists) between 21 and 25 years. Finally, the majority 
(43.2% - 102 pharmacists) of this study sample had a length of service of more than 25 
years. Only one pharmacist (0.4%) did not answer the length of service question.  
For the purpose of data analysis, the pharmacists’ lengths of service were re-grouped to 
three main categories; 0 – 10 years, 11 – 25 years, and over 25 years. In comparing the 
study’s sample with pharmacists general population (only pharmacists’ age data 
available) (137); table 6.2 shows that whilst the age range of the general population of 
pharmacists is normally distributed, the study sample is bi-modal with greater 
proportions in the younger and older groups.  
 
 
Chapter 6: Community pharmacists’ views of their role in combating counterfeit 
medicines 
 
PhD Thesis: Developing a national strategy for combating counterfeit medicines     186 
Table 6. 2 Pharmacists’ length of service (n=235) 
Pharmacists sampled Pharmacists’ general population1 
Length of service Percentage of the 
study sample Age 
Percentage of General 
population 
0 – 10 years 32.6% less than 30 years 21.6% 
11 – 25 years 23.7% 30 – 49 years 54.3% 
over 25 years 43.2% 50 years or more 24.2% 
1
 Phelps A, Nass L, Blake M. GPhC Registrant Survey 2013: General Pharmaceutical Council; March 2014. 
http://www.pharmacyregulation.org/sites/default/files/gphc_registrant_survey_2013_main_report_by_natcen.pdf 
With respect to pharmacists’ membership of professional bodies, 127 of the pharmacists 
in the study sample were members of the Royal Pharmaceutical Society (RPS), 99 of 
the pharmacists were members of the National Pharmacy Association (NPA), and 87 of 
the pharmacists were members of the Pharmacists Defence Association (PDA). Four 
pharmacists (1.7%) did not state a professional body. 
 
6.4.3 Descriptive analysis 
6.4.3.1 Pharmacists’ experiences of the counterfeiting issue 
In relation to any past experiences the pharmacists had had (Figure 6.1), only 52 (22%) 
pharmacists in the study sample had had an experience of a medicine being recalled due 
to suspicion of counterfeiting. In addition, 23 of those pharmacists reported having had 
only one experience of this kind of recall, 20 pharmacists reported experiencing 
medicines being recalled between two and five times, and one pharmacist had 
experienced it eight times. The other two pharmacists did not declare the frequency. 
As to whether pharmacists had had any past experiences of counterfeit medicines 
through their supply chain, 22 (9.3%) pharmacists reported they had had this 
experience. Also, thirteen of the pharmacists had had this experience once or twice, and 
three pharmacists had had it three times or more. 
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For the question of whether the pharmacist had been offered a product from his 
wholesaler or distributor that he or she suspect might be counterfeit, only 6 (2.5%) 
pharmacists reported they had had such an experience. Three pharmacists believed they 
had had it once, and one pharmacist reported he had had it more than 10 times. 
Thirty (12.7%) pharmacists in this study had experience of a patient reporting or 
showing a medicine that might be counterfeit. While 23 of the pharmacists had had this 
experience between one and four times, and two pharmacists had had such experiences 
five times or more. 
In respect of any experience of adverse effects due to counterfeit medicines that a 
patient might have used, 11 (4.7%) pharmacists have had such an experience. Also, five 
pharmacists had one such experience, one pharmacist reported three such experiences, 
and one pharmacist had had this kind of experience a few times. 
Figure 6.1 Pharmacist’s experiences of counterfeit medicine issue 
 
Table 6.3 shows the actions undertaken by pharmacists as a result of their past 
experience with counterfeit medicines. Five pharmacists selected “Other”; from those 
one said the medicines have been destroyed, one said the medicine has been returned to 
the patient, and three pharmacists did not provide any information. 
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Table 6.3 Pharmacists’ selection for their action as a result of counterfeiting experience 
(n=236) 
 Rank of action taken by the pharmacists No. (%) 
1 Gave the patient advice 20 (36%) 
2 Isolated the item from their stock 13 (24%) 
3 Did not do anything 9 (16%) 
4 Other 5 (9%) 
5 Used the Yellow Card Scheme to report the 
incident 4 (7%) 
6 Communicated to someone within their 
organization 4 (7%) 
On the action that the pharmacists would take in the future if they suspected that a 
medicine could be counterfeit, the actions selected by this study sample are ranked in 
order of frequency stated in table 6.4. Seven of the respondents selected “Other”; from 
those: two said will give an advice to the patient, one will report it to the police, one 
will contact the patient, one will give it back to the patient, and two were missing.   
Table 6.4 Pharmacist stated future action when counterfeiting suspected 
 Rank of action will be taken by the pharmacists No. (%) 
1 Report to the supplier of the medicine 202 (85.6%) 
2 Isolate the item from the stock 185 (78.4%) 
3 Report to MHRA 149 (63.1%) 
4 Communicate to someone within their organization 134 (56.8%) 
5 Report to the manufacturer of the medicine 112 (47.5%) 
6 Report to the pharmacist’s professional body 43 (18.2%) 
7 Other 7 (3%) 
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6.4.3.2 Pharmacists’ education in respect to counterfeit medicines 
issues 
Only 10.6% (25 pharmacists) of this study sample had previously received formal 
education or training programme regarding counterfeit medicines. From those, 15 
pharmacists had received the past education or training programme within their 
undergraduate degree, 3 pharmacists received it within the pre-registration year and 7 
pharmacists post-registration. 
Furthermore, figure 6.2 shows types of educational or training opportunity that the 
pharmacists had had in the past regarding counterfeit medicines. The most common 
types were workshops and journal articles.  
Figure 6. 2 The type of pharmacists’ past education or training programme (n=25) 
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With respect to the education and training programme that should be given to 
pharmacists regarding the counterfeit medicines issue that been selected by the 
pharmacists, 30.1% (80 pharmacists) recommended the education and training 
programme take place within an undergraduate degree at pharmacy school, 35.6% (84 
pharmacists) of the study population said it should be within the pharmacists pre-
registration year, and 33.9% (80 pharmacists) preferred it to be delivered at the post-
registration stage. 
Moreover, 105 pharmacists preferred their education and training on counterfeit 
medicines issues (table 6.5), to be delivered through workshops, 84 pharmacists 
preferred distance learning, and 47 pharmacists preferred journal articles. However, few 
pharmacists selected more than one preferred method.  
Table 6. 5 Pharmacists’ preferred delivery method for education or training programme 
 Rank of preferred education and training delivery method No. (%) 
1 Workshop 105 (44.5%) 
2 Distance learning 84 (35.6%) 
3 Journal articles 47 (19.9%) 
4 Conference 18 (7.6%) 
5 Other 2 (0.8%) 
 
6.4.3.3 Pharmacists’ dispensing and purchasing practice 
Figure 6.3 summarizes dispensing practices performed by the community pharmacists. 
It can be seen that the most common approach reported by pharmacists was to checking 
the package seal and checking for an altered expiry date; while, checking all printing on 
flaps and surfaces of the box were reported to be undertaken by a very small proportion. 
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Figure 6. 3 Pharmacists’ dispensing practices (n=236) 
 
 
Table 6.6 summarizes purchasing practices performed by the pharmacists and relevant 
to the counterfeiting issue. This table shows that the majority of pharmacists who 
perform purchasing practice were trying to secure their supply chain. Also, pharmacists 
reported their practices in the event that they were offered a product at an unusually low 
price or in an unusually high quantity, which show that they will be very cautious when 
they receive such offers. 
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Table 6. 6 Pharmacist reported purchasing practices 
Purchasing practice 
Performed 
by someone 
else 
Performed by pharmacists 
Total Never Rarely Some-times Often Always 
Establish integrity of the 
supplier prior to ordering 93 (39.6%) 142 
12 
(8.5%) 
9   
(6.3%) 
6  
(4.2%) 
13 
(9.2%) 
102 
(71.8%) 
Establish a list of approved 
suppliers 98 (41.7%) 137 
11   
(8%) 
7     
(5.1%) 
4  
(2.9%) 
14 
(10.2%) 
101 
(73.7%) 
Develop a list of products 
purchased only from the 
manufacturer or authorised 
distributers 
104 (44.3%) 131 24 (18.6%) 
9      
(7%) 
11 
(5.8%) 
16 
(12.4%) 
71  
(55%) 
Purchasing practice Not 
applicable 
Performed by pharmacists 
Total 
Accept 
the offer 
Treat with 
caution 
Reject 
the offer 
If a product is being offered at 
an unusually cheap price 105 (44.7%) 129 10 (7.8%) 95 (73.6%) 24 (18.6%) 
If a product is being offered in 
an unusually large quantity 107 (44.5%) 128 7 (5.5%) 83 (64.8%) 38 (29.7%) 
 
With regard to the place of work for pharmacists who reported not carrying out a 
particular purchasing practice is shown in figure 6.4. It can be seen that pharmacists 
employed in multi-chain pharmacies were not involved in the purchasing practice. 
Chapter 6: Community pharmacists’ views of their role in combating counterfeit 
medicines 
 
PhD Thesis: Developing a national strategy for combating counterfeit medicines     193 
Figure 6. 4 Place of work of those pharmacists who reported not performing a particular 
purchasing practice 
 
 
6.4.3.4 Pharmacists’ views on their roles in combating counterfeit 
medicines 
The roles pharmacists believed could be carried out by them in combating counterfeit 
medicines are shown in figure 6.5. 217 pharmacists saw it as their duty to report any 
suspicion of counterfeit medicines to the medicines regulatory agency. Whereas, the 
other 17 pharmacists did not believe this is the role of the pharmacist; five of them said 
it would be the responsibility of someone from their organization and three pharmacists 
said it was a supplier responsibility. 
For the responsibility of raising patient awareness about counterfeit medicines, 190 
pharmacists said it would be part of the pharmacist’s role to raise patients’ awareness of 
counterfeit medicines. On the other hand, 43 pharmacists did not agree that it was a 
pharmacists responsibility; and among them 22 pharmacists (9.3%) saw it as would be 
the government’s responsibility to raise patient awareness. 
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With regard to providing the patient with advice about the counterfeit medicines issue, 
211 of the pharmacists in the study said it would be part of their role in combating 
counterfeit medicines. But, the other part of the study sample, 22 pharmacists did not 
see it as their duty to provide the patient with advice about counterfeit medicines; and 6 
of them (2.5%) saw it as the government’s responsibility. 
Figure 6. 5 Pharmacists’ view on their roles in combating counterfeit medicines (n=236) 
 
6.4.3.5 The communication methods preferred by pharmacists 
For the methods of communication that the pharmacists in this study preferred to 
receive information regarding counterfeit medicines issue (figure 6.6); it can been seen 
that pharmacists preferred such information through a professional journal or email. 
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Figure 6. 6 Pharmacists’ selection of their preferred methods of communication (n=236) 
84 (35.6%)
51 (21.6%)
46 (19.5%)
36 (15.3%)
10 (4.2%)
4 (1.7%)
4 (1.7%)
1 (0.4%)
9
Through professional journal Through email Through their professional bodies
Through their organization Through Fax Through Press release
Through General media Post
 
 
6.4.4 Comparative analysis 
6.4.4.1 Past pharmacist experiences 
This section compares the pharmacists’ opinion between those who had past experience 
about counterfeit medicines and the pharmacists who did not have such experiences. 
The researcher formulated the hypothesis that any past expertise regarding counterfeit 
medicines would reflect on the answers given by the pharmacists. To examine the 
hypothesis five comparisons (future actions, preferences for education, pharmacist role, 
preferred method of communication and dispensing/purchasing practices) have been 
conducted to compare data between the 74 pharmacists who said they had had an 
experience with counterfeit medicines and the 162 pharmacists who had not had any 
such experience.  
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i) Comparisons of opinion on the future actions 
Table 6.7 shows the comparison between the pharmacists who had had an experience 
and those who had not in their selection of the actions that they would take in case of an 
incidence of counterfeit medicines. The results show no significant difference between 
the two pharmacist groups. 
Table 6.7 Past experiences and pharmacists’ stated future actions 
Pharmacists’ selection for their future action 
Pharmacists with past counterfeit 
medicine experience 
No. (%) 
P* 
No experience Experience 
Total 162 (68.6%) 74 (31.4%) 
Report to the medicine’s supplier 143 (88.3%) 60 (81.1%) 0.158 
Report to the medicine’s manufacturer 82 (50.6%) 30 (40.5%) 0.162 
Report to MHRA 108 (66.7%) 41 (55.4%) 0.110 
Isolate the item from the stock 127 (78.4%) 57 (77%) 0.866 
Report to someone within their organization 92 (56.8%) 40 (54.1%) 0.778 
Report to the pharmacists’ professional body 25 (15.4%) 19 (25.7%) 0.072 
Other 4 (2.5%) 6 (8.1%) 0.075 
* Fisher's exact test 
ii) Comparisons of opinion on the future education preferences 
Table 6.8 shows the responses of the two pharmacist groups regarding where any 
education or training programmes about counterfeit medicines should be delivered. 
Moreover, table 6.9 highlights which kind of education or training programmes each 
pharmacist group recommended. There was no significant difference between the 
pharmacists with past counterfeiting experiences and the pharmacists without such an 
experience. 
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Table 6. 8 Past experiences and the recommendations for future education timing 
Pharmacists’ selection for future education 
timing 
Pharmacists with past counterfeit 
medicine experience 
No. (%) 
P* 
No experience Experience 
Total 161 (68.2%) 74 (31.4%) 
Within undergraduate degree 42 (26.1%) 25 (33.8%) 
0.478 Within the pre-registration year 59 (36.6%) 24 (32.4%) 
in the post- registration 60 (37.3%) 25 (33.8%) 
* Chi-squared analysis 
Table 6. 9 Past experience and the recommendations for future education preferences 
Pharmacists’ selection for future education 
delivery method 
Pharmacists with past counterfeit 
medicine experience 
No. (%) 
P* 
No experience Experience 
Total 161 (68.2%) 74 (31.4%) 
Workshop 71 (44.1%) 34 (45.9%) 0.888 
Conference 10 (6.2%) 8 (10.8%) 0.290 
Distance learning 56 (34.8%) 28 (37.8%) 0.663 
Journal articles 36 (22.4%) 11 (14.9%) 0.220 
Other 2 (1.2%) 0 1.000 
* Fisher's exact test 
iii) Comparisons of opinion on the pharmacist roles 
This comparison (table 6.10) will address the view of the study sample on the 
pharmacists’ roles in combating counterfeit medicines between the pharmacists with 
past experience and pharmacists without past experience. There is no significant 
difference found between the two pharmacists groups. 
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Table 6. 10 Past experience on pharmacist’s role 
Role of pharmacist in combating counterfeit 
medicines 
Pharmacists with past counterfeit 
medicine experience 
No. (%) 
P* 
No experience Experience 
Total 160 (67.8%) 74 (31.4%) 
Reporting to the medicines regulatory agency 151 (94.4%) 66 (89.2%) 0.179 
Raising patient awareness about counterfeit 
medicines 133 (93.6%) 57 (77%) 0.276 
Advice patient about counterfeit medicines 146 (91.8%) 65 (87.8%) 0.343 
* Fisher's exact test 
iv) Comparison of opinions on the preferred methods of communication 
Table 6.11 shows that there are no real differences in the preferred methods of 
communication regarding counterfeiting information between pharmacists with and 
without experience of it.  
Table 6. 11 Past experience on the preferred communication methods 
Pharmacists’ preferred communication method 
Pharmacists with past counterfeit 
medicine experience 
No. (%) 
P* 
No experience Experience 
Total 162 (68.6%) 74 (31.4%) 
Professional journal 62 (38.3%) 22 (29.7%) 
Te
st
 
in
v
al
id
 
Professional bodies 30 (18.5%) 16 (21.6%) 
Via their organization 24 (14.8%) 12 (16.2%) 
Fax 5 (3.1%) 5 (6.8%) 
Email 33 (20.4%) 18 (24.3%) 
Press release 4 (2.5%) 0 
General media 3 (1.9%) 1 (1.4%) 
Other 1 (0.6%) 0 
* Chi-squared analysis  
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v) Comparisons between dispensing and purchasing practices 
Tables 6.12 and 6.13 compare the pharmacists’ past experiences of counterfeit 
medicines with reported pharmacists’ dispensing and purchasing practices that would 
help to protect patient from counterfeit medicines. No significant differences were seen 
between those who had previous experiences of counterfeit medicines and those without 
experience. 
Table 6. 12 Past experiences and reported dispensing practices 
Dispensing practice 
Pharmacists with past counterfeit medicine 
experience 
P* 
No experience Experience 
No. Median (IQ)+ No. Median (IQ)+ 
Check the package seal 162 5 (4, 5) 72 5 (4, 5) 0.308 
Check for an altered expiry date 162 5 (3, 5) 73 4 (2.5, 5) 0.585 
Check the physical characteristics of the 
product 161 3 (2, 5) 74 3 (2, 3) 0.974 
Check for any signs of a removed or switched 
product label 161 4 (2, 3.5) 74 3 (2, 4) 0.359 
Check for subtle changes in the product’s 
package 161 3 (2, 4) 74 3 (2, 4) 0.382 
Check the package for changes in paper 
texture, size and thickness of the labels 160 2 (1, 3) 74 2 (2, 3) 0.526 
Check for changes in fonts and font sizes, print 
colour or raised print 160 2 (1, 3) 74 2 (2, 3) 0.593 
Check all printing on flaps and surfaces of the 
box 160 2 (1, 3) 73 2 (2, 3.5) 0.356 
Check for overt security (e.g. hologram) 161 3 (2, 4) 73 3 (2, 4) 0.152 
Check for changes in the size of the container 161 3 (2, 4) 74 1 (2, 4) 0.995 
* Mann-Whitney U test   + (1=Never; 5=Always) 
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Table 6. 13 Past experiences and reported purchasing practices 
Purchasing practice 
Pharmacists with past counterfeit medicine 
experience 
P* 
No experience Experience 
No. Median (IQ) No. Median (IQ) 
Establish integrity of the supplier prior to 
ordering+ 102 5 (4, 5) 40 5 (4.25, 5) 0.639 
Establish a list of approved suppliers+ 97 5 (4, 5) 40 5 (4, 5) 0.968 
Develop a list of products purchased only from 
the manufacturer or authorised distributers+ 93 5 (3, 5) 38 4 (2, 5) 0.331 
If a product is being offered at an unusually 
cheap price# 95 2 (2, 2) 36 2 (2, 2) 0.529 
If a product is being offered in an unusually 
large quantity# 96 2 (2, 3) 34 2 (2, 2) 0.71 
* Mann-Whitney U test   + (1=Never; 5=Always)  
# (1=Accept the offer; 2= Treat with caution, 3=Reject the offer) 
 
6.4.4.2 Past education or training programmes 
Past educational or training opportunities which pharmacists had had regarding 
counterfeit medicines is examined by comparing the answers of the pharmacists who 
had had a chance to have this with those who had received no previous education or 
training on the topic. The researcher formulated the hypothesis that any educational or 
training opportunity about counterfeit medicines would reflect on the answers given by 
the pharmacists. To test the hypothesis five comparisons (future actions, preferences for 
education, pharmacist role, preferred method of communication and 
dispensing/purchasing practices) were conducted to compare data between the 25 
pharmacists who said they had had an educational or training opportunity and the 211 
pharmacists who had not had any such experience.  
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i) Comparisons of opinion on the future actions 
Table 6.14 provides a comparison between those pharmacists who have had past 
educational experience of counterfeit medicines and those who haven’t on their reported 
actions in cases of an incidence of suspected counterfeiting. The only significant 
difference was found with reporting to the MHRA, as those with past educational 
experience are more likely to report to the MHRA. 
Table 6. 14 Past educational experiences and pharmacists’ stated future actions 
Pharmacists’ selection for their future action 
Pharmacists past educational or 
training experience 
No. (%) 
P* 
No experience Experience 
Total 211 (89.4%) 25 (10.6%) 
Report to the medicine’s supplier 182 (86.3%) 21 (84%) 0.761 
Report to the medicine’s manufacture 105 (49.8%) 7 (28%) 0.055 
Report to MHRA 128 (60.7%) 21 (84%) 0.027 
Isolate the item from the stock 167 (79.1%) 17 (68%) 0.208 
Report to someone within their organization 120 (56.9%) 12 (48%) 0.404 
Report to the pharmacists’ professional body 36 (17.1%) 8 (32%) 0.099 
Other 8 (3.8%) 2 (8%) 0.287 
* Fisher's exact test 
ii) Comparisons of opinion on the future education preferences 
Tables 6.15 and 6.16 shows the responses of the two pharmacist groups regarding the 
timing and delivery of any education or training programmes for pharmacists regarding 
counterfeit medicines. No significant differences were found between the pharmacist 
with past experience and the pharmacists without past experience in their selection for 
the timing of educational or training programs regarding counterfeit medicines. For the 
educational or training program type it was found that those who had had previous 
experience of counterfeit medicine were more likely to prefer training to be provided at 
conferences. 
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Table 6. 15 Past educational experiences and the recommendations for future education 
timing 
Pharmacist’s selection for future education 
timing 
Pharmacists with past educational 
or training experience 
No. (%) 
P* 
No experience Experience 
Total 211 (89.4%) 25 (10.6%) 
Within undergraduate degree 58 (27.6%) 9 (36%) 
0.586 Within the pre-registration year 74 (35.2%) 9 (36%) 
in the post- registration 78 (37.1%) 7 (28%) 
* Chi-squared analysis 
Table 6. 16 Past educational experience and the recommendations for future education 
preferences 
Pharmacists’ selection for future education 
delivery method 
Pharmacists with past educational 
or training experience 
No. (%) 
P* 
No experience Experience 
Total 211 (89.4%) 25 (10.6%) 
Workshop 92 (43.8%) 13 (52%) 0.525 
Conference 12 (5.7%) 6 (24%) 0.006 
Distance learning 79 (36.7%) 5 (20%) 0.121 
Journal articles 44 (21%) 3 (12%) 0.428 
Other 1 (0.5%) 1 (4%) 0.202 
* Fisher's exact test 
iii) Comparisons of opinion on the pharmacist roles 
This comparison (table 6.17) will address the view of the study sample on the 
pharmacists’ roles in combating the counterfeiting of medicines between the 
pharmacists with past educational or training experience and pharmacists without such 
experience. There is no significant difference found between the two pharmacists 
groups. 
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Table 6. 17 Past educational experience on pharmacist’ role 
Role of pharmacist in combating counterfeit 
medicines 
Pharmacists with past educational 
or training experience 
No. (%) 
P* 
No experience Experience 
Total 211 (89.4%) 25 (10.6%) 
Reporting to the medicines regulatory agency 193 (92.3%) 24 (96%) 1.000 
Raising patient awareness about counterfeit 
medicines 167 (80.3%) 23 (92%) 0.183 
Advice patient about counterfeit medicines 187 (89.9%) 24 (96%)) 0.482 
* Fisher's exact test 
iv) Comparisons of opinion on the preferred methods of communication 
The comparison that will examine pharmacists’ past educational or training experience 
of counterfeit medicines and preferred methods of communication (table 6.18), showed 
that both groups of the pharmacists preferred similar methods of communication.  
Table 6. 18 Past educational experience on the preferred communication methods 
Pharmacists’ preferred communication method 
Pharmacists’ with past educational 
or training experience 
No. (%) 
P* 
No experience Experience 
Total 211 (89.4%) 25 (10.6%) 
Professional journal 76 (36%) 8 (32%) 
Te
st
 
in
v
al
id
 
Professional bodies 40 (19%) 6 (24%) 
Via their organization 31 (14.7%) 5 (20%) 
Fax 9 (4.3%) 1 (4%) 
Email 46 (21.8%) 5 (20%) 
Press release 4 (1.9%) 0 
General media 4 (1.9%) 0 
Other 1 (0.5%) 0 
* Chi-squared analysis  
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v) Comparisons of the dispensing and purchasing practices 
This comparisons (Table 6.19) examines the pharmacists’ past educational or training 
experience covering counterfeit medicines on the pharmacist’s dispensing practices that 
would help to protect patient from counterfeit medicines. Also, table 6.20 compares the 
pharmacists’ purchasing practices with respect to the pharmacists’ past educational or 
training experience. The p-values in the both tables show no significant difference 
between the pharmacists with past educational or training experience and the 
pharmacists without such experience. 
Table 6. 19 Past educational experience and dispensing practices 
Dispensing practice 
Pharmacists’ past educational or training 
experience 
P* 
No experience Experience 
No. Median (IQ)+ No. Median (IQ)+ 
Check the package seal 209 5 (4, 5) 25 5 (4, 5) 0.516 
Check for an altered expiry date 210 4.5 (3, 5) 25 4 (2, 5) 0.137 
Check the physical characteristics of the 
product 210 3 (2, 3.25) 25 3 (2, 3) 0.883 
Check for any signs of a removed or switched 
product label 210 3 (2, 4.25) 25 4 (2.5, 4) 0.442 
Check for subtle changes in the product’s 
package 210 3 (2, 4) 25 3 (2, 4) 0.971 
Check the package for changes in paper 
texture, size and thickness of the labels 209 2 (1, 3) 25 2 (2, 3) 0.486 
Check for changes in fonts and font sizes, print 
colour or raised print 209 2 (1, 3) 25 2 (2, 3) 0.701 
Check all printing on flaps and surfaces of the 
box 208 2 (1, 3) 25 2 (2, 3) 0.557 
Check for overt security (e.g. hologram) 209 3 (2, 4) 25 3 (2, 4) 0.281 
Check for changes in the size of the container 210 2.5 (2, 4) 25 2 (2, 3) 0.591 
* Mann-Whitney U test   + (1=Never; 5=Always) 
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Table 6. 20 Past educational experience and purchasing practices 
Purchasing practice 
Pharmacists’ past educational or training 
experience 
P* 
No experience Experience 
No. Median (IQ) No. Median (IQ) 
Establish integrity of the supplier prior to 
ordering+ 130 5 (4, 5) 12 5 (4.25, 5) 0.591 
Establish a list of approved suppliers+ 127 5 (4, 5) 10 5 (4.75, 5) 0.657 
Develop a list of products purchased only from 
the manufacturer or authorised distributers+ 121 5 (2, 5) 10 5 (4, 5) 0.206 
If a product is being offered at an unusually 
cheap price# 118 2 (2, 2) 13 2 (2, 2) 0.883 
If a product is being offered in an unusually 
large quantity# 117 2 (2, 3) 13 2 (2, 2) 0.391 
* Mann-Whitney U test   + (1=Never; 5=Always) 
# (1=Accept the offer; 2= Treat with caution, 3=Reject the offer) 
 
6.4.4.3 Length of service of the pharmacists 
The study also compares the opinions of the pharmacists based on their length of 
service, which is categorised into three groups. As the attention to the counterfeit 
medicines issue increased in recent years (the first MHRA’s anti-counterfeiting 
medicines strategy was published in 2005) (1) the researcher formulated the hypothesis 
that the pharmacists’ length of service would reflect on the answers given by the 
pharmacists. To test the hypothesis five comparisons (future actions, preferences for 
education, pharmacist role, preferred method of communication and 
dispensing/purchasing practices) have been conducted to compare data between 
pharmacists with less than 10 years’ length of service (77 pharmacists), pharmacists 
with 11 to 25 years length of service (56 pharmacists) and pharmacists with over 25 
years length of service (102 pharmacists).  
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i) Comparisons of opinion on the future actions 
Table 6.21 shows the answers of the study sample about the action that would be taken 
if they had to deal with counterfeit medicines cases in the future. Some tests in the table 
were invalid, and others found no significant difference between the pharmacist groups. 
The only significant difference was found with reporting to the MHRA; it appeared that 
young pharmacists (have length of service 10 years or less) are more likely to report to 
the MHRA than other pharmacists. 
Table 6. 21 Length of service and pharmacists’ stated future actions 
Pharmacist’s selection for their future 
action 
Length of Service in years 
No. (%) 
p* 
0-10 11-25 Over 25 
Total 77 (32.6%) 56 (23.7%) 102 (43.2%) 
Report to the medicine’s supplier 66 (85.7%) 47 (83.9%) 90 (88.2%) 0.736 
Report to the medicine’s manufacturer 41 (53.2%) 24 (42.9%) 47 (46.1%) 0.453 
Report to MHRA 56 (72.7%) 29 (51.8%) 63 (61.8%) 0.045 
Isolate the item from the stock 62 (80.5%) 44 (78.6%) 77 (75.5%) 0.717 
Report to someone within their 
organization 49 (63.6%) 27 (48.2%) 56 (54.9%) 0.197 
Report to the pharmacists’ professional 
body 13 (16.9%) 10 (17.9%) 21 (20.6%) 0.806 
Report to the other 4 (5.2%) 2 (3.6%) 4 (3.6%) Test invalid 
* Chi-squared analysis 
ii) Comparisons of opinion on the future education preferences 
Tables 6.22 and 6.23 show the responses of three pharmacist groups regarding the 
timing of any education or training programmes covering counterfeit medicines, and 
which kind of education or training programmes each pharmacist group recommended. 
The results in both tables show no significant difference between the pharmacist groups.  
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Table 6. 22 Length of service and the recommendations for future education timing 
Pharmacists’ selection of future education 
timing 
Length of service in years 
No. (%) 
p* 
0-10 11-25 Over 25 
Total 77 (32.6%) 56 (23.7%) 101 (42.8%) 
Within undergraduate degree 23 (29.9%) 16 (28.6%) 28 (27.7%) 
0.224 Within the pre-registration year 34 (44.2%) 17 (30.4%) 32 (31.7%) 
in the post- registration 20 (26.0%) 23 (41.1%) 41 (40.6%) 
* Chi-squared analysis 
Table 6. 23 Length of service and the recommendations for future education preferences 
Pharmacists’ selection for future 
education delivery method 
Length of service in years 
No. (%) 
p* 
0-10 11-25 Over 25 
Total 77 (32.6%) 56 (23.7%) 101 (42.8%) 
Workshop 40 (51.9%) 23 (41.1%) 42 (41.6%) 0.312 
Conference 9 (11.7%) 2 (3.6%) 7 (6.9%) 0.207 
Distance learning 23 (29.9%) 23 (41.1%) 37 (36.6%) 0.390 
Journal articles 13 (16.9%) 11 (19.6%) 23 (22.8%) 0.621 
Other 1 (1.3%) 0 1 (1%) Test invalid 
* Chi-squared analysis 
iii) Comparisons of opinion on the pharmacist’s roles 
The view of pharmacists roles in combating counterfeit medicines based on the 
pharmacists’ length of service has been summarized in table 6.24. There is no 
significant difference found between the pharmacists’ groups. 
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Table 6. 24 Length of service and the pharmacist’s roles 
Role of pharmacists in combating 
counterfeit medicines 
Length of service in years 
No. (%) 
p* 
0-10 11-25 Over 25 
Total 77 (32.6%) 56 (23.7%) 101 (42.8%) 
Reporting to the medicines regulatory 
agency 69 (90.8%) 52 (92.9%) 95 (94.1%) 0.709 
Raising patient awareness about 
counterfeit medicines 60 (78.9%) 48 (85.7%) 81 (81%) 0.606 
Advice patient about counterfeit 
medicines 70 (92.1%) 51 (91.1%) 89 (89%) 0.774 
* Chi-squared analysis 
iv) Comparisons of opinion on the preferred methods of communication 
The methods of communication about counterfeiting information preferred by the three 
pharmacist groups based on their length of service are shown in table 6.25. No real 
differences can be seen other than those with over 25 years of experience preferring 
communication via professional journals. 
Table 6. 25 Length of service and preferred communication methods 
Pharmacists’ preferred communication 
method 
Length of service in years 
No. (%) 
p* 
0-10 11-25 Over 25 
Total 77 (32.6%) 56 (23.7%) 102 (43.2%) 
Professional journal 28 (36.4%) 18 (32.1%) 38 (37.3%) 
Te
st
 
in
v
al
id
 
Professional bodies 17 (22.1%) 11 (19.6%) 18 (17.6%) 
Via their organization 11 (14.3%) 11 (19.6%) 13 (12.7%) 
Fax 3 (3.9%) 2 (3.6%) 5 (4.9%) 
Email 15 (19.5%) 13 (23.2%) 23 (22.5%) 
Press release 1 (1.3%) 0 3 (2.9%) 
General media 2 (2.6%) 1 (1.8%) 1 (1%) 
Other 0 0 1 (1%) 
* Chi-squared analysis 
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v) Comparisons of the dispensing and purchasing practices 
These comparisons (table 6.26) examine pharmacists’ length of service and the 
pharmacists’ dispensing practices that would help to protect patient from counterfeit 
medicines. Also, table 6.27 compares the pharmacists’ purchasing practices with the 
pharmacists’ length of service. Table 6.26 shows no significant difference in the 
pharmacists’ dispensing practices by their length of service.  
Table 6. 26 Length of service and the dispensing practices 
Dispensing practice 
Pharmacists’ length of service 
 
p* 
0 – 10 years 11 – 25 Over 25 years 
No. Median (IQ)+ No. 
Median 
(IQ)+ No. 
Median 
(IQ)+ 
Check the package seal 76 5 (4, 5) 55 5 (4, 5) 102 5 (4, 5) 0.546 
Check for an altered expiry date 77 4 (3, 5) 55 4 (2, 5) 102 4.5 (3, 5) 0.858 
Check the physical characteristics of the 
product 77 2 (2, 3) 56 3 (2, 4) 101 3 (2, 4) 0.229 
Check for any signs of a removed or switched 
product label 77 3 (2, 4) 56 3 (2, 5) 101 4 (2, 5) 0.518 
Check for subtle changes in the product’s 
package 77 3 (2, 4) 56 3 (2, 4) 101 3 (2, 4) 0.237 
Check the package for changes in paper 
texture, size and thickness of the labels 76 2 (1, 3) 56 2 (1, 3) 101 2 (2, 3) 0.134 
Check for changes in fonts and font sizes, 
print colour or raised print 76 2 (1, 3) 56 2 (1, 3) 101 2 (2, 3.5) 0.099 
Check all printing on flaps and surfaces of the 
box 76 2 (1, 3) 55 2 (1, 3) 101 2 (2, 3) 0.360 
Check for overt security (e.g. hologram) 77 2 (2, 4) 55 3 (2, 5) 101 3 (2, 4) 0.169 
Check for changes in the size of the container 77 2 (2, 4) 56 3 (2, 4) 101 2 (2, 3) 0.583 
+ Kruskal-Wallis Test   + (1=Never; 5=Always) 
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Table 6.27, which relates length of service to purchasing practice, shows two significant 
differences in the pharmacists’ purchasing practices in establishing integrity of the 
supplier prior to ordering and establishing a list of approved suppliers, which shows that 
older pharmacists are more likely to follow those good purchasing practices than other 
two pharmacists group. 
Table 6. 27 Length of service and the purchasing practices 
Purchasing practice 
Pharmacists’ length of service 
 
p* 
0 – 10 years 11 – 25 Over 25 years 
No. Median (IQ) No. 
Median 
(IQ) No. 
Median 
(IQ) 
Establish integrity of the supplier prior to 
ordering+ 38 4.5 (2, 5) 34 5 (4, 5) 70 5 (5, 5) 0.001 
Establish a list of approved suppliers+ 34 5 (2, 5) 34 5 (4, 5) 69 5 (5, 5) 0.035 
Develop a list of products purchased only 
from the manufacturer or authorised 
distributers+ 
33 4 (1, 5) 33 5 (2, 5) 65 5 (3, 5) 0.402 
If a product is being offered at an unusually 
cheap price# 40 2 (2, 2) 28 2 (2, 2) 63 2 (2, 2) 0.544 
If a product is being offered in an unusually 
large quantity# 41 2 (2, 2) 28 2 (2, 3) 61 2 (2, 3) 0.232 
+ Kruskal-Wallis Test   + (1=Never; 5=Always) 
# (1=Accept the offer; 2= Treat with caution, 3=Reject the offer 
Table 6.28 shows young pharmacists (have 10 years or less) length of service are less 
likely to establish integrity of the supplier prior to ordering than other pharmacists and 
they are less likely to establish a list of approved suppliers than those who have over 25 
years length of service. 
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Table 6. 28 Length of service and the purchasing practices (Further comparisons) 
Purchasing practice 
Pharmacists’ length of service 
 
p* 
0 – 10 years 11 – 25 
No. Median (IQ)+ No. 
Median 
(IQ)+ 
Establish integrity of the supplier prior to 
ordering 38 4.5 (2, 5) 34 5 (4, 5) 0.030 
Establish a list of approved suppliers 34 5 (2, 5) 34 5 (4, 5) 0.124 
Purchasing practice 
0 – 10 years Over 25 years 
 
p* No. 
Median 
(IQ)+ No. 
Median 
(IQ)+ 
Establish integrity of the supplier prior to 
ordering 38 4.5 (2, 5) 70 5 (5, 5) 0.000 
Establish a list of approved suppliers 34 5 (2, 5) 69 5 (5, 5) 0.011 
Purchasing practice 
11 – 25 Over 25 years 
 
p* No. 
Median 
(IQ)+ No. 
Median 
(IQ)+ 
Establish integrity of the supplier prior to 
ordering 34 5 (4, 5) 70 5 (5, 5) 0.316 
Establish a list of approved suppliers 34 5 (4, 5) 69 5 (5, 5) 0.425 
* Mann-Whitney U test   + (1=Never; 5=Always) 
 
6.4.4.4 Professional body membership 
This section of the comparisons covers the opinions between pharmacists’ membership 
with different professional bodies on the responses given; the differences in views of 
those within and not within professional bodies have been examined. Therefore, the 
researcher formulated the hypothesis that there will be differences in the opinions 
between the pharmacists regarding the counterfeit medicines issue according to their 
membership of the professional bodies (127 pharmacists are members of the RPS, 88 
pharmacists are members of the PDA and 99 pharmacists are members the NPA). To 
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test this hypothesis the following comparisons (future actions, preferences for 
education, pharmacist role, preferred method of communication and 
dispensing/purchasing practices) have been analysed. 
i) Comparisons of opinion on the future actions  
Table 6.29 shows the comparison between pharmacists in their responses on the future 
actions they would take in case of an incidence of counterfeit medicine based on their 
membership of a given professional body. No significant difference between the 
pharmacist groups is found in the table, except with those who are members of the NPA 
will more likely to report to their professional body. 
Table 6. 29 Professional body membership and pharmacists’ stated future actions 
Pharmacist’s selection of 
their future action 
Membership of RPS 
No. (%) 
Membership of NPA 
No. (%) 
Membership of PDA 
No. (%) 
No Yes 
p* 
No Yes 
p* 
No Yes 
p* 
Total 
105 
(44.5%) 
127 
(53.8%) 
133 
(56.4%) 
99 
(41.9%) 
144 
(41.9%) 
88 
(37.3%) 
Report to the medicine’s 
supplier 
93 
(88.6%) 
107 
(84.3%) 0.445 
116 
(87.2%) 
84 
(84.4%) 0.701 
126 
(87.5%) 
74 
(84.1%) 0.557 
Report to the medicine’s 
manufacturer 
49 
(46.7%) 
60 
(47.2%) 1 
57 
(42.9%) 52 (52.5 0.183 
62 
(43.1%) 
47 
(53.4%) 0.137 
Report to MHRA 62  (59%) 
86 
(67.7%) 0.217 
83 
(62.4%) 
65 
(65.7%) 0.679 95 (66%) 
53 
(60.2%) 0.401 
Isolate the item from the 
stock 
84  
(80%) 
96 
(75.6%) 0.435 
109 
(82%) 
71 
(71.7%) 0.080 
113 
(78.5%) 
67 
(76.1%) 0.746 
Report to someone 
within their organization 
62  
(59%) 
68 
(53.5%) 0.427 
78 
(58.6%) 
52 
(52.5%) 0.422 
75 
(52.1%) 
55 
(62.5%) 0.135 
Report to pharmacist’s 
professional body 20 (19%) 
23(18.1
%) 0.867 
15 
(11.3%) 
28 
(28.3%) 0.001 
30 
(20.8%) 
13 
(14.8%) 0.298 
Report to the pharmacist 6 (5.7%) 4 (3.1%) 0.354 8 (6%) 2 (2%) 0.195 6 (4.2%) 4 (4.5%) 1.000 
* Fisher's exact test 
ii) Comparisons of opinion on the future education preferences 
The comparisons between the responses of the pharmacists who were members of the 
RPS, the NPA and the PDA regarding the timing and kind of education or training 
programmes about counterfeit medicines are presented in table 6.30 and table 6.31. No 
Chapter 6: Community pharmacists’ views of their role in combating counterfeit 
medicines 
 
PhD Thesis: Developing a national strategy for combating counterfeit medicines     213 
significant difference between the pharmacist groups is found in table 6.30. In table 
6.31, two results showed a significant difference in journal articles as future education 
preferences; pharmacists who are members of the NPA prefer this method of education 
whereas pharmacists who are members of the PDA prefer this method of education less. 
Table 6. 30 Professional body membership and the recommendations for future education 
timing 
Pharmacist’s selection for 
the timing of future 
education 
Membership of RPS 
No. (%) 
Membership of NPA 
No. (%) 
Membership of PDA 
No. (%) 
No Yes 
p* 
No Yes 
p* 
No Yes 
p* 
Total 
104 
(44.1%) 
127 
(53.8%) 
133 
(47.9%) 
98 
(41.5%) 
143 
(60.6%) 
88 
(37.3%) 
Within undergraduate 
degree 
35 
(33.7%) 
31 
(24.4%) 
0.295 
37 
(27.8%) 
29 
(29.6%) 
0.953 
38 
(26.6%) 
28 
(31.8%) 
0.669 Within the pre-registration 
year 
35 
(33.7%) 47 (37%) 
48 
(36.1%) 
34 
(34.7%) 
53 
(37.1%) 
29  
(33%) 
in the post- registration 34 (32.7%) 
49 
(38.6%) 
48 
(36.1%) 
35 
(35.7%) 
52 
(36.4%) 
31 
(35.2%) 
* Chi-squared analysis 
 
Table 6. 31 Professional body membership and the recommendations for future education 
preferences 
Pharmacist’s selection of 
future education delivery 
method 
Membership of RPS 
No. (%) 
Membership of NPA 
No. (%) 
Membership of PDA 
No. (%) 
No Yes 
p* 
No Yes 
p* 
No Yes 
p* Total 
104 
(44.1%) 
127 
(53.8%) 
133 
(56.4%) 
98 
(41.5%) 
143 
(60.6%) 
88 
(37.3%) 
Workshop 51  (49%) 
52 
(40.9%) 0.233 
58 
(43.6%) 
45 
(45.9%) 0.789 
57 
(39.9%) 
46 
(52.3%) 0.077 
Conference 11 (10.6%) 
7   
(5.5%) 0.217 
14 
(10.5%) 
4   
(4.1%) 0.085 
13 
(9.1%) 
5   
(5.7%) 0.452 
Distance learning 35 (33.7%) 
47  
(37%) 0.679 
53 
(39.8%) 
29 
(29.6%) 0.126 
48 
(33.6%) 
34 
(38.6%) 0.480 
Journal articles 16 (15.4%) 
31 
(24.4%) 0.102 
20  
(15%) 
27 
(27.6%) 0.022 
36 
(25.2%) 
11 
(12.5%) 0.028 
Other 0 2   (1.6%) 0.503 0 
2      
(2%) 0.179 
1   
(0.7%) 
1   
(1.1%) 1.000 
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* Fisher's exact test 
iii) Comparisons of opinion on the pharmacist’s roles 
The pharmacists’ membership with the professional body and their views regarding the 
roles of pharmacist in combating counterfeit medicines has been compared in table 6.32. 
The results show significant differences only with pharmacists who are members of the 
NPA who have a greater belief that reporting to the medicines regulatory agency is part 
of pharmacist’s role in combating counterfeit medicines. 
Table 6. 32 Professional body membership and the pharmacist’s roles 
Pharmacist’s selection for 
their future education 
delivery method 
Membership of RPS 
No. (%) 
Membership of NPA 
No. (%) 
Membership of PDA 
No. (%) 
No Yes 
p* 
No Yes 
p* 
No Yes 
p* Total 
104 
(44.1%) 
126 
(53.4%) 
132 
(55.9%) 
98 
(41.5%) 
142 
(60.2%) 
88 
(37.3%) 
Reporting to the medicines 
regulatory agency 
95 
(91.3%) 
118 
(93.7%) 0.615 
118 
(89.4%) 
95 
(96.9%) 0.04 
131 
(92.3%) 
82 
(93.2%) 1.000 
Raising patient awareness 
about counterfeit medicines 
84 
(80.8%) 
103 
(82.4%) 0.864 
111 
(84.7%) 
76 
(77.6%) 0.172 
113 
(80.1%) 
74 
(84.1%) 0.488 
Advice patient about 
counterfeit medicines 
92 
(88.5%) 
115 
(92%) 0.378 
118 
(90.1%) 
89 
(90.8%) 1.000 
127 
(90.1%) 
80 
(90.9%) 1.000 
* Fisher's exact test 
iv) Comparisons of opinion on the preferred methods of communication 
Table 6.33 shows the comparison examining the pharmacists’ memberships of a given 
professional body and their preferred methods of communication regarding counterfeit 
information.  
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Table 6. 33 Professional body membership and the preferred communication methods 
Pharmacists preferred 
communication method 
Membership of RPS 
No. (%) 
Membership of NPA 
No. (%) 
Membership of PDA 
No. (%) 
No Yes 
p* 
No Yes 
p* 
No Yes 
p* Total 
127 
(53.8%) 
127 
(53.8%) 
133 
(56.4%) 
99 
(41.9%) 
144 
(61%) 
88 
(37.3%) 
Professional journal 27 (25.7%) 
55 
(43.3%) 
Te
st
 
in
v
al
id
 
46 
(34.6%) 
36 
(36.4%) 
Te
st
 
in
v
al
id
 
51 
(35.4%) 
31 
(35.2%) 
Te
st
 
in
v
al
id
 
Professional bodies 30 (28.6%) 
15 
(11.8%) 
31 
(23.3%) 
14 
(14.1%) 
26 
(18.1%) 
19 
(21.6%) 
Via their organization 17 (16.2%) 
19  
(15%) 
23 
(17.3%) 
13 
(13.1%) 
23  
(16%) 
13 
(14.8%) 
Fax 5   (4.8%) 
5   
(3.9%) 
7   
(5.3%) 
3   
(3.0%) 
7   
(4.9%) 
3      
(3.4%) 
Email 22  (21%) 
28  
(22%) 
21 
(15.8%) 
29 
(29.3%) 
34 
(23.6%) 
16 
(18.2%) 
Press release 1      (1%) 
3    
(2.4%) 
2   
(1.5%) 
2      
(2%) 
2   
(1.4%) 
2      
(2.2%) 
General media 2   (1.9%) 
2   
(1.6%) 
3   
(2.3%) 1 (1%) 0 
4   
(4.5%) 
Other 1 (1%) 0 0 1 (1%) 1  (0.7%) 0 
* Chi-squared analysis  
v) Comparisons of the dispensing and purchasing practices 
Table 6.34 compares the pharmacists’ membership of a given professional body with 
their dispensing practices that would help to protect patients from counterfeit medicines. 
The results show significant differences in checking the physical characteristics of the 
product as the pharmacists who are members of the RPS are more likely to perform this 
practice compared with those who are not members of the RPS; whereas, those who are 
members of the PDA are less likely to perform that practice compared with those who 
are not members of the PDA.  
Furthermore, table 6.35 compares the pharmacists’ purchasing practices with the 
pharmacists’ memberships of different professional bodies. Results show that 
pharmacists who are members of the PDA are less likely to establish the integrity of the 
supplier prior to ordering compared to those who are not members of the PDA. Also, 
pharmacists not members of the PDA will be more likely to reject a product if it being 
offered at an unusually cheap price or large quantity compared to the pharmacists 
members of the PDA. 
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Table 6. 34 Professional body membership and the dispensing practices 
Dispensing practice 
Membership of RPS 
No. (%) 
Membership of NPA 
No. (%) 
Membership of PDA 
No. (%) 
No Yes 
p* 
No Yes 
p* 
No Yes 
p* 
No. Median (IQ)+ No. 
Median 
(IQ)+ No. 
Median 
(IQ)+ No. 
Median 
(IQ)+  No. 
Median 
(IQ)+ No. 
Median 
(IQ)+  
Check the package seal 105 5 (4, 5) 125 5 (4, 5) 0.923 132 5 (4, 5) 98 5 (4, 5) 0.974 142 5 (4, 5) 88 5 (4, 5) 0.223 
Check for an altered expiry date 105 5 (3, 5) 126 4 (2, 5) 0.097 132 4 (2.25, 5) 99 4 (3, 5) 0.594 143 4 (3, 5) 88 4 (3, 5) 0.714 
Check the physical characteristics of the product 105 2 (1.5, 3) 126 3 (2, 4) 0.021 132 3 (2, 3) 99 3 (2, 3) 0.648 143 3 (2, 4) 88 2 (2, 3) 0.034 
Check for any signs of a removed or switched 
product label 105 4 (2, 5) 126 4 (2, 4) 0.998 132 3.5 (2, 4.75) 99 4 (2, 4) 0.839 143 4 (2, 5) 88 3 (2, 4) 0.115 
Check for subtle changes in the product’s package 105 3 (2, 4) 126 3 (2, 4) 0.894 132 3 (2, 4) 99 3 (2, 3) 0.357 143 3 (2, 4) 88 3 (2, 4) 0.813 
Check the package for changes in paper texture, 
size and thickness of the labels 104 2 (1, 3) 126 2 (2, 3) 0.237 131 2 (1, 3) 99 2 (2, 3) 0.118 143 2 (2, 3) 87 2 (1, 3) 0.186 
Check for changes in fonts and font sizes, print 
colour or raised print 104 2 (1, 3) 126 2 (1, 3) 0.519 131 2 (1, 3) 99 2 (1, 3) 0.232 143 2 (1, 3) 87 2 (1, 3) 0.492 
Check all printing on flaps and surfaces of the box 104 2 (1, 3) 125 2 (1.5, 3) 0.780 130 2 (1, 3) 99 2 (2, 3) 0.185 142 2 (1.75, 3) 87 2 (1, 3) 0.531 
Check for overt security (e.g. hologram) 105 3 (2, 4) 125 3 (2, 4) 0.450 131 3 (2, 4) 99 3 (2, 4) 0.347 142 4 (2, 4) 88 3 (2, 4) 0.252 
Check for changes in the size of the container 105 2 (2, 4) 125 3 (2, 4) 0.475 132 2 (2, 3) 99 3 (2, 4) 0.466 143 2 (2, 3) 88 2 (2, 4) 0.930 
* Mann-Whitney U test              + (1=Never; 5=Always) 
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Table 6. 35 Professional body membership and the purchasing practices 
Purchasing practice 
Membership of RPS 
No. (%) 
Membership of NPA 
No. (%) 
Membership of PDA 
No. (%) 
No Yes 
p* 
No Yes 
p* 
No Yes 
p* 
No. Median (IQ) No. 
Median 
(IQ) No. 
Median 
(IQ) No. 
Median 
(IQ)  No. 
Median 
(IQ) No. 
Median 
(IQ)  
Establish integrity of the supplier prior to 
ordering+ 58 5 (4, 5) 82 5 (4, 5) 0.686 73 5 (4, 5) 67 5 (5, 5) 0.299 91 5 (5, 5) 49 5 (3, 5) 
0.059 
Establish a list of approved suppliers+ 57 5 (4, 5) 78 5 (4, 5) 0.970 70 5 (4, 5) 65 5 (5, 5) 0.216 87 5 (5, 5) 48 5 (4, 5) 0.144 
Develop a list of products purchased only from the 
manufacturer or authorised distributers+ 51 5 (2, 5) 78 5 (3, 5) 0.960 66 5 (2.75, 5) 63 5 (2, 5) 0.760 83 5 (2, 5) 46 5 (2.75, 5) 0.929 
If a product is being offered at an unusually cheap 
price# 56 2 (2, 2) 73 2 (2, 2) 0.640 64 2 (2, 2) 65 2 (2, 2) 0.612 83 2 (2, 3) 46 2 (2, 2) 0.029 
If a product is being offered in an unusually large 
quantity# 59 2 (2, 2) 69 2 (2, 3) 0.640 66 2 (2, 3) 62 2 (2, 3) 0.910 80 2 (2, 3) 48 2 (2, 2) 0.009 
* Mann-Whitney U test              + (1=Never; 5=Always)  # (1=Accept the offer; 2= Treat with caution, 3=Reject the offer 
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6.4.4.5 Pharmacists’ workplace 
This section compares the opinions of pharmacists based on their workplace about 
counterfeit medicines. The researcher formulated the hypothesis that pharmacists’ 
workplaces may affect the answers given by the pharmacists. To test the hypothesis five 
comparisons (future actions, preferences for education, pharmacist role, preferred 
method of communication and dispensing/purchasing practices) have been conducted to 
compare data between 91 pharmacists who worked at an independent pharmacy and 143 
pharmacists who worked at a multi-chain pharmacy.  
i) Comparisons of opinions on future actions 
Table 6.36 compares the two pharmacists groups’ selection of actions that they would 
do in case they found counterfeit medicines. This identified three significant differences 
between the two groups. Pharmacists working in independent pharmacies were more 
likely to report to the MHRA and to their professional body than those working at a 
multi-chain pharmacy, while pharmacists working at a multi-chain pharmacy were more 
likely to report this to someone within their organization. 
Table 6. 36 The workplace and pharmacists’ stated future actions 
Pharmacists’ selection for their future action 
Pharmacists’ workplace 
No. (%) 
P* 
Independent 
pharmacy 
Multi-chain 
pharmacy 
Total 91 (38.6%) 144 (61%) 
Report to the medicine’s supplier 81 (89%) 121 (84%) 0.338 
Report to the medicine’s manufacturer 44 (48.4%) 68 (47.2%) 0.894 
Report to MHRA 66 (72.5%) 83 (57.6%) 0.026 
Isolate the item from the stock 73 (80.2%) 110 (76.4%) 0.523 
Report to someone within their organization 30 (33%) 101 (70.1%) 0.000 
Report to the pharmacist’s professional body 24 (26.4%) 20 (13.9%) 0.025 
Report to the pharmacist 3 (3.3%) 7 (4.9%) 0.745 
* Fisher's exact test 
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ii) Comparisons of opinion on the future education preferences 
Table 6.37 shows the responses of the two pharmacist groups regarding the timing of 
any education or training programmes about counterfeit medicines. Moreover, table 
6.38 highlights which kind of education or training programmes they preferred. There 
were no significant difference between the two pharmacist groups in their selection for 
the timing of educational or training programmes regarding counterfeit medicines. 
Table 6. 37 The workplace and the recommendations for future education timing 
Pharmacist’s selection for the timing of future 
education 
Pharmacists’ workplace 
No. (%) 
P* 
Independent 
pharmacy 
Multi-chain 
pharmacy 
Total 90 (38.1%) 144 (61%) 
Within undergraduate degree 24 (26.7%) 43 (29.9%) 
0.869 Within the pre-registration year 33 (36.7%) 50 (34.7%) 
in the post- registration 33 (36.7%) 51 (35.4%) 
* Chi-squared analysis 
Table 6. 38 The workplace and the recommendations for future education preferences 
Pharmacist’s selection for future education 
delivery method 
Pharmacists’ workplace 
No. (%) 
P* 
Independent 
pharmacy 
Multi-chain 
pharmacy 
Total 90 (38.1%) 144 (61%) 
Workshop 41 (45.6%) 63 (43.8%) 0.789 
Conference 4 (4.4%) 14 (9.7%) 0.207 
Distance learning 35 (38.9%) 49 (34%) 0.485 
Journal articles 17 (18.9%) 30 (20.8%) 0.426 
Other 2 (2.2%) 0 0.147 
* Fisher's exact test 
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iii) Comparisons of opinion on the pharmacist roles 
This comparison (table 6.39) addresses the views of the study sample on the 
pharmacists’ roles in combating counterfeit medicines based on their place of work. 
There is no significant difference between the two pharmacist groups. 
Table 6. 39 The workplace and the pharmacist’ role 
Role of pharmacist in combating counterfeit 
medicines 
Pharmacists’ workplace 
No. (%) 
P* 
Independent 
pharmacy 
Multi-chain 
pharmacy 
Total 90 (38.1%) 143 (60.6%) 
Reporting to the medicines regulatory agency 86 (95.6%) 130 (90.9%) 0.208 
Raising patient awareness about counterfeit 
medicines 76 (85.4%) 113 (79%) 0.297 
Advice patient about counterfeit medicines 82 (92.1%) 128 (89.5%) 0.646 
* Fisher's exact test 
 
iv) Comparisons of opinion on the preferred methods of communication 
The comparison that examines the pharmacists’ place of work and their preferred 
methods of communication regarding counterfeiting information between the two 
pharmacist groups is given in table 6.40. Results show that the first selection for both 
groups of pharmacists is a professional journal. On the other hand, the second selection 
for pharmacists working in independent pharmacy is Email; whereas, for pharmacists 
working in multi-chain pharmacy it would be via their organization. 
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Table 6. 40 The workplace on their preferred communication methods 
Pharmacists preferred communication 
method 
Pharmacists’ workplace 
No. (%) 
P* 
Independent 
pharmacy 
Multi-chain 
pharmacy 
Total 91 (38.6%) 144 (61%) 
Professional journal 35 (38.5 %) 48 (33.3%) 
Te
st
 
in
v
al
id
 
Professional bodies 16 (17.6%) 30 (20.8%) 
Via their organization 1 (1.1%) 35 (24.3%) 
Fax 4 (4.4%) 6 (4.2%) 
Email 29 (31.9%) 22 (15.3%) 
Press release 2 (2.2%) 2 (1.4%) 
General media 3 (3.3%) 1 (0.7%) 
Other 1 (1.1%) 0 
* Chi-squared analysis  
 
v) Comparisons of dispensing and purchasing practices  
These comparisons (table 6.41) compare pharmacists’ place of work on the pharmacists’ 
dispensing practices that would help to protect patients from counterfeit medicines. 
Also, table 6.42 compares the pharmacists’ purchasing practices by the pharmacists’ 
workplace. Results show that pharmacists working in independent pharmacies are more 
likely to check the package for changes in paper texture, size and thickness of the labels. 
Also, pharmacists working in independent pharmacies are more likely to establish 
integrity of the supplier prior to ordering and to establish a list of approved suppliers. 
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Table 6. 41 The workplace and the dispensing practices 
Dispensing practice 
Pharmacists’ workplace 
P* 
Independent 
pharmacy 
Multi-chain 
pharmacy 
No. Median (IQ)+ No. Median (IQ)+ 
Check the package seal 90 5 (4, 5) 143 5 (4, 5) 0.315 
Check for an altered expiry date 91 5 (3, 5) 143 4 (2, 5) 0.161 
Check the physical characteristics of the 
product 90 3 (2, 4) 144 2 (2, 3) 0.187 
Check for any signs of a removed or switched 
product label 91 4 (2, 5) 143 3 (2, 4) 0.201 
Check for subtle changes in the product’s 
package 91 3 (2, 4) 143 3 (2, 4) 0.201 
Check the package for changes in paper 
texture, size and thickness of the labels 91 2 (2, 3) 142 2 (1, 3) 0.021 
Check for changes in fonts and font sizes, print 
colour or raised print 91 2 (2, 3) 142 2 (1, 3) 0.067 
Check all printing on flaps and surfaces of the 
box 91 2 (2, 3) 141 2 (1, 3) 0.061 
Check for overt security (e.g. hologram) 91 3 (2, 4) 142 3 (2, 4) 0.138 
Check for changes in the size of the container 91 3 (2, 3) 143 2 (2, 4) 0.632 
* Mann-Whitney U test   + (1=Never; 5=Always) 
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Table 6. 42 The workplace and purchasing practices 
Purchasing practice 
Pharmacists’ workplace 
P* 
Independent 
pharmacy 
Multi-chain 
pharmacy 
No. Median (IQ) No. Median (IQ) 
Establish integrity of the supplier prior to 
ordering+ 83 5 (5, 5) 59 5 (3, 5) 0.002 
Establish a list of approved suppliers+ 80 5 (5, 5) 57 5 (2, 5) <0.001 
Develop a list of products purchased only from 
the manufacturer or authorised distributers+ 79 5 (3, 5) 52 4 (1.25, 5) 0.107 
If a product is being offered at an unusually 
cheap price# 82 2 (2, 2) 49 2 (2, 2) 0.942 
If a product is being offered in an unusually 
large quantity# 80 2 (2, 3) 50 2 (2, 2) 0.352 
* Mann-Whitney U test   + (1=Never; 5=Always) 
# (1=Accept the offer; 2= Treat with caution, 3=Reject the offer) 
 
6.5 Discussion 
This study was designed to obtain a better understanding of pharmacists’ knowledge 
and experiences of counterfeit medicines. It also aimed to explore pharmacists’ 
perceptions of their possible roles in combating counterfeit medicines. The study found 
that less than a quarter of the pharmacists had had a past experience of counterfeit 
medicines and that they preferred to report any future incidents to their suppliers rather 
than the MHRA. Only one in ten pharmacists had received past education or training 
regarding counterfeit medicines. They also said that they would prefer workshops and 
distance learning as the delivery method for these education or training programmes. It 
was also found that many of the dispensing practices that were recommended by the 
MHRA and the RPS to secure the supply chain and to protect patients from counterfeit 
medicines were not being performed or were rarely being performed by pharmacists. 
Fewer than half of pharmacists were following the purchasing practices that were 
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recommended by the MHRA and the RPS to secure their supply chain from counterfeit 
medicines. Not all pharmacists agreed that reporting to the medicines regulatory agency 
was a role for the pharmacist in combating counterfeit medicines, nor did they all agree 
that it was their role to raise patients’ awareness or to provide advice to patients. 
Although very few pharmacists had previously received any formal training or 
education regarding counterfeit medicines, they were receptive to future training in a 
wide variety of formats.  
In comparing the responses between the pharmacists in respect to any past experience of 
counterfeit medicines, education experience, length of service, membership of a 
professional body, and working place; there was no significant differences in the 
responses between the pharmacists. As the number of pharmacists who participated in 
this study and who had had past experience of counterfeit medicines or had past 
education experiences was small, the few significant differences that were found might 
perhaps be considered as false positives. However, those few significant differences 
indicated between younger pharmacists and older ones as well as between pharmacists 
working in independent and multi-chain pharmacies with regard to reporting any 
counterfeit medicines incident to the medicines regulatory agency might provide some 
indications of the pharmacists’ attitudes and responses to counterfeit medicines. 
This study, to the best knowledge of the researcher, was the first to be designed and 
implemented in the UK to understand the practices, experience and opinions of 
community pharmacists regarding counterfeit medicines. The questionnaire was 
completed well with limited missing data suggesting that it was relatively easy to use. It 
may have been useful to follow up with a limited sub-sample of respondents to 
determine their views on the content, their understanding of questions and on what we 
could have done to further enhance our response rate. Also, the sampling process was 
random giving all of England’s community pharmacist population the same probability 
of being part of the study; this could be seen from the demographic data collected on the 
participants. According to a report published in 2013 by the General Pharmaceutical 
Council (GPhC) (138), 39.6% of overall registered pharmacists were male and 60.4% 
were female; whereas, in this study 58.7% of the participants were male and 41.3% 
were female. This difference could be partially explained by the fact that female 
pharmacists are more likely to work in hospital pharmacies than male pharmacists and 
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are also more likely to be working part-time and therefore would have been less likely 
to see the questionnaire. Regarding pharmacists’ workplaces, according to the report by 
the Health & Social Care Information Centre (HSCIC) published in 2014 (135); 39% of 
community pharmacists in England are working in independent pharmacies and 61% 
are working in multi-chain pharmacies which very closely reflects the numbers seen 
within the study sample. 
The results need to be considered while noting the survey response rate, which was only 
36.3%, as this limits the generalizability of the findings of the study to suggest whether 
the opinions of respondents reflect those of non-respondents. This response rate might 
be because pharmacists perceived that the questionnaire was assessing their practice. 
Also, as the questionnaire was sent at the end of the month which considered a busy 
time for the pharmacists which could affect the response rate. Another, unexpected, 
finding of the study was the low percentage of community pharmacists who had had 
past experiences of counterfeit medicines; as well as there being only a small number of 
pharmacists taking part in the study had received prior education and training regarding 
counterfeit medicines. These limitations affected the data analysis when comparing the 
answers of the pharmacists to find out the impact of those past experiences or education. 
Also, this study was conducted with a very limited range of published literature to 
support its design. 
This study suggests, with less than a quarter of community pharmacists in England 
reporting having experienced counterfeit medicines, that either it is not a major problem 
or that it is not being detected. The most regularly reported relevant experience was of 
medicines being recalled by the MHRA due to a counterfeit medicine incident. The last 
such recall was issued by the MHRA in 2009 (131) and this could explain why such a 
low number of pharmacists (22%) reported that they had had a past experience with 
such recalls. These results could also reflect that those kinds of recalls may be dealt with 
by wholesalers and senior pharmacy managers who may have done so without sharing 
the information with their community pharmacists.  
This study also shows that one out of ten of the pharmacists had received a counterfeit 
medicine from their supply chain; a few pharmacists even said that they had been 
offered medicines from their supply chain that had made them suspicious that they 
might be counterfeited. These results highlighted the importance of pharmacists 
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applying the guidance published by the MHRA with the RPS (84). Interestingly, more 
than one out of ten pharmacists reported patients showing them medicines they believed 
were counterfeit. This indicates that patients are obtaining medicines from the black 
market and suggests that, with such a high prevalence of occurrence, pharmacists could 
be used to report such instances to the MHRA. This, however, would only be effective 
if the pharmacists collected data in a standardised manner which was acceptable to 
patients. Consequently, they may have a role in supporting the identification of websites 
which are supplying counterfeit medicines. It is also interesting that pharmacists are 
approached by patients for such advice as they are seeking advice on a potentially 
unsafe action which they have undertaken. Pharmacists are increasingly being 
recognised as having a public health role due to the anonymity they afford patients (who 
do not have to register with them) and therefore identifying potential counterfeit 
medicines may be another potential public health role. 
The fact that most pharmacists stated that if they came across a counterfeit medicine 
issue they would report it to their supplier is perhaps to be expected. By reporting this to 
the supplier, the supplier can then retrace the supply chain and contact the manufacturer 
to identify the likelihood of the medicine being counterfeit. The pharmacist, however, 
needs to recognise that the supplier would be responsible for any harm resulting from 
poor purchasing practices and therefore it may not be in their interest to identify or 
highlight counterfeit medicines. Consequently, pharmacists should be encouraged to 
report to the MHRA who are independent and can quickly identify repeated reports. It is 
perhaps pleasing that almost two-thirds of pharmacists stated that they would report 
incidents of counterfeit medicines to the MHRA. On the other hand, with such 
questionnaires it is not possible to determine whether respondent answers accurately 
reflect true practice. Therefore, it could be that providing the MHRA as an option may 
have encouraged participants to select this option, although without prompting the 
respondent may not have spontaneously considered this or even been aware of it. It is of 
some concern that although pharmacists may report their concerns to their supplier they 
would not all immediately isolate the stock to prevent it from reaching the patient. A 
medicine for which the pharmacist has any concerns should be immediately isolated to 
ensure that it is not supplied until its authenticity has been verified or not. 
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With highly regulated pharmacist training in the UK and EU it is perhaps surprising that 
the subject of counterfeit medicines does not seem to be routinely included. Whilst this 
may reflect respondent inability to recall training which occurred along time ago it is 
not whether they recall the training which is important it is whether previous knowledge 
informs their current practice; the results suggest that this is not the case. This study 
shows how large numbers of pharmacists were not aware of best practice when dealing 
with any suspected case of counterfeit medicines. As the pharmacists’ first selection in a 
case of counterfeit medicines is reporting to the supplier, the decision-makers at the 
medicines regulatory agency could use these findings to understand the current 
knowledge of pharmacists and to increase the education and training activities for 
pharmacists about the prompt reporting of any suspicious counterfeit medicine incident 
to the agency; also, to working closely with medicine suppliers in improving the 
pharmacists’ knowledge of best practice when dealing with counterfeit medicines. 
As the majority of pharmacists in this study had not had any training with respect to 
counterfeit medicines in the past, their recommendation on the best timing for 
delivering such education to pharmacists could be purely speculative as seen in their 
lack of agreement on the issue. However, pharmacists deal with medicines physically in 
their daily work life a fact which could the reason for almost half of the pharmacists 
preferring workshops as a training method for counterfeit medicines. Community 
pharmacists have to obtain cover for the whole day if they attend workshops at this time 
and may not want to give up their own time; this could explain the selection of distance 
learning by one-third of the pharmacists. In spite of this, the guidance for pharmacists 
published by the MHRA and RPS with respect to counterfeit medicines which could be 
considered as a distance learning tool was not identified by the respondents and did not 
seem to have affected the reported practice of pharmacists. These results could help the 
decision-makers at the medicines regulatory agency to work more with pharmacy 
schools to design workshop training about counterfeit medicines that would be 
delivered to them within undergraduate degree courses and within pharmacists’ pre-
registration year as the pharmacists will have more time for education and training 
during these two periods. Furthermore it is perhaps appropriate to ensure that 
practitioners are trained in counterfeit medicines before registration and autonomous 
patient facing practice. 
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Most of the dispensing practices examined in this study, which are aimed at protecting 
patients from counterfeit medicines, were never or rarely performed by the pharmacists. 
Due to the pharmacists’ workloads, they might be delegating these tasks to pharmacy 
technicians or pharmacists might assume the pharmacy’s management checked all 
medicines before being stocked on the shelves. However, according to this study, nearly 
half of pharmacists did not even perform a check of the medicine’s name and expiry 
date something which should be part of the pharmacists’ routine before dispensing the 
medicines to patients and which might indicate a weakness in the system. Two things 
are worth considering at this point; firstly pharmacists may not have time to do all of the 
tasks recommended for them concerning counterfeit medicines and may not prioritise 
them as they believe the provenance of their suppliers; secondly medicines are 
increasingly supplied through robots and therefore this checking would be undertaken in 
the future by a technician when filling the machine. In addition, this study showed that 
between 40% and 45% of the pharmacists did not have any responsibility for purchasing 
the medicines; which could be understood as more than half of the pharmacists in this 
study worked at a multi-pharmacy chain and the purchasing process would be 
conducted centrally by a dedicated buying department. However, the results show that 
not all pharmacists involved in the purchasing process (who could be those working at 
an independent pharmacy) were applying MHRA and RPS recommendations to secure 
the supply chain from counterfeit medicines. These results might be helpful for the 
decision-makers within a medicines regulatory agency, as well as for the pharmacists’ 
regulatory agency, in considering the content of any training. Also it can help achieve a 
better understanding of the real dispensing and purchasing practices of community 
pharmacists which will help identify the weaknesses in the medicines supply chain.  
It was found that not all pharmacists agreed with the roles that had been identified for 
them in combating counterfeit medicines in the MHRA study and the stakeholders study 
(chapter 4 and chapter 5) and in some literatures. However, findings showed that some 
pharmacists saw reporting to the medicines regulatory agency as the responsibility of 
the pharmacy management or the medicines supplier to whom this study has shown 
pharmacists are most likely to report any case of the counterfeit medicines. It may be 
that pharmacists need to be educated with regard to the importance of reporting to the 
medicines regulatory agency as the medicines’ supplier might have a conflict of interest 
and they may not report it onwards to the medicines regulatory agency. Also, in this 
Chapter 6: Community pharmacists’ views of their role in combating counterfeit 
medicines 
 
PhD Thesis: Developing a national strategy for counterfeit medicines                            229 
study not all pharmacists agreed that raising patient awareness and education was part 
of their role. Pharmacists might see themselves as not having enough time to carry out 
such roles as they are operating under the pressure of a high workload (139, 140). 
Nevertheless, pharmacists should realise that patients have a high regard for them and 
view them as medicine experts from whom advice can be sought as part of the 
pharmacist’s non-dispensing responsibilities (141, 142). These results suggest that the 
roles proposed for the pharmacists may not have been communicated sufficiently to the 
pharmacists and that more effort would be needed to re-design the methods of 
communications used in line with the preferred methods identified in this study.  
 
6.5.1 Comparing pharmacists’ responses 
This study compared the pharmacists’ answers about counterfeit medicines based on 
their past experience, past education, length of service, membership of professional 
bodies and workplace. In general no significant difference was found for those 
comparisons. This finding might be due to the small number of pharmacists who had 
had past experiences or might be a consequence of a low response rate. The fact that 
very few differences between experience and education and reported practices were 
seen could be due to the small number of pharmacists in this study with such past 
experience and therefore the limited power of the tests, or it may just be that those 
experiences were so limited that they did not change pharmacists’ views or practices.  
Certain comparisons revealed some interesting results; but, due to the large number of 
tests performed there is a possibility of false positives. However, for the purposes of 
discussion these are considered to be true differences whilst it is accepted that this could 
be proved otherwise with a larger sample. Pharmacists without any past experiences of 
counterfeiting incidents were found to say they were more likely to report to the 
MHRA; whereas the pharmacists with such past experiences stated that they would be 
more likely to report to their professional bodies. Also, the pharmacists without any past 
experiences of counterfeit medicines agreed more on the roles of the pharmacists in 
combating counterfeit medicines. These were unexpected results as pharmacists with 
past experiences should be more aware of good practice when dealing with counterfeit 
medicines including reporting to the MHRA which is not shown in these results. It also 
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worth considering the possibility that pharmacists with previous experience might have 
found reporting to the MHRA to be difficult and therefore choose an alternative route.  
This study also shows that pharmacists who had had a past educational or training 
experience related to counterfeit medicines were more likely to choose to report to the 
MHRA than those who had not had a past educational or training experience; 
additionally, the first selection for pharmacists who had had a past educational or 
training experience was to report to the MHRA as well as to their supplier should a 
suspected case of counterfeiting arise. In addition, pharmacists with past education or 
training experience are more agreed on the roles of pharmacists in combating 
counterfeit medicines. This result might suggests that education or training would make 
a difference to pharmacists’ actions when they come across a counterfeit medicines 
case.  
Also by comparing pharmacists’ length of service, it was found that less experienced 
pharmacists would be more likely to report any counterfeit medicines incident to the 
medicines regulatory agency, which might suggests that those pharmacists might be 
being trained on counterfeit medicines during their degree or pre-registration year. Also, 
the results showed less experienced pharmacists preferred the education and training 
programmes on counterfeit medicines to be integrated into the pharmacist’s pre-
registration year as workshops, which may support that explanation. 
When comparing pharmacists’ responses based on their workplace (independent 
pharmacy or multi-chain pharmacy), the study showed that pharmacists working in an 
independent pharmacy would be more likely to report to the MHRA and to their 
professional body than those working in a multi-chain pharmacy; which may be because 
pharmacists working in independent pharmacy would be more involved in management 
roles whereas in multi-chain pharmacy the pharmacists might believe this would be the 
pharmacy management’s duties. Pharmacists working at an independent pharmacy are 
slightly more likely to be following the recommendations published by the MHRA for 
good practice to combat counterfeit medicines; which could be expected as pharmacists 
in independent pharmacy are more involved in the purchasing process than those in 
multi-chain pharmacy. The same pharmacists had more conviction in their roles in 
combating medicine counterfeiting. The study also showed pharmacists working at a 
multi-chain pharmacy were more likely to report to their organization, which might be 
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because many independent pharmacies are not part of an organisation therefore the 
option of reporting to their organization is not applicable for them. Another point to be 
considered, pharmacists working in multi-chain pharmacy might believe that as they are 
part of a larger organization that all work related issues should be handled through the 
organization including the reporting of counterfeit medicines cases. This is supported by 
the view the second preferred method of communication regarding counterfeit 
medicines for the pharmacists working at a multi-chain pharmacy would be via their 
organization. This third study added to the previous two (chapters 4 and 5) and has 
made an important contribution to constructing a complete conceptualisation of the 
process of developing, implementing and evaluating the strategy. The health 
professional studies in this chapter and the following chapter involved highly significant 
actors in the issue of combating counterfeit medicines which have contributed to the 
overall research aim. 
 
6.6 Conclusion 
This study investigated current community pharmacists’ knowledge and experiences of 
counterfeit medicines as well as identifying pharmacists’ views on their own roles in 
combating this problem. It also highlighted the distribution of types of views and 
practices according to a set of variables including past experiences of counterfeit 
medicines, past education of training programmes, length of service, membership of 
professional bodies and the nature of their workplace. The study was able to establish 
the extent to which certain views and practices were shared and what variables may 
influence the holding of a particular view or the adoption of a particular practice. It 
showed that fewer than one in four community pharmacists in England had had a past 
experience of counterfeit medicines during their professional life; also, the first action 
for pharmacists should they have to deal with any counterfeit medicine incident in the 
future would be to report it to the medicine’s supplier. This study showed that only a 
low percentage of pharmacists had attended an education or training programme about 
counterfeit medicines in the past. Pharmacists were also found not to apply the 
dispensing and purchasing practices recommended by the medicines regulatory agency 
to combat counterfeit medicines. Not all pharmacists agreed that reporting any 
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suspicion of counterfeiting medicines to the medicines regulatory agency is part of their 
role in combating counterfeit medicines; also, less agreement was seen between 
pharmacists on their role to raise patients’ awareness and to provide advice to patients 
about counterfeit medicines. Finally, this study could not distinguish any differences in 
opinion between the community pharmacists’ responses regarding their views on 
counterfeit medicines based on their past experience or past education of counterfeit 
medicines, length of service or workplace.  
The study could not identify any impact from pharmacists’ past experience of 
counterfeiting incidents or past education, pharmacists’ length of service or workplace 
or membership of professional bodies. Nevertheless this study suggested that a 
medicine regulatory agency might need to work closely with schools of pharmacy, the 
pharmacists’ professional bodies and multi-chain pharmacy organizations which would 
improve the education and communication activities with the pharmacists which in turn 
would help in combating counterfeit medicines. This study might be useful for the 
decision-makers within a medicines regulatory agency in understanding the knowledge 
and views of pharmacists on their roles in combating counterfeit medicines together 
with their dispensing and purchasing practices, something which would help in their 
efforts to engage pharmacists in the planning and implementation of its counterfeit 
medicines strategy.  
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7.1 Introduction 
The MHRA plays the leading role in developing and implementing an anti-counterfeit 
medicines strategy as do its stakeholders; however, their contact with the end users of 
such medicines, the general public, is limited. It is health professionals such as 
pharmacists and GPs who have most of this direct contact. Pharmacists were the subject 
of the previous study and in this chapter attention turns to GPs currently working in 
England. Most GPs do not dispense medicines in England, which is the role of 
pharmacists. They are, however, responsible for prescribing medicines and for treating 
patients who may have health problems arising from the use of counterfeit medicines. 
As such GPs represent an important group for this research if we are to build a multi-
dimensional, triangulated conceptualisation of the processes of developing, 
implementing and evaluating an anti-counterfeit medicines strategy and so address the 
research problem. The views, perceptions and practices of GPs need to be understood. 
As with pharmacists, the quantitative data collected from GPs is intended to provide a 
broadly representative picture of the views, preferences and practices of the GP 
population concerning a range of counterfeit medicines issues.  
Discussion of the extent and nature of GPs role in combating counterfeit medicines has 
been largely a matter of conjecture to this point. GP magazine had published results of a 
polling survey and subsequently reported by the MHRA in which 423 GPs had taken 
part. One finding was that 25% of GPs reported having treated patients for adverse 
reactions to medicines they had purchased online, where counterfeit medicines are 
known to be particularly prevalent (85, 143). While this suggests that GPs frequently 
encounter cases of counterfeit medicines, the full published results of the study could 
not be located for examination in this study, for its methodology and robustness of 
findings to be evaluated. 
GPs do not normally deal directly and physically with medicines in the UK (except for 
dispensing doctors who are usually in rural areas where patients live remotely from a 
pharmacy). However, GPs are likely to regularly encounter patients who experience 
side effects from medicines prescribed for them and GPs are required to report these 
side effects to the MHRA via the “Yellow Card Scheme”. In this scheme, GPs also have 
an option to report a counterfeit medicines case if they suspect the side effect is from a 
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counterfeit medicine (144). Participants from the MHRA study (chapter 4) and the 
stakeholder study (chapter 5) identified roles that GPs could play in combating 
counterfeit medicines. These roles were: reporting to the MHRA through the Yellow 
Card scheme, being vigilant for any suspicion of counterfeit cases, and giving advice to 
and raising awareness of the dangers of counterfeit medicines among their patients. 
However, the views of GPs on these proposed roles have not been systematically 
investigated outside this study nor elucidated in MHRA publications.  
Additionally, the need for communication with and education of health professionals 
(including GPs) with respect to counterfeit medicines had both been mentioned within 
the MHRA and WHO publications on the counterfeit medicines issue. Communication 
methods that could be used with GPs were identified in the MHRA study (reported in 
Chapter 4) and the stakeholders study (Chapter 5). The preferences of GPs themselves 
concerning these communication methods have not yet been examined. If such 
communication is to be effective then the views of those receiving the communication 
are highly relevant. Furthermore, our understanding of GPs’ views can be deepened by 
exploring, through comparative analysis, whether these views are consistently held or 
whether they change according to variables such as past experiences of counterfeit 
medicines, length of service and membership of a professional body. Taken together 
these gaps in knowledge and understanding of GP views on matters related to 
counterfeit medicines are significant and represent an opportunity to add new and 
valuable information to the field of study and particularly to the process of developing 
and implementing an anti-counterfeit medicines strategy. To address the research 
problem it is necessary to construct a complete and multi-dimensional conceptualisation 
of the process of developing, implementing and evaluating an anti-counterfeit medicines 
strategy and to achieve this within this study requires the addition of the GPs’ 
dimension. It is an important dimension as GPs prescribe medicines, treat patients who 
may have health problems arising from the use of counterfeit medicines and could have 
a prime role in educating and advising patients on matters related to counterfeit 
medicines.   
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7.2 Aims and Objectives 
This study aims to understand the views and describe the roles of general practitioners 
(GPs) in combating counterfeit medicines.  
Therefore, the objectives of this research in relation to counterfeit medicines are: 
- to describe the knowledge and experience of GPs practising in England and the 
educational opportunities available to them to enhance this.  
- to describe how GPs practising in England view their roles in combating 
counterfeit medicines. 
- to identify GPs’ views on what methods they may prefer for a medicines 
regulatory agency to communicate with GPs practising in England. 
- to relate the educational opportunities and past experience of GPs practising in 
England to the views and practices they describe. 
 
7.3 Methods 
In this study the aim was to gain an understanding of GPs’ views on a range of issues 
related to counterfeit medicines. As with pharmacists, this constituted a large and 
geographically spread population and as the sample needed to offer a reasonable degree 
of generalizability for the results, certain research methods were ruled out, including the 
face-to-face interviews used in the two studies involving MHRA participants and 
MHRA stakeholder participants (chapters 4 and 5). Therefore, a survey questionnaire 
would be a more appropriate method of data collection and as the full addresses of the 
workplaces of GPs were readily identifiable it was further decided to administer this by 
post. 
This study is the second of two aimed at providing support to the findings of the 
previous two studies involving MHRA participants and MHRA stakeholder 
participants. Including a quantitative research design offered the means of triangulating 
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within this group of studies by addressing its objective of describing the knowledge and 
experience of England’s GPs of the counterfeit medicines issue. The quantitative 
research method is most appropriate where pre-existing knowledge must be taken into 
consideration; this allows the researcher to employ standardised data collection methods 
to document any prevalence of knowledge being examined (102). As with the 
pharmacist study, this study needed quantifiable answers to questions aimed at 
establishing the distribution of types of views and practices across members of a group, 
the extent to which these views and practices were shared and what variables may 
influence the holding a particular view or the adoption of a particular practice. All these 
requirements indicate that a quantitative study was appropriate. Hence, a retrospective 
descriptive survey was used to describe the sample and to examine any associations 
between variables. In order to ensure a reasonable degree of comparability with the 
pharmacist study, this GP study adopted very similar questionnaire survey methods to 
those described in Chapter 6, however, with some differences in the questionnaire 
items. 
Furthermore, the quantitative methods used in this study were selected as it would be 
most appropriate for the second objective of the study which was to describe and 
understand the views and roles of pharmacists and GPs in combating counterfeit 
medicines. These methods were also appropriate for accessing the population and were 
consistent with the desire for generalisability. The benefits of triangulation as “an 
opportunity to enrich research findings and deepen insight” were a consequence of the 
choices as the qualitative approach of the first two studies could now be complemented 
and strengthened with quantitative input from two groups of health professionals with 
important roles to play in any anti-counterfeit medicines strategy (133).   
 
7.3.1 Ethical approval 
This study was approved by the University of East Anglia, Faculty of Medicine and 
Health Ethics Committee (Appendix 4.1) with NHS ethical approval not required as this 
study included only GPs. 
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7.3.2 Questionnaire development 
7.3.2.1 Questionnaire design 
This study is designed based on two qualitative studies of the views of MHRA staff and 
stakeholders respectively, carried out by the researcher and relating to the process of 
developing a national strategy for a medicines regulatory agency to combat counterfeit 
medicines (chapter 4 and chapter 5). Those studies captured the views of members of 
the MHRA and of key stakeholders about the issues associated with developing an anti-
counterfeit medicines strategy. The participants from those earlier studies defined some 
roles that could be carried out by GPs to assist in combating counterfeit medicines. 
Also, those participants described the methods that could be used by the medicines 
regulatory agency to communicate with GPs. This study is also based on the guidance 
leaflet for pharmacists and dispensing doctors called “Counterfeit Medicines Advice for 
Healthcare Professionals”, which was published by the MHRA, the RPS and the DDA; 
which assisted the researcher confirm some of the ongoing issues, shape parts of the 
questionnaire and anticipate the themes likely to emerge from the data (10). 
The researcher then designed a questionnaire which was sent to GPs practising in 
England including dispensing doctors (Appendix 4.2). The questionnaire aimed to 
provide data which could specifically address the aims and objectives of this study. 
Section 1 of the questionnaire covered any past experiences GPs might have had about 
counterfeit medicines. Section 2 covered any education or training opportunities and 
experiences of counterfeit medicines that GPs might have had, and any 
recommendations they may have for such education or training opportunities. Section 3 
sought GPs’ views on about their role in combating counterfeit medicines, and what the 
best method would be to communicate information on counterfeit medicines to them. 
Section 4 covered the personal information of the participants, to help the researcher to 
show whether the study participants were representative of the general GPs’ population. 
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7.3.2.2 Questionnaire validity 
Validity in a survey study can be measured through assessing how far the questions 
collect accurate data and whether or not they are relevant to the study objective (117). 
To achieve face validity, the questionnaire was evaluated by academics and practice 
pharmacists as well as two GPs working at the UEA’s Pharmacy School and UEA’s 
School of Medicine prior to launching the survey. Its face validity has been further 
examined during the piloting stage. Content validity was established in this research 
through the careful selection and refinement of items during questionnaire development, 
based on the qualitative data derived from the previous studies as well as on the 
evaluation and judgement of peers at the UEA’s Pharmacy School UEA’s School of 
Medicine. 
 
7.3.2.3 Improving the response rate  
To increase the response rate for these questionnaires, the researcher applied the 
findings of the review study conducted by Edwards et al. (2009) (134). The 
questionnaire was therefore designed to be short and usually not to take more than ten 
minutes to complete. The UEA logo was added to the front page to clearly indicate that 
these questionnaires are sponsored by the university. The researcher reassured recipients 
in the invitation letter and on the first page of the questionnaires that confidentiality 
would be maintained and that questionnaires were anonymous. All invitation letters 
were personalized and all the potential participants received a pen with the UEA logo as 
an unconditional incentive. A stamped addressed return envelope was provided with 
each questionnaire to increase the response rate. A follow-up letter, which contained a 
second copy of the questionnaire, was sent to potential participants who had yet to 
return the postcard.  
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7.3.3 Participants and sample size calculation 
7.3.3.1 Sampling unit 
The target population for this study was GPs practising in England; it has been reported 
that the total number of doctors licensed to work as GPs in England is 47,438 (138). 
The researcher used the GPs as the sampling unit. Currently, in England there are 211 
NHS clinical commissioning groups (CCGs) that provide medical services for patients 
(145); each of these CCGs consists of many surgery clinics.  
 
7.3.3.2 Sample size estimation 
A final sample size of 400 respondents provides 95% CI of + or – 3% around a response 
to question of 10%; and + or – 5% around a response to question of 50%. Assuming that 
60% of the sample return the questionnaire the researcher needed to post the 
questionnaire to approximately 630 GPs (136). 
 
7.3.3.3 Method of sampling 
A random sampling method is desirable as it allows the application of probability 
statistics and generalisation to the population from which the sample is drawn (96). This 
method is fundamental to achieving external validity for the study (102). The researcher 
used the random sampling to identify the GPs from clinical commissioning groups 
(CCGs). All 211 CCGs within England that provide medical services to patients have 
been included in the sampling (145). From those CCGs; three surgery clinics have been 
randomly selected; and among those surgery clinics selected, one GP from each CCG 
was randomly selected to be part of this study (using a random number generator 
provided within Excel). The total number of GPs included in this study was 633. 
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7.3.4 Implementation and follow-up 
7.3.4.1 Questionnaire implementation 
Once the surgery clinics were selected and the GPs from those surgery clinics identified, 
the researcher used the surgery clinic’s website to identify the names of the GPs 
working there. This assisted the researcher to personalise the invitation letter and the 
envelope sent to each GP. Each envelope sent to a GP included a personalised invitation 
letter (Appendix 4.3), a questionnaire (Appendix 4.2), a prepaid envelope to return the 
questionnaire, a postcard (Appendix 4.4), a prepaid envelope to return the postcard and 
an incentive pen. 
 
7.3.4.2 Follow-up process 
Three weeks after despatching the packs, those who had yet to return their postcard 
were sent a follow-up reminder letter (Appendix 4.5). A second copy of the 
questionnaire was included with the reminder letter. No more follow up action was 
taken after this point. 
 
7.3.5 Data analysis 
All data were analysed using Microsoft Excel and the Statistical Package for the Social 
Sciences (SPSS) software. The data were summarised using descriptive statistics; 
Fisher's exact test and chi-squared analysis were used to compare between GP groups 
based on their responses on the questionnaire. The chi-squared test is considered invalid 
if 20% or more of the cells have expected values of less than 5. 
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7.4 Results 
7.4.1 Response rates 
The initial response rate for the pilot stage (65 questionnaires) after one follow up was 
20% (13 out of 65 questionnaires). To improve the response rate, the questionnaire was 
modified by decreasing the total number of questions, increasing the font size, and 
adding the WHO definition for counterfeit medicines. In addition, the invitation letter 
was rewritten and the WHO definition for a counterfeit medicines added to it. The 
invitation letter and the follow-up letter were signed by a professor from Norwich 
Medical School and the researcher to encourage the GPs to take part in the study 
(Appendix 4.3 and Appendix 4.5). 
The response rate after the modification slightly improved to 22.5% (128 out of 568 
questionnaires); 533 GPs (93.7%) were sent a follow-up reminder letter. The overall 
response rate to the GPs’ questionnaire was 22.3% (141 out of 633 questionnaires). In 
addition, the overall missing data from the GPs’ answers to the questionnaire was 
0.99%. 
 
7.4.2 Demographic data 
Eighty-one of the respondents were male, among those 66 were working as GPs and 15 
were working as dispensing doctors. Fifty-nine of the responded were female, among 
those 47 were working as GPs and 11 were working as dispensing doctors (table 7.1).  
Table 7. 1 GPs’ gender and workplace 
 Number of GPs (%) 
working as 
GP (%) Dispensing doctor (%) 
Gender 
Male 81 (57.4%) 66 (57.9 %) 15 (55.6%) 
Female 59 (41.8%) 47 (41.2%) 11 (40.7%) 
 Missing 1 (0.7%) 1 (0.9%) 1 (3.7%) 
 Total 141 114 27 
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In respect of the GPs’ length of service; 2.1% (3 GPs) of the study sample had a length 
of service of 5 years or less, 4.3% (6 GPs) between 6 to 10 years, 12.1% (17 GPs) 
between 11 to 15 years, 9.9% (14 GPs) between 16 to 20 years and 12.1% (17 GPs) 
between 21 and 25 years. Finally, the majority (58.9% - 83 GPs) of this study sample 
had a length of service of more than 25 years. One GP only (0.7%) did not answer the 
length of service question 
For the purpose of data analysis the GPs’ lengths of service were re-grouped to three 
main categories; 0 – 10 years, 11 – 25 years, and over 25 years. In comparing the 
study’s sample with GPs general population (only GPs’ age data available) (138); table 
7.2 shows that whilst the age range of the general population of GPs is normally 
distributed, the study sample is skewed with greater proportions to the older groups. 
Table 7. 2 GPs’ length of service (n=140) 
GPs sampled GPs’ general population1 
Length of service Percentage of the 
study sample Age 
Percentage of General 
population 
0 – 10 years 6.4% less than 30 years 15% 
11 – 25 years 34% 30 – 49 years 58% 
over 25 years 58.9% 50 years or more 27% 
1
 Council GM. The state of medical education and practice in the UK report: 2014: General Medical Council; 
http://www.gmc-uk.org/publications/25452.asp. 
With respect to GPs’ membership of professional bodies, 97 of the GPs in the study 
sample were members of the British Medical Association (BMA), and 69 of the GPs 
were members of the Royal College of General Practitioners (RCGP). One GP only 
(0.7%) did not state a professional body. 
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7.4.3 Descriptive analysis 
7.4.3.1 GPs’ experiences in respect of counterfeit medicines 
In relating to any past experiences the GPs might have had (figure 7.1); only six (4.3%) 
GPs of the study’s sample have had experience of a medicine being recalled due to 
counterfeiting. In addition, two of those GPs had had only one experience with this kind 
of recall, one GP had two such experiences, and one GP had six. The other two GPs did 
not report a frequency. 
13 (9.2%) GPs in this study had experience of a patient reporting or showing a medicine 
that might be counterfeit. Moreover, 3 GPs had had this experience once, one GP twice, 
two GPs had it three times, and one GP five times. The remaining GPs did not state the 
frequency. 
In respect of any experience of adverse effects due to counterfeit medicines that patients 
had used, only four (2.8%) GPs had had such an experience. Also, one GP did not 
answer how many times he had seen that kind of adverse effect whereas three GPs said 
they had had such an experience once. 
Figure 7. 1 GPs’ experiences of counterfeit medicine issues 
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For the action that the GPs who had had an experience of counterfeit medicines, table 
7.3 show the actions undertaken by GPs as a result of the past experience with the 
counterfeit medicines. 
Table 7. 3 GPs’ selection for their action as a result of a counterfeiting experience 
 Rank of action taken by the GPs No. GPs (%) 
1 Gave the patient advice 6 (30%) 
2 Treated the patient for the adverse effect 4 (20%) 
3 Did not do anything 4 (20%) 
4 Used the Yellow Card Scheme to report the incident 2 (10%) 
5 Informed someone within their organization 2 (10%) 
6 Isolated the item from their stock 1 (5%) 
7 Other 1 (5%) 
 
With respect to the actions that the GPs would take in the future if they suspected that a 
medicine could be counterfeit, these are ranked in table 7.4 in order of frequency. 
Table 7. 4 GPs’ selection for their future action when suspecting counterfeiting 
 Rank of GP future action intentions No. GPs (%) 
1 Report to the MHRA 81 (57.4%) 
2 Report to someone within their organization 72 (51.1%) 
3 Report to the supplier of the medicine 57 (40.4%) 
4 Isolate the item from the stock 55 (39%) 
5 Report to the manufacturer of the medicine 44 (31.2%) 
6 Report to the GP’s professional body 14 (9.9%) 
7 Report to the pharmacist 12 (8.5%) 
8 Other 2 (1.4%) 
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7.4.3.2 GPs’ education in respect of the counterfeit medicines issue 
None of the GPs in this study sample had previously received formal education or a 
training programme regarding counterfeit medicines. On the education and training 
programmes that GPs believe should be given; 29.8% (42 GPs) recommended the 
education and training programme should be within a medicine school undergraduate 
degree; 31.2% (44 GPs) in the study sample said it should fall within the GPs’ 
foundation year; and 37.6% (53 GPs) indicated it should be in the GPs’ post-foundation 
year. 
Moreover, regarding the delivery method for the education and training that covers the 
counterfeit medicines issue (table 7.5), 57 GPs preferred it to be delivered through 
distance learning; 51 GPs preferred workshops; and 21 GPs said through journal 
articles. In their answer few GPs selected more than one preferred method.  
Table 7. 5 GPs’ preferred delivery method for education or training programme 
 Rank of preferred education and training delivery method No. GPs (%) 
1 Distance learning 57 (40.4%) 
2 Workshop 51 (36.2%) 
3 Journal article 21 (14.9%) 
4 Conference 16 (11.3%) 
5 Other 8 (5.7%) 
 
7.4.3.3 GPs’ views on their roles in combating counterfeit medicines 
The roles GPs believed they could carry out in combating counterfeit medicines are 
shown in figure 7.2. One hundred and twenty-two GPs saw it as their duty to report any 
suspicion of counterfeiting medicines to the medicines regulatory agency. However, the 
other 19 GPs said it would be the pharmacist’s responsibility to do this. 
For the responsibility of raising patient awareness about counterfeit medicines, only 77 
GPs said it would be part of their role to raise patients’ awareness of counterfeit 
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medicines. On the other hand, 64 GPs did not agree that it would be their responsibility; 
and among them 21 GPs saw it as the government’s responsibility and 19 GPs believed 
it would be the pharmacist’s responsibility. 
With regard to providing the patient with advice about the counterfeit medicines issue: 
72 GPs of the study sample said it would be part of their role in combating counterfeit 
medicines; however, 69 GPs saw it as not their duty to provide the patient with advice 
about counterfeit medicines; and 21 of them said it was the pharmacist’s responsibility 
and 14 of them believed it to be the government’s responsibility. 
Figure 7. 2 GPs’ views on their roles in combating counterfeiting medicines 
 
7.4.3.4 The communication methods preferred by GPs  
For the methods of communication through which the GPs preferred to receive 
information about counterfeit medicines issues (figure 7.3); results show that they 
preferred the professional journal or through their organization. 
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Figure 7. 3 GPs’ selection of the preferred methods of communication 
 
7.4.4 Comparative analysis 
7.4.4.1 Past GP experiences 
This section compares the opinions of the GPs who had had past experience of 
counterfeit medicines and those who had not had such experiences. The researcher 
formulated the hypothesis that any past expertise on counterfeit medicines would reflect 
on the answers given by the GPs. To examine the hypothesis, four comparisons (future 
actions, preferences for education, GPs role, and preferred method of communication) 
were conducted to compare data between the 17 GPs who said they had had an 
experience with counterfeit medicines and the 124 GPs who had not had any 
experience.  
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i) Comparisons of opinion on the future actions 
Table 7.6 shows the comparison between the GPs who have experience and those who 
did not in their selection of the actions that would be taken by them in case of an 
incidence of counterfeit medicines. The results show no significant difference between 
the two GP groups. 
Table 7. 6 Past experiences and GPs’ stated future actions 
GP’s selection for their future action 
GPs with past counterfeit medicine 
experience 
No. (%) 
P* 
No experience Experience 
Total 124 (87.9%) 17 (12.1%) 
Report to the medicine’s supplier 54 (43.5%) 3 (17.6%) 0.063 
Report to the medicine’s manufacturer 41 (33.1%) 3 (17.6%) 0.269 
Report to the MHRA 74 (59.7%) 7 (41.2%) 0.192 
Isolate the item from the stock 50 (40.3%) 5 (29.4%) 0.439 
Report to someone within their organization 64 (51.6%) 8 (47.1%) 0.799 
Report to the GP’s professional body 14 (11.3%) 0 0.219 
Report to the pharmacist 12 (9.7%) 2 (11.8%) 0.677 
* Fisher's exact test 
ii) Comparisons of opinion on the future education preferences 
Table 7.7 shows the responses of the two GP groups regarding when any education or 
training programmes about the counterfeiting of medicines should be delivered. 
Moreover, Table 7.8 highlights which kind of education or training programmes each 
GPs group recommended. There was no significant difference between the GPs with 
past experience and the GPs without such an experience. 
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Table 7. 7 Past experiences and recommendations for future education timing 
GPs’ selection for the timing of future 
education 
GPs with past counterfeit medicine 
experience 
No. (%) 
P* 
No experience Experience 
Total 123 (88.5%) 16 (11.5%) 
Within undergraduate degree 37 (30.1%) 3 (18.8%) 
0.136 Within the GPs’ foundation year 41 (33.3%) 3 (18.8%) 
Post-foundation year 45 (36.6%) 10 (62.5%) 
* Chi-squared analysis 
Table 7. 8 Past experience and recommendations for future education preferences 
GPs’ selection for the delivery method of 
future education 
GPs with past counterfeit medicine 
experience 
No. (%) 
P* 
No experience Experience 
Total 123 (88.5%) 16 (11.5%) 
Workshop 43 (35%) 8 (50%) 0.276 
Conference 15 (12.2%) 1 (6.3%) 0.694 
Distance learning 48 (39%) 6 (37.5%) 1.000 
Journal article 19 (15.4%) 2 (12.5%) 1.000 
Other 8 (6.5%) 0 0.596 
* Fisher's exact test 
iii) Comparisons of opinion on the role of the GP 
This comparison (table 7.9) addresses the view of the study sample on the GPs’ roles in 
combating counterfeit medicines between the GPs with past experience and GPs 
without. There is no significant difference found between the two GPs group. 
 
Chapter 7: General Practitioners’ views on their role in combating counterfeit 
medicines 
 
PhD Thesis: Developing a national strategy for counterfeit medicines                            252 
Table 7. 9 Past experience and opinion on GP role 
Role of GP in combating counterfeit medicines 
GPs with past counterfeit medicine 
experience 
No. (%) 
P* 
No experience Experience 
Total 124 (87.9%) 17 (12.1%) 
Reporting to the medicines regulatory agency 110 (88.7%) 12 (70.6%) 0.056 
Raising patient awareness about counterfeit 
medicines 68 (54.8%) 9 (52.9%) 1.000 
Advise patient about counterfeit medicines 64 (51.6%) 8 (47.1%) 0.799 
* Fisher's exact test 
iv) Comparisons of opinion on the preferred methods of communication 
The final comparison (table 7.10) shows that there are no real differences in the 
preferred methods of communication regarding counterfeiting information between GPs 
with and without experience of it.  
Table 7. 10 Past experience and preferred communication methods 
GPs’ preferred communication method 
GPs with past counterfeit medicine 
experience 
No. (%) 
P* 
No experience Experience 
Total 124 (87.9%) 17 (12.1%) 
Professional journal 33 (26.6%) 6 (35.3%) 
Te
st
 
in
v
al
id
 
Professional bodies 19 (15.3% 0 1 (5.9%) 
Via their organization 32 (25.8%) 3 (17.6%) 
Fax 3 (2.4%) 3 (17.6%) 
Email 30 (24.2%) 4 (23.5%) 
Press release 3 (2.4%) 0 (0.0%) 
General media 3 (2.4%) 0 (0.0%) 
Other 1 (0.8%) 0 (0.0%) 
* Chi-squared analysis  
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7.4.4.2 Length of service of the GPs 
The study also compares the opinions between the GPs based on their length of service 
which had been categorised into three groups. As the attention to the counterfeit 
medicines issue had increased in recent years (the first MHRA anti-counterfeiting 
medicines strategy was published in 2007) (25), the researcher formulated the 
hypothesis that any past expertise regarding counterfeit medicines would reflect on the 
answers given by the GPs. To test the hypothesis, four comparisons (future actions, 
preferences for education, GPs role, and preferred method of communication) were 
conducted to compare data between GPs with less than 10 years’ service (9 GPs), GPs 
with 11 to 25 years’ service (48 GPs) and GPs’ with over 25 years’ service (83 GPs).  
i) Comparisons of opinion on the future actions and length of service 
Table 7.11 shows the answers of the study sample about the action that would be taken 
if they had to deal with a counterfeit medicines case in the future. Some tests on the 
table were invalid, and others found no significant difference between the GP groups. 
The only significant difference was found with reporting to the medicine’s supplier; it 
appeared that GPs with length of service between 11 and 25 years are more likely to 
report to the medicine’s supplier than other GPs.   
Table 7. 11 Length of service and GPs’ stated future actions 
GP’s selection for their future action 
Length of service in years No. (%) 
p* 
0-10 11-25 Over 25 
Total 9 (6.4%) 48 (34%) 83 (58.9%) 
Report to the medicine’s supplier 1 (11.1%) 27 (56.3%) 28 (33.7%) 0.008 
Report to the medicine’s manufacturer 2 (22.2%) 15 (31.3%) 27 (32.5%) 0.818 
Report to the MHRA 7 (77.8%) 27 (56.3%) 47 (56.6%) 0.457 
Isolate the item from the stock 5 (55.6%) 20 (41.4%) 29 (34.9%) 0.416 
Report to someone within their 
organization 5 (55.6%) 29 (60.4%) 38 (45.8%) 
Test 
invalid Report to the GP’s professional body 1 (11.1%) 5 (10.45%) 8 (9.6%) 
Report to other 0 3 (6.3%) 11 (13.3%) 
* Chi-squared analysis 
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ii) Comparison of opinion on the future education preferences and length of service 
Table 7.12 and table 7.13 show the responses of the three GP groups regarding when 
any education or training programmes about counterfeit medicines should be delivered, 
and which kind of education or training programmes each GP group recommended. The 
results in table 7.12 and table 7.13 show no significant difference between the GP 
groups. Whereas, one result in table 7.13 suggested that the distance learning for 
education are preferred by GPs who have 11-25 years length of service.  
Table 7. 12 Length of service and the recommendations for future education timing 
GPs’ selection for future education timing 
Length of Service in years No. (%) 
p* 
0-10 11-25 Over 25 
Total 9 (6.4%) 48 (34%) 83 (58.9%) 
Within undergraduate degree 4 (44.4%) 17 (35.4%) 25 (30.9%) 0.665 
Within the GPs’ foundation year 4 (44.4%) 21 (43.8%) 25 (30.9%) 0.294 
Post-foundation year 2 (22.2%) 16 (33.3%) 37 (45.7%) 0.205 
* Fisher's exact test 
Table 7. 13 Length of service and the recommendations for future education preferences 
GPs’ selection of the delivery method for 
future education 
Length of service in years 
No. (%) 
p* 
0-10 11-25 Over 25 
Total 9 (6.4%) 48 (34%) 83 (58.9%) 
Workshop 4 (44.4%) 15 (31.3%) 32 (39.5%) 0.573 
Conference 1 (11.1%) 3 (6.3%) 12 (14.8%) 0.340 
Distance learning 3 (33.3%) 26 (54.2%) 25 (30.9%) 0.030 
Journal article 1 (11.1%) 8 (16.7%) 12 (14.8%) 0.902 
Other 0 (0.0%) 4 (8.3%) 3 (3.7%) Test invalid 
* Chi-squared analysis 
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iii) Comparisons of opinion on the GP roles and length of service 
The view of GPs’ roles in combating counterfeit medicines based on the GPs’ length of 
service has been summarized in table 7.14. Two tests were invalid and the third shows 
no significant difference between the GP groups. 
 
Table 7. 14 Length of service and the GP’s role 
Role of GP in combating counterfeit 
medicines 
Length of service in years 
No. (%) 
p* 
0-10 11-25 Over 25 
Total 9 (6.4%) 48 (34%) 83 (58.9%) 
Reporting to the medicines regulatory 
agency 9 (100%) 44 (91.7%) 69 (83.1%) 0.183 
Raising patient awareness about 
counterfeit medicines 5 (55.6%) 26 (54.2%) 46 (55.4%) 
Test 
invalid 
Advice patient about counterfeit 
medicines 8 (88.9%) 21 (43.8%) 43 (51.8%) 
Test 
invalid 
* Chi-squared analysis 
 
iv) Comparisons of opinion on the preferred methods of communication and length of 
service 
The preferred methods of communication about information on counterfeit medicines 
recommended by the three GP groups based on their length of service is shown in table 
7.15; no real differences can be seen.  
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Table 7. 15 Length of service and preferred communication methods 
GPs’ preferred communication method 
Length of Service in years 
No. (%) 
p* 
0-10 11-25 Over 25 
Total 9 (6.4%) 48 (34%) 83 (58.9%) 
Professional journal 1 (11.1%) 13 (27.1%) 25 (30.1%) 
Te
st
 
in
v
al
id
 
Professional bodies 2 (22.2%) 6 (12.5%) 12 (14.5%) 
Via their organization 4 (44.4%) 11 (22.9%) 19 (22.9%) 
Fax 0 2 (4.2%) 4 (4.8%) 
Email 2 (22.2%) 14 (29.2%) 18 (21.7%) 
Press release 0 1 (2.1%) 2 (2.4%) 
General media 0 1 (2.1%) 2 (2.4%) 
Other 0 0 1 (1.2%) 
* Chi-squared analysis 
 
7.4.4.3 Professional body membership 
The final section of the comparisons covers the GPs’ membership of professional 
bodies and their responses; the differences in the views of those within and not within 
professional bodies have been examine. Therefore, the researcher formulated the 
hypothesis that there will be differences in the opinion between the GPs about the 
counterfeit medicines issue according to their membership of the professional bodies 
(69 GPs are members of the RCGP and 97 are members of the BMA). To examine this 
hypothesis four comparisons (future actions, preferences for education, GPs role, and 
preferred method of communication) have been analysed. 
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i) Comparisons of opinion on the future actions and professional membership 
Table 7.16 shows the comparison between GPs in their responses to their selection for 
the actions they would take in case of a counterfeit medicines case based on their 
membership of a professional body. No significant difference between the GP groups 
was found in the table. 
Table 7. 16 Professional body membership and GP’s stated future actions 
GP’s selection for their future 
action 
Membership of RCGP 
No. (%) 
Membership of BMA 
No. (%) 
No Yes 
p* 
No Yes 
p* Total 
71 
(50.4%) 
69 
(48.9%) 
43 
(30.5%) 
97 
(68.8%) 
Report to the medicine’s supplier 
30 
(42.3%) 
26 
(37.7%) 0.608 
19 
(44.2%) 
37 
(38.1%) 0.576 
Report to the medicine’s 
manufacturer 
21 
(29.6%) 
23 
(33.3%) 0.717 
11 
(25.6%) 
33 
(34%) 0.430 
Report to the MHRA 
39 
(54.9%) 
42 
(60.9%) 0.498 
28 
(65.1%) 
53 
(54.6%) 0.271 
Isolate the item from the stock 
22 
(31%) 
32 
(46.4%) 0.082 
17 
(39.5%) 
37 
(38.1%) 1.000 
Report to someone within their 
organization 
34 
(47.9%) 
38 
(55.1%) 0.404 
21 
(48.8%) 
51 
(52.6%) 0.717 
Report to the GP’s professional 
body 
7 
(9.9%) 
7 
(10.1%) 1.000 
5 
(11.6%) 
9 
(9.3%) 0.762 
Report to the pharmacist 
7 
(9.9%) 
7 
(10.1%) 1.000 
4 
(9.3%) 
10 
(10.3%) 1.000 
* Fisher's exact test 
 
 
Chapter 7: General Practitioners’ views on their role in combating counterfeit 
medicines 
 
PhD Thesis: Developing a national strategy for counterfeit medicines                            258 
ii) Comparisons of opinion on the future education preferences and professional body 
membership 
The comparisons between the responses of GPs who were members of the RCGP and 
the GPs who were members of the BMA regarding when any education or training 
programmes about counterfeit medicines should be delivered to the GPs and which kind 
of education or training programmes are shown in table 7.17 and table 7.18. One 
significant difference found in table 7.17 that show GPs who are members of the BMA 
were more likely to recommend training within the undergraduate degree. Table 7.18 
shows two significant differences between the GP membership groups; which suggested 
that the distance learning method is preferred by those with RCGP membership whereas 
journal articles are preferred by GPs without RCGP membership. 
Table 7. 17 Professional body membership and the recommendations for future education 
timing 
GP’s selection for their future 
education timing 
Membership of RCGP 
No. (%) 
Membership of BMA 
No. (%) 
No Yes 
p* 
No Yes 
p* Total 
71 
(50.4%) 
69      
(48.9%) 
43 
(30.5%) 
95 
(67.4%) 
Within undergraduate degree 
21 
(29.6%) 
25 
(37.3%) 0.370 
7 
(16.3%) 
39 
(41.1%) 0.006 
Within the GPs’ foundation year 
24 
(33.8%) 
26 
(38.8%) 0.597 
19 
(44.2%) 
31 
(32.6%) 0.251 
Post-foundation year 
33 
(46.5%) 
22 
(32.8%) 0.119 
19 
(44.2%) 
36 
(37.9%) 0.574 
* Fisher's exact test 
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Table 7. 18 Professional body membership and the recommendations for future education 
preferences 
GP’s selection for their future 
education type 
Membership of RCGP 
No. (%) 
Membership of BMA 
No. (%) 
No Yes 
p* 
No Yes 
p* Total 
71 
(50.4%) 
67 
(47.5%) 
43 
(30.5%) 
95 
(67.4%) 
Workshop 
26 
(36.6%) 
25 
(37.7%) 1.000 
19 
(44.2%) 
32 
(33.7%) 0.258 
Conference 
11 
(15.5%) 
5 
(7.5%) 0.186 
7 
(16.3%) 
9 
(9.5%) 0.261 
Distance learning 
20 
(28.2%) 
34 
(50.7%) 0.009 
13 
(30.2%) 
41 
(43.2%) 0.188 
Journal article 
16 
(22.5%) 
5 
(7.5%) 0.017 
7 
(16.3%) 
14 
(14.7%) 0.803 
Other 
2 
(2.8%) 
5 
(7.5%) 0.265 
4 
(9.3%) 
3 
(3.2%) 0.204 
* Fisher's exact test 
 
iii) Comparisons of opinions on the GP’s roles 
GP membership with the professional bodies and their views on the roles of GPs in 
combating counterfeit medicines has been examined in table 7.19. The results show no 
significant difference between the GP groups. 
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Table 7. 19 Professional body membership and the reported role of GP 
Role of GPs in combating 
counterfeit medicines 
Membership of RCGP 
No. (%) 
Membership of BMA 
No. (%) 
No Yes 
p* 
No Yes 
p* Total 
71 
(50.4%) 
69 
(48.9%) 
43 
(30.5%) 
97 
(68.8%) 
Reporting to the medicines 
regulatory agency 
58 
(81.7%) 
64 
(92.8%) 0.076 
38 
(88.4%) 
84 
(86.6%) 1.000 
Raising patient awareness about 
counterfeit medicines 
44 
(62%) 
33 
(47.8%) 0.126 
26 
(60.5%) 
51 
(52.6%) 0.462 
Advice patient about counterfeit 
medicines 
38 
(53.5%) 
34 
(49.3%) 0.735 
25 
(58.1%) 
47 
(48.5%) 0.360 
* Fisher's exact test 
iv) Comparisons of opinion on the preferred methods of communication 
Table 7.20 shows the comparison examining the GPs’ membership of professional 
bodies and their preferred methods of communication about counterfeiting information. 
Table 7. 20 Professional body membership and the preferred communication methods 
GP’s preferred 
communication method 
Membership of RCGP 
No. (%) 
Membership of BMA 
No. (%) 
No Yes 
p* 
No Yes 
p* Total 71 (50.4%) 69 (48.9%) 43 (30.5%) 97 (68.8%) 
Professional journal 20 (28.2%) 19 (27.5%) 
Te
st
 
in
v
al
id
 
11 (25.6%) 28 (28.9%) 
Te
st
 
in
v
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Professional bodies 7 (9.9%) 13 (18.8%) 5 (11.6%) 15 (15.5%) 
Via their organization 18 (25.4%) 16 (23.2%) 13 (30.2%) 21 (21.6%) 
Fax 4 (5.6%) 2 (2.9%) 1 (2.3%) 5 (5.2%) 
Email 16 (22.5%) 18 (26.1%) 10 (23.3%) 24 (24.7%) 
Press release 2 (2.8%) 1 (1.4%) 1 (2.3%) 2 (2.1%) 
General media 3 (4.2%) 0 2 (4.7%) 1 (1%) 
Other 1 (1.4%) 0 0 1 (1%) 
* Chi-squared analysis 
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7.5 Discussion 
This study aimed to gain a better understanding of the GPs’ knowledge and experiences 
of counterfeit medicines. It also aimed to explore the views of GPs regarding their 
possible roles in combating counterfeit medicines. The study found that only a small 
percentage of GPs had reported a past experience of a counterfeit medicine case and that 
just under half of GPs would report any future incidents involving counterfeit medicines 
to the MHRA. Findings also showed that none of the GPs had received any kind of 
education or training programme regarding counterfeit medicines and that the GPs 
preferred distance learning and workshops to deliver such education or training 
programmes. This study also found that most of the GPs agreed that reporting to the 
medicines regulatory agency was a legitimate role for them in combating counterfeit 
medicines; however, around half did not agree on the other roles proposed for them by 
the participants from the MHRA and the stakeholders studies. Although, none of the 
GPs had had any education or training experiences regarding counterfeit medicines, 
they were receptive to future training in a wide variety of formats. Also, this study 
compared the responses between the GPs with respect to any past experience of 
counterfeit medicines, length of service, and membership of a professional body which 
revealed no significant difference in the responses among the GPs. As the number of 
GPs who took part in this study and who had had past experience of counterfeit 
medicines was small, the few significant differences that were found in the comparisons 
could be considered as false positives. However, a few comparisons indicated a number 
of significant differences that could provide some understanding of the GPs’ attitudes 
and behaviour with respect to counterfeit medicines. 
This study, to the best knowledge of the researcher, was the first to be designed and 
implemented in the UK to understand the practices, experience and opinions of GPs 
regarding counterfeit medicines. The study methods also gave GPs the opportunity to 
voice their own views on their preferred education and training programmes and on the 
role of GPs in combating counterfeit medicines. Another strength is that there was very 
little missing data which suggests a high degree of engagement among the participants 
and the ease of use of the survey. Also, the sampling process used random sampling 
techniques which gave all members of the GP population the same chance of being part 
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of the study; this was demonstrated in the demographic characteristics of the study 
sample which broadly reflected what is known about the wider GP population.  
In this study, the gender representation among the GPs who participated was broadly in 
line with the overall GP population; according to the UK General Medical Council 
(GMC), from all licensed GPs 56% were male and 44% were female; whereas, in this 
study 57.4% of the participants were male and 41.1% were female (138). Regarding the 
place of work of GPs, in the general population the percentage of dispensing doctors 
working in England is 13% and GPs 87% (146); whereas, in this study 18.7% of the 
participants were dispensing doctors and 81.3% were GPs. However, the GPs length of 
service were skewed to the older GPs which might be those GPs were more aware of 
past counterfeit cases issued by MHRA.  
When considering the results it is important to consider the survey response rate, which 
was only 22.3%, as this one of the limitations of this study and it made the findings 
more difficult to generalize which might impose a bias on this study’s findings. Another 
limitation affecting this research was the participation of a low number of GPs with past 
experiences regarding counterfeit medicines as well as the fact that most of the GPs who 
participated in the study had not received any prior education and training regarding the 
counterfeiting of medicines. These limitations affected the data analysis when 
comparing the answers of the GPs with respect to past experiences or education. Also, 
this study was conducted with a very limited range of published literature to support its 
design. 
This study showed that only a small percentage of GPs in England had had past 
experience(s) of counterfeit medicines, as only a few of the GPs stated that they had had 
experiences with a medicine being recalled by the MHRA due to suspected 
counterfeiting. This could be due to the GPs not being a target audience of the MHRA 
regarding recall alerts, which is understandable as the participants in the MHRA study 
mentioned that GPs do not physically deal with the medicines. Moreover, the MHRA’s 
last recall due to suspected counterfeiting was issued in 2009 (131); which might 
account for the low number of GPs reporting such an experience.  
Also, this study showed that one in ten GPs had received reports from patients regarding 
a medicine that might be counterfeit, and only a few GPs had experience of dealing with 
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patients who might have been affected by counterfeit medicines. This percentage is 
much lower than the figure published by the MHRA (2012) which stated that 25% of 
GPs had dealt with patients suffering from adverse effects from counterfeit medicines 
(85). However, it should be recognised the response rate was low and among those who 
participated in the survey few of them had had past experience with counterfeit 
medicines. In this study, more than half of the GPs reported that if they came across a 
counterfeit medicine issue in future their action would be to report it to the MHRA, the 
second most commonly reported future action was to report it to someone within their 
organization. The action to report suspected counterfeit medicines to the MHRA, which 
was reported by GPs, would fall within the existing GP practice of reporting any 
adverse patient incidents including drug reactions to the medicine regulatory agency via 
the UK’s yellow card scheme.  
The results showed that none of the GPs participating in this study had taken part in any 
kind of education or training programme related to medicine counterfeiting. This is an 
unexpected result as the MHRA stated in its strategy documents that one of the 
activities would be to communicate with the health professionals. This raises a concern 
that GPs might not be fully aware of the counterfeit medicines issue and may not 
consider counterfeit medicines as a cause of unexpected side effects or treatment failure. 
However, because of the small number of GPs involved in this study, the researcher 
could not conclude that this scenario reflected the overall situation for the general GP 
population in England.  
As none of the GPs in this study had had any past training or education experience on 
counterfeit medicines, their views on the best timing for delivering such education to 
GPs could be rather speculative which could be seen by their disagreement on the issue. 
However, GPs saw distance learning as the preferred method of delivery for such 
education and training programmes, which could be explained by the fact that GPs in 
England do not normally physically deal with medicines they prescribe, also such 
training may not be perceived as a priority and hence travel to a workshop may not be 
viewed as the best use of their time, explaining why they selected distance learning. 
Furthermore, GPs in this study preferred professional journals first and their 
organisation (i.e. Clinical Commissioning Groups (CCGs)) second as a methods of 
communication. 
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In relation to the roles that GPs could perform in combating counterfeit medicines. This 
study showed that the majority of GPs considered reporting to the agency as their role. 
This result is in line with the GPs selection of reporting any future counterfeit medicines 
case to the MHRA as first choice meaning that GPs would deal with an incidence of 
suspected counterfeit medicines  in the same way as they handle a case of medicine side 
effects, thus avoiding the need for separate, potentially time-consuming, procedures. 
However, as none of GPs had had any past training experience and only a few of them 
had had a past experience of counterfeit medicines, it would be hard to anticipate how 
and when the GPs would consider using the reporting system to report a counterfeit 
medicine. Conversely, barely over half of the GPs considered raising awareness among 
the patients was their role; and slightly less than half believed that providing advice to 
patients was their role. This could be because GPs see themselves more involved with 
educating patients on health matters whereas the pharmacists would be more involved 
with topics specifically related to the prescribed medicines. Also, these findings might 
give rise to a concern related to the flow of information to the GPs and suggests that 
GPs need to be trained with respect to their roles in combating counterfeit medicines.  
 
7.5.1 Comparisons of GPs responses 
This study compared the GPs’ answers based on their past experience, length of service, 
and membership of professional bodies. The comparisons could not identify significant 
differences between GPs response which could be a result of the limited number of the 
GPs who had had past experience with respect to counterfeit medicines or could be due 
to the low response rate from the GPs, which therefore limited the power of the tests. 
Also, GP responses could have been influenced by the fact that none of the GPs who 
participated in the study had attended education or training activities.  
A few comparisons showed significant differences; but, due to the large number of tests 
performed there is a possibility of false positives. However, it considered to be true 
differences for the purposes of the discussion (whilst accepting that they may not 
actually exist) they still could show some indications of GPs’ views toward the 
counterfeit medicines issue. The GPs who had had past experiences of counterfeit 
medicines were seen to be less likely to report an incident to the MHRA which was also 
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seen with the pharmacists (chapter 6); also, they were less agreeable to the roles 
proposed for the GPs in combating counterfeit medicines identified in the studies with 
MHRA participants and stakeholder participants (chapter 3 and chapter 4). These were 
unexpected results as having had these past experiences should have reminded the GPs 
of the importance of reporting to the medicines regulatory agency. Perhaps those GPs 
had found the process of reporting to the agency inefficient or time consuming and as a 
result preferred to advise the patient or refer the patient to the pharmacists for reporting 
rather than to report it themselves to the medicines regulatory agency, which might be 
worth the agency exploring. 
These few significant differences indicated that newer GPs were more likely to report 
any counterfeit incident to the MHRA and showed more conviction in their roles in 
combating counterfeit medicines than other groups of GPs. This might suggest that 
newer GPs were adhering more closely to the good practice of reporting to the agency 
via the Yellow Card Scheme.  
Also, the younger GPs were more likely to be in favour of integrating any education and 
training programmes regarding counterfeit medicines within the undergraduate degree 
or within the foundation year and to be delivered to them as workshops. These GPs had 
more recently completed their formal training so may place a greater value on such 
programmes than those whose formal training is a more distant memory. Also, the 
longer serving GPs might not favour such education and training programmes within 
undergraduate courses as it would not be relevant to them at this point of time. Finally, 
results showed that younger GPs were more likely to favour receiving information via 
their professional organisations than those with greater lengths of service suggesting 
that newer GPs may have a greater reliance on these organisations to evaluate and filter 
information than more experienced GPs.  
Regarding professional body membership, GPs who were members of the RCGP were 
more likely to report any counterfeiting incident to the MHRA and to their organization 
than GPs who were members of the BMA. This could suggest that the RCGP is more 
active in informing members on the counterfeit medicines issue and the role of the 
MHRA than the BMA, something which may be of interest to decision makers at the 
MHRA when accessing communication strategy. This study has made a valuable 
contribution to constructing a complete conceptualisation of the process of developing, 
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implementing and evaluating the strategy. The health professional studies in this chapter 
involved highly significant actors in the issue of combating counterfeit medicines which 
contribute to the overall research aim. 
 
7.6 Conclusion 
This study provides findings which contribute to understanding of GPs’ current 
knowledge and experiences of counterfeit medicines as well as identifying the views of 
GPs on their roles in combating this problem. It also highlighted the distribution of 
types of views and practices according to a set of variables including past experiences of 
counterfeit medicines, length of service and membership of professional bodies. The 
study was able to establish the extent to which certain views and practices were shared 
and what variables may influence the holding a particular view or the adoption of a 
particular practice. 
It was revealed that only a small percentage of GPs had had any past experience of 
counterfeit medicines during their professional life. According to this study, in case of 
any counterfeit medicine incident in the future GPs’ first action would be to report it to 
the medicines regulatory agency and then to their organization. In addition, this study 
showed that none of the GPs had attended an education or training programme about 
counterfeit medicines in the past. The majority of the GPs agreed that reporting any 
suspicion of counterfeit medicines to the medicines regulatory agency is part of their 
role in combating counterfeit medicines. However, about half of the GPs did not see it 
as part of their role to raise patients’ awareness and to provide advice to patients about 
counterfeit medicines. Finally, this study could not distinguish any differences in 
opinion between the GPs’ responses regarding their views on counterfeit medicines 
based on their past experience, length of service or workplace. These results indicate 
that it may be helpful to develop education and training activities for the GPs which 
would encourage the prompt reporting of any suspicious counterfeit medicine incident 
to the medicine regulatory agency. This study also highlighted the need for close co-
operation between the medicines regulatory agency and GP organizations (i.e. CCGs) as 
well as with their professional bodies to facilitate developing a better plan for the 
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education programmes intended to inform GPs of best practice and may be a way to 
improve communication with GPs with respect to counterfeit medicines; in both cases 
this is aimed at enabling GPs to fulfil their roles in the overall effort to combat 
counterfeit medicines. Finally, the results of comparing different GP sub-groups in this 
study may be valuable to and strengthening for the medicines regulatory agency 
decision-makers and evaluators in evaluating relevant activities in targeting GPs and 
planning future such activities. 
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8.1 Introduction 
The problem of counterfeit medicines spans the globe and affects all kind of medicines. 
The literature has detailed how it imposes a great threat to public health and 
encouraging national and international efforts to tackle it. Health and medicines 
regulatory agencies may now be recognising the need to have a systemic and 
collaborative approach in order to effectively combat this threat. One way of achieving 
this has been to develop a national strategy for combating counterfeit medicines. 
Therefore, this research aimed to examine the views of participants from the MHRA 
and stakeholders on current practice with respect to combating counterfeit medicines in 
the UK in order to understand the key components in developing anti-counterfeit 
medicines strategies. To do this, the researcher conducted two studies to describe and 
understand the processes involved in developing, implementing and evaluating a 
national anti-counterfeit medicines strategy through capturing the perceptions of 
participants from the MHRA and MHRA stakeholders of an anti-counterfeit medicines 
strategy. To support those studies, a further two studies were conducted to describe and 
understand the views and roles of pharmacists and GPs in combating counterfeit 
medicines. In order to fulfil the research aim and objectives, a mixed method approach 
that combined qualitative and quantitative methods to collect and analyse the data were 
operationalised. 
The data collected in this research comprised the views, perceptions, preferences and 
self-reported practices of four groups involved in the anti-counterfeit medicines strategy 
development process in some way, and/or with a role to play in implementing such a 
strategy and in combating counterfeit medicines. This research cannot measure the 
success of the existing MHRA strategy or know for sure what effect a given preference, 
recommendation or interpretation would have in making any future strategy more or 
less effective. There are, however, a wide range of questions concerning the 
development, implementation and evaluation of an anti-counterfeit medicines strategy 
which can be considered in the light of the findings of this research, which this chapter 
aim to address. 
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8.2 Research Findings 
This research showed agreement between the MHRA and stakeholder participants about 
the dangerous consequences to the public arising from counterfeit medicines and 
suggesting that the main source of this risk was online supply. Therefore, they saw an 
anti-counterfeit medicines strategy as a requirement for any national medicines 
regulatory agency for successfully combat counterfeit medicines. Participants saw in 
order to develop an anti-counterfeit medicines strategy, a national medicines regulatory 
agency should fully understand its operating environment. Therefore, participants 
expressed the view that the agency needs to understand and evaluate its external and 
internal motivating factors as well as its limitations and boundaries for developing such 
a strategy. Participants believed that the appearance of counterfeit medicines in the 
supply chain, protection of public health, securing the supply chain, and pressure from 
stakeholders were each identified as external motivating factors. On the other hand, they 
saw the internal motivating factors as personality and attitude of the agency’s staff, 
along with the availability of management support. Also, this research found that 
participants identified the agency’s limited staff and resources, the lack of internal 
communication and resistance within the agency as internal limitations; whereas, 
regional and international legislation, support from other government agencies and from 
industry were considered as external limitations for the agency when planning to 
develop an anti-counterfeit medicines strategy.  
This research also highlighted the design process for an anti-counterfeit medicines 
strategy as seen by the MHRA and stakeholder participants. Participants focused on the 
need for a national medicines regulatory agency to formulate an internal drafting 
committee from its departments/divisions which might be led by one of the agency’s 
department/divisions (such as the enforcement department). Moreover, this research 
revealed appreciation from both participant groups for the role of the agency 
stakeholders in the design process as being consultative and as providing feedback to 
the agency throughout the process. With regard to the implementation phase for such a 
strategy, this research showed that for the implementation to be effective, the agency 
should appoint a department/division to be responsible for this implementation in 
cooperation with other departments/divisions. In the case of the MHRA, their 
participants saw the enforcement department as being the best for this task. However, a 
senior manager from the agency might be another option to be considered. Results 
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highlighted the need to involve the agency’s stakeholders in the implementation stage. 
The roles of stakeholders identified by participants from this research as: collaboration, 
cooperation and sharing information with the agency, securing the supply chain, 
educating and raising awareness among their own members and the general public, 
being vigilant and reporting any suspicions to the medicine regulatory agency. 
This research also showed that both MHRA participants and stakeholder participants 
perceived that identifying an anti-counterfeit medicines strategy’s outcomes and 
evaluating them post hoc would be a problematic task for the agency due to the lack of 
nationally recorded data on counterfeiting cases combined with resource limitations. 
Nevertheless, those participants suggested several outcomes that could be identified as 
outcomes from such a strategy: securing the supply chain, decreasing the number of 
counterfeiting cases, changing people’s behaviour, protecting the public, and changing 
legislation and regulations. However, the findings showed that both MHRA and 
stakeholder participants thought in order for the agency to overcome the challenges for 
evaluating such a strategy, the agency needed to develop quantitative metrics for the 
evaluation process such as the number of counterfeit medicine incidents that reached the 
supply chain, the number of reports to the agency regarding suspicion of counterfeit 
medicines and the number of incoming reports from patients, pharmacists and GPs. 
Furthermore, this research identified which roles MHRA and stakeholder participants 
believed were appropriate for pharmacists and GPs to play in combating counterfeit 
medicines. Both participants groups indicated that pharmacists could play a significant 
part in combating counterfeit medicines. They identified five roles for pharmacists: 
securing their supply chain, being vigilant, being attentive to the feedback from patients, 
reporting any suspicions to the medicines regulatory agency and being a source of 
awareness and education for patients. Whereas, three roles were identified for GPs: 
being a source of education and awareness for patients, being vigilant and reporting any 
suspicions to the agency. However, when the views of pharmacists and GPs on these 
proposed roles were examined in this research not all pharmacists and GPs agreed with 
them. In fact, only the role of reporting suspicions to a medicines regulatory agency was 
agreed by a majority of both pharmacists and GPs. Nearly half of the GPs did not agree 
that they should have roles in raising patients’ awareness or providing advice to 
patients. This research also found that many recommended dispensing practices were 
not being performed or were rarely being performed; and that fewer than half of the 
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pharmacists were following the recommended purchasing practices which were aimed 
at securing the supply chain. 
Another finding from this research was that only a small minority of pharmacists and 
GPs reported having had any past experience of dealing with one or more counterfeit 
medicines cases. Findings showed that pharmacists would prefer to report any future 
incidents of counterfeit medicines to their suppliers rather than the medicine regulatory 
agency; and, just more than half of the GPs indicated an intention to report any future 
incidents involving counterfeit medicines to the medicine regulatory agency. With 
respect to any past education or training regarding counterfeit medicines, it was found 
that only 10% of pharmacists had received such training. Furthermore, none of the GPs 
in this research had received any kind of education or training programme regarding 
counterfeit medicines. Both pharmacists and GPs were seen to prefer workshop and 
distance learning as the delivery method for any future education or training 
programmes regarding counterfeit medicines. Finally, the pharmacists and GPs 
participating in this study expressed a preference for receiving information in 
counterfeit medicines via professional journals, by email and through their 
organizations. 
 
8.2.1 Comparing MHRA and stakeholders’ views with respect 
to an anti-counterfeit medicines strategy 
This research revealed shared interpretations between MHRA and stakeholder 
participant groups about the serious risks counterfeit medicines pose to public health. 
However, the risk associated with counterfeit medicines supplied via online sources 
were perceived more strongly by stakeholder participants than by the MHRA 
participants, as only the stakeholder participants urged that more efforts need to be 
directed toward the supply route. This view from stakeholders might arise because they 
operate more directly in the field of supplying medicines and are more closely involved 
in the medicines supply chain than the agency. Also, some stakeholder participants were 
found to argue that the risk to branded medicines from counterfeiting was greater than 
that for generic medicines, a view also supported by one of the MHRA participants. 
This view could be considered controversial as many cases of counterfeiting of generic 
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medicines have been reported around the world and the majority view of participants 
was that branded and generic medicines should be treated equally in terms of anti-
counterfeiting measures. Stakeholders, particularly those from pharmaceutical 
manufacturers, are likely to see the risk from counterfeit branded medicines as being 
greater in commercial terms as brands may be devalued and higher value sales lost. 
Whereas, the risks to public health from counterfeiting remain the same whether the 
counterfeit is reproducing a branded medicine or a generic one.    
The MHRA and stakeholder participants were found to agree that any medicines 
regulatory agency should have an anti-counterfeit medicines strategy. However, only 
MHRA participants were able to identify the factors motivating an agency to develop 
such a strategy as well as the agency’s limitations and boundaries. This might be 
because the strategy was developed and owned by the MHRA, meaning the MHRA 
participants would be more familiar with it than stakeholder participants. Furthermore, 
to develop the strategy, the MHRA and stakeholder participants suggested that the 
agency needed to have a drafting committee. The MHRA participants may have 
supported the concept of a drafting committee because it reflects current practice while 
the stakeholders viewed it as a means for them to become more directly involved at an 
earlier stage. MHRA participants thought the drafting committee should be internal; 
whereas, the stakeholders participants saw themselves as part of that drafting committee 
as they saw themselves adding value to the drafting process. However, in this research, 
both sets of participants identified the roles of the stakeholders at the drafting stage as 
consultative and providing feedback to the agency which would fit in with the MHRA 
participants preference for an internal drafting committee as this committee could 
involve and consult with stakeholders as required without them actually becoming part 
of the committee. The process of developing an anti-counterfeit medicines was 
identified only by the MHRA participants perhaps because they had either had past 
experience in the drafting of such a strategy or their work within the MHRA was related 
to the strategy. Therefore, MHRA participants in this research had the opportunity to 
express their personal but informed views on the drafting process of an anti-counterfeit 
medicines strategy. Similarly, only the MHRA participants commented on the 
implementation process for the strategy including which department should lead the 
implementation, which roles should be allocated to which department and how the 
actual implementation process should unfold. However, both MHRA and stakeholder 
participants agreed on which roles were important for stakeholders to play in 
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implementation. Findings showed that both participant groups thought that the 
stakeholders could support the strategy by collaboration, cooperation and sharing 
information with the agency; securing the supply chain, being vigilant; reporting any 
suspicious activities to the agency. Also, stakeholder participants suggested further roles 
that the agency’s stakeholders could play in the implementation process, based on their 
likely capabilities to be effective in conducting those roles, which were: stakeholders 
could conduct their own intelligence activities, they could support the agency with skills 
and expertise, and assist the agency in educating and rising awareness activities among 
their members and the general public. These capabilities would vary from one 
stakeholder group to another. Major pharmaceutical manufacturers are highly resourced 
organisations employing leading scientists in state of the art laboratories and so are in a 
strong position to lend testing and technical support. 
Also, this research showed closely related views between MHRA and stakeholder 
participants on the roles that pharmacists and GPs could play in combating counterfeit 
medicines. Both groups suggested that pharmacists would have more relevant roles than 
GPs. This may be because pharmacists are perceived by both groups as the final link in 
the supply chain before the medicine reaches the patients and also because they 
physically deal with medicines on a daily basis. These two groups defined the roles of 
pharmacists as: securing their supply chain, being vigilant, reporting any suspicion of 
counterfeiting to the agency, and being a source of awareness and education for 
patients. The GP roles were defined by MHRA and stakeholder participants as: being a 
source of education and awareness for the patients, being vigilant, and reporting any 
suspicion to the agency. Correspondingly, MHRA and stakeholder participants were 
seen to agree on the need to use effective methods to communicate these role to 
pharmacists and GPs, and they suggested that this might best be achieved through their 
respective professional bodies as professional bodies would be the best able to 
communicate these roles. 
Neither the MHRA nor stakeholder participant groups were able to present a definitive 
and comprehensive view of the outcomes that the medicines regulatory agency could 
expect from an anti-counterfeit medicines strategy or the methods which should be used 
to evaluate those outcomes. This may be because the MHRA’s strategies did not clearly 
identify any outcomes for its strategies meaning the MHRA’s participants could not 
refer to officially stated desired outcomes in their responses and could only offer their 
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own views about what these could or should be an outcome. For stakeholder 
participants there was also no official reference point and so their views were likely to 
be formed by the interests of their own particular stakeholder group. Also, none of the 
MHRA or stakeholder participants were aware of any evaluation of any such strategy 
including the MHRA’s strategies. With so much emphasis on the performance and 
‘value for money’ of public agencies in the UK this finding is of particular interest. 
The participants recognised that the task of setting outcomes for such a strategy and 
evaluating those outcomes would not be an easy task for the agency. They also stressed 
the need for the agency to try to identify the desired outcomes right from the outset of 
drafting the strategy which would be helpful for directing the strategy and would be the 
starting point for the evaluation process. Nevertheless, certain outcomes to be expected 
from such strategy were identified by the MHRA or stakeholder participants in this 
research as: changing people’s behaviour, securing the supply chain and decreasing the 
number of counterfeiting cases. Also, they saw other outcomes as including changes to 
legislation and regulations presumably because, as a government agency, the MHRA 
would be expected to take the lead in recommending changes to legislation and 
regulations that relate to counterfeit medicines. Both MHRA and stakeholder participant 
groups also suggested that the agency might use specific quantitative metrics criteria for 
the evaluation process, such as the number of counterfeit medicine incidents reported in 
the supply chain, the number of reports to the agency regarding suspicions of 
counterfeit medicines, the number of counterfeit medicine cases and the number of 
reports made by patients, pharmacists and GPs. 
Both study groups perceived strategy evaluation as problematic due to the lack of 
nationally recorded data on counterfeiting cases combined with resource limitations. 
Other reasons which had not been highlighted by the participants and might help the 
understanding of the problematic nature of the evaluation of such a strategy are worth 
considering. It come from the dilemma that comes with all crime statistics whereby 
more effective detection and enforcement will lead to increasing levels of recorded 
crime, which then might appear to reflect an increasing problem. Consequently, it will 
lead to greater resources being applied to the issue, leading to more recorded crime. 
Perversely, however, a reduction in the number of recorded cases can just as much 
reflect poor detection and enforcement as it can be seen as a successful strategy and a 
rise in recorded cases could reflect either an increase in the supply of counterfeit 
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medicines or improved detection, or indeed both. Furthermore, the participants’ 
suggestion that changing legislation and/or regulations was a viable desired outcome 
and/or a valid evaluation method is also problematic because while such a change could 
indeed be a result of the agency’s proactivity, a lack of change could also reflect the 
effectiveness of the existing regulatory and legislative framework. Likewise, changing 
legislation/ regulation in itself may not help or at least may take years to properly 
evaluate.   
 
8.2.2 Comparing GPs’ and pharmacists’ views on counterfeit 
medicines issues 
In great contrast to the reported, though largely estimated, scale of the global counterfeit 
medicines trade, the pharmacists reported a low level of past experiences and the GPs 
an exceptionally low level. This finding raises important questions concerning the 
nature of the relationship between GPs, patients and the medications they physically 
obtain from pharmacists. The research findings on past experiences of counterfeit 
medicine incidents showed that GPs had had less experience with counterfeit medicines 
than pharmacists. This was perhaps because the GPs would be less aware of the 
counterfeit medicines issue than pharmacists or could be because patients usually go to 
the pharmacist rather than their GP if they have a query regarding a medicine’s 
authenticity or efficacy. While pharmacists had rather more previous experiences than 
GPs, the number reporting such experiences was still relatively low which raises a 
concern for the degree of awareness among the pharmacists and GPs that will be 
essential in combating counterfeit medicines. As counterfeit medicines widely reported 
is increasingly going through the online supply chain; then it should considered that 
patients may not wish to reveal the source of their medicines for fear of being criticised 
by either their GP or pharmacist for making such irresponsible purchases.   
This research showed that the first action that GPs said they would take when 
encountering counterfeit medicines in the future would be to report it to the medicines 
regulatory agency. In contrast, the pharmacists would report it to their medicine supplier 
as a first choice with the medicines regulatory agency only their third choice. This could 
have been because GPs were trained to report any adverse patient effects to the 
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medicines regulatory agency (via the UK’s Yellow Card Scheme) so for GPs, 
counterfeit medicines would fall within that reporting procedure. On the other hand, the 
pharmacists might be more aware of the counterfeit medicines issue because of their 
past experiences but they might need more training on best practice in reporting a 
suspected counterfeit medicines case to the medicines regulatory agency. 
In relation to education and training programmes, the research raises significant 
concerns because of the very low numbers of health professionals reporting receiving 
such education and training. Indeed no GPs in this study reported having attended any 
such programmes. This might be why the GPs reported having had less experiences of 
counterfeit medicines than the pharmacists. The lack of previous education and training 
programmes might have had an impact on the pharmacists’ and GPs’ reported future 
action if they suspected a counterfeit medicines case. Furthermore, if GPs are unaware 
of the counterfeit medicine problem and particularly that from online purchases they are 
unlikely to consider it as a possible cause of a patient presenting with therapeutic failure 
or adverse event. Also, the lack of specific education and training programmes might be 
the reason for the majority of pharmacists in this research to report that they do not 
follow good dispensing and purchasing practices that have been recommended by the 
MHRA and the RPS to protect patients from counterfeit medicines.  
The lack of past education and training programmes for pharmacists and GPs might also 
be a reason why there was no majority view as to the timing of training and education 
programmes in the future, with broadly equal support for holding it within the 
undergraduate degree, during the pre-registration/foundation year and post- 
registration/post-foundation year. Nonetheless, this research reported distance learning 
as the first choice for GPs to deliver a training programme with workshops as the 
second choice, which could be because of the GPs’ busy work schedule. In contrast, the 
pharmacists preferred workshops as their first option and distance learning as the 
second option; which is understandable as they are dealing physically with medicines 
on a daily basis.  
Pharmacists were found to be slightly more inclined to see it as part of their role to 
report incidents of counterfeit medicines to the medicines regulatory agency than the 
GPs. However, only half of the GPs agreed with having the roles of raising patient 
awareness and providing advice to patients regarding counterfeit medicines, whereas 
most of the pharmacists agreed this was their role. This could be explained by the 
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pharmacists having had relatively more experience with counterfeit medicines as well as 
some education on this in contrast to GPs. These results could also suggest that those 
roles identified were not sufficiently well communicated to either GPs or pharmacists 
which would be reflected in their normal work practices. The only role agreed by a 
majority of both pharmacists and GPs was reporting suspicions to a medicines 
regulatory agency. 
Findings showed the need for more educational activities targeted at health 
professionals (GPs and pharmacists) based on their preferences which could help them 
to protect the public from counterfeit medicines. Findings also could help decision-
makers within the medicines regulatory agency to identify where and how to plan its 
education activities for the health professionals. Both studies may help decision-makers 
at the medicines regulatory agency to appreciate the importance and feasibility of 
engaging GPs and pharmacists more in efforts to combat counterfeit medicines by 
increasing their understanding of their roles. Likewise, the decision-makers could be 
informed about the communication methods preferred by the GPs and pharmacists. 
Overall a number of the findings from the pharmacist and GP studies, including low 
levels of past experiences of counterfeit medicines, low or non-existent reported training 
and education about counterfeit medicines and their different views with the regulatory 
agency concerning what roles they should carry out in implementing the anti-counterfeit 
medicines suggest that there is a need for greater awareness raising and communication 
between the regulatory agency, the health professionals and their professional bodies. In 
turn this may increase the awareness raising and communication between these 
healthcare professionals and their patients. 
 
8.3 Findings related to the processes of developing, 
implementing and evaluating an anti-counterfeit 
medicines strategy. 
In addition to recognizing the findings of this research with respect to areas of 
agreement and disagreement among the four study groups; it would be important also to 
recognize the overall research contribution to understanding the way different groups 
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may engage in the processes of developing, implementing and evaluating an anti-
counterfeit medicines strategy. The feasibility of strategy development, the 
organisational demands of developing a strategy in this area and the challenges of 
including health professionals in the implementation need to be understood.  
First, it should not be surprising that both MHRA representatives and stakeholder 
participants recognised the threat posed by counterfeit medicines on a range of levels. It 
is also understandable that having a strategy to combat counterfeiting was seen as a pre-
requisite. Such agreement is a first step in developing a strategy. Nevertheless effective 
implementation is an altogether more complex task not least because of the number of 
actors involved in such an implementation and the different characteristics of their 
organisations, as such a strategy will have an effect on the public sector, private sector, 
government agencies and professional associations. Also, the health dimensions, the law 
enforcement dimensions and the commercial dimensions will all have an effect on the 
complexity of such a strategy. Therefore, by involving many of the significant actors in 
this study a picture of this complexity has been highlighted and confirmed.    
Secondly, with regards to the different actors’ engagement in a strategy, this research 
has shown that stakeholders are keen to engage in such a strategy from the drafting 
stage. Though it should be recognised that the motivations of stakeholders vary from 
one type to another. There would, for example, be a great contrast between the priorities 
of a law enforcement agency and a multi-national pharmaceutical manufacturer. 
Therefore, such contrasts may make multi-lateral cooperation more problematic for the 
medicines regulatory agency in developing the strategy. Nevertheless, this study 
confirmed that those stakeholder groups included in the study appeared to be fully 
engaged in the strategy. On the other hand, the engagement of the health professionals 
was less easy to determine as this research showed lack of past experience of counterfeit 
medicines, absence of education and training, inconsistent application of best practices 
and lack of agreement over roles all of which revealed the scope for greater 
engagement. Although, it perhaps equally revealed the workload pressures and priorities 
of both GPs and pharmacists. 
Thirdly, it should consider that the MHRA is a pioneer in the field of developing an 
anti-counterfeit medicines strategy. However, this study has revealed that there are 
substantial organisational demands on the agency and that there appear to be areas 
which can yield further strategy improvements in the future. These include discussing 
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and agreeing the nature and timing of the input that stakeholders should have at the 
drafting stage, the communication and agreement of precisely what roles healthcare 
professionals have in the implementation of a strategy and an overall re-evaluation of 
communication activities and the MHRA’s role in developing training programmes or 
materials for healthcare professionals as such programmes seem largely lacking at 
present. Furthermore, term-based strategies require evaluation which improve the 
overall strategy process over time. However, there appears to be no evaluation process 
in place in the case of the MHRA which could be drawn from both their own 
publications and the findings of this research. Therefore, this research showed this is an 
important area for the MHRA to consider in the future.    
Fourthly, this research highlighted the organisational demands of implementing such a 
strategy in this area with pharmacists and GPs. A number of gaps emerged between 
what the MHRA might hope for in regard of the position of health professionals in 
regard to implementing an anti-counterfeit medicines strategy and what the results of 
this research indicate. Low awareness arising from lack of past experiences and lack of 
relevant training would appear to be a major challenge as does the more effective 
communication of the desired roles these healthcare professionals should have in the 
overall effort to combat counterfeiting of medicines.  
There are also significant findings concerning the practices of pharmacists and GPs in 
securing the supply chain and reporting cases of counterfeiting to the agency which 
suggests that there is more work to be done in this area. It also important to recognize 
that health professionals usually have busy schedules and they are responsible for 
delivering a range of health messages to patients. Also, pharmacists and GPs are dealing 
with so many demands and guidelines already set for their patient consultations; 
therefore, it should be considered how they view the risks of counterfeit medicines to 
their patients and they may have a low priority which could account for some of the 
findings in this study. To raise this priority would require a major effort which probably 
cannot done by the medicines regulatory agency only and need contributions from other 
parties like professional bodies.  
Pharmacies want to protect their reputations by supplying only legitimate medicines but 
they might have a range of commercial considerations and pressures on resources which 
may mitigate against prioritizing the advising and educating of patients and even the 
reporting of counterfeit cases to the MHRA. Overall, this research has provided 
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evidence that there are major challenges facing a medicines regulatory agency in fully 
and appropriately engaging health professionals in the implementation of an anti-
counterfeit medicines strategy. 
 
8.4 Research limitations 
While the findings of this research combine to contribute new knowledge to the field of 
study, several limitations need to be considered. The researcher’s background as a 
pharmacist working with another country’s national medicines regulatory agency and 
past working experience and knowledge of the counterfeit medicines topic may have 
had an influence of being subjective during the design stages of the studies and might 
have imposed a bias during data analysis. Additionally, the views of participants as 
expressed in the interview studies might have been affected by the fact that they knew 
that the researcher was working for another national medicines regulatory agency and 
that therefore they might have presented partial or less authentic descriptions of their 
real perceptions and interpretations of the issues being discussed. 
The selection of participants for this research has been affected by the decision-makers 
at the MHRA making changes to the proposed participants list for the MHRA study 
should be recognized as it might have introduced some recruitment bias to the sample. 
However, the researcher’s efforts to overcome any possible bias should also be noted by 
explaining to the participants at the beginning of each interview that the study was not 
aimed at evaluating the MHRA’s work; also, the researcher tried not to ask questions 
that could be directly linked to the MHRA’s performance. Similarly, in the 
stakeholders’ study, not all stakeholder groups were represented and many of the 
participants did not have direct involvement with the MHRA’s activities in combating 
counterfeit medicines. It is entirely plausible that those stakeholder groups were not 
represented may have expressed different views that those who were.  
When considering the results from the two survey studies, it is important to consider 
that the relatively low response rate for pharmacists and GPs questionnaires might limit 
the generalizability of the research findings. Also, the percentage of pharmacists and 
GPs who had had past experiences of counterfeit medicines was surprisingly low as was 
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the number reporting prior education and training regarding counterfeit medicines, 
something which would have affected the results.  
The final limitation for this research was related to the lack of existing literature on anti-
counterfeit medicines strategy, particularly empirical studies, but also literature which 
explored the views of pharmacists or GPs on the counterfeit medicines issue. While this 
is not so pertinent in an exploratory study such as this, having a literature base to refer 
to can assist a researcher in identifying appropriate methodologies and in providing 
some context in which to discuss the findings.   
 
8.5 Research implications and recommendations 
This research was the first aiming to understand the process of developing an anti-
counterfeit medicines strategy by drawing on the perspectives of a medicines regulatory 
agency and the agency’s stakeholders together with two groups of health professionals, 
pharmacists and GPs in order to build a multi-dimensional, triangulated 
conceptualisation of the processes of developing, implementing and evaluating an anti-
counterfeit medicines strategy and so address the research problem. 
The findings of this research would therefore help highlight to the decision-makers in 
many national medicines regulatory agencies the reasons that having such a strategy is 
important. Also, it will provide an understanding of the processes of the drafting, 
implementing, and evaluating the strategy through this research into the case of the UK, 
its regulatory agency and the experience of having already developed such strategies. 
This research was also the first to attempt to understand the current knowledge, 
experience and practices of pharmacists and GPs in relation to counterfeit medicines, 
enabling these health professionals to express their views on the roles they should play 
in combating counterfeit medicines. Therefore, this research should be useful for the 
decision-makers within national medicines regulatory agencies when planning to 
engage pharmacists and GPs in activities aimed at combating counterfeit medicines and 
the methods of communicating with them. It also highlighted to the decision-makers the 
need for working collaboratively with pharmacists’ and GPs’ professional bodies and 
organizations in education and communication about counterfeit medicines.  
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The findings from this research indicate several recommendations which provide 
evidence to underpin a guidance framework for the decision-makers of a national 
medicines regulatory agency who wish to develop an anti-counterfeit medicines 
strategy. This framework is set out below. 
I. Evaluating and understanding the agency’s environment in respect to 
counterfeit medicines 
1. Identify the scale of counterfeit medicines 
i. Via the medicines supply chain 
ii. Via online websites 
2. Identify the requisite agency’s strengths  
i. Well-developed departmental and divisional structure 
ii. Supportive agency senior management 
iii. Support from other government agencies 
iv. Support from the agency’s stakeholders 
3. Recognise the agency’s limitations 
i. Resources and capability. 
ii. Resistance for any change from agency’s staff. 
iii. Overall government regulations and legislation. 
II. Pre-drafting stage of an anti-counterfeit medicines strategy 
1. Identify the agency’s departments/divisions that will be part of the 
drafting process.  
Recommended departments/divisions are the enforcement department, 
the inspection department, the laboratory department and, the department 
responsible for dealing with defective product reports (Defective 
Medicines Report Centre), the pharmacovigilance department/division, 
the policy department/division, and the communications 
department/division, the licensing department/division and the legal 
department or government lawyers. 
2. Identify the agency’s stakeholders that might be part of the drafting 
process. 
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Recommended agency’s stakeholders are the pharmaceuticals 
manufacturers (branded and generic), wholesalers, distributors, brokers, 
and the pharmaceuticals importers, police and customs. 
3. Formulate an internal drafting committee from those 
departments/divisions, which could be led by either enforcement 
department or the policy department/division. 
III. Drafting process of an anti-counterfeit medicines strategy 
1. The agency’s internal drafting committee write a first draft of proposed 
activities and actions that will be the core of the strategy. The committee 
might need to consider and propose initial desired strategy outcomes and 
the evaluation process, including specific performance metrics, at this 
stage. 
2. The first draft is shared with the agency’s stakeholders for comments and 
feedback which might be in written format or via a meeting with the 
internal drafting committee. 
3. The internal drafting committee write the second draft of a proposed 
strategy. 
4. Share the second draft with agency’s stakeholders for feedback, which 
will be in writing. 
5. The internal drafting committee finalize the strategy, and then the agency 
may or may not share it with the general public for consultation. 
6. The internal drafting committee send the strategy to the agency’s senior 
management to be reviewed and approved. 
7. The agency publish the strategy. 
IV. Implementing process of an anti-counterfeit medicines strategy 
1. Identify a department/division to lead the strategy implementation 
process from those involved in the drafting process. 
Recommended to be led by the head of the enforcement department or an 
agency’s senior manager. 
2. Identify departments/divisions that will be part of the implementation 
stage. 
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Recommended departments/divisions are the policy, the 
communications, the pharmacovigilance, the laboratory, the Good 
Distribution Practice (GDP) department, inspection department and 
finance department and possibly the legal department or government 
lawyers. 
3. As part of the department/division roles in the implementation, setting an 
anti-counterfeit medicines objectives for each department/division which 
will be part of its overall department/division objectives. 
4. Identify the agency’s stakeholders that might be part of the 
implementation process. 
Recommended agency’s stakeholders are: the pharmaceuticals 
manufacturers (branded and generic), wholesalers, distributors, brokers, 
and the pharmaceuticals importers, police and customs. 
5. Allocate specific roles to the stakeholders 
Recommended stakeholders’ roles are: securing the supply chain, 
collaboration, cooperation and sharing information with agency, being 
vigilant, reporting to the medicines regulatory agency any suspicions and 
educating and raising awareness among their own members and the 
general public. 
6. Ensure good communication of the stakeholders’ roles which might be 
achieved via regular agency-stakeholders meetings. 
7.  Identify the roles of pharmacists and GPs in the anti-counterfeit 
medicines activities. 
Recommended pharmacists and GPs roles are being vigilant for any 
suspicion of counterfeit cases, to report any suspicion to the medicine 
regulatory agency, to provide awareness and advice to the patients, and 
to source their medicines from a secured supply chain. 
8. Ensure good communication of the pharmacists and GPs roles which 
might be achieved via their professional bodies. 
V. Strategy outcomes and evaluation process 
1. Set the desired outcomes of the anti-counterfeit medicines strategy at the 
drafting stage. 
Chapter 8: General Discussion and Conclusion 
PhD Thesis: Developing a national strategy for combating counterfeit medicines                     287    
Recommended outcomes are changing people’s behaviour and 
perceptions to counterfeit medicines, more securing of the supply chain, 
increased collaboration and sharing of information among stakeholders, 
increased public health protection from counterfeit medicines, decreasing 
the number of counterfeit medicines cases that reach the supply chain, 
more tightening of the legislation and regulations, more convictions of 
people involved in this crime, growth in the incidences reported to the 
agency and improvement in international cooperation. 
2. Set quantitative metrics criteria for evaluation the strategy. 
Recommended criteria are the number of counterfeit medicine incidents 
that reached the supply chain, the number of inspections carried out by 
agency inspectors, the number of reports to the agency regarding 
suspicion of counterfeit medicines from stakeholders, pharmacists, GPs 
and patients, and number of prosecutions and sentences for people 
trading in counterfeit medicines. 
3. Assign responsible person for conducting the evaluation which might be 
from within the agency or an external audit.  
4. Review the strategy based on the evaluation outcome for improving the 
future anti-counterfeit medicines strategy. 
Moreover, this research presents three recommendations which might be considered by 
agency decision-makers aimed at improving the involvement of pharmacists and GPs in 
the overall effort to combat counterfeit medicines: 
I. The agency needs to work with universities in order to increase the 
awareness and education of the counterfeit medicines topic for pharmacists 
and GPs from undergraduate degrees and assist in incorporating relevant 
modules within degree courses. 
II. The agency needs to collaborate with pharmacists’ and GPs’ professional 
bodies to develop education and training programs about counterfeit 
medicines which may be in workshop format for pharmacists and distance 
learning for GPs. 
III. The agency needs to work with pharmacists’ and GPs’ professional bodies 
as well as pharmacists’ and GPs’ work organizations to develop the best 
method to communicate with pharmacists and GPs regarding counterfeit 
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medicines information which might be via professional journals or via their 
organizations. 
 
8.6 Future research 
This research was conducted within the UK context with participants from the UK’s 
medicines regulatory agency and its stakeholders as well as pharmacists and GPs 
practising in England. This might limit the applicability of the findings to the UK 
context. Therefore, further studies that examine strategy development in other contexts 
and tests the relevance of the guidance framework developed in this research would be 
valuable. A comparative study investigating one developed country (such as USA or 
Canada) and one developing country (such as Saudi Arabia) is therefore needed to 
extend both researchers and agencies’ decision-makers understanding the key 
components that are involved in the development, implementation and evaluation of an 
anti-counterfeit medicines strategy.  
A limitation of this research related to the recruitment of MHRA’s stakeholders, as a 
relatively small numbers of participants were involved in this research and certain 
stakeholders groups were not represented. Therefore, further research might be needed 
to involve more participant from all stakeholders groups and to re-examine their views 
on the guidance framework developed in this research. 
Further interview-based research with pharmacists and GPs could help in gaining a 
more in-depth understanding of their views related to their knowledge and experiences 
of counterfeit medicines and their roles in combating them. This would also enable the 
survey study to be redesigned in order to capture wider views of pharmacists and GPs 
related to their knowledge and experiences of counterfeit medicines and their roles in 
combating them.  
Patients’ views on anti-counterfeit medicines strategy and their perceptions of the 
counterfeit medicines issue were not part of this research. Therefore, further research 
may be needed to understand the patients’ knowledge, experience and attitudes to 
counterfeit medicines something which would help the national regulatory agency in its 
efforts to combat the problem. 
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8.7 Conclusion  
This research examined key components in the process of developing a national anti-
counterfeit medicines strategy from the perspective of a national medicines regulatory 
agency and the stakeholders of that agency together with the views of pharmacists and 
GPs on their roles in combating counterfeit medicines. An anti-counterfeit medicines 
strategy was identified as essential for a national medicines regulatory agency to 
successfully combat this problem. This research recommended that to develop such a 
strategy, the decision-makers at the national medicines regulatory agency need to 
evaluate and understand the agency’s operating environment in respect to counterfeit 
medicines as this would help identify the scale and nature of the problem in the country 
and also to identify the agency’s own strengths and limitations in being able to deal with 
it. Those decision-makers also need to evaluate which departments/divisions would be 
best to involve in drafting the strategy and how stakeholders can best provide 
consultation and feedback. This research also recommended that these decision-makers 
identify which departments/divisions should implement the strategy and where the 
responsibility for leading the strategy should lie. Stakeholders were found to have an 
important role in implementing such a strategy through securing the supply chain, being 
collaborative and co-operative, and sharing information with their agency, being 
vigilant, reporting any suspicions and having a role in educating and raising awareness 
of their own groups and the public. Decision-makers should appreciate that defining the 
strategy’s outcomes and evaluating them would be a challenging task; and few 
outcomes might be seen as results from an anti-counterfeit medicines strategy. 
However, this research recommended likely outcomes of a strategy as changing 
people’s behaviour toward counterfeit medicines, securing the supply chain, increasing 
collaboration and information-sharing among stakeholders, increasing public health 
protection from counterfeit medicines, decreasing the number of counterfeit medicines 
cases, tightening future legislation and regulations, more punitive convictions for those 
involved in counterfeit medicines, increasing levels of incidence reported to the agency 
and improving international cooperation. Results suggested that the agency could use 
metrics criteria for evaluation of some of those outcomes such as numbers of incidents 
that reached the supply chain, the number of inspections, the number of reports to the 
agency from stakeholders, pharmacists, GPs and patients, and the number of 
prosecutions and sentences for people trading in counterfeit medicines. 
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Also, this research showed pharmacists and GPs might help in combating counterfeit 
medicines by being vigilant for any suspicion of counterfeit cases, reporting any 
suspicion to the medicine regulatory agency, providing awareness and advice to the 
patients, and sourcing medicines from a secured supply chain. However, not all 
pharmacists and GPs in this research were agreed on those roles. Therefore, this 
research raised a concern about the degree of knowledge and awareness of pharmacists 
and GPs with respect to counterfeit medicines and their roles in combating the problem. 
This research showed that only a small percentage of pharmacists and GPs had had past 
experience of counterfeit medicines and only a limited number of pharmacists had had 
past education or training about counterfeit medicines. This research recommended that 
regulatory agencies need to work more closely with universities, the pharmacists’ and 
GPs’ professional bodies and work organizations to increase the awareness and 
education of counterfeit medicines topic and to improve communication methods with 
pharmacists and GPs. 
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